data_2kqf_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kqf _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 69.4 mtp 63.93 85.46 0.13 Allowed 'General case' 0 C--N 1.33 -0.241 0 O-C-N 123.869 0.731 . . . . 0.0 111.45 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.437 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 6.8 mpt_? -71.7 137.19 82.94 Favored Pre-proline 0 C--N 1.325 -0.485 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -88.05 113.94 0.84 Allowed 'Trans proline' 0 CA--C 1.53 0.304 0 C-N-CA 123.097 2.531 . . . . 0.0 113.134 -178.747 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.414 ' CB ' ' HB2' ' A' ' 88' ' ' ALA . 13.0 Cg_exo -70.93 128.01 14.41 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.141 1.894 . . . . 0.0 112.681 178.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.563 ' O ' HG21 ' A' ' 89' ' ' ILE . 3.1 mt -93.55 113.04 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.679 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mm -78.25 101.08 3.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.7 -178.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.503 HG12 ' HA ' ' A' ' 49' ' ' ALA . 5.4 mt -79.42 168.12 2.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 177.159 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -145.88 114.38 6.75 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 178.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.9 ttt180 -66.48 99.57 0.58 Allowed 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.068 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.61 55.95 1.09 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.331 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.37 14.42 71.76 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.911 -0.586 . . . . 0.0 113.113 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.44 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 8.3 ptpt -140.48 -80.05 0.27 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 117.01 0.405 . . . . 0.0 111.777 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.44 ' H ' ' HG3' ' A' ' 15' ' ' LYS . 24.4 pttt -155.97 178.02 10.75 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.541 0.21 . . . . 0.0 111.192 -178.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . 0.627 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 23.2 m-85 -87.5 2.35 50.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.253 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.542 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 53.37 49.84 55.09 Favored Glycine 0 C--O 1.215 -1.083 0 N-CA-C 116.436 1.334 . . . . 0.0 116.436 176.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.501 ' HA ' ' O ' ' A' ' 42' ' ' HIS . 11.4 p90 -163.91 146.53 9.48 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 122.34 1.067 . . . . 0.0 112.314 176.185 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 32.7 m -93.35 119.59 32.65 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 113.48 -1.691 . . . . 0.0 113.534 -178.242 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -92.63 84.16 5.0 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.783 0.325 . . . . 0.0 110.222 177.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.408 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 4.4 tpt180 . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.142 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 t . . . . . 0 C--O 1.235 0.293 0 CA-C-O 120.562 0.22 . . . . 0.0 110.685 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 13.5 m-70 -110.51 177.17 4.77 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.992 0.425 . . . . 0.0 110.752 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.604 ' CD2' HG12 ' A' ' 76' ' ' VAL . 98.5 m-70 -150.19 152.8 35.21 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.277 -0.874 . . . . 0.0 108.709 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 44.6 mtm -147.53 141.7 26.12 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -178.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 20' ' ' THR . 2.5 p -73.14 103.19 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.981 0.896 . . . . 0.0 109.693 179.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.408 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 4.7 t-105 -69.28 -37.32 77.81 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.209 -1.359 . . . . 0.0 111.638 -178.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' HIS . . . . . 0.501 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 2.5 t60 -158.75 125.54 4.75 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.295 -178.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.542 HG21 ' O ' ' A' ' 18' ' ' GLY . 4.3 p -121.47 124.78 72.55 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 CA-C-O 121.475 0.655 . . . . 0.0 109.746 178.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -63.72 109.31 1.66 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.524 -1.216 . . . . 0.0 111.922 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.575 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 8.8 p-10 -82.3 49.37 1.41 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.635 0.731 . . . . 0.0 109.708 179.008 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -131.05 13.62 5.49 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.447 -179.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.489 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 157.22 -68.79 0.28 Allowed Glycine 0 CA--C 1.523 0.546 0 C-N-CA 119.085 -1.531 . . . . 0.0 115.176 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_exo -60.18 -129.92 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 0 C-N-CA 123.748 2.965 . . . . 0.0 117.341 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.627 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -41.86 -38.79 1.62 Allowed 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 114.625 1.343 . . . . 0.0 114.625 -176.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.575 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 1.0 OUTLIER -62.17 -56.18 21.25 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.722 -178.844 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.489 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 7.3 mm-40 -63.45 -28.58 70.07 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.306 0.574 . . . . 0.0 110.432 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.46 -28.72 69.86 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.567 178.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.43 -5.15 5.57 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.931 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.482 ' CD2' HG12 ' A' ' 40' ' ' VAL . 1.7 tt -71.14 112.28 7.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.257 0.551 . . . . 0.0 111.463 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.434 ' N ' HD23 ' A' ' 54' ' ' LEU . 0.0 OUTLIER -90.96 120.81 32.26 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.704 178.61 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.48 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 33.2 tt0 -49.76 140.87 10.87 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.002 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.45 13.78 57.98 Favored Glycine 0 CA--C 1.52 0.357 0 C-N-CA 121.032 -0.604 . . . . 0.0 113.125 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.528 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 2.2 t0 -94.81 151.64 19.07 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.978 0.418 . . . . 0.0 111.116 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.522 HD11 ' O ' ' A' ' 38' ' ' HIS . 4.6 tp -98.26 129.94 44.98 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.192 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.8 mp -86.81 124.21 40.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.055 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 66.3 p -100.4 -37.81 8.69 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.774 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.42 ' HB2' ' CB ' ' A' ' 90' ' ' SER . 59.1 m80 -143.11 162.54 35.27 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.927 -178.688 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.8 p -143.45 116.13 3.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.998 177.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 58.58 24.33 11.88 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.386 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.82 41.75 8.62 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.538 -178.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.433 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.1 tp10 -151.4 109.49 2.97 Favored Pre-proline 0 N--CA 1.434 -1.246 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 1.0 OUTLIER -47.29 128.88 15.18 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 123.947 3.098 . . . . 0.0 111.921 178.923 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.1 m -87.43 -13.76 10.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.165 0 CA-C-N 114.359 -1.291 . . . . 0.0 109.203 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 9.1 m170 -57.47 95.08 0.02 OUTLIER 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 112.846 -1.979 . . . . 0.0 111.163 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 119.41 -14.18 10.92 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.08 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 43.3 mt -76.01 142.52 41.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.592 0.234 . . . . 0.0 110.577 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -78.08 169.66 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.882 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -42.42 -48.18 5.12 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.907 0.883 . . . . 0.0 113.119 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 12.0 p -88.21 -15.45 35.93 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -68.4 -42.45 79.01 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 122.361 -0.212 . . . . 0.0 111.212 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.604 HG12 ' CD2' ' A' ' 38' ' ' HIS . 9.6 m -64.16 -46.36 93.76 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.233 0 CA-C-O 121.198 0.523 . . . . 0.0 110.0 179.275 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.577 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 72.8 t -55.18 -48.96 75.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.268 177.555 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -61.63 -44.01 97.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.161 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.19 -39.45 63.68 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-O 121.263 0.554 . . . . 0.0 109.937 178.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 14.3 mt -72.27 -50.34 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.807 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.577 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 39.6 mt -58.33 -36.85 74.01 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-O 121.329 0.585 . . . . 0.0 110.515 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 24.0 ttmt -60.34 -39.94 88.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.634 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 43.4 t -54.69 -36.47 64.69 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.359 -0.837 . . . . 0.0 111.49 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 127.85 -130.42 6.7 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.207 -0.997 . . . . 0.0 112.637 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 25.0 p30 -92.07 13.87 17.6 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.208 0.528 . . . . 0.0 111.047 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -163.47 176.69 9.53 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.064 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -171.81 145.99 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.414 ' HB2' ' CB ' ' A' ' 7' ' ' PRO . . . -92.38 95.82 9.89 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.276 -0.874 . . . . 0.0 111.108 178.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.563 HG21 ' O ' ' A' ' 8' ' ' ILE . 11.2 tt -89.09 113.64 25.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 120.945 0.403 . . . . 0.0 111.06 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.42 ' CB ' ' HB2' ' A' ' 62' ' ' HIS . 0.2 OUTLIER -87.52 110.14 20.12 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.929 0.395 . . . . 0.0 110.911 -179.535 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.528 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 40.0 p -108.32 164.37 12.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.151 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' THR . . . . . 0.442 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 2.1 t -99.78 105.51 34.89 Favored Pre-proline 0 C--N 1.328 -0.356 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -177.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . 0.433 ' HD3' ' O ' ' A' ' 91' ' ' THR . 52.6 Cg_exo -54.64 176.2 0.12 Allowed 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 122.328 2.018 . . . . 0.0 113.089 178.014 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.01 164.05 13.52 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.695 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.321 -0.673 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.341 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.5 m . . . . . 0 N--CA 1.452 -0.339 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 84.9 mtp 58.31 79.76 0.2 Allowed 'General case' 0 N--CA 1.463 0.2 0 O-C-N 123.685 0.616 . . . . 0.0 111.483 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.462 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 3.4 mpt_? -72.26 132.5 84.11 Favored Pre-proline 0 C--N 1.325 -0.498 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 3.6 Cg_exo -83.46 114.33 2.1 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 123.059 2.506 . . . . 0.0 112.745 -178.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 13.6 Cg_exo -70.84 124.31 10.52 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.245 1.963 . . . . 0.0 112.381 178.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.553 ' O ' HG21 ' A' ' 89' ' ' ILE . 5.2 mt -91.46 111.02 23.28 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.079 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mm -77.79 101.45 3.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -177.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.544 HG12 ' CB ' ' A' ' 49' ' ' ALA . 5.3 mt -78.05 164.95 3.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 177.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . 0.403 ' N ' HG23 ' A' ' 10' ' ' ILE . 32.7 t-80 -142.78 114.29 7.95 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.8 ttt180 -63.39 114.09 3.65 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.401 0.62 . . . . 0.0 110.725 -179.504 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -84.67 43.82 1.01 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.185 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.55 3.95 83.9 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.735 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.3 ptpt -127.64 -82.65 0.6 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.699 0.285 . . . . 0.0 111.138 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.519 ' HE2' ' OE1' ' A' ' 44' ' ' GLU . 22.7 pttm -158.51 -179.55 8.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.924 -178.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . 0.475 ' HA ' ' HB3' ' A' ' 48' ' ' PRO . 12.8 m-85 -89.98 -0.41 57.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.524 0.678 . . . . 0.0 109.182 179.214 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.98 -24.92 0.11 Allowed Glycine 0 C--N 1.331 0.274 0 N-CA-C 116.704 1.442 . . . . 0.0 116.704 177.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.56 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.7 p90 -81.96 142.48 32.38 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 122.615 1.197 . . . . 0.0 113.636 -176.562 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 58.6 m -93.14 114.65 27.21 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 113.225 -1.807 . . . . 0.0 111.481 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -86.4 84.28 7.48 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 178.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.564 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 1.9 tpt180 . . . . . 0 C--N 1.327 -0.387 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.936 -179.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.6 t . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 120.898 0.38 . . . . 0.0 110.656 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 8.0 m-70 -108.63 -174.0 2.41 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.465 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.428 ' O ' HD11 ' A' ' 59' ' ' LEU . 99.1 m-70 -151.39 161.61 42.39 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -179.762 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' MET . . . . . 0.436 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 68.5 mtm -150.02 144.79 26.02 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.755 0.312 . . . . 0.0 110.488 -178.566 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.485 HG13 ' CD2' ' A' ' 54' ' ' LEU . 2.7 p -74.41 104.5 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-O 121.823 0.82 . . . . 0.0 109.67 179.202 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.564 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 5.3 t-105 -69.82 -40.09 76.1 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.659 -1.155 . . . . 0.0 112.167 -178.389 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' HIS . . . . . 0.497 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.8 t60 -158.91 127.82 5.39 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.329 -178.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.56 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 2.4 p -120.93 129.33 75.8 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.109 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.519 ' OE1' ' HE2' ' A' ' 16' ' ' LYS . 27.5 mt-10 -64.09 113.12 3.31 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.911 -179.049 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.641 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 9.4 p-10 -84.88 34.33 0.54 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.134 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -124.3 17.07 7.52 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.151 -1.024 . . . . 0.0 113.926 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.04 -64.99 0.28 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 118.884 -1.627 . . . . 0.0 115.049 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.475 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 49.6 Cg_exo -62.36 -133.33 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.316 2.677 . . . . 0.0 116.913 -177.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.544 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -43.33 -35.48 1.52 Allowed 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 -176.578 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.641 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 2.0 m -63.42 -53.32 54.21 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 118.399 0.545 . . . . 0.0 111.674 -178.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -63.2 -30.96 72.01 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-O 121.52 0.676 . . . . 0.0 109.807 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.15 -31.75 73.07 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.913 -1.039 . . . . 0.0 110.067 178.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.65 -5.87 5.52 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.551 179.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.485 ' CD2' HG13 ' A' ' 40' ' ' VAL . 1.1 tt -67.02 117.28 8.86 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.249 0.547 . . . . 0.0 111.44 -179.455 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.416 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -91.19 121.78 33.26 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.311 178.821 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -51.85 138.95 23.03 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.597 177.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.19 15.98 56.5 Favored Glycine 0 CA--C 1.52 0.399 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.713 -179.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.618 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 5.2 t0 -94.28 153.87 17.81 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.773 0.32 . . . . 0.0 110.553 179.581 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.436 ' HA ' ' HG2' ' A' ' 39' ' ' MET . 4.8 tp -101.02 128.46 47.05 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.589 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.406 HD12 ' N ' ' A' ' 60' ' ' ILE . 4.0 mp -85.42 124.46 40.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.88 -179.652 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 64.6 p -101.88 -39.95 7.13 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.351 0.596 . . . . 0.0 110.519 179.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 62.0 m80 -139.75 157.19 46.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.969 -178.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.6 p -139.82 109.73 3.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.562 178.004 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 61.73 30.64 18.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.654 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.38 45.44 18.8 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -178.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.467 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 4.0 tp10 -149.84 105.11 3.22 Favored Pre-proline 0 N--CA 1.436 -1.166 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.467 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.2 Cg_endo -49.97 127.85 20.43 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 123.474 2.783 . . . . 0.0 111.264 178.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.7 m -88.7 -11.25 10.49 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.644 -179.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -55.25 93.77 0.01 OUTLIER 'General case' 0 N--CA 1.427 -1.6 0 CA-C-N 113.029 -1.896 . . . . 0.0 111.806 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 114.41 -10.03 22.1 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.523 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 25.6 mt -75.66 145.05 41.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.783 0.325 . . . . 0.0 110.295 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -77.91 166.48 2.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.607 ' O ' HG21 ' A' ' 76' ' ' VAL . 77.8 t60 -46.04 -52.74 11.39 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.966 0.888 . . . . 0.0 112.3 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.2 p -72.57 -19.71 61.45 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 114.986 -1.006 . . . . 0.0 112.868 -176.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 21.5 mt-10 -70.69 -42.97 69.98 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 121.218 -0.193 . . . . 0.0 110.97 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.607 HG21 ' O ' ' A' ' 73' ' ' HIS . 15.5 m -64.8 -47.22 89.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.132 0 C-N-CA 120.354 -0.538 . . . . 0.0 109.764 179.273 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.528 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 48.6 t -54.71 -45.79 73.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.077 177.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.436 ' O ' ' HB2' ' A' ' 82' ' ' LYS . 17.9 mt-10 -63.15 -44.6 95.07 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.633 179.092 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -54.37 -41.14 68.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.207 0.527 . . . . 0.0 110.313 179.247 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 18.5 mt -69.3 -51.83 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.224 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 61.4 mt -59.74 -36.24 76.2 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.183 0.516 . . . . 0.0 110.477 179.095 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 78' ' ' GLU . 25.5 ttmt -59.37 -41.38 89.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.63 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 38.4 t -54.82 -36.47 65.03 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.527 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 127.01 -121.31 3.89 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 119.86 -1.162 . . . . 0.0 113.859 178.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -98.57 8.97 44.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.24 0.543 . . . . 0.0 110.893 -179.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 16.5 pttp -161.72 174.83 12.69 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.006 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.2 p -169.21 146.14 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.67 93.8 8.68 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.282 -0.872 . . . . 0.0 111.007 179.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.553 HG21 ' O ' ' A' ' 8' ' ' ILE . 9.3 tt -87.39 111.39 21.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 121.122 0.486 . . . . 0.0 110.659 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -89.43 106.9 18.76 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.716 0.293 . . . . 0.0 110.67 -179.291 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.618 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 81.5 p -104.51 169.13 8.65 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.839 179.396 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' THR . . . . . 0.412 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 8.6 t -100.01 107.24 45.89 Favored Pre-proline 0 CA--C 1.537 0.448 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 -177.264 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -54.84 174.6 0.19 Allowed 'Trans proline' 0 C--N 1.352 0.715 0 C-N-CA 122.345 2.03 . . . . 0.0 113.012 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.48 167.72 8.36 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.17 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.326 -0.44 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.968 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.4 m . . . . . 0 C--O 1.233 0.191 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 91.1 mtp 60.23 78.34 0.28 Allowed 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.686 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.459 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.6 mpt_? -71.25 137.46 84.21 Favored Pre-proline 0 C--N 1.323 -0.581 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 179.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.459 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 2.9 Cg_endo -84.57 112.67 1.6 Allowed 'Trans proline' 0 N--CA 1.462 -0.334 0 C-N-CA 122.92 2.414 . . . . 0.0 112.813 -178.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.463 ' CB ' ' HB2' ' A' ' 88' ' ' ALA . 17.4 Cg_exo -68.48 125.83 13.36 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.227 1.951 . . . . 0.0 112.526 178.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.529 ' O ' HG21 ' A' ' 89' ' ' ILE . 5.9 mt -92.85 115.82 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.5 mm -79.23 104.26 7.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 CA-C-N 116.191 -0.458 . . . . 0.0 112.208 -178.118 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.513 HD13 ' HB3' ' A' ' 17' ' ' TYR . 5.5 mt -80.14 160.73 4.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 176.341 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 39.8 t-80 -141.75 114.31 8.37 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 53.2 ttt180 -63.44 98.14 0.16 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.773 -179.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.89 55.77 2.17 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.357 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.28 7.56 77.96 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.826 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.478 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 10.9 ptpt -132.47 -87.73 0.45 Allowed 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.855 -0.203 . . . . 0.0 111.272 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.478 ' H ' ' HG3' ' A' ' 15' ' ' LYS . 32.1 pttt -155.5 -172.62 4.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.454 0.169 . . . . 0.0 110.717 -178.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . 0.635 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 21.0 m-85 -88.17 2.12 52.85 Favored 'General case' 0 CA--C 1.519 -0.236 0 CA-C-O 121.062 0.458 . . . . 0.0 109.925 179.443 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.55 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 52.2 49.79 48.86 Favored Glycine 0 C--O 1.219 -0.821 0 N-CA-C 116.728 1.451 . . . . 0.0 116.728 176.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.427 ' HB3' HG21 ' A' ' 43' ' ' VAL . 8.1 p90 -164.21 148.86 10.0 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-O 122.345 1.069 . . . . 0.0 112.477 176.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 42.3 m -94.63 113.99 25.88 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 113.722 -1.581 . . . . 0.0 112.806 -179.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -88.1 82.85 7.07 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.939 0.4 . . . . 0.0 109.941 178.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.516 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 3.6 tpt180 . . . . . 0 C--N 1.323 -0.555 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.727 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 t . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 -113.5 -179.06 3.53 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.28 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.497 ' O ' HD11 ' A' ' 59' ' ' LEU . 94.4 m-70 -149.66 153.57 37.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' MET . . . . . 0.451 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 27.2 mtm -148.57 145.5 27.85 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -178.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.483 HG11 ' CD2' ' A' ' 54' ' ' LEU . 3.4 p -73.25 103.32 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 CA-C-O 122.006 0.908 . . . . 0.0 109.793 179.274 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.516 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.6 t-105 -70.65 -40.37 73.07 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.468 -1.242 . . . . 0.0 111.499 -178.682 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' HIS . . . . . 0.486 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 1.9 t60 -156.64 132.09 9.35 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.952 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.55 HG21 ' O ' ' A' ' 18' ' ' GLY . 5.1 p -127.96 125.48 64.81 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.012 0 CA-C-O 121.919 0.866 . . . . 0.0 110.348 178.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.479 ' O ' ' HB2' ' A' ' 50' ' ' SER . 28.3 mt-10 -65.24 114.09 4.47 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 114.284 -1.325 . . . . 0.0 112.117 -178.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.539 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 10.6 p-10 -83.65 46.07 1.12 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.646 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -119.44 -2.77 13.16 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.399 -0.905 . . . . 0.0 113.595 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.4 ' CA ' ' HG3' ' A' ' 51' ' ' GLU . . . 163.63 -59.09 0.27 Allowed Glycine 0 CA--C 1.521 0.411 0 C-N-CA 119.119 -1.515 . . . . 0.0 114.884 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -59.24 -130.98 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 0.98 0 C-N-CA 123.463 2.776 . . . . 0.0 116.593 -178.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.635 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -43.69 -40.81 4.43 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 114.382 1.253 . . . . 0.0 114.382 -176.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.539 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -60.03 -59.99 4.55 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -178.312 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.4 ' HG3' ' CA ' ' A' ' 47' ' ' GLY . 5.5 mt-10 -63.37 -28.62 70.12 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.064 0.459 . . . . 0.0 110.713 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.13 -29.99 70.72 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.947 178.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 135.69 -9.28 4.28 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.767 179.444 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.483 ' CD2' HG11 ' A' ' 40' ' ' VAL . 0.9 OUTLIER -68.34 117.76 10.54 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.374 0.607 . . . . 0.0 111.42 -179.615 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.432 ' N ' HD23 ' A' ' 54' ' ' LEU . 0.1 OUTLIER -92.85 121.24 34.03 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.726 178.419 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.486 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 37.1 tt0 -50.13 135.09 21.47 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.15 59.5 1.75 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.569 -0.824 . . . . 0.0 111.231 -178.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.425 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 3.4 t0 -142.81 147.58 35.71 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.497 HD11 ' O ' ' A' ' 38' ' ' HIS . 10.9 tp -92.95 131.28 38.09 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.408 -179.541 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.6 mp -89.13 125.35 42.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.9 p -101.87 -40.02 7.11 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.259 0.552 . . . . 0.0 110.799 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -139.76 158.44 44.09 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.591 -179.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.6 p -141.62 110.4 2.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-O 121.11 0.481 . . . . 0.0 109.981 178.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.9 t30 59.49 33.91 22.37 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.093 179.399 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.0 42.26 25.27 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.17 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.491 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 5.6 tp10 -151.37 106.67 2.95 Favored Pre-proline 0 N--CA 1.434 -1.234 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.491 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.2 Cg_endo -50.4 129.1 25.09 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.557 2.838 . . . . 0.0 110.962 178.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 20.2 m -85.85 -13.31 11.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.258 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.0 m170 -56.6 96.98 0.02 OUTLIER 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 112.732 -2.031 . . . . 0.0 110.835 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.94 -12.88 26.93 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.405 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 21.7 mt -76.1 141.61 41.93 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -75.46 165.65 3.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.54 ' O ' HG21 ' A' ' 76' ' ' VAL . 83.2 t60 -42.97 -55.19 3.87 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-O 121.765 0.793 . . . . 0.0 112.82 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.0 p -74.53 -16.96 60.81 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 114.93 -1.032 . . . . 0.0 113.04 -176.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -70.57 -42.03 71.64 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 120.95 -0.3 . . . . 0.0 111.121 -179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.54 HG21 ' O ' ' A' ' 73' ' ' HIS . 15.6 m -65.59 -46.44 89.54 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.46 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 60.9 t -53.05 -48.59 52.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.632 176.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -63.47 -44.44 94.45 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.847 179.266 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.38 -42.01 66.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.269 0.557 . . . . 0.0 109.933 178.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 22.7 mt -67.35 -48.83 76.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.621 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.46 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 50.2 mt -60.84 -39.4 88.94 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-O 121.032 0.444 . . . . 0.0 110.657 178.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 23.1 ttmt -60.35 -40.5 90.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.142 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 41.4 t -54.22 -31.79 54.16 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.714 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 129.52 -127.81 5.56 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.672 179.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -99.1 10.53 41.27 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.432 0.634 . . . . 0.0 110.413 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 17.3 pttp -161.99 172.51 15.85 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.862 179.2 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.5 p -168.03 149.82 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -178.326 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.463 ' HB2' ' CB ' ' A' ' 7' ' ' PRO . . . -93.37 97.66 10.72 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.309 178.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.529 HG21 ' O ' ' A' ' 8' ' ' ILE . 10.2 tt -89.62 112.91 25.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 120.884 0.373 . . . . 0.0 110.862 179.392 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.9 OUTLIER -88.67 105.02 17.4 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.729 0.3 . . . . 0.0 111.296 -179.008 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.484 ' O ' ' HD3' ' A' ' 93' ' ' PRO . 42.3 p -102.36 163.2 12.37 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' THR . . . . . 0.43 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 1.6 t -98.65 104.92 27.18 Favored Pre-proline 0 C--N 1.326 -0.439 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' A' ' 91' ' ' THR . 73.2 Cg_exo -53.73 176.06 0.1 Allowed 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.503 2.135 . . . . 0.0 113.036 178.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -64.26 166.12 8.48 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.319 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.321 -0.657 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.899 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.452 -0.354 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 37.8 mtp 55.85 78.93 0.18 Allowed 'General case' 0 C--O 1.235 0.336 0 O-C-N 123.58 0.55 . . . . 0.0 111.471 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.423 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.0 mpt_? -70.92 137.47 85.07 Favored Pre-proline 0 C--N 1.325 -0.464 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.0 OUTLIER -86.93 111.08 0.87 Allowed 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.795 2.33 . . . . 0.0 112.899 -178.284 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.523 ' CB ' ' HB3' ' A' ' 88' ' ' ALA . 15.5 Cg_exo -69.12 119.87 6.8 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 121.935 1.756 . . . . 0.0 112.15 178.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.637 ' O ' HG21 ' A' ' 89' ' ' ILE . 7.0 mt -87.85 110.94 21.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-N 115.07 -0.968 . . . . 0.0 108.967 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.2 mm -76.77 101.45 2.93 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.825 -0.625 . . . . 0.0 112.045 -178.045 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.518 HG12 ' HA ' ' A' ' 49' ' ' ALA . 5.2 mt -78.92 159.27 4.64 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.368 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 176.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 15.1 t-80 -135.44 109.98 8.54 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 178.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.1 ttt180 -64.64 100.71 0.4 Allowed 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.419 -0.81 . . . . 0.0 111.05 -179.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.95 55.68 1.81 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.275 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.7 -45.31 3.38 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.479 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.2 ptpt -79.23 -85.79 0.08 Allowed 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 23.7 pttt -157.29 -174.09 4.73 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.52 0.193 . . . . 0.0 111.52 -178.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . 0.634 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 21.4 m-85 -85.49 2.42 44.74 Favored 'General case' 0 CA--C 1.518 -0.25 0 CA-C-O 121.103 0.478 . . . . 0.0 109.757 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.551 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 51.04 53.54 26.6 Favored Glycine 0 C--O 1.215 -1.044 0 N-CA-C 116.124 1.21 . . . . 0.0 116.124 177.328 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.461 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 12.4 p90 -163.94 149.03 10.54 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 122.744 1.259 . . . . 0.0 112.965 176.156 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.5 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 40.5 m -95.16 117.48 30.29 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 112.904 -1.953 . . . . 0.0 113.109 -178.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -94.45 80.78 3.91 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 178.286 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.486 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 1.6 tpt180 . . . . . 0 C--N 1.327 -0.376 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.995 -179.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.6 t . . . . . 0 N--CA 1.45 -0.46 0 CA-C-O 120.907 0.384 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 89.2 m-70 -125.43 -177.73 3.99 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.464 179.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.541 ' CD2' HG13 ' A' ' 76' ' ' VAL . 98.0 m-70 -147.71 154.7 40.9 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -179.269 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 35.4 mtm -149.13 146.56 27.74 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -178.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.541 HG12 ' CD2' ' A' ' 54' ' ' LEU . 2.6 p -74.0 101.75 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.976 0.893 . . . . 0.0 109.774 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.486 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 2.9 t-105 -70.39 -39.21 74.67 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.37 -178.598 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' HIS . . . . . 0.45 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -156.53 129.57 7.92 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.975 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.551 HG21 ' O ' ' A' ' 18' ' ' GLY . 3.8 p -124.28 127.06 73.02 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.555 0.693 . . . . 0.0 110.248 179.06 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -66.64 113.23 4.64 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 114.507 -1.224 . . . . 0.0 112.043 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.552 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 10.4 p-10 -81.5 40.2 0.57 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.918 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -108.15 -8.75 28.93 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.376 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.55 -49.91 0.37 Allowed Glycine 0 CA--C 1.526 0.761 0 C-N-CA 119.491 -1.338 . . . . 0.0 114.867 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -60.11 -128.98 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.09 0 C-N-CA 123.094 2.529 . . . . 0.0 116.233 -179.223 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.634 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -45.12 -39.97 6.49 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 114.195 1.183 . . . . 0.0 114.195 -177.113 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.552 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 5.5 m -57.34 -62.86 1.47 Allowed 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -179.158 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -63.25 -23.15 67.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.295 -179.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.66 -26.16 66.07 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.256 178.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 130.21 -8.36 5.99 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.677 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.557 HD21 ' N ' ' A' ' 55' ' ' ARG . 1.1 tt -70.0 117.99 12.28 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-O 121.435 0.636 . . . . 0.0 111.324 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.557 ' N ' HD21 ' A' ' 54' ' ' LEU . 0.0 OUTLIER -96.45 121.52 38.35 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.941 178.357 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.42 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 46.3 tt0 -50.45 141.14 12.59 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.771 0.319 . . . . 0.0 111.51 178.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.24 6.0 63.31 Favored Glycine 0 C--N 1.333 0.415 0 C-N-CA 121.239 -0.505 . . . . 0.0 113.231 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.533 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 2.0 t0 -89.9 155.71 18.95 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.032 0.444 . . . . 0.0 111.036 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.483 HD11 ' O ' ' A' ' 38' ' ' HIS . 2.5 tp -100.14 133.97 43.75 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.7 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.5 mp -91.26 122.74 42.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 26.2 p -99.7 -40.61 7.68 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.401 0.619 . . . . 0.0 110.361 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 72.7 m80 -138.28 157.21 46.71 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.761 -178.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.57 111.51 5.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.965 -0.562 . . . . 0.0 109.889 178.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 60.39 30.04 19.49 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.811 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.46 44.29 17.14 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.182 -179.036 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.466 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.1 tp10 -149.99 106.26 3.21 Favored Pre-proline 0 N--CA 1.437 -1.084 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 -179.066 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.466 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 4.4 Cg_endo -49.62 129.32 23.22 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.66 2.907 . . . . 0.0 111.124 178.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 22.3 m -86.82 -7.96 10.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 114.594 -1.185 . . . . 0.0 109.039 -178.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 22.1 m170 -55.17 101.01 0.04 OUTLIER 'General case' 0 N--CA 1.426 -1.629 0 CA-C-N 112.741 -2.027 . . . . 0.0 111.676 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.68 -6.77 49.07 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.842 179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 26.3 mt -78.29 141.41 38.53 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.669 0.271 . . . . 0.0 110.469 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.435 HG12 ' HG3' ' A' ' 75' ' ' GLU . 2.0 p -78.58 169.82 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 177.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.599 ' O ' HG21 ' A' ' 76' ' ' VAL . 8.6 t60 -48.19 -53.62 16.28 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.682 0.753 . . . . 0.0 112.352 -179.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 16.7 p -69.44 -22.66 63.64 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.192 -0.913 . . . . 0.0 112.456 -177.247 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.435 ' HG3' HG12 ' A' ' 72' ' ' VAL . 24.4 mt-10 -69.06 -43.28 74.94 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 121.224 -0.191 . . . . 0.0 111.476 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.599 HG21 ' O ' ' A' ' 73' ' ' HIS . 10.0 m -66.24 -44.61 91.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.726 178.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.489 HG21 ' O ' ' A' ' 73' ' ' HIS . 54.0 t -56.57 -47.26 82.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.929 177.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -62.78 -43.46 98.73 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.55 178.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.38 -40.75 65.26 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.339 0.59 . . . . 0.0 109.915 178.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 28.1 mt -68.84 -51.58 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.889 179.478 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 64.1 mt -59.88 -36.03 76.08 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.1 0.476 . . . . 0.0 110.644 179.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -57.91 -39.15 77.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.231 -0.895 . . . . 0.0 111.58 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 34.0 t -56.21 -44.87 79.91 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.244 179.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 136.29 -116.61 1.48 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.323 -0.941 . . . . 0.0 113.71 178.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -102.85 9.1 39.1 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.475 0.655 . . . . 0.0 110.506 -178.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 10.1 pttp -161.36 173.53 14.82 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.499 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.4 p -167.76 145.13 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -179.583 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.523 ' HB3' ' CB ' ' A' ' 7' ' ' PRO . . . -91.15 96.22 10.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.37 178.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.637 HG21 ' O ' ' A' ' 8' ' ' ILE . 11.1 tt -88.72 111.08 22.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.196 0.522 . . . . 0.0 110.831 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.93 106.0 17.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.982 -179.089 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.533 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 64.6 p -102.33 170.86 7.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.21 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' THR . . . . . 0.421 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 4.9 t -104.85 99.95 21.41 Favored Pre-proline 0 CA--C 1.534 0.358 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -178.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 74.6 Cg_exo -51.73 167.63 0.41 Allowed 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.487 2.125 . . . . 0.0 113.204 178.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -63.75 158.71 21.01 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.953 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.327 -0.392 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.529 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 53.2 m . . . . . 0 N--CA 1.453 -0.288 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 9.0 mtp 60.65 77.53 0.32 Allowed 'General case' 0 C--O 1.233 0.185 0 O-C-N 123.476 0.485 . . . . 0.0 111.619 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.422 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.0 mpt_? -73.26 136.86 78.6 Favored Pre-proline 0 C--N 1.326 -0.421 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 179.198 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.5 Cg_endo -89.22 110.02 0.48 Allowed 'Trans proline' 0 C--O 1.235 0.326 0 C-N-CA 123.196 2.597 . . . . 0.0 113.021 -179.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.481 ' CB ' ' HB2' ' A' ' 88' ' ' ALA . 16.9 Cg_exo -69.78 122.52 9.19 Favored 'Trans proline' 0 CA--C 1.515 -0.453 0 C-N-CA 122.327 2.018 . . . . 0.0 113.112 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.503 ' O ' HG21 ' A' ' 89' ' ' ILE . 0.9 OUTLIER -87.42 112.0 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.258 0 CA-C-N 115.129 -0.941 . . . . 0.0 108.778 178.317 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.403 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 3.2 mm -77.5 101.42 3.37 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.336 -178.721 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.48 HD13 ' HB3' ' A' ' 17' ' ' TYR . 5.4 mt -77.81 162.65 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 N-CA-C 106.904 -1.517 . . . . 0.0 106.904 176.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 15.0 t-80 -140.79 113.15 7.97 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.212 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 47.2 ttt180 -63.39 101.7 0.34 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.995 -178.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.12 49.95 1.0 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.45 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.12 12.7 81.5 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 121.199 -0.524 . . . . 0.0 113.1 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 3.8 ptpt -136.51 -82.59 0.38 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.849 0.325 . . . . 0.0 111.12 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 8.6 pttt -156.16 -179.59 8.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.421 -178.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . 0.613 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 19.3 m-85 -86.58 5.34 36.14 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-O 121.245 0.545 . . . . 0.0 110.191 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.599 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 54.46 49.22 61.49 Favored Glycine 0 C--O 1.215 -1.069 0 N-CA-C 116.697 1.439 . . . . 0.0 116.697 176.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.469 ' HA ' ' O ' ' A' ' 42' ' ' HIS . 9.3 p90 -165.6 149.23 8.07 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-O 122.345 1.069 . . . . 0.0 113.068 176.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.423 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 94.8 m -95.25 118.37 31.91 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 113.643 -1.617 . . . . 0.0 112.724 -179.161 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -89.91 84.86 6.24 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.802 0.334 . . . . 0.0 110.248 178.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.543 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 5.1 tpt180 . . . . . 0 C--N 1.328 -0.352 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.222 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 6.2 t . . . . . 0 C--O 1.234 0.28 0 CA-C-O 120.676 0.274 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -117.82 177.97 4.58 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.469 ' CD2' HG13 ' A' ' 76' ' ' VAL . 98.7 m-70 -148.15 153.35 38.71 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 -179.509 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.0 mtm -147.24 145.25 29.38 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.083 -178.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.531 HG13 ' CD2' ' A' ' 54' ' ' LEU . 3.4 p -73.33 102.52 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.71 0 CA-C-O 121.946 0.879 . . . . 0.0 109.576 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.543 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 2.5 t-105 -70.48 -39.36 74.26 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.699 -1.137 . . . . 0.0 111.89 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' HIS . . . . . 0.469 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 4.3 t60 -155.23 124.5 6.3 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.368 -178.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.599 HG21 ' O ' ' A' ' 18' ' ' GLY . 4.2 p -122.04 124.92 72.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-O 121.575 0.702 . . . . 0.0 109.975 179.258 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.489 ' OE1' ' HA2' ' A' ' 18' ' ' GLY . 49.3 mt-10 -66.99 120.12 13.11 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 114.396 -1.275 . . . . 0.0 111.307 -179.391 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.547 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 14.7 p-10 -85.84 24.8 1.2 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.84 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -82.98 -23.4 55.54 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.959 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.454 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 170.92 -51.78 0.19 Allowed Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 119.568 -1.301 . . . . 0.0 114.745 -179.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -55.33 -128.45 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.085 0 C-N-CA 123.505 2.803 . . . . 0.0 116.92 -178.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.613 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -45.23 -40.01 6.97 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 -176.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.547 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -60.5 -61.08 2.85 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -177.956 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.454 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 5.5 mm-40 -61.01 -32.49 72.08 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.372 0.606 . . . . 0.0 110.781 -178.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -60.34 -29.84 69.14 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.677 179.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 136.8 -11.84 3.95 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.511 -0.852 . . . . 0.0 113.092 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.531 ' CD2' HG13 ' A' ' 40' ' ' VAL . 0.8 OUTLIER -68.08 116.04 8.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.406 0.622 . . . . 0.0 111.074 -179.642 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.423 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -93.77 125.56 38.45 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.026 178.975 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -51.42 140.18 18.14 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.876 0.37 . . . . 0.0 111.036 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.71 10.09 67.72 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.95 -0.643 . . . . 0.0 113.161 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.557 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 5.3 t0 -88.5 148.91 23.91 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.0 0.429 . . . . 0.0 110.659 179.59 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.43 HD11 ' O ' ' A' ' 38' ' ' HIS . 10.1 tp -95.91 130.03 42.99 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.726 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.4 HD12 ' N ' ' A' ' 60' ' ' ILE . 3.6 mp -88.15 126.14 41.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.127 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 41.9 p -102.8 -38.62 7.35 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.646 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -141.23 159.49 42.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.922 -178.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.3 p -140.65 111.14 3.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.125 0.488 . . . . 0.0 110.208 178.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.8 t30 60.76 26.34 16.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.372 179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.18 44.41 7.57 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.935 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.485 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.5 tp10 -153.19 110.5 2.64 Favored Pre-proline 0 N--CA 1.433 -1.312 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.519 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.485 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 3.7 Cg_endo -49.99 131.88 31.24 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 123.725 2.95 . . . . 0.0 111.407 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.5 m -88.23 -8.61 10.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.289 -178.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -56.75 94.85 0.01 OUTLIER 'General case' 0 N--CA 1.429 -1.51 0 CA-C-N 112.95 -1.932 . . . . 0.0 111.566 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 112.47 -11.82 25.91 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.435 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 29.7 mt -74.87 138.82 42.72 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 179.527 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -77.79 167.19 2.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.434 ' O ' HG21 ' A' ' 76' ' ' VAL . 48.2 t60 -44.75 -46.42 10.46 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.779 0.8 . . . . 0.0 112.939 -179.314 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 19.3 p -80.51 -21.06 42.27 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.274 -0.875 . . . . 0.0 112.755 -176.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -70.23 -40.31 74.56 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 121.319 -0.153 . . . . 0.0 111.354 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.469 HG13 ' CD2' ' A' ' 38' ' ' HIS . 4.5 m -65.45 -45.76 91.97 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.183 0 C-N-CA 120.251 -0.58 . . . . 0.0 109.597 178.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 99.5 t -55.24 -47.02 78.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.187 -0.915 . . . . 0.0 109.926 177.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -64.81 -43.97 91.41 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.607 179.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.48 -42.08 66.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.768 178.346 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 16.2 mt -67.81 -52.15 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.719 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 93.1 mt -59.95 -32.78 71.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.017 179.312 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 8.3 ttmm -61.55 -38.91 89.19 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.352 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 36.2 t -56.0 -52.99 62.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.961 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 137.73 -134.43 6.96 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 119.96 -1.114 . . . . 0.0 113.132 179.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -73.67 -2.01 21.37 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.853 0.358 . . . . 0.0 111.799 -179.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -159.93 175.26 13.26 Favored 'General case' 0 N--CA 1.444 -0.773 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.503 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 13.4 p -166.84 147.1 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 O-C-N 123.596 0.56 . . . . 0.0 112.465 -179.062 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.481 ' HB2' ' CB ' ' A' ' 7' ' ' PRO . . . -93.51 96.76 10.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.642 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.503 HG21 ' O ' ' A' ' 8' ' ' ILE . 6.9 tt -88.8 111.57 22.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 120.973 0.416 . . . . 0.0 110.255 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -89.11 112.25 23.19 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.825 0.345 . . . . 0.0 111.074 -178.908 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.557 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 61.3 p -109.76 171.73 7.27 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.306 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.9 t -104.21 105.48 49.34 Favored Pre-proline 0 CA--C 1.537 0.464 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -55.73 175.24 0.22 Allowed 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.622 2.215 . . . . 0.0 113.403 178.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -63.71 159.95 18.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.287 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.347 0 CA-C-O 121.073 0.463 . . . . 0.0 110.677 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.0 m . . . . . 0 N--CA 1.453 -0.276 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 28.6 mtp 57.06 74.05 0.43 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.008 0.432 . . . . 0.0 111.3 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.455 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.6 mpt_? -73.31 135.53 79.23 Favored Pre-proline 0 C--N 1.32 -0.692 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.9 Cg_endo -87.31 116.88 1.22 Allowed 'Trans proline' 0 N--CA 1.462 -0.371 0 C-N-CA 123.3 2.666 . . . . 0.0 112.842 -178.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.458 ' CB ' ' HB2' ' A' ' 88' ' ' ALA . 7.5 Cg_exo -75.12 122.08 6.93 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.078 1.852 . . . . 0.0 112.843 178.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.558 ' O ' HG21 ' A' ' 89' ' ' ILE . 2.3 mt -86.71 112.41 22.91 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.356 178.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.8 mm -79.06 99.74 3.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.218 -0.446 . . . . 0.0 112.049 -178.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.514 HG21 ' HB3' ' A' ' 17' ' ' TYR . 4.3 mt -77.64 160.47 4.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 177.059 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 24.8 t-80 -138.17 111.59 8.06 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.01 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 30.8 ttt180 -62.89 103.71 0.47 Allowed 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.838 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.77 47.7 0.76 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.482 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.17 -4.86 65.04 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.287 -0.482 . . . . 0.0 113.344 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.422 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 9.8 ptpt -120.61 -80.12 0.62 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.996 0.398 . . . . 0.0 111.44 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.422 ' H ' ' HG3' ' A' ' 15' ' ' LYS . 20.5 pttt -155.76 -174.96 5.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.64 0.257 . . . . 0.0 110.558 -178.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . 0.63 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 18.4 m-85 -89.71 5.65 44.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.254 0.55 . . . . 0.0 109.661 179.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.536 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 54.26 48.31 64.49 Favored Glycine 0 C--O 1.219 -0.842 0 N-CA-C 116.423 1.329 . . . . 0.0 116.423 176.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 42' ' ' HIS . 10.4 p90 -164.09 146.56 9.2 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-O 122.627 1.203 . . . . 0.0 112.836 176.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 91.8 m -93.64 114.83 27.24 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 113.46 -1.7 . . . . 0.0 112.51 -178.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -91.14 82.47 5.53 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-O 120.577 0.227 . . . . 0.0 111.218 179.119 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 1.3 tpt180 . . . . . 0 C--N 1.326 -0.431 0 CA-C-N 116.761 -0.2 . . . . 0.0 111.185 179.279 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t . . . . . 0 N--CA 1.453 -0.277 0 CA-C-O 120.586 0.231 . . . . 0.0 110.605 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.6 m-70 -112.86 179.65 3.91 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.18 -0.463 . . . . 0.0 109.953 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.495 ' O ' HD11 ' A' ' 59' ' ' LEU . 99.1 m-70 -148.92 152.43 36.38 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 41.0 mtm -148.07 146.15 28.73 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.482 HG11 ' CD2' ' A' ' 54' ' ' LEU . 2.7 p -72.28 102.89 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.989 0.9 . . . . 0.0 109.342 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 2.1 t-105 -68.86 -39.92 79.61 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.442 -178.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' HIS . . . . . 0.488 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 2.0 t60 -158.34 128.46 6.02 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.67 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.536 HG21 ' O ' ' A' ' 18' ' ' GLY . 4.3 p -124.66 126.06 71.01 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-O 121.642 0.734 . . . . 0.0 110.422 179.426 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.501 ' O ' ' HB2' ' A' ' 50' ' ' SER . 5.7 mt-10 -68.69 123.06 19.85 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.279 -1.328 . . . . 0.0 111.914 -179.103 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.492 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 12.2 p-10 -86.11 20.3 2.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.925 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.36 -19.63 66.17 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 116.006 -0.543 . . . . 0.0 113.666 -179.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 168.18 -49.77 0.23 Allowed Glycine 0 CA--C 1.522 0.486 0 C-N-CA 119.134 -1.508 . . . . 0.0 114.733 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -60.33 -132.48 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.967 0 C-N-CA 123.117 2.544 . . . . 0.0 116.318 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.63 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -39.79 -41.63 1.15 Allowed 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 -176.703 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.501 ' HB2' ' O ' ' A' ' 44' ' ' GLU . 0.4 OUTLIER -63.07 -59.5 4.7 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 118.385 0.538 . . . . 0.0 112.227 -178.098 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -63.62 -21.93 66.63 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.272 0.558 . . . . 0.0 110.847 -179.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.2 -26.15 61.94 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.463 178.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 135.09 -12.95 4.41 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.204 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.482 ' CD2' HG11 ' A' ' 40' ' ' VAL . 1.2 tt -69.54 115.24 8.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.312 0.577 . . . . 0.0 111.646 -179.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.433 ' N ' HD23 ' A' ' 54' ' ' LEU . 0.0 OUTLIER -93.86 123.53 37.27 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.666 178.035 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.488 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 34.4 tt0 -49.36 143.77 6.13 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.945 0.402 . . . . 0.0 111.893 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.6 5.66 74.54 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.951 -0.643 . . . . 0.0 112.737 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.487 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 6.3 t0 -86.61 144.07 27.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.854 0.359 . . . . 0.0 110.693 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.495 HD11 ' O ' ' A' ' 38' ' ' HIS . 4.0 tp -92.17 134.12 35.16 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.509 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.4 mp -91.45 125.23 44.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.042 -179.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 45.8 p -101.66 -37.56 8.3 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.386 0.612 . . . . 0.0 110.886 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 69.5 m80 -141.73 157.68 44.75 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.148 -178.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.2 p -144.29 122.07 5.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 56.78 27.06 12.23 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.611 -179.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.28 43.25 26.04 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.917 -0.659 . . . . 0.0 111.596 -178.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.418 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.8 tp10 -150.42 104.4 3.11 Favored Pre-proline 0 N--CA 1.433 -1.319 0 C-N-CA 122.949 0.5 . . . . 0.0 109.732 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 47.3 Cg_exo -41.48 128.41 3.42 Favored 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 124.114 3.21 . . . . 0.0 111.512 177.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 32.7 m -86.25 -11.32 11.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 114.675 -1.148 . . . . 0.0 109.321 -178.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -54.6 97.09 0.02 OUTLIER 'General case' 0 N--CA 1.424 -1.728 0 CA-C-N 112.697 -2.047 . . . . 0.0 111.667 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.03 -13.86 23.97 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.828 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 41.2 mt -74.54 145.13 43.69 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.693 0.246 . . . . 0.0 110.349 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -79.2 168.95 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 179.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -45.79 -50.19 14.28 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 121.45 0.643 . . . . 0.0 112.628 -179.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 18.0 p -81.64 -14.54 56.56 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.84 -177.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -69.81 -42.6 73.48 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 121.25 -0.18 . . . . 0.0 111.286 -179.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 4.3 m -65.1 -44.56 95.63 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 CA-C-O 121.369 0.604 . . . . 0.0 109.43 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.42 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 83.5 t -53.14 -49.5 50.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 114.829 -1.078 . . . . 0.0 110.043 177.315 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -59.84 -45.33 92.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.005 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -54.16 -40.78 67.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.347 0.594 . . . . 0.0 110.216 178.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 14.5 mt -73.17 -49.75 36.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.091 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.42 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 91.1 mt -57.83 -41.67 82.75 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.837 0.351 . . . . 0.0 111.069 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 18.8 ttmt -60.58 -37.85 82.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.703 -0.68 . . . . 0.0 112.026 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 8.1 t -51.41 -45.81 62.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.456 -179.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.71 -132.49 7.95 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 119.879 -1.153 . . . . 0.0 114.023 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -73.14 -6.66 47.19 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 111.948 0.351 . . . . 0.0 111.948 -178.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.1 pttp -160.17 175.1 13.3 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-O 120.618 0.247 . . . . 0.0 110.985 -179.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.4 p -167.42 146.19 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.737 -0.665 . . . . 0.0 112.516 -179.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.458 ' HB2' ' CB ' ' A' ' 7' ' ' PRO . . . -92.87 98.57 11.46 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.886 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.558 HG21 ' O ' ' A' ' 8' ' ' ILE . 8.6 tt -92.62 113.32 27.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 120.81 0.338 . . . . 0.0 110.352 178.606 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.42 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -92.03 112.77 24.83 Favored 'General case' 0 C--N 1.323 -0.559 0 O-C-N 122.189 -0.32 . . . . 0.0 111.106 -179.052 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.487 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 77.6 p -108.41 175.68 5.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.525 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 4.1 t -104.04 102.14 30.12 Favored Pre-proline 0 CA--C 1.535 0.403 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -177.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -53.99 170.9 0.41 Allowed 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 122.403 2.068 . . . . 0.0 112.913 177.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -63.66 157.86 22.91 Favored 'General case' 0 C--N 1.319 -0.717 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.57 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.465 0 CA-C-O 120.943 0.402 . . . . 0.0 111.311 -179.202 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.45 -0.441 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 39.2 ttp 55.24 70.48 0.62 Allowed 'General case' 0 C--N 1.331 -0.223 0 O-C-N 123.514 0.508 . . . . 0.0 110.915 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.419 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.1 mpt_? -70.73 132.47 87.07 Favored Pre-proline 0 C--N 1.323 -0.558 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -87.28 109.58 0.74 Allowed 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.884 2.39 . . . . 0.0 113.15 -178.396 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 15.0 Cg_exo -69.16 124.22 11.11 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.183 1.922 . . . . 0.0 112.34 178.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.443 HD11 ' HA ' ' A' ' 54' ' ' LEU . 2.6 mt -88.49 109.43 19.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.166 -0.924 . . . . 0.0 108.784 178.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.42 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 4.2 mm -76.1 99.97 2.07 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.586 -178.519 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.506 HG21 ' HB3' ' A' ' 17' ' ' TYR . 4.8 mt -76.67 159.85 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 14.7 t-80 -137.98 109.67 7.08 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.358 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 47.2 ttt180 -63.58 104.32 0.64 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.59 -179.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.4 50.07 1.06 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.539 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.05 -37.86 2.85 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.289 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.5 ptpt -84.09 -86.63 0.12 Allowed 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.5 pttp -154.89 -174.4 4.97 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 121.116 -0.234 . . . . 0.0 111.374 -178.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . 0.686 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 19.8 m-85 -87.98 1.63 53.68 Favored 'General case' 0 C--O 1.224 -0.238 0 CA-C-O 121.019 0.438 . . . . 0.0 109.858 179.119 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.541 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 52.38 53.37 31.99 Favored Glycine 0 C--O 1.22 -0.766 0 N-CA-C 116.738 1.455 . . . . 0.0 116.738 176.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.49 ' HB3' HG21 ' A' ' 43' ' ' VAL . 9.3 p90 -165.49 144.88 6.51 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 122.409 1.099 . . . . 0.0 113.018 175.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . 0.434 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 92.2 m -91.27 116.08 28.54 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 113.434 -1.712 . . . . 0.0 112.921 -178.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -90.34 82.15 5.98 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 121.063 0.459 . . . . 0.0 110.133 178.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.51 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 4.5 tpt180 . . . . . 0 C--N 1.325 -0.492 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.379 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.9 t . . . . . 0 N--CA 1.45 -0.456 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -110.06 -173.88 2.36 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.816 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.481 ' O ' HD11 ' A' ' 59' ' ' LEU . 95.2 m-70 -149.7 166.29 29.82 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 48.4 ttm -153.19 138.17 17.22 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.515 HG11 ' CD2' ' A' ' 54' ' ' LEU . 2.6 p -71.6 102.52 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 CA-C-O 122.007 0.908 . . . . 0.0 108.871 178.848 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.51 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.1 t-105 -69.75 -41.16 75.59 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.814 -177.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' HIS . . . . . 0.46 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -154.59 128.09 8.55 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.076 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.541 HG21 ' O ' ' A' ' 18' ' ' GLY . 5.8 p -125.47 124.77 67.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 CA-C-O 121.834 0.826 . . . . 0.0 110.534 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.583 ' O ' ' HB2' ' A' ' 50' ' ' SER . 32.5 mt-10 -68.63 118.38 11.56 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 114.171 -1.377 . . . . 0.0 112.41 -178.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.601 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 14.7 p-10 -87.47 32.66 0.7 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.772 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -92.21 -22.66 29.16 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.866 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . 0.518 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 174.85 -51.42 0.13 Allowed Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 119.534 -1.317 . . . . 0.0 114.281 -179.095 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -60.81 -131.13 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.401 2.734 . . . . 0.0 116.409 -179.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.686 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -42.12 -44.71 3.75 Favored 'General case' 0 N--CA 1.464 0.273 0 N-CA-C 114.644 1.35 . . . . 0.0 114.644 -176.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.601 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -62.12 -58.32 8.24 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -177.661 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.518 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 2.3 mm-40 -62.2 -24.68 67.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.213 0.53 . . . . 0.0 110.799 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -70.68 -24.58 62.7 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.267 178.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 136.31 -12.87 4.07 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.914 179.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.515 ' CD2' HG11 ' A' ' 40' ' ' VAL . 1.1 tt -69.29 116.29 9.55 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.623 0.725 . . . . 0.0 112.036 -179.201 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.494 ' N ' HD23 ' A' ' 54' ' ' LEU . 0.0 OUTLIER -97.86 125.71 42.88 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.587 177.883 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -50.87 141.76 12.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.894 0.378 . . . . 0.0 111.209 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 86.19 37.85 8.83 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.628 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.619 ' OD1' ' HB ' ' A' ' 91' ' ' THR . 1.9 t70 -120.52 142.73 49.04 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 179.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.481 HD11 ' O ' ' A' ' 38' ' ' HIS . 12.2 tp -89.72 128.1 36.05 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.89 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 4.0 mp -86.19 126.63 40.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.975 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 41.1 p -102.27 -41.27 6.42 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.871 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 59.3 m80 -138.94 160.24 40.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.176 -178.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.6 p -142.74 115.81 3.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.192 -0.458 . . . . 0.0 109.913 177.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 56.45 31.17 18.37 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.745 -0.662 . . . . 0.0 111.467 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.31 41.03 17.92 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.973 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.443 ' HA ' ' OE1' ' A' ' 66' ' ' GLU . 2.2 tp10 -152.15 108.48 2.82 Favored Pre-proline 0 N--CA 1.432 -1.373 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -48.48 134.61 26.48 Favored 'Trans proline' 0 N--CA 1.45 -1.061 0 C-N-CA 123.636 2.891 . . . . 0.0 111.066 178.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 32.9 m -87.57 -7.65 10.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-N 114.373 -1.285 . . . . 0.0 109.288 -178.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.9 m170 -55.59 96.12 0.02 OUTLIER 'General case' 0 N--CA 1.427 -1.591 0 CA-C-N 112.771 -2.013 . . . . 0.0 111.744 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.9 -12.56 27.1 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.291 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 31.1 mt -74.84 138.22 42.37 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.413 HG13 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -77.93 169.86 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.267 179.801 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -42.79 -48.9 5.76 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 123.76 0.824 . . . . 0.0 112.711 -179.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.1 p -84.52 -15.38 46.06 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.309 0.855 . . . . 0.0 113.309 -177.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . 0.413 ' HG3' HG13 ' A' ' 72' ' ' VAL . 18.7 mt-10 -69.56 -43.39 73.0 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 121.096 -0.242 . . . . 0.0 111.35 -179.176 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.41 HG12 ' CD2' ' A' ' 38' ' ' HIS . 3.8 m -64.4 -45.23 96.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.26 0.552 . . . . 0.0 109.632 179.185 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 79.4 t -54.48 -48.28 69.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.877 177.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -59.56 -49.53 77.4 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.825 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.13 -41.31 62.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.605 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 16.0 mt -68.75 -52.88 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.972 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 46.4 mt -59.05 -37.5 77.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.201 0.524 . . . . 0.0 111.088 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -61.71 -38.62 88.53 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.928 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 40.4 t -52.76 -47.29 67.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.283 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 136.57 -135.39 7.7 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.122 -1.037 . . . . 0.0 112.921 179.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -79.6 1.76 24.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.132 0.491 . . . . 0.0 111.374 -179.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 10.9 pttp -159.67 175.46 13.15 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.173 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.42 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 12.2 p -167.55 147.18 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 O-C-N 123.567 0.542 . . . . 0.0 112.342 -179.105 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.43 93.84 7.9 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.867 179.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.418 HG21 ' O ' ' A' ' 8' ' ' ILE . 7.3 tt -88.3 113.59 25.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-O 121.055 0.455 . . . . 0.0 110.474 179.078 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -90.58 110.83 21.97 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.945 0.402 . . . . 0.0 111.235 -179.005 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.619 ' HB ' ' OD1' ' A' ' 58' ' ' ASP . 26.1 p -103.77 169.54 8.46 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.217 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' THR . . . . . 0.425 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 8.6 t -107.25 104.59 52.92 Favored Pre-proline 0 CA--C 1.534 0.342 0 C-N-CA 120.444 -0.502 . . . . 0.0 112.191 -178.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_exo -53.09 172.24 0.2 Allowed 'Trans proline' 0 C--N 1.351 0.669 0 C-N-CA 122.311 2.007 . . . . 0.0 113.039 178.099 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -64.28 163.39 13.0 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.048 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.324 -0.529 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.4 -179.106 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.6 m . . . . . 0 C--O 1.234 0.273 0 N-CA-C 110.38 -0.229 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 93.4 mtp 61.23 75.75 0.4 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.148 0.499 . . . . 0.0 110.752 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.448 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.0 mpt_? -72.91 134.98 80.77 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.515 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.448 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 5.0 Cg_endo -92.24 116.02 0.37 Allowed 'Trans proline' 0 CA--C 1.531 0.355 0 C-N-CA 123.326 2.684 . . . . 0.0 113.408 -178.623 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.483 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 12.3 Cg_exo -73.88 124.22 9.02 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 122.439 2.093 . . . . 0.0 113.17 178.396 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.489 ' O ' HG22 ' A' ' 89' ' ' ILE . 1.1 mt -87.45 110.33 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.836 177.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.411 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 3.2 mm -78.16 97.91 2.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.569 -178.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.537 HG12 ' CB ' ' A' ' 49' ' ' ALA . 5.2 mt -77.35 162.08 4.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 177.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 53.0 t-80 -137.51 114.44 10.64 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 108.11 -1.071 . . . . 0.0 108.11 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 30.6 ttt180 -61.34 107.14 0.72 Allowed 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.675 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -80.68 50.68 1.37 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.432 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.34 23.54 74.97 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.638 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.516 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 9.8 ptpt -150.76 -80.6 0.11 Allowed 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.516 ' H ' ' HG3' ' A' ' 15' ' ' LYS . 21.7 pttm -158.42 178.25 10.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.377 0.132 . . . . 0.0 110.822 -178.705 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . 0.478 ' HB3' HG21 ' A' ' 10' ' ' ILE . 6.4 m-85 -89.22 4.44 48.67 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-O 121.54 0.686 . . . . 0.0 109.536 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.16 -27.48 0.09 OUTLIER Glycine 0 C--N 1.335 0.528 0 N-CA-C 116.925 1.53 . . . . 0.0 116.925 177.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.559 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.4 p90 -81.7 147.64 29.38 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 122.445 1.117 . . . . 0.0 113.459 -176.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 87.5 m -97.0 112.55 24.26 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 113.344 -1.753 . . . . 0.0 111.575 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -85.37 86.78 7.35 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.316 178.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.498 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 5.5 tpt180 . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.472 179.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 t . . . . . 0 N--CA 1.45 -0.452 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 41.6 m-70 -104.94 -174.88 2.64 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.61 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.515 ' O ' HD11 ' A' ' 59' ' ' LEU . 99.1 m-70 -150.9 164.61 35.9 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -152.44 139.74 19.45 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.586 -178.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.459 HG13 HD21 ' A' ' 54' ' ' LEU . 1.9 p -73.64 105.51 3.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 121.808 0.813 . . . . 0.0 109.466 178.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.498 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 4.4 t-105 -69.87 -44.39 69.9 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.446 -1.252 . . . . 0.0 112.292 -177.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' HIS . . . . . 0.475 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 2.1 t60 -154.29 133.75 12.72 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.229 -0.896 . . . . 0.0 110.046 -178.332 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.559 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 3.0 p -126.87 129.16 71.36 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 CA-C-O 121.629 0.728 . . . . 0.0 110.859 179.238 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.422 ' O ' ' HB2' ' A' ' 50' ' ' SER . 15.5 mt-10 -66.05 119.79 12.01 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 114.74 -1.118 . . . . 0.0 111.583 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.556 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 9.4 p-10 -88.07 19.16 3.78 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.174 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.03 4.12 60.7 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.372 -0.918 . . . . 0.0 113.837 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 161.27 -55.74 0.31 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 118.795 -1.669 . . . . 0.0 115.187 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -60.57 -135.14 0.0 OUTLIER 'Trans proline' 0 CA--C 1.545 1.04 0 C-N-CA 123.043 2.495 . . . . 0.0 116.679 -178.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.537 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -43.17 -36.99 1.9 Allowed 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 115.208 1.558 . . . . 0.0 115.208 -176.582 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.556 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 1.9 m -62.29 -55.08 31.77 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 118.655 0.661 . . . . 0.0 111.546 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -63.5 -24.31 67.76 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.008 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.08 -24.79 60.71 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.905 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.54 -7.33 6.23 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.565 -0.826 . . . . 0.0 113.104 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.459 HD21 HG13 ' A' ' 40' ' ' VAL . 5.1 tt -70.59 113.81 8.07 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.044 0.45 . . . . 0.0 110.88 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.17 122.32 32.35 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.931 178.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.444 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 36.3 tt0 -49.49 131.73 20.88 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 120.905 0.383 . . . . 0.0 110.664 177.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.37 65.89 1.35 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.294 -178.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.495 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.7 t0 -144.84 148.31 33.84 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.515 HD11 ' O ' ' A' ' 38' ' ' HIS . 8.7 tp -92.5 127.78 38.12 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.22 -179.635 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 4.0 mp -87.05 125.18 40.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.704 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 52.8 p -102.07 -39.08 7.46 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.379 0.609 . . . . 0.0 110.599 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 59.0 m80 -139.31 155.26 47.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.089 -178.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.7 p -138.2 113.07 9.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.851 177.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.8 t30 56.46 32.84 21.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.786 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.12 43.22 22.02 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.12 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.44 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.5 tp10 -149.99 106.2 3.21 Favored Pre-proline 0 N--CA 1.44 -0.949 0 C-N-CA 122.578 0.351 . . . . 0.0 110.375 179.673 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.44 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.7 Cg_exo -45.09 129.51 10.16 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 123.71 2.94 . . . . 0.0 111.538 177.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 31.3 m -86.76 -9.56 11.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-N 114.419 -1.264 . . . . 0.0 109.18 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.3 m170 -54.51 97.64 0.02 OUTLIER 'General case' 0 N--CA 1.426 -1.633 0 CA-C-N 112.602 -2.09 . . . . 0.0 112.074 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 108.98 -11.02 34.44 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.63 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.6 mt -75.79 139.96 42.08 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -79.3 170.47 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.566 ' O ' HG21 ' A' ' 76' ' ' VAL . 55.4 t60 -44.37 -54.75 5.55 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.668 0.747 . . . . 0.0 112.417 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 27.6 p -73.14 -20.69 60.86 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.111 -0.949 . . . . 0.0 112.788 -177.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -69.21 -41.81 76.57 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 121.271 -0.171 . . . . 0.0 111.168 -179.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.566 HG21 ' O ' ' A' ' 73' ' ' HIS . 13.6 m -67.05 -46.95 83.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 C-N-CA 120.476 -0.49 . . . . 0.0 110.024 178.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.455 HG21 ' O ' ' A' ' 73' ' ' HIS . 40.6 t -53.13 -46.49 55.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.18 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -66.6 -42.48 86.82 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.836 179.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -54.04 -39.27 66.06 Favored 'General case' 0 C--N 1.327 -0.388 0 O-C-N 123.681 0.613 . . . . 0.0 109.801 178.076 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 16.4 mt -71.28 -51.91 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.494 179.472 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 82.5 mt -57.95 -32.69 68.08 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-O 121.104 0.478 . . . . 0.0 110.609 179.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 24.8 ttmt -58.67 -40.0 82.28 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.226 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 26.1 t -56.9 -55.04 39.65 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.745 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 134.99 -127.96 4.59 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.069 -1.063 . . . . 0.0 113.807 178.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -75.18 -2.9 29.95 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -178.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.4 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 18.5 pttp -159.77 175.33 13.25 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.249 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 13.5 p -166.67 145.1 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.505 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . 0.465 ' HB2' ' CB ' ' A' ' 7' ' ' PRO . . . -93.88 92.36 7.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.3 -0.864 . . . . 0.0 111.665 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.489 HG22 ' O ' ' A' ' 8' ' ' ILE . 6.8 tt -88.05 112.24 23.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-O 121.014 0.435 . . . . 0.0 110.346 179.262 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 1.0 OUTLIER -91.95 115.39 28.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.779 0.323 . . . . 0.0 111.326 -178.829 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.495 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 64.5 p -109.4 175.39 5.47 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.315 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' THR . . . . . 0.489 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 6.3 t -103.9 105.16 46.96 Favored Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 113.04 0.755 . . . . 0.0 113.04 -178.059 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -52.8 171.86 0.2 Allowed 'Trans proline' 0 C--O 1.236 0.421 0 C-N-CA 122.64 2.226 . . . . 0.0 112.928 177.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -66.47 159.16 27.74 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.796 179.532 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.218 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 N--CA 1.451 -0.399 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 89.9 mtp 62.3 78.28 0.3 Allowed 'General case' 0 N--CA 1.463 0.192 0 O-C-N 123.715 0.635 . . . . 0.0 110.631 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.412 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.9 mpt_? -72.02 148.92 92.07 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.264 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 8.4 Cg_endo -95.43 113.06 0.15 Allowed 'Trans proline' 0 N--CA 1.461 -0.414 0 C-N-CA 123.742 2.961 . . . . 0.0 113.173 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 12.5 Cg_exo -72.86 122.87 8.51 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.463 2.109 . . . . 0.0 113.299 178.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.442 HG22 ' N ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -83.38 109.14 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.28 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.072 177.708 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.2 mm -77.36 97.31 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.174 -178.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.506 HG12 ' CB ' ' A' ' 49' ' ' ALA . 5.7 mt -76.89 159.1 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . 0.421 ' N ' HG23 ' A' ' 10' ' ' ILE . 47.3 t-80 -136.5 112.18 9.41 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 46.7 ttt180 -63.67 109.16 1.6 Allowed 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.728 -178.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -83.36 52.31 2.19 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.87 178.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.54 -49.65 4.21 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-N 115.767 -0.652 . . . . 0.0 112.243 -179.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.5 ptpt -71.76 -90.41 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 16.4 pttm -158.53 -171.56 3.5 Favored 'General case' 0 C--N 1.327 -0.4 0 O-C-N 122.434 -0.166 . . . . 0.0 111.092 -178.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . 0.462 ' HB3' HG21 ' A' ' 10' ' ' ILE . 12.2 m-85 -88.11 -1.76 58.2 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.517 0.675 . . . . 0.0 109.744 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.522 ' HA3' ' HB2' ' A' ' 44' ' ' GLU . . . 63.62 -19.34 0.09 OUTLIER Glycine 0 CA--C 1.519 0.342 0 N-CA-C 117.057 1.583 . . . . 0.0 117.057 177.507 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.57 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.4 p90 -85.44 146.89 26.75 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 122.505 1.145 . . . . 0.0 113.524 -177.253 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 86.1 m -94.65 113.55 25.37 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.601 -1.636 . . . . 0.0 112.364 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.49 81.5 6.54 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.931 0.396 . . . . 0.0 110.692 178.694 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.437 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--N 1.323 -0.545 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.259 179.417 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 9.4 t . . . . . 0 N--CA 1.451 -0.403 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -108.48 -176.06 2.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.238 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.503 ' CD2' HG13 ' A' ' 76' ' ' VAL . 97.7 m-70 -148.46 168.5 22.51 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 3.1 mtm -157.05 137.76 13.24 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 120.61 0.243 . . . . 0.0 110.425 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.47 ' CG1' HD22 ' A' ' 54' ' ' LEU . 1.9 p -72.83 100.63 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-O 122.126 0.965 . . . . 0.0 108.817 178.625 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.437 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.2 t-105 -69.77 -41.08 75.61 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.025 -1.443 . . . . 0.0 112.711 -177.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' HIS . . . . . 0.453 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -156.39 127.19 6.81 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.374 -178.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.57 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 2.4 p -118.84 129.0 75.65 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 CA-C-O 121.251 0.548 . . . . 0.0 110.024 179.18 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.522 ' HB2' ' HA3' ' A' ' 18' ' ' GLY . 5.2 mt-10 -63.9 114.04 3.83 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 114.735 -1.121 . . . . 0.0 111.645 -178.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.476 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 11.8 p-10 -83.17 39.54 0.65 Allowed 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.92 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -122.75 11.88 8.83 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.407 -0.901 . . . . 0.0 113.935 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 156.75 -61.99 0.33 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 118.633 -1.746 . . . . 0.0 115.153 179.314 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . 0.415 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 51.2 Cg_exo -61.04 -133.41 0.0 OUTLIER 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 123.17 2.58 . . . . 0.0 116.958 -177.46 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.506 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -42.13 -35.36 0.91 Allowed 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 114.95 1.463 . . . . 0.0 114.95 -176.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.476 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -61.13 -59.61 5.07 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 118.33 0.513 . . . . 0.0 111.706 -178.921 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -63.61 -30.24 71.38 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.548 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.19 -29.28 70.26 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.673 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.3 -10.5 5.59 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.196 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.47 HD22 ' CG1' ' A' ' 40' ' ' VAL . 5.6 tt -66.85 114.45 5.71 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.849 0.357 . . . . 0.0 110.48 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.15 122.49 32.5 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.486 178.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.427 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 40.2 tt0 -51.34 138.0 22.17 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.989 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 83.14 47.35 5.82 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.222 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.578 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.3 t0 -127.24 149.23 50.1 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.493 HD11 ' O ' ' A' ' 38' ' ' HIS . 19.9 tp -93.03 125.8 37.8 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.149 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.8 mp -83.82 124.74 39.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.276 -179.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 57.8 p -99.51 -40.0 8.06 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.378 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -142.05 157.31 45.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.122 -178.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.67 115.21 8.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 177.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 59.62 31.1 20.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.418 -179.4 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 73.23 45.5 30.78 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.372 -178.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.4 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 1.5 tp10 -151.75 111.23 2.93 Favored Pre-proline 0 N--CA 1.433 -1.316 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 -179.246 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 4.7 Cg_endo -50.99 133.47 40.65 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 123.551 2.834 . . . . 0.0 111.257 178.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 35.1 m -90.01 -7.87 10.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.806 -178.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.8 m170 -55.41 95.06 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.54 0 CA-C-N 112.977 -1.919 . . . . 0.0 111.96 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.29 -9.37 24.59 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.394 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 32.2 mt -77.39 139.76 39.78 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -81.14 171.18 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.162 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.437 ' O ' HG21 ' A' ' 77' ' ' VAL . 2.1 t60 -42.02 -49.02 4.71 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 123.682 0.793 . . . . 0.0 112.934 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 30.6 p -82.11 -21.14 36.88 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 -176.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -67.53 -40.83 85.06 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 121.082 -0.247 . . . . 0.0 111.38 -178.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.503 HG13 ' CD2' ' A' ' 38' ' ' HIS . 3.9 m -65.68 -46.85 88.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.267 0.556 . . . . 0.0 109.599 178.66 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.437 HG21 ' O ' ' A' ' 73' ' ' HIS . 58.4 t -54.79 -45.71 74.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.295 177.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -62.96 -45.12 93.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.942 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.53 -41.66 66.63 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.34 0.59 . . . . 0.0 110.041 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 12.0 mt -68.77 -50.66 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.964 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 65.9 mt -59.23 -39.54 83.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.252 0.549 . . . . 0.0 110.478 178.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -61.46 -36.58 80.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.69 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 44.3 t -53.76 -47.64 70.49 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.129 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 138.06 -124.45 2.96 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.264 -0.969 . . . . 0.0 113.295 179.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -93.65 7.07 46.16 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.265 0.555 . . . . 0.0 110.887 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 19.8 pttp -161.12 179.21 8.59 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.859 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.4 p -170.15 143.68 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 O-C-N 123.609 0.568 . . . . 0.0 112.439 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.09 90.44 6.4 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.649 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 5.0 tt -87.78 115.65 28.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-O 120.954 0.407 . . . . 0.0 110.553 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 3.6 t -94.76 116.04 28.25 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.777 0.322 . . . . 0.0 111.395 -178.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.578 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 81.4 p -109.37 173.31 6.38 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.7 179.026 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.6 t -101.44 104.18 32.11 Favored Pre-proline 0 CA--C 1.536 0.414 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 91' ' ' THR . 77.1 Cg_exo -54.37 177.46 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.577 2.185 . . . . 0.0 113.015 177.609 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -62.55 156.47 23.0 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.396 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.321 -0.635 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.764 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.7 m . . . . . 0 N--CA 1.453 -0.305 0 N-CA-C 110.386 -0.227 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 77.4 mtp 63.41 78.94 0.27 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.183 0.516 . . . . 0.0 110.939 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? -72.78 139.31 80.26 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.733 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -87.87 109.8 0.66 Allowed 'Trans proline' 0 C--O 1.236 0.418 0 C-N-CA 123.204 2.603 . . . . 0.0 112.826 -179.026 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.45 ' HA ' ' O ' ' A' ' 89' ' ' ILE . 12.0 Cg_exo -72.81 121.39 7.31 Favored 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 122.368 2.045 . . . . 0.0 113.041 179.02 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -83.0 110.86 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 CA-C-N 115.388 -0.824 . . . . 0.0 108.802 178.12 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.4 mm -77.16 100.75 2.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.75 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.488 HG21 ' HB3' ' A' ' 17' ' ' TYR . 6.0 mt -76.54 163.51 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 29.0 t-80 -141.53 107.1 5.06 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.105 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 52.6 ttt-85 -62.19 110.31 1.58 Allowed 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.164 -178.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -81.72 46.47 0.98 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.774 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.79 -0.26 66.32 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 121.163 -0.541 . . . . 0.0 112.814 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' LYS . . . . . 0.41 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 9.1 ptpt -119.65 -82.38 0.64 Allowed 'General case' 0 C--N 1.325 -0.458 0 O-C-N 122.891 -0.182 . . . . 0.0 111.277 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.41 ' H ' ' HG3' ' A' ' 15' ' ' LYS . 17.1 pttt -155.14 -178.71 7.45 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.702 -178.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' TYR . . . . . 0.616 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 16.9 m-85 -88.28 5.64 40.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.17 0.51 . . . . 0.0 110.223 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . 0.595 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 53.27 48.99 58.18 Favored Glycine 0 C--O 1.217 -0.909 0 N-CA-C 116.744 1.458 . . . . 0.0 116.744 177.062 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.43 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 6.3 p90 -164.42 147.38 9.04 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 122.457 1.123 . . . . 0.0 112.977 176.304 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 97.9 m -92.39 115.31 27.97 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 113.42 -1.718 . . . . 0.0 112.414 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.22 84.48 6.51 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.74 0.305 . . . . 0.0 110.449 178.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.493 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 6.1 tpt180 . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.453 179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 t . . . . . 0 N--CA 1.452 -0.344 0 CA-C-O 120.699 0.285 . . . . 0.0 110.789 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 54.9 m-70 -115.41 -175.46 2.71 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.676 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.506 ' CD2' HG13 ' A' ' 76' ' ' VAL . 97.1 m-70 -148.79 153.3 37.95 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 48.3 mtm -148.68 141.02 24.15 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.033 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.428 HG13 HD21 ' A' ' 54' ' ' LEU . 2.3 p -72.55 104.78 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-O 121.784 0.802 . . . . 0.0 109.581 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . 0.493 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.2 t-105 -70.07 -42.55 72.65 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.476 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' HIS . . . . . 0.432 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 0.9 OUTLIER -155.08 132.56 11.18 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.158 -179.125 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.595 HG21 ' O ' ' A' ' 18' ' ' GLY . 4.0 p -127.75 130.08 70.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 121.575 0.702 . . . . 0.0 110.508 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.556 ' O ' ' HB2' ' A' ' 50' ' ' SER . 37.1 mt-10 -67.04 115.07 6.34 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 114.583 -1.19 . . . . 0.0 111.811 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . 0.533 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 11.9 p-10 -84.19 35.72 0.55 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.649 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.94 -26.12 8.09 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.708 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -179.93 -54.4 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 119.439 -1.362 . . . . 0.0 114.688 -178.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -58.07 -129.57 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 0.975 0 C-N-CA 123.524 2.816 . . . . 0.0 116.68 -178.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.616 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -43.36 -42.87 4.8 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -176.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.556 ' HB2' ' O ' ' A' ' 44' ' ' GLU . 0.4 OUTLIER -62.09 -62.25 1.91 Allowed 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 112.742 0.645 . . . . 0.0 112.742 -177.668 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -62.04 -22.69 65.94 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.02 0.438 . . . . 0.0 111.072 -178.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -71.06 -24.57 62.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.692 179.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.05 -15.05 3.76 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.75 -0.738 . . . . 0.0 113.03 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LEU . . . . . 0.428 HD21 HG13 ' A' ' 40' ' ' VAL . 5.1 tt -69.42 113.07 6.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.049 0.452 . . . . 0.0 110.787 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ARG . . . . . 0.511 ' HD3' ' O ' ' A' ' 55' ' ' ARG . 0.0 OUTLIER -93.74 123.73 37.27 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.573 178.313 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.432 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 37.0 tt0 -49.08 134.43 17.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.247 0.546 . . . . 0.0 111.31 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 89.77 60.79 1.4 Allowed Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.734 -0.745 . . . . 0.0 111.681 -179.222 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.607 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.4 t0 -140.75 155.25 46.48 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.495 HD11 ' O ' ' A' ' 38' ' ' HIS . 13.3 tp -102.75 125.27 49.42 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.931 -179.414 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.5 mp -82.68 122.75 37.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.276 -179.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.43 ' O ' HG22 ' A' ' 68' ' ' VAL . 44.8 p -100.59 -34.1 10.03 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.652 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 75.2 m80 -146.04 162.53 37.68 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.081 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.3 p -145.89 114.83 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.65 177.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 57.58 32.57 22.03 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.766 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 68.98 47.44 54.47 Favored Glycine 0 N--CA 1.444 -0.768 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -178.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -149.55 99.98 3.34 Favored Pre-proline 0 N--CA 1.442 -0.835 0 C-N-CA 122.834 0.454 . . . . 0.0 110.079 -179.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -36.37 124.36 0.35 Allowed 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 124.424 3.416 . . . . 0.0 112.564 177.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.43 HG22 ' O ' ' A' ' 61' ' ' THR . 27.0 m -86.68 -11.11 11.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.055 -179.411 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.5 m170 -56.57 98.14 0.03 OUTLIER 'General case' 0 N--CA 1.425 -1.688 0 CA-C-N 112.83 -1.986 . . . . 0.0 111.301 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 109.51 -6.41 31.71 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.441 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 25.0 mt -79.01 137.76 37.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.717 0.259 . . . . 0.0 110.517 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -79.92 170.05 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.28 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.485 ' O ' HG21 ' A' ' 76' ' ' VAL . 38.3 t60 -44.09 -54.4 5.56 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.643 0.735 . . . . 0.0 112.764 -179.452 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 21.1 p -73.53 -21.0 60.5 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 115.312 -0.858 . . . . 0.0 113.236 -176.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -68.4 -41.97 79.72 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 120.969 -0.292 . . . . 0.0 111.608 -179.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.506 HG13 ' CD2' ' A' ' 38' ' ' HIS . 3.4 m -66.39 -44.58 90.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.95 179.04 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.434 HG21 ' O ' ' A' ' 73' ' ' HIS . 50.2 t -53.68 -47.99 60.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.826 177.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 56.8 mt-10 -63.6 -45.2 91.45 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.894 178.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.41 -40.48 65.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.294 0.569 . . . . 0.0 109.822 178.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 21.8 mt -70.58 -53.21 23.39 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.775 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.267 179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 83.8 mt -57.57 -38.39 74.73 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 120.887 0.375 . . . . 0.0 111.294 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 17.8 ttmt -59.6 -37.96 79.95 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.753 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 34.8 t -56.25 -39.52 72.71 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.972 -179.286 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.63 -141.38 12.91 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.11 -1.043 . . . . 0.0 112.997 179.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 23.5 p30 -75.13 5.5 5.3 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -179.101 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 16.0 pttp -162.71 171.18 17.22 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.726 -0.215 . . . . 0.0 110.452 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.6 p -164.96 147.06 2.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.73 94.22 7.98 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.748 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.45 ' O ' ' HA ' ' A' ' 7' ' ' PRO . 4.5 tt -88.61 116.16 29.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.749 0.309 . . . . 0.0 110.492 179.277 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.436 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.1 OUTLIER -93.39 112.9 24.93 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.628 0.251 . . . . 0.0 111.508 -178.752 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.607 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 80.4 p -107.14 179.99 4.1 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 178.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' THR . . . . . 0.414 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 4.0 t -114.1 104.11 54.95 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-O 121.232 0.539 . . . . 0.0 112.322 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -56.31 175.53 0.25 Allowed 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.68 2.253 . . . . 0.0 113.344 178.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -65.32 162.33 17.74 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.476 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.327 -0.393 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.143 179.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.75 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.28 164.52 27.26 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 121.068 -0.586 . . . . 0.0 111.886 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m -125.9 146.33 49.88 Favored 'General case' 0 C--N 1.319 -0.735 0 O-C-N 122.78 -0.247 . . . . 0.0 110.42 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 69.4 mtp 63.93 85.46 0.13 Allowed 'General case' 0 C--N 1.33 -0.241 0 O-C-N 123.869 0.731 . . . . 0.0 111.45 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.437 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 6.8 mpt_? -71.7 137.19 82.94 Favored Pre-proline 0 C--N 1.325 -0.485 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -88.05 113.94 0.84 Allowed 'Trans proline' 0 CA--C 1.53 0.304 0 C-N-CA 123.097 2.531 . . . . 0.0 113.134 -178.747 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.414 ' CB ' ' HB2' ' A' ' 88' ' ' ALA . 13.0 Cg_exo -70.93 128.01 14.41 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.141 1.894 . . . . 0.0 112.681 178.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.563 ' O ' HG21 ' A' ' 89' ' ' ILE . 3.1 mt -93.55 113.04 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.679 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mm -78.25 101.08 3.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.7 -178.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.503 HG12 ' HA ' ' A' ' 49' ' ' ALA . 5.4 mt -79.42 168.12 2.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 177.159 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -145.88 114.38 6.75 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 178.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.9 ttt180 -66.48 99.57 0.58 Allowed 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.068 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.61 55.95 1.09 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.331 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.37 14.42 71.76 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.911 -0.586 . . . . 0.0 113.113 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.44 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 8.3 ptpt -140.48 -80.05 0.27 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 117.01 0.405 . . . . 0.0 111.777 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.613 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 24.4 pttt -155.97 178.02 10.75 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.541 0.21 . . . . 0.0 111.192 -178.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . 0.627 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 23.2 m-85 -87.5 2.35 50.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.253 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.542 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 53.37 49.84 55.09 Favored Glycine 0 C--O 1.215 -1.083 0 N-CA-C 116.436 1.334 . . . . 0.0 116.436 176.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.501 ' HA ' ' O ' ' A' ' 42' ' ' HIS . 11.4 p90 -163.91 146.53 9.48 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 122.34 1.067 . . . . 0.0 112.314 176.185 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.529 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 32.7 m -93.35 119.59 32.65 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 113.48 -1.691 . . . . 0.0 113.534 -178.242 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -92.63 84.16 5.0 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.783 0.325 . . . . 0.0 110.222 177.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.408 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 4.4 tpt180 -69.76 121.79 17.91 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.142 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.585 ' HA ' ' ND1' ' A' ' 38' ' ' HIS . . . -87.46 134.53 33.58 Favored 'General case' 0 C--N 1.328 -0.343 0 O-C-N 123.207 0.317 . . . . 0.0 110.846 179.338 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.479 HG23 ' CE3' ' B' ' 102' ' ' TRP . 1.5 pt -153.04 104.97 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 179.324 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 20.9 mtm180 -77.55 101.37 6.48 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 176.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.8 m -77.71 105.07 6.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.187 0.518 . . . . 0.0 112.217 -178.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 29.6 m-85 -78.02 151.56 33.48 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 18.3 mmt -89.58 -2.1 58.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.857 0.36 . . . . 0.0 110.875 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.41 -133.21 4.01 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.902 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -83.1 -18.04 40.98 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.051 0.453 . . . . 0.0 110.431 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.02 164.51 25.41 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.117 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -78.14 -3.51 42.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.147 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.7 p -77.46 126.56 38.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.729 0.776 . . . . 0.0 111.096 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -157.93 154.17 27.39 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.38 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -113.99 129.75 56.58 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.769 0.319 . . . . 0.0 110.205 178.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 t -82.17 97.75 4.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 116.644 -0.253 . . . . 0.0 110.685 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 13.5 m-70 -110.51 177.17 4.77 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.992 0.425 . . . . 0.0 110.752 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.604 ' CD2' HG12 ' A' ' 76' ' ' VAL . 98.5 m-70 -150.19 152.8 35.21 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.277 -0.874 . . . . 0.0 108.709 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 44.6 mtm -147.53 141.7 26.12 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -178.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 20' ' ' THR . 2.5 p -73.14 103.19 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.981 0.896 . . . . 0.0 109.693 179.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.408 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 4.7 t-105 -69.28 -37.32 77.81 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.209 -1.359 . . . . 0.0 111.638 -178.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' HIS . . . . . 0.501 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 2.5 t60 -158.75 125.54 4.75 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.295 -178.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.542 HG21 ' O ' ' A' ' 18' ' ' GLY . 4.3 p -121.47 124.78 72.55 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 CA-C-O 121.475 0.655 . . . . 0.0 109.746 178.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -63.72 109.31 1.66 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.524 -1.216 . . . . 0.0 111.922 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.575 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 8.8 p-10 -82.3 49.37 1.41 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.635 0.731 . . . . 0.0 109.708 179.008 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -131.05 13.62 5.49 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.447 -179.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.489 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 157.22 -68.79 0.28 Allowed Glycine 0 CA--C 1.523 0.546 0 C-N-CA 119.085 -1.531 . . . . 0.0 115.176 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_exo -60.18 -129.92 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 0 C-N-CA 123.748 2.965 . . . . 0.0 117.341 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.627 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -41.86 -38.79 1.62 Allowed 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 114.625 1.343 . . . . 0.0 114.625 -176.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.575 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 1.0 OUTLIER -62.17 -56.18 21.25 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.722 -178.844 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.489 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 7.3 mm-40 -63.45 -28.58 70.07 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.306 0.574 . . . . 0.0 110.432 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.46 -28.72 69.86 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.567 178.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.43 -5.15 5.57 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.931 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.482 ' CD2' HG12 ' A' ' 40' ' ' VAL . 1.7 tt -71.14 112.28 7.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.257 0.551 . . . . 0.0 111.463 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.434 ' N ' HD23 ' A' ' 54' ' ' LEU . 0.0 OUTLIER -90.96 120.81 32.26 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.704 178.61 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.48 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 33.2 tt0 -49.76 140.87 10.87 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.002 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.45 13.78 57.98 Favored Glycine 0 CA--C 1.52 0.357 0 C-N-CA 121.032 -0.604 . . . . 0.0 113.125 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.528 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 2.2 t0 -94.81 151.64 19.07 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.978 0.418 . . . . 0.0 111.116 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.522 HD11 ' O ' ' A' ' 38' ' ' HIS . 4.6 tp -98.26 129.94 44.98 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.192 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.8 mp -86.81 124.21 40.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.055 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 66.3 p -100.4 -37.81 8.69 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.774 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.42 ' HB2' ' CB ' ' A' ' 90' ' ' SER . 59.1 m80 -143.11 162.54 35.27 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.927 -178.688 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.8 p -143.45 116.13 3.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.998 177.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 58.58 24.33 11.88 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.386 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.82 41.75 8.62 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.538 -178.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.433 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.1 tp10 -151.4 109.49 2.97 Favored Pre-proline 0 N--CA 1.434 -1.246 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 1.0 OUTLIER -47.29 128.88 15.18 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 123.947 3.098 . . . . 0.0 111.921 178.923 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.1 m -87.43 -13.76 10.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.165 0 CA-C-N 114.359 -1.291 . . . . 0.0 109.203 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 9.1 m170 -57.47 95.08 0.02 OUTLIER 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 112.846 -1.979 . . . . 0.0 111.163 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 119.41 -14.18 10.92 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.08 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 43.3 mt -76.01 142.52 41.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.592 0.234 . . . . 0.0 110.577 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -78.08 169.66 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.882 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -42.42 -48.18 5.12 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.907 0.883 . . . . 0.0 113.119 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 12.0 p -88.21 -15.45 35.93 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -68.4 -42.45 79.01 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 122.361 -0.212 . . . . 0.0 111.212 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.604 HG12 ' CD2' ' A' ' 38' ' ' HIS . 9.6 m -64.16 -46.36 93.76 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.233 0 CA-C-O 121.198 0.523 . . . . 0.0 110.0 179.275 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.577 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 72.8 t -55.18 -48.96 75.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.268 177.555 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -61.63 -44.01 97.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.161 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.19 -39.45 63.68 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-O 121.263 0.554 . . . . 0.0 109.937 178.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.45 HD12 ' HG ' ' B' ' 113' ' ' LEU . 14.3 mt -72.27 -50.34 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.807 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.577 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 39.6 mt -58.33 -36.85 74.01 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-O 121.329 0.585 . . . . 0.0 110.515 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 24.0 ttmt -60.34 -39.94 88.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.634 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 43.4 t -54.69 -36.47 64.69 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.359 -0.837 . . . . 0.0 111.49 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 127.85 -130.42 6.7 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.207 -0.997 . . . . 0.0 112.637 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 25.0 p30 -92.07 13.87 17.6 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.208 0.528 . . . . 0.0 111.047 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -163.47 176.69 9.53 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.064 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.6 p -171.81 145.99 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.414 ' HB2' ' CB ' ' A' ' 7' ' ' PRO . . . -92.38 95.82 9.89 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.276 -0.874 . . . . 0.0 111.108 178.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.563 HG21 ' O ' ' A' ' 8' ' ' ILE . 11.2 tt -89.09 113.64 25.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 120.945 0.403 . . . . 0.0 111.06 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.42 ' CB ' ' HB2' ' A' ' 62' ' ' HIS . 0.2 OUTLIER -87.52 110.14 20.12 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.929 0.395 . . . . 0.0 110.911 -179.535 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.528 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 40.0 p -108.32 164.37 12.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.151 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.442 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 2.1 t -99.78 105.51 34.89 Favored Pre-proline 0 C--N 1.328 -0.356 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -177.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.433 ' HD3' ' O ' ' A' ' 91' ' ' THR . 52.6 Cg_exo -54.64 176.2 0.12 Allowed 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 122.328 2.018 . . . . 0.0 113.089 178.014 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.01 164.05 13.52 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.695 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -163.32 159.45 22.56 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.341 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 5.5 p30 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.576 -0.726 . . . . 0.0 110.256 179.981 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.6 m . . . . . 0 N--CA 1.478 0.961 0 N-CA-C 110.669 -0.123 . . . . 0.0 110.669 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 102' ' ' TRP . . . . . 0.479 ' CE3' HG23 ' A' ' 24' ' ' ILE . 35.8 t-105 72.16 113.88 0.06 Allowed 'General case' 0 N--CA 1.47 0.528 0 O-C-N 123.764 0.665 . . . . 0.0 110.67 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 8.7 tm-20 -155.82 -46.67 0.08 Allowed 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 -178.155 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.88 22.76 0.37 Allowed 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 114.076 1.139 . . . . 0.0 114.076 -176.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 40.9 p-80 -67.04 -26.49 66.78 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.233 0.54 . . . . 0.0 109.756 179.253 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 106' ' ' LYS . . . . . 0.416 ' HD3' ' N ' ' B' ' 107' ' ' SER . 0.0 OUTLIER -111.05 -19.91 12.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.817 178.203 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 107' ' ' SER . . . . . 0.416 ' N ' ' HD3' ' B' ' 106' ' ' LYS . 1.4 m -80.91 89.98 5.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.68 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 125.47 -11.59 7.55 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.643 -179.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 93.18 -141.48 15.55 Favored Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.483 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -139.85 47.01 1.85 Allowed 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 7.0 m -64.02 135.63 56.6 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.016 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 112' ' ' ARG . . . . . 0.524 ' NH2' ' HD2' ' A' ' 16' ' ' LYS . 8.7 ptm180 -131.57 171.29 13.61 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.123 -179.361 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . 0.613 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 3.3 mm? . . . . . 0 C--O 1.243 0.735 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.03 -179.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.75 0 N-CA-C 112.009 -0.437 . . . . 0.0 112.009 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -155.24 166.77 32.73 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.787 -0.72 . . . . 0.0 111.853 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.5 m -134.83 155.59 50.38 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 84.9 mtp 58.31 79.76 0.2 Allowed 'General case' 0 N--CA 1.463 0.2 0 O-C-N 123.685 0.616 . . . . 0.0 111.483 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.462 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 3.4 mpt_? -72.26 132.5 84.11 Favored Pre-proline 0 C--N 1.325 -0.498 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 3.6 Cg_exo -83.46 114.33 2.1 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 123.059 2.506 . . . . 0.0 112.745 -178.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 13.6 Cg_exo -70.84 124.31 10.52 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.245 1.963 . . . . 0.0 112.381 178.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.553 ' O ' HG21 ' A' ' 89' ' ' ILE . 5.2 mt -91.46 111.02 23.28 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.079 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mm -77.79 101.45 3.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -177.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.544 HG12 ' CB ' ' A' ' 49' ' ' ALA . 5.3 mt -78.05 164.95 3.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 177.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . 0.403 ' N ' HG23 ' A' ' 10' ' ' ILE . 32.7 t-80 -142.78 114.29 7.95 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.8 ttt180 -63.39 114.09 3.65 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.401 0.62 . . . . 0.0 110.725 -179.504 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -84.67 43.82 1.01 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.185 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.55 3.95 83.9 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.735 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.3 ptpt -127.64 -82.65 0.6 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.699 0.285 . . . . 0.0 111.138 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.519 ' HE2' ' OE1' ' A' ' 44' ' ' GLU . 22.7 pttm -158.51 -179.55 8.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.924 -178.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . 0.475 ' HA ' ' HB3' ' A' ' 48' ' ' PRO . 12.8 m-85 -89.98 -0.41 57.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.524 0.678 . . . . 0.0 109.182 179.214 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.98 -24.92 0.11 Allowed Glycine 0 C--N 1.331 0.274 0 N-CA-C 116.704 1.442 . . . . 0.0 116.704 177.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.56 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.7 p90 -81.96 142.48 32.38 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 122.615 1.197 . . . . 0.0 113.636 -176.562 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 58.6 m -93.14 114.65 27.21 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 113.225 -1.807 . . . . 0.0 111.481 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -86.4 84.28 7.48 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 178.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.564 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 1.9 tpt180 -66.07 135.93 55.3 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.936 -179.454 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.495 ' HA ' ' ND1' ' A' ' 38' ' ' HIS . . . -90.92 132.58 35.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.651 0.262 . . . . 0.0 110.841 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.49 HG22 ' CZ2' ' B' ' 102' ' ' TRP . 18.4 pt -137.29 166.95 24.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.977 0.418 . . . . 0.0 111.226 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -140.15 91.72 2.48 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.698 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 1.7 m -79.4 123.36 36.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.639 -179.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -81.15 146.07 30.72 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.822 0.344 . . . . 0.0 110.079 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 90.5 mtp -124.79 45.13 2.61 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.824 -178.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.76 -167.06 31.52 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.387 -0.911 . . . . 0.0 112.989 179.397 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -84.44 -34.28 23.5 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.857 0.36 . . . . 0.0 110.668 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.451 ' C ' ' H ' ' A' ' 33' ' ' VAL . 2.4 m -71.67 -178.33 2.2 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.602 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -77.62 30.42 0.16 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 121.011 0.434 . . . . 0.0 111.225 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.451 ' H ' ' C ' ' A' ' 31' ' ' SER . 2.2 p -85.95 120.14 35.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.478 0.656 . . . . 0.0 110.332 179.255 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -149.82 149.74 30.95 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.484 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.49 128.12 52.34 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.844 178.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.6 t -80.63 94.94 2.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-O 120.898 0.38 . . . . 0.0 110.656 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 8.0 m-70 -108.63 -174.0 2.41 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.465 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.495 ' ND1' ' HA ' ' A' ' 23' ' ' ALA . 99.1 m-70 -151.39 161.61 42.39 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -179.762 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' MET . . . . . 0.436 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 68.5 mtm -150.02 144.79 26.02 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.755 0.312 . . . . 0.0 110.488 -178.566 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.485 HG13 ' CD2' ' A' ' 54' ' ' LEU . 2.7 p -74.41 104.5 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-O 121.823 0.82 . . . . 0.0 109.67 179.202 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.564 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 5.3 t-105 -69.82 -40.09 76.1 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.659 -1.155 . . . . 0.0 112.167 -178.389 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' HIS . . . . . 0.497 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.8 t60 -158.91 127.82 5.39 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.329 -178.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.56 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 2.4 p -120.93 129.33 75.8 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.109 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.519 ' OE1' ' HE2' ' A' ' 16' ' ' LYS . 27.5 mt-10 -64.09 113.12 3.31 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.911 -179.049 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.641 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 9.4 p-10 -84.88 34.33 0.54 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.134 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -124.3 17.07 7.52 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.151 -1.024 . . . . 0.0 113.926 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.04 -64.99 0.28 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 118.884 -1.627 . . . . 0.0 115.049 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.475 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 49.6 Cg_exo -62.36 -133.33 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.316 2.677 . . . . 0.0 116.913 -177.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.544 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -43.33 -35.48 1.52 Allowed 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 -176.578 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.641 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 2.0 m -63.42 -53.32 54.21 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 118.399 0.545 . . . . 0.0 111.674 -178.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -63.2 -30.96 72.01 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-O 121.52 0.676 . . . . 0.0 109.807 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.15 -31.75 73.07 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.913 -1.039 . . . . 0.0 110.067 178.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.65 -5.87 5.52 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.551 179.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.485 ' CD2' HG13 ' A' ' 40' ' ' VAL . 1.1 tt -67.02 117.28 8.86 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.249 0.547 . . . . 0.0 111.44 -179.455 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.416 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -91.19 121.78 33.26 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.311 178.821 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -51.85 138.95 23.03 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.597 177.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.19 15.98 56.5 Favored Glycine 0 CA--C 1.52 0.399 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.713 -179.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.618 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 5.2 t0 -94.28 153.87 17.81 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.773 0.32 . . . . 0.0 110.553 179.581 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.436 ' HA ' ' HG2' ' A' ' 39' ' ' MET . 4.8 tp -101.02 128.46 47.05 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.589 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.406 HD12 ' N ' ' A' ' 60' ' ' ILE . 4.0 mp -85.42 124.46 40.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.88 -179.652 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 64.6 p -101.88 -39.95 7.13 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.351 0.596 . . . . 0.0 110.519 179.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 62.0 m80 -139.75 157.19 46.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.969 -178.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.6 p -139.82 109.73 3.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.562 178.004 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 61.73 30.64 18.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.654 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.38 45.44 18.8 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -178.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.467 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 4.0 tp10 -149.84 105.11 3.22 Favored Pre-proline 0 N--CA 1.436 -1.166 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.467 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.2 Cg_endo -49.97 127.85 20.43 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 123.474 2.783 . . . . 0.0 111.264 178.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.7 m -88.7 -11.25 10.49 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.644 -179.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -55.25 93.77 0.01 OUTLIER 'General case' 0 N--CA 1.427 -1.6 0 CA-C-N 113.029 -1.896 . . . . 0.0 111.806 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 114.41 -10.03 22.1 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.523 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 25.6 mt -75.66 145.05 41.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.783 0.325 . . . . 0.0 110.295 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -77.91 166.48 2.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.607 ' O ' HG21 ' A' ' 76' ' ' VAL . 77.8 t60 -46.04 -52.74 11.39 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.966 0.888 . . . . 0.0 112.3 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.2 p -72.57 -19.71 61.45 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 114.986 -1.006 . . . . 0.0 112.868 -176.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 21.5 mt-10 -70.69 -42.97 69.98 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 121.218 -0.193 . . . . 0.0 110.97 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.607 HG21 ' O ' ' A' ' 73' ' ' HIS . 15.5 m -64.8 -47.22 89.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.132 0 C-N-CA 120.354 -0.538 . . . . 0.0 109.764 179.273 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.528 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 48.6 t -54.71 -45.79 73.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.077 177.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.436 ' O ' ' HB2' ' A' ' 82' ' ' LYS . 17.9 mt-10 -63.15 -44.6 95.07 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.633 179.092 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -54.37 -41.14 68.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.207 0.527 . . . . 0.0 110.313 179.247 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.426 HD12 ' HG ' ' B' ' 113' ' ' LEU . 18.5 mt -69.3 -51.83 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.224 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 61.4 mt -59.74 -36.24 76.2 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.183 0.516 . . . . 0.0 110.477 179.095 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 78' ' ' GLU . 25.5 ttmt -59.37 -41.38 89.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.63 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 38.4 t -54.82 -36.47 65.03 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.527 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 127.01 -121.31 3.89 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 119.86 -1.162 . . . . 0.0 113.859 178.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -98.57 8.97 44.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.24 0.543 . . . . 0.0 110.893 -179.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 16.5 pttp -161.72 174.83 12.69 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.006 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 9.2 p -169.21 146.14 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.67 93.8 8.68 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.282 -0.872 . . . . 0.0 111.007 179.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.553 HG21 ' O ' ' A' ' 8' ' ' ILE . 9.3 tt -87.39 111.39 21.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 121.122 0.486 . . . . 0.0 110.659 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -89.43 106.9 18.76 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.716 0.293 . . . . 0.0 110.67 -179.291 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.618 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 81.5 p -104.51 169.13 8.65 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.839 179.396 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.412 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 8.6 t -100.01 107.24 45.89 Favored Pre-proline 0 CA--C 1.537 0.448 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 -177.264 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -54.84 174.6 0.19 Allowed 'Trans proline' 0 C--N 1.352 0.715 0 C-N-CA 122.345 2.03 . . . . 0.0 113.012 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.48 167.72 8.36 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.17 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -156.15 161.79 40.29 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.968 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 8.6 p30 . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.77 -0.633 . . . . 0.0 110.83 -179.579 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 5.0 m . . . . . 0 N--CA 1.476 0.832 0 CA-C-O 121.109 0.481 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 102' ' ' TRP . . . . . 0.49 ' CZ2' HG22 ' A' ' 24' ' ' ILE . 23.3 t90 -137.98 127.06 24.25 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.23 179.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -79.97 -87.79 0.07 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.288 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -144.4 -166.61 2.42 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.184 -179.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 9.9 m80 -61.5 122.0 14.12 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.201 0.524 . . . . 0.0 111.778 -179.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -132.02 9.7 4.53 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -114.22 151.63 32.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.891 -179.609 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -87.89 136.37 13.76 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.851 -179.571 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 99.05 136.22 9.26 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.654 179.4 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . 0.562 ' OE1' ' HD2' ' A' ' 22' ' ' ARG . 4.5 mm-40 -154.51 75.31 0.98 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.197 0.522 . . . . 0.0 110.695 178.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 111' ' ' THR . . . . . 0.408 HG23 ' NE2' ' A' ' 73' ' ' HIS . 5.1 t -108.68 177.61 4.73 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 112' ' ' ARG . . . . . 0.563 ' HG2' ' N ' ' B' ' 113' ' ' LEU . 0.0 OUTLIER -132.14 151.38 51.82 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.83 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . 0.563 ' N ' ' HG2' ' B' ' 112' ' ' ARG . 3.8 mm? . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.442 -0.789 . . . . 0.0 110.434 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.742 0 N-CA-C 112.138 -0.385 . . . . 0.0 112.138 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.88 -178.92 45.12 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.873 -0.68 . . . . 0.0 111.796 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.4 m -155.97 155.3 32.53 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 91.1 mtp 60.23 78.34 0.28 Allowed 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.686 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.459 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.6 mpt_? -71.25 137.46 84.21 Favored Pre-proline 0 C--N 1.323 -0.581 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 179.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.459 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 2.9 Cg_endo -84.57 112.67 1.6 Allowed 'Trans proline' 0 N--CA 1.462 -0.334 0 C-N-CA 122.92 2.414 . . . . 0.0 112.813 -178.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.463 ' CB ' ' HB2' ' A' ' 88' ' ' ALA . 17.4 Cg_exo -68.48 125.83 13.36 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.227 1.951 . . . . 0.0 112.526 178.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.529 ' O ' HG21 ' A' ' 89' ' ' ILE . 5.9 mt -92.85 115.82 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.5 mm -79.23 104.26 7.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 CA-C-N 116.191 -0.458 . . . . 0.0 112.208 -178.118 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.513 HD13 ' HB3' ' A' ' 17' ' ' TYR . 5.5 mt -80.14 160.73 4.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 176.341 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 39.8 t-80 -141.75 114.31 8.37 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 53.2 ttt180 -63.44 98.14 0.16 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.773 -179.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.89 55.77 2.17 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.357 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.28 7.56 77.96 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.826 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.478 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 10.9 ptpt -132.47 -87.73 0.45 Allowed 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.855 -0.203 . . . . 0.0 111.272 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.567 ' HB2' ' OXT' ' B' ' 113' ' ' LEU . 32.1 pttt -155.5 -172.62 4.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.454 0.169 . . . . 0.0 110.717 -178.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . 0.635 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 21.0 m-85 -88.17 2.12 52.85 Favored 'General case' 0 CA--C 1.519 -0.236 0 CA-C-O 121.062 0.458 . . . . 0.0 109.925 179.443 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.55 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 52.2 49.79 48.86 Favored Glycine 0 C--O 1.219 -0.821 0 N-CA-C 116.728 1.451 . . . . 0.0 116.728 176.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.427 ' HB3' HG21 ' A' ' 43' ' ' VAL . 8.1 p90 -164.21 148.86 10.0 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-O 122.345 1.069 . . . . 0.0 112.477 176.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 42.3 m -94.63 113.99 25.88 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 113.722 -1.581 . . . . 0.0 112.806 -179.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -88.1 82.85 7.07 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.939 0.4 . . . . 0.0 109.941 178.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.516 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 3.6 tpt180 -67.99 129.53 40.21 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.727 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.417 ' HB2' ' HD1' ' A' ' 73' ' ' HIS . . . -94.38 136.16 34.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.794 -0.185 . . . . 0.0 110.582 179.66 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.2 pt -149.46 122.71 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.101 0.477 . . . . 0.0 111.437 179.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.464 ' HD2' ' CE2' ' A' ' 34' ' ' TYR . 82.1 mtm180 -96.38 99.8 11.46 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 1.6 m -76.09 110.5 11.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.201 0.524 . . . . 0.0 111.519 -179.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 48.4 m-85 -79.8 99.23 7.39 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.377 178.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.7 mtm -127.36 126.37 42.38 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.493 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 131.54 168.57 12.17 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -69.3 -46.55 66.89 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 117.006 0.403 . . . . 0.0 110.59 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.439 ' C ' ' H ' ' A' ' 33' ' ' VAL . 0.8 OUTLIER -76.81 -177.87 4.55 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.702 179.833 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.5 32.94 0.2 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.108 0.48 . . . . 0.0 110.681 179.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.439 ' H ' ' C ' ' A' ' 31' ' ' SER . 3.6 p -80.8 138.81 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-O 121.353 0.597 . . . . 0.0 110.313 -179.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.464 ' CE2' ' HD2' ' A' ' 25' ' ' ARG . 43.5 p90 -145.29 152.95 40.73 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.352 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -110.58 125.05 52.98 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.679 -0.409 . . . . 0.0 110.162 178.428 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 t -81.55 100.41 5.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.992 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 -113.5 -179.06 3.53 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.28 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.497 ' O ' HD11 ' A' ' 59' ' ' LEU . 94.4 m-70 -149.66 153.57 37.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' MET . . . . . 0.451 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 27.2 mtm -148.57 145.5 27.85 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -178.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.483 HG11 ' CD2' ' A' ' 54' ' ' LEU . 3.4 p -73.25 103.32 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 CA-C-O 122.006 0.908 . . . . 0.0 109.793 179.274 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.516 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.6 t-105 -70.65 -40.37 73.07 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.468 -1.242 . . . . 0.0 111.499 -178.682 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' HIS . . . . . 0.486 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 1.9 t60 -156.64 132.09 9.35 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.952 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.55 HG21 ' O ' ' A' ' 18' ' ' GLY . 5.1 p -127.96 125.48 64.81 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.012 0 CA-C-O 121.919 0.866 . . . . 0.0 110.348 178.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.479 ' O ' ' HB2' ' A' ' 50' ' ' SER . 28.3 mt-10 -65.24 114.09 4.47 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 114.284 -1.325 . . . . 0.0 112.117 -178.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.539 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 10.6 p-10 -83.65 46.07 1.12 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.646 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -119.44 -2.77 13.16 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.399 -0.905 . . . . 0.0 113.595 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.4 ' CA ' ' HG3' ' A' ' 51' ' ' GLU . . . 163.63 -59.09 0.27 Allowed Glycine 0 CA--C 1.521 0.411 0 C-N-CA 119.119 -1.515 . . . . 0.0 114.884 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -59.24 -130.98 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 0.98 0 C-N-CA 123.463 2.776 . . . . 0.0 116.593 -178.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.635 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -43.69 -40.81 4.43 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 114.382 1.253 . . . . 0.0 114.382 -176.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.539 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -60.03 -59.99 4.55 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -178.312 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.4 ' HG3' ' CA ' ' A' ' 47' ' ' GLY . 5.5 mt-10 -63.37 -28.62 70.12 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.064 0.459 . . . . 0.0 110.713 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.13 -29.99 70.72 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.947 178.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 135.69 -9.28 4.28 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.767 179.444 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.483 ' CD2' HG11 ' A' ' 40' ' ' VAL . 0.9 OUTLIER -68.34 117.76 10.54 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.374 0.607 . . . . 0.0 111.42 -179.615 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.432 ' N ' HD23 ' A' ' 54' ' ' LEU . 0.1 OUTLIER -92.85 121.24 34.03 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.726 178.419 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.486 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 37.1 tt0 -50.13 135.09 21.47 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.15 59.5 1.75 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.569 -0.824 . . . . 0.0 111.231 -178.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.425 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 3.4 t0 -142.81 147.58 35.71 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.497 HD11 ' O ' ' A' ' 38' ' ' HIS . 10.9 tp -92.95 131.28 38.09 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.408 -179.541 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.6 mp -89.13 125.35 42.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.9 p -101.87 -40.02 7.11 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.259 0.552 . . . . 0.0 110.799 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -139.76 158.44 44.09 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.591 -179.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.6 p -141.62 110.4 2.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-O 121.11 0.481 . . . . 0.0 109.981 178.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.9 t30 59.49 33.91 22.37 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.093 179.399 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.0 42.26 25.27 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.17 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.491 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 5.6 tp10 -151.37 106.67 2.95 Favored Pre-proline 0 N--CA 1.434 -1.234 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.491 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.2 Cg_endo -50.4 129.1 25.09 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.557 2.838 . . . . 0.0 110.962 178.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 20.2 m -85.85 -13.31 11.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.258 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.0 m170 -56.6 96.98 0.02 OUTLIER 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 112.732 -2.031 . . . . 0.0 110.835 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.94 -12.88 26.93 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.405 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 21.7 mt -76.1 141.61 41.93 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -75.46 165.65 3.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.54 ' O ' HG21 ' A' ' 76' ' ' VAL . 83.2 t60 -42.97 -55.19 3.87 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-O 121.765 0.793 . . . . 0.0 112.82 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.0 p -74.53 -16.96 60.81 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 114.93 -1.032 . . . . 0.0 113.04 -176.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -70.57 -42.03 71.64 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 120.95 -0.3 . . . . 0.0 111.121 -179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.54 HG21 ' O ' ' A' ' 73' ' ' HIS . 15.6 m -65.59 -46.44 89.54 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.46 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 60.9 t -53.05 -48.59 52.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.632 176.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -63.47 -44.44 94.45 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.847 179.266 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.38 -42.01 66.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.269 0.557 . . . . 0.0 109.933 178.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 22.7 mt -67.35 -48.83 76.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.621 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.46 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 50.2 mt -60.84 -39.4 88.94 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-O 121.032 0.444 . . . . 0.0 110.657 178.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 23.1 ttmt -60.35 -40.5 90.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.142 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 41.4 t -54.22 -31.79 54.16 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.714 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 129.52 -127.81 5.56 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.672 179.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -99.1 10.53 41.27 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.432 0.634 . . . . 0.0 110.413 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 17.3 pttp -161.99 172.51 15.85 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.862 179.2 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 8.5 p -168.03 149.82 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -178.326 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.463 ' HB2' ' CB ' ' A' ' 7' ' ' PRO . . . -93.37 97.66 10.72 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.309 178.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.529 HG21 ' O ' ' A' ' 8' ' ' ILE . 10.2 tt -89.62 112.91 25.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 120.884 0.373 . . . . 0.0 110.862 179.392 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.9 OUTLIER -88.67 105.02 17.4 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.729 0.3 . . . . 0.0 111.296 -179.008 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.484 ' O ' ' HD3' ' A' ' 93' ' ' PRO . 42.3 p -102.36 163.2 12.37 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.43 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 1.6 t -98.65 104.92 27.18 Favored Pre-proline 0 C--N 1.326 -0.439 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' A' ' 91' ' ' THR . 73.2 Cg_exo -53.73 176.06 0.1 Allowed 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.503 2.135 . . . . 0.0 113.036 178.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -64.26 166.12 8.48 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.319 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -161.67 173.42 14.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.899 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 4.7 p30 . . . . . 0 C--O 1.252 1.232 0 CA-C-O 118.826 -0.607 . . . . 0.0 110.358 179.547 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.479 1.023 0 CA-C-O 120.602 0.239 . . . . 0.0 111.087 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 102' ' ' TRP . . . . . 0.418 ' HH2' ' CH2' ' A' ' 41' ' ' TRP . 13.6 t90 -117.55 88.9 3.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.332 0.586 . . . . 0.0 110.295 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 20.2 mp0 -94.32 -36.98 11.71 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.395 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 29.8 m -153.74 -170.25 3.52 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.029 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 13.6 m80 -70.78 69.76 0.45 Allowed 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.135 0.493 . . . . 0.0 110.592 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 51.5 mttt -81.88 62.07 5.5 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.071 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.1 p -157.07 -70.68 0.1 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.636 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 111.95 113.68 3.33 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.144 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 121.4 136.17 4.96 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.794 -0.717 . . . . 0.0 113.002 179.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -125.11 17.85 8.42 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.781 0.324 . . . . 0.0 110.184 179.114 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 1.4 m -59.36 149.97 27.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.488 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 112' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -135.74 170.71 15.55 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.823 -179.493 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . 0.567 ' OXT' ' HB2' ' A' ' 16' ' ' LYS . 3.3 mm? . . . . . 0 C--O 1.253 1.265 0 CA-C-O 118.111 -0.947 . . . . 0.0 109.219 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.48 ' HA2' ' HG3' ' A' ' 95' ' ' GLU . . . . . . . . 0 N--CA 1.481 1.7 0 N-CA-C 112.104 -0.398 . . . . 0.0 112.104 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -119.86 -157.47 10.27 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.159 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.6 t -158.13 162.83 38.01 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 37.8 mtp 55.85 78.93 0.18 Allowed 'General case' 0 C--O 1.235 0.336 0 O-C-N 123.58 0.55 . . . . 0.0 111.471 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.423 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.0 mpt_? -70.92 137.47 85.07 Favored Pre-proline 0 C--N 1.325 -0.464 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.0 OUTLIER -86.93 111.08 0.87 Allowed 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.795 2.33 . . . . 0.0 112.899 -178.284 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.523 ' CB ' ' HB3' ' A' ' 88' ' ' ALA . 15.5 Cg_exo -69.12 119.87 6.8 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 121.935 1.756 . . . . 0.0 112.15 178.616 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.637 ' O ' HG21 ' A' ' 89' ' ' ILE . 7.0 mt -87.85 110.94 21.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-N 115.07 -0.968 . . . . 0.0 108.967 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.2 mm -76.77 101.45 2.93 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.825 -0.625 . . . . 0.0 112.045 -178.045 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.518 HG12 ' HA ' ' A' ' 49' ' ' ALA . 5.2 mt -78.92 159.27 4.64 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.368 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 176.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 15.1 t-80 -135.44 109.98 8.54 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 178.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.1 ttt180 -64.64 100.71 0.4 Allowed 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.419 -0.81 . . . . 0.0 111.05 -179.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.95 55.68 1.81 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.275 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.7 -45.31 3.38 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.479 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.2 ptpt -79.23 -85.79 0.08 Allowed 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.621 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 23.7 pttt -157.29 -174.09 4.73 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.52 0.193 . . . . 0.0 111.52 -178.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . 0.634 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 21.4 m-85 -85.49 2.42 44.74 Favored 'General case' 0 CA--C 1.518 -0.25 0 CA-C-O 121.103 0.478 . . . . 0.0 109.757 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.551 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 51.04 53.54 26.6 Favored Glycine 0 C--O 1.215 -1.044 0 N-CA-C 116.124 1.21 . . . . 0.0 116.124 177.328 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.461 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 12.4 p90 -163.94 149.03 10.54 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 122.744 1.259 . . . . 0.0 112.965 176.156 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.545 ' HA ' ' HB2' ' B' ' 112' ' ' ARG . 40.5 m -95.16 117.48 30.29 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 112.904 -1.953 . . . . 0.0 113.109 -178.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -94.45 80.78 3.91 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 178.286 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.486 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 1.6 tpt180 -65.26 140.78 58.75 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.995 -179.51 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -103.7 129.01 50.98 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.882 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.483 HG21 ' CZ3' ' B' ' 102' ' ' TRP . 3.4 pt -140.22 165.83 20.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.013 0.435 . . . . 0.0 111.061 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.403 ' O ' ' HB2' ' B' ' 103' ' ' GLU . 0.1 OUTLIER -135.87 111.38 9.22 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.336 0.589 . . . . 0.0 110.43 -179.373 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.431 HG13 ' H ' ' B' ' 102' ' ' TRP . 8.9 m -84.84 115.86 27.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.726 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -79.6 106.3 11.53 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -81.9 -0.63 44.62 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.789 -178.434 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -158.54 163.42 33.02 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.21 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -81.84 62.7 5.76 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.547 0.689 . . . . 0.0 109.903 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.0 m -163.51 -160.03 0.56 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.942 -179.216 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.03 7.81 8.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.823 0.344 . . . . 0.0 111.426 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.2 p -82.24 123.89 38.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.404 0.621 . . . . 0.0 111.341 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -158.8 150.75 21.14 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.919 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.405 ' O ' HG22 ' A' ' 26' ' ' VAL . 0.1 OUTLIER -112.27 129.71 56.18 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.918 0.39 . . . . 0.0 110.248 178.797 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.6 t -83.92 117.0 28.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.895 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 89.2 m-70 -125.43 -177.73 3.99 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.464 179.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.541 ' CD2' HG13 ' A' ' 76' ' ' VAL . 98.0 m-70 -147.71 154.7 40.9 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -179.269 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 35.4 mtm -149.13 146.56 27.74 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -178.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.541 HG12 ' CD2' ' A' ' 54' ' ' LEU . 2.6 p -74.0 101.75 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.976 0.893 . . . . 0.0 109.774 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.486 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 2.9 t-105 -70.39 -39.21 74.67 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.37 -178.598 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' HIS . . . . . 0.45 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -156.53 129.57 7.92 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.975 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.551 HG21 ' O ' ' A' ' 18' ' ' GLY . 3.8 p -124.28 127.06 73.02 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.555 0.693 . . . . 0.0 110.248 179.06 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -66.64 113.23 4.64 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 114.507 -1.224 . . . . 0.0 112.043 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.552 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 10.4 p-10 -81.5 40.2 0.57 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.918 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -108.15 -8.75 28.93 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.376 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.55 -49.91 0.37 Allowed Glycine 0 CA--C 1.526 0.761 0 C-N-CA 119.491 -1.338 . . . . 0.0 114.867 -179.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -60.11 -128.98 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.09 0 C-N-CA 123.094 2.529 . . . . 0.0 116.233 -179.223 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.634 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -45.12 -39.97 6.49 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 114.195 1.183 . . . . 0.0 114.195 -177.113 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.552 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 5.5 m -57.34 -62.86 1.47 Allowed 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -179.158 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 9.5 mm-40 -63.25 -23.15 67.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.295 -179.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.66 -26.16 66.07 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.256 178.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 130.21 -8.36 5.99 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.677 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.557 HD21 ' N ' ' A' ' 55' ' ' ARG . 1.1 tt -70.0 117.99 12.28 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-O 121.435 0.636 . . . . 0.0 111.324 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.557 ' N ' HD21 ' A' ' 54' ' ' LEU . 0.0 OUTLIER -96.45 121.52 38.35 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.941 178.357 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.42 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 46.3 tt0 -50.45 141.14 12.59 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.771 0.319 . . . . 0.0 111.51 178.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.24 6.0 63.31 Favored Glycine 0 C--N 1.333 0.415 0 C-N-CA 121.239 -0.505 . . . . 0.0 113.231 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.533 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 2.0 t0 -89.9 155.71 18.95 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.032 0.444 . . . . 0.0 111.036 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.483 HD11 ' O ' ' A' ' 38' ' ' HIS . 2.5 tp -100.14 133.97 43.75 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.7 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.5 mp -91.26 122.74 42.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 26.2 p -99.7 -40.61 7.68 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.401 0.619 . . . . 0.0 110.361 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 72.7 m80 -138.28 157.21 46.71 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.761 -178.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.57 111.51 5.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.965 -0.562 . . . . 0.0 109.889 178.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 60.39 30.04 19.49 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.811 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.46 44.29 17.14 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.182 -179.036 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.466 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.1 tp10 -149.99 106.26 3.21 Favored Pre-proline 0 N--CA 1.437 -1.084 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 -179.066 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.466 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 4.4 Cg_endo -49.62 129.32 23.22 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.66 2.907 . . . . 0.0 111.124 178.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 22.3 m -86.82 -7.96 10.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 114.594 -1.185 . . . . 0.0 109.039 -178.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 22.1 m170 -55.17 101.01 0.04 OUTLIER 'General case' 0 N--CA 1.426 -1.629 0 CA-C-N 112.741 -2.027 . . . . 0.0 111.676 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.68 -6.77 49.07 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.842 179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 26.3 mt -78.29 141.41 38.53 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.669 0.271 . . . . 0.0 110.469 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.435 HG12 ' HG3' ' A' ' 75' ' ' GLU . 2.0 p -78.58 169.82 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 177.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.599 ' O ' HG21 ' A' ' 76' ' ' VAL . 8.6 t60 -48.19 -53.62 16.28 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.682 0.753 . . . . 0.0 112.352 -179.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 16.7 p -69.44 -22.66 63.64 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.192 -0.913 . . . . 0.0 112.456 -177.247 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.435 ' HG3' HG12 ' A' ' 72' ' ' VAL . 24.4 mt-10 -69.06 -43.28 74.94 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 121.224 -0.191 . . . . 0.0 111.476 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.599 HG21 ' O ' ' A' ' 73' ' ' HIS . 10.0 m -66.24 -44.61 91.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.726 178.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.489 HG21 ' O ' ' A' ' 73' ' ' HIS . 54.0 t -56.57 -47.26 82.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.929 177.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -62.78 -43.46 98.73 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.55 178.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.38 -40.75 65.26 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.339 0.59 . . . . 0.0 109.915 178.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 28.1 mt -68.84 -51.58 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.889 179.478 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 64.1 mt -59.88 -36.03 76.08 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.1 0.476 . . . . 0.0 110.644 179.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -57.91 -39.15 77.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.231 -0.895 . . . . 0.0 111.58 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 34.0 t -56.21 -44.87 79.91 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.244 179.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 136.29 -116.61 1.48 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.323 -0.941 . . . . 0.0 113.71 178.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -102.85 9.1 39.1 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.475 0.655 . . . . 0.0 110.506 -178.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 10.1 pttp -161.36 173.53 14.82 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.499 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 10.4 p -167.76 145.13 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -179.583 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.523 ' HB3' ' CB ' ' A' ' 7' ' ' PRO . . . -91.15 96.22 10.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.37 178.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.637 HG21 ' O ' ' A' ' 8' ' ' ILE . 11.1 tt -88.72 111.08 22.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.196 0.522 . . . . 0.0 110.831 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.93 106.0 17.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.982 -179.089 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.533 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 64.6 p -102.33 170.86 7.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.21 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.421 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 4.9 t -104.85 99.95 21.41 Favored Pre-proline 0 CA--C 1.534 0.358 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -178.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 74.6 Cg_exo -51.73 167.63 0.41 Allowed 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.487 2.125 . . . . 0.0 113.204 178.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -63.75 158.71 21.01 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.953 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . 0.48 ' HG3' ' HA2' ' A' ' 1' ' ' GLY . 0.0 OUTLIER -159.7 167.13 29.07 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.529 -179.716 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 8.3 p30 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.497 -0.763 . . . . 0.0 111.043 -179.934 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.476 0.847 0 N-CA-C 110.581 -0.155 . . . . 0.0 110.581 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 102' ' ' TRP . . . . . 0.483 ' CZ3' HG21 ' A' ' 24' ' ' ILE . 65.0 t-105 72.25 150.23 0.1 Allowed 'General case' 0 N--CA 1.466 0.348 0 O-C-N 123.718 0.636 . . . . 0.0 111.796 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 103' ' ' GLU . . . . . 0.403 ' HB2' ' O ' ' A' ' 25' ' ' ARG . 0.0 OUTLIER -158.96 172.05 18.92 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.765 179.448 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 3.4 p -70.43 168.77 15.41 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.803 179.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -72.66 122.08 20.85 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.327 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 106' ' ' LYS . . . . . 0.412 ' HB3' ' H ' ' B' ' 107' ' ' SER . 12.9 mptt -116.83 -155.62 0.59 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.003 -179.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 107' ' ' SER . . . . . 0.412 ' H ' ' HB3' ' B' ' 106' ' ' LYS . 1.5 m -50.21 132.93 24.07 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-O 121.086 0.47 . . . . 0.0 111.698 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 134.61 -41.46 1.45 Allowed Glycine 0 N--CA 1.445 -0.744 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.656 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 79.73 -151.03 33.49 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.424 179.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . 0.459 ' HA ' ' CE1' ' A' ' 73' ' ' HIS . 2.6 mm-40 -141.16 111.16 6.62 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -179.714 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 20.2 m -131.92 88.94 2.62 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.234 0.54 . . . . 0.0 109.915 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 112' ' ' ARG . . . . . 0.545 ' HB2' ' HA ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -83.06 150.08 26.54 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.954 -179.084 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . 0.621 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 0.3 OUTLIER . . . . . 0 C--O 1.244 0.787 0 CA-C-O 118.48 -0.772 . . . . 0.0 110.297 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.409 ' HA2' ' HG3' ' A' ' 95' ' ' GLU . . . . . . . . 0 N--CA 1.479 1.549 0 N-CA-C 112.171 -0.372 . . . . 0.0 112.171 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 159.88 -173.47 36.57 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 121.078 -0.582 . . . . 0.0 111.702 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 53.2 m -148.59 169.88 19.35 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 9.0 mtp 60.65 77.53 0.32 Allowed 'General case' 0 C--O 1.233 0.185 0 O-C-N 123.476 0.485 . . . . 0.0 111.619 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.422 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.0 mpt_? -73.26 136.86 78.6 Favored Pre-proline 0 C--N 1.326 -0.421 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 179.198 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.5 Cg_endo -89.22 110.02 0.48 Allowed 'Trans proline' 0 C--O 1.235 0.326 0 C-N-CA 123.196 2.597 . . . . 0.0 113.021 -179.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.481 ' CB ' ' HB2' ' A' ' 88' ' ' ALA . 16.9 Cg_exo -69.78 122.52 9.19 Favored 'Trans proline' 0 CA--C 1.515 -0.453 0 C-N-CA 122.327 2.018 . . . . 0.0 113.112 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.503 ' O ' HG21 ' A' ' 89' ' ' ILE . 0.9 OUTLIER -87.42 112.0 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.258 0 CA-C-N 115.129 -0.941 . . . . 0.0 108.778 178.317 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.403 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 3.2 mm -77.5 101.42 3.37 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.336 -178.721 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.48 HD13 ' HB3' ' A' ' 17' ' ' TYR . 5.4 mt -77.81 162.65 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 N-CA-C 106.904 -1.517 . . . . 0.0 106.904 176.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 15.0 t-80 -140.79 113.15 7.97 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.212 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 47.2 ttt180 -63.39 101.7 0.34 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.995 -178.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.12 49.95 1.0 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.45 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.12 12.7 81.5 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 121.199 -0.524 . . . . 0.0 113.1 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 3.8 ptpt -136.51 -82.59 0.38 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.849 0.325 . . . . 0.0 111.12 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.512 ' HB2' ' OXT' ' B' ' 113' ' ' LEU . 8.6 pttt -156.16 -179.59 8.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.421 -178.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . 0.613 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 19.3 m-85 -86.58 5.34 36.14 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-O 121.245 0.545 . . . . 0.0 110.191 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.599 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 54.46 49.22 61.49 Favored Glycine 0 C--O 1.215 -1.069 0 N-CA-C 116.697 1.439 . . . . 0.0 116.697 176.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.469 ' HA ' ' O ' ' A' ' 42' ' ' HIS . 9.3 p90 -165.6 149.23 8.07 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-O 122.345 1.069 . . . . 0.0 113.068 176.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.424 ' HA ' ' CB ' ' B' ' 112' ' ' ARG . 94.8 m -95.25 118.37 31.91 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 113.643 -1.617 . . . . 0.0 112.724 -179.161 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -89.91 84.86 6.24 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.802 0.334 . . . . 0.0 110.248 178.511 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.543 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 5.1 tpt180 -68.74 142.66 54.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.222 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.529 ' HB2' ' HD1' ' A' ' 73' ' ' HIS . . . -108.55 144.8 35.75 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 110.679 -0.119 . . . . 0.0 110.679 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 2.7 pt -148.29 141.0 18.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 CA-C-O 120.828 0.347 . . . . 0.0 111.389 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 11.6 mtm180 -105.93 93.6 4.72 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.469 HG13 ' C ' ' B' ' 101' ' ' SER . 10.9 m -81.43 114.29 22.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.508 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 4.5 m-85 -82.83 121.91 27.54 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 36.6 mmt -84.8 93.58 8.51 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.898 -179.2 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.72 -146.7 18.34 Favored Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.008 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -100.09 -14.02 18.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.11 0.481 . . . . 0.0 110.643 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.47 ' HB2' HG13 ' A' ' 33' ' ' VAL . 0.7 OUTLIER -72.3 169.53 16.05 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.959 -179.836 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.77 9.72 4.88 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.47 HG13 ' HB2' ' A' ' 31' ' ' SER . 3.6 p -78.75 130.02 36.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.425 0.631 . . . . 0.0 110.204 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.433 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 51.2 p90 -142.21 146.69 35.49 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.786 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -107.69 133.8 51.59 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 178.404 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 6.2 t -84.91 108.7 17.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.893 -179.52 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -117.82 177.97 4.58 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.469 ' CD2' HG13 ' A' ' 76' ' ' VAL . 98.7 m-70 -148.15 153.35 38.71 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 -179.509 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.0 mtm -147.24 145.25 29.38 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.083 -178.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.531 HG13 ' CD2' ' A' ' 54' ' ' LEU . 3.4 p -73.33 102.52 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.71 0 CA-C-O 121.946 0.879 . . . . 0.0 109.576 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.543 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 2.5 t-105 -70.48 -39.36 74.26 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.699 -1.137 . . . . 0.0 111.89 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' HIS . . . . . 0.469 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 4.3 t60 -155.23 124.5 6.3 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.368 -178.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.599 HG21 ' O ' ' A' ' 18' ' ' GLY . 4.2 p -122.04 124.92 72.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-O 121.575 0.702 . . . . 0.0 109.975 179.258 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.489 ' OE1' ' HA2' ' A' ' 18' ' ' GLY . 49.3 mt-10 -66.99 120.12 13.11 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 114.396 -1.275 . . . . 0.0 111.307 -179.391 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.547 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 14.7 p-10 -85.84 24.8 1.2 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.84 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -82.98 -23.4 55.54 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.959 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.454 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 170.92 -51.78 0.19 Allowed Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 119.568 -1.301 . . . . 0.0 114.745 -179.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -55.33 -128.45 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.085 0 C-N-CA 123.505 2.803 . . . . 0.0 116.92 -178.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.613 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -45.23 -40.01 6.97 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 -176.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.547 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -60.5 -61.08 2.85 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -177.956 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.454 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 5.5 mm-40 -61.01 -32.49 72.08 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.372 0.606 . . . . 0.0 110.781 -178.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -60.34 -29.84 69.14 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.677 179.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 136.8 -11.84 3.95 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.511 -0.852 . . . . 0.0 113.092 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.531 ' CD2' HG13 ' A' ' 40' ' ' VAL . 0.8 OUTLIER -68.08 116.04 8.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.406 0.622 . . . . 0.0 111.074 -179.642 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.423 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -93.77 125.56 38.45 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.026 178.975 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -51.42 140.18 18.14 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.876 0.37 . . . . 0.0 111.036 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.71 10.09 67.72 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.95 -0.643 . . . . 0.0 113.161 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.557 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 5.3 t0 -88.5 148.91 23.91 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.0 0.429 . . . . 0.0 110.659 179.59 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.43 HD11 ' O ' ' A' ' 38' ' ' HIS . 10.1 tp -95.91 130.03 42.99 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.726 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.4 HD12 ' N ' ' A' ' 60' ' ' ILE . 3.6 mp -88.15 126.14 41.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.127 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 41.9 p -102.8 -38.62 7.35 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.646 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -141.23 159.49 42.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.922 -178.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.3 p -140.65 111.14 3.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.125 0.488 . . . . 0.0 110.208 178.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.8 t30 60.76 26.34 16.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.372 179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.18 44.41 7.57 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.935 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.485 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.5 tp10 -153.19 110.5 2.64 Favored Pre-proline 0 N--CA 1.433 -1.312 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.519 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.485 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 3.7 Cg_endo -49.99 131.88 31.24 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 123.725 2.95 . . . . 0.0 111.407 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.5 m -88.23 -8.61 10.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.289 -178.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -56.75 94.85 0.01 OUTLIER 'General case' 0 N--CA 1.429 -1.51 0 CA-C-N 112.95 -1.932 . . . . 0.0 111.566 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 112.47 -11.82 25.91 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.435 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 29.7 mt -74.87 138.82 42.72 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 179.527 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -77.79 167.19 2.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.529 ' HD1' ' HB2' ' A' ' 23' ' ' ALA . 48.2 t60 -44.75 -46.42 10.46 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.779 0.8 . . . . 0.0 112.939 -179.314 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 19.3 p -80.51 -21.06 42.27 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.274 -0.875 . . . . 0.0 112.755 -176.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 25.5 mt-10 -70.23 -40.31 74.56 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 121.319 -0.153 . . . . 0.0 111.354 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.469 HG13 ' CD2' ' A' ' 38' ' ' HIS . 4.5 m -65.45 -45.76 91.97 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.183 0 C-N-CA 120.251 -0.58 . . . . 0.0 109.597 178.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 99.5 t -55.24 -47.02 78.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.187 -0.915 . . . . 0.0 109.926 177.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -64.81 -43.97 91.41 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.607 179.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.48 -42.08 66.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.768 178.346 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.415 HD12 ' HG ' ' B' ' 113' ' ' LEU . 16.2 mt -67.81 -52.15 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.719 179.484 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 93.1 mt -59.95 -32.78 71.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.017 179.312 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 8.3 ttmm -61.55 -38.91 89.19 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.352 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 36.2 t -56.0 -52.99 62.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.961 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 137.73 -134.43 6.96 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 119.96 -1.114 . . . . 0.0 113.132 179.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -73.67 -2.01 21.37 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.853 0.358 . . . . 0.0 111.799 -179.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -159.93 175.26 13.26 Favored 'General case' 0 N--CA 1.444 -0.773 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.503 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 13.4 p -166.84 147.1 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 O-C-N 123.596 0.56 . . . . 0.0 112.465 -179.062 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.481 ' HB2' ' CB ' ' A' ' 7' ' ' PRO . . . -93.51 96.76 10.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.642 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.503 HG21 ' O ' ' A' ' 8' ' ' ILE . 6.9 tt -88.8 111.57 22.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 120.973 0.416 . . . . 0.0 110.255 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.475 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -89.11 112.25 23.19 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.825 0.345 . . . . 0.0 111.074 -178.908 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.557 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 61.3 p -109.76 171.73 7.27 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.306 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.9 t -104.21 105.48 49.34 Favored Pre-proline 0 CA--C 1.537 0.464 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -55.73 175.24 0.22 Allowed 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.622 2.215 . . . . 0.0 113.403 178.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -63.71 159.95 18.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.287 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . 0.409 ' HG3' ' HA2' ' A' ' 1' ' ' GLY . 0.0 OUTLIER -157.05 157.19 34.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.073 0.463 . . . . 0.0 110.677 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 8.1 p30 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 118.504 -0.76 . . . . 0.0 110.891 -179.586 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 101' ' ' SER . . . . . 0.469 ' C ' HG13 ' A' ' 26' ' ' VAL . 11.2 m . . . . . 0 N--CA 1.48 1.042 0 CA-C-O 120.658 0.266 . . . . 0.0 110.953 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 102' ' ' TRP . . . . . . . . . . . . . 4.3 t-105 179.2 83.93 0.01 OUTLIER 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 8.5 mp0 -106.93 -76.46 0.61 Allowed 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.44 -177.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -99.99 144.88 28.51 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.796 0.332 . . . . 0.0 111.098 -179.438 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 3.4 t60 -108.9 -14.4 14.58 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.109 0.481 . . . . 0.0 110.592 179.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -67.42 97.3 0.56 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.792 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -156.58 25.83 0.34 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.29 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 147.65 -98.08 0.19 Allowed Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 121.066 -0.588 . . . . 0.0 111.945 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -175.71 -129.59 1.23 Allowed Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.939 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -130.71 35.83 3.97 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.208 0.528 . . . . 0.0 110.11 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 8.4 m -71.14 98.3 1.66 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.218 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 112' ' ' ARG . . . . . 0.424 ' CB ' ' HA ' ' A' ' 20' ' ' THR . 6.1 ptm180 -91.28 173.58 7.84 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.542 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . 0.512 ' OXT' ' HB2' ' A' ' 16' ' ' LYS . 3.4 mm? . . . . . 0 C--O 1.249 1.063 0 CA-C-O 117.907 -1.044 . . . . 0.0 109.223 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.671 0 N-CA-C 112.029 -0.428 . . . . 0.0 112.029 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -127.73 177.58 17.47 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 121.078 -0.582 . . . . 0.0 111.725 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.0 m -128.09 -178.93 4.73 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 28.6 mtp 57.06 74.05 0.43 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.008 0.432 . . . . 0.0 111.3 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.455 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.6 mpt_? -73.31 135.53 79.23 Favored Pre-proline 0 C--N 1.32 -0.692 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.9 Cg_endo -87.31 116.88 1.22 Allowed 'Trans proline' 0 N--CA 1.462 -0.371 0 C-N-CA 123.3 2.666 . . . . 0.0 112.842 -178.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.458 ' CB ' ' HB2' ' A' ' 88' ' ' ALA . 7.5 Cg_exo -75.12 122.08 6.93 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.078 1.852 . . . . 0.0 112.843 178.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.558 ' O ' HG21 ' A' ' 89' ' ' ILE . 2.3 mt -86.71 112.41 22.91 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.356 178.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.8 mm -79.06 99.74 3.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.218 -0.446 . . . . 0.0 112.049 -178.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.514 HG21 ' HB3' ' A' ' 17' ' ' TYR . 4.3 mt -77.64 160.47 4.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 177.059 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 24.8 t-80 -138.17 111.59 8.06 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.01 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 30.8 ttt180 -62.89 103.71 0.47 Allowed 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.838 -179.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.77 47.7 0.76 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.482 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.17 -4.86 65.04 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.287 -0.482 . . . . 0.0 113.344 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.422 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 9.8 ptpt -120.61 -80.12 0.62 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.996 0.398 . . . . 0.0 111.44 -179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.493 ' HB2' ' OXT' ' B' ' 113' ' ' LEU . 20.5 pttt -155.76 -174.96 5.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.64 0.257 . . . . 0.0 110.558 -178.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . 0.63 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 18.4 m-85 -89.71 5.65 44.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.254 0.55 . . . . 0.0 109.661 179.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.536 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 54.26 48.31 64.49 Favored Glycine 0 C--O 1.219 -0.842 0 N-CA-C 116.423 1.329 . . . . 0.0 116.423 176.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 42' ' ' HIS . 10.4 p90 -164.09 146.56 9.2 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-O 122.627 1.203 . . . . 0.0 112.836 176.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 91.8 m -93.64 114.83 27.24 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 113.46 -1.7 . . . . 0.0 112.51 -178.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -91.14 82.47 5.53 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-O 120.577 0.227 . . . . 0.0 111.218 179.119 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 1.3 tpt180 -73.22 144.63 46.68 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.761 -0.2 . . . . 0.0 111.185 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -100.66 146.08 27.63 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.039 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.5 pt -145.25 139.74 22.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 178.613 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.469 ' HB3' ' CD1' ' A' ' 34' ' ' TYR . 29.7 mtt180 -111.09 101.7 10.21 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.734 0.302 . . . . 0.0 110.998 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.3 m -84.3 115.47 26.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.696 179.081 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . 0.468 ' CD1' ' HB2' ' B' ' 103' ' ' GLU . 8.6 m-85 -80.22 148.08 30.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 48.3 mtt -87.18 62.82 7.5 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.9 -134.05 16.46 Favored Glycine 0 N--CA 1.447 -0.623 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -90.47 86.08 6.33 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 178.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.0 p -163.32 162.29 25.03 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.858 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -81.63 -17.16 49.11 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.454 0.645 . . . . 0.0 110.615 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.7 p -79.75 138.78 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 CA-C-N 115.434 -0.803 . . . . 0.0 110.879 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.469 ' CD1' ' HB3' ' A' ' 25' ' ' ARG . 51.3 p90 -149.71 155.96 41.07 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.827 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -103.78 128.53 51.19 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.021 0.439 . . . . 0.0 110.138 179.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t -86.3 107.17 16.35 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.605 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.6 m-70 -112.86 179.65 3.91 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.18 -0.463 . . . . 0.0 109.953 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.495 ' O ' HD11 ' A' ' 59' ' ' LEU . 99.1 m-70 -148.92 152.43 36.38 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 41.0 mtm -148.07 146.15 28.73 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.482 HG11 ' CD2' ' A' ' 54' ' ' LEU . 2.7 p -72.28 102.89 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.989 0.9 . . . . 0.0 109.342 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 2.1 t-105 -68.86 -39.92 79.61 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.442 -178.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' HIS . . . . . 0.488 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 2.0 t60 -158.34 128.46 6.02 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.67 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.536 HG21 ' O ' ' A' ' 18' ' ' GLY . 4.3 p -124.66 126.06 71.01 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-O 121.642 0.734 . . . . 0.0 110.422 179.426 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.501 ' O ' ' HB2' ' A' ' 50' ' ' SER . 5.7 mt-10 -68.69 123.06 19.85 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.279 -1.328 . . . . 0.0 111.914 -179.103 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.492 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 12.2 p-10 -86.11 20.3 2.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.925 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.36 -19.63 66.17 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 116.006 -0.543 . . . . 0.0 113.666 -179.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 168.18 -49.77 0.23 Allowed Glycine 0 CA--C 1.522 0.486 0 C-N-CA 119.134 -1.508 . . . . 0.0 114.733 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -60.33 -132.48 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.967 0 C-N-CA 123.117 2.544 . . . . 0.0 116.318 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.63 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -39.79 -41.63 1.15 Allowed 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 -176.703 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.501 ' HB2' ' O ' ' A' ' 44' ' ' GLU . 0.4 OUTLIER -63.07 -59.5 4.7 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 118.385 0.538 . . . . 0.0 112.227 -178.098 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -63.62 -21.93 66.63 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.272 0.558 . . . . 0.0 110.847 -179.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.2 -26.15 61.94 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.463 178.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 135.09 -12.95 4.41 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.204 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.482 ' CD2' HG11 ' A' ' 40' ' ' VAL . 1.2 tt -69.54 115.24 8.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.312 0.577 . . . . 0.0 111.646 -179.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.433 ' N ' HD23 ' A' ' 54' ' ' LEU . 0.0 OUTLIER -93.86 123.53 37.27 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.666 178.035 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.488 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 34.4 tt0 -49.36 143.77 6.13 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.945 0.402 . . . . 0.0 111.893 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.6 5.66 74.54 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.951 -0.643 . . . . 0.0 112.737 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.487 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 6.3 t0 -86.61 144.07 27.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.854 0.359 . . . . 0.0 110.693 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.495 HD11 ' O ' ' A' ' 38' ' ' HIS . 4.0 tp -92.17 134.12 35.16 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.509 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.4 mp -91.45 125.23 44.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.042 -179.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 45.8 p -101.66 -37.56 8.3 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.386 0.612 . . . . 0.0 110.886 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 69.5 m80 -141.73 157.68 44.75 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.148 -178.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.2 p -144.29 122.07 5.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 56.78 27.06 12.23 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.611 -179.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.28 43.25 26.04 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.917 -0.659 . . . . 0.0 111.596 -178.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.418 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.8 tp10 -150.42 104.4 3.11 Favored Pre-proline 0 N--CA 1.433 -1.319 0 C-N-CA 122.949 0.5 . . . . 0.0 109.732 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 47.3 Cg_exo -41.48 128.41 3.42 Favored 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 124.114 3.21 . . . . 0.0 111.512 177.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 32.7 m -86.25 -11.32 11.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 114.675 -1.148 . . . . 0.0 109.321 -178.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -54.6 97.09 0.02 OUTLIER 'General case' 0 N--CA 1.424 -1.728 0 CA-C-N 112.697 -2.047 . . . . 0.0 111.667 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.03 -13.86 23.97 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.828 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 41.2 mt -74.54 145.13 43.69 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.693 0.246 . . . . 0.0 110.349 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.414 HG21 ' O ' ' B' ' 107' ' ' SER . 0.3 OUTLIER -79.2 168.95 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 179.268 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.483 ' HB2' ' O ' ' B' ' 107' ' ' SER . 2.2 t60 -45.79 -50.19 14.28 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 121.45 0.643 . . . . 0.0 112.628 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 18.0 p -81.64 -14.54 56.56 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.84 -177.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -69.81 -42.6 73.48 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 121.25 -0.18 . . . . 0.0 111.286 -179.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 4.3 m -65.1 -44.56 95.63 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 CA-C-O 121.369 0.604 . . . . 0.0 109.43 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.42 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 83.5 t -53.14 -49.5 50.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 114.829 -1.078 . . . . 0.0 110.043 177.315 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -59.84 -45.33 92.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.005 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -54.16 -40.78 67.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.347 0.594 . . . . 0.0 110.216 178.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.401 HD12 ' HG ' ' B' ' 113' ' ' LEU . 14.5 mt -73.17 -49.75 36.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.091 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.42 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 91.1 mt -57.83 -41.67 82.75 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.837 0.351 . . . . 0.0 111.069 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 18.8 ttmt -60.58 -37.85 82.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.703 -0.68 . . . . 0.0 112.026 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 8.1 t -51.41 -45.81 62.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.456 -179.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.71 -132.49 7.95 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 119.879 -1.153 . . . . 0.0 114.023 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -73.14 -6.66 47.19 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 111.948 0.351 . . . . 0.0 111.948 -178.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.1 pttp -160.17 175.1 13.3 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-O 120.618 0.247 . . . . 0.0 110.985 -179.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.4 p -167.42 146.19 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.737 -0.665 . . . . 0.0 112.516 -179.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.458 ' HB2' ' CB ' ' A' ' 7' ' ' PRO . . . -92.87 98.57 11.46 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.886 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.558 HG21 ' O ' ' A' ' 8' ' ' ILE . 8.6 tt -92.62 113.32 27.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 120.81 0.338 . . . . 0.0 110.352 178.606 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.42 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -92.03 112.77 24.83 Favored 'General case' 0 C--N 1.323 -0.559 0 O-C-N 122.189 -0.32 . . . . 0.0 111.106 -179.052 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.487 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 77.6 p -108.41 175.68 5.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.525 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 4.1 t -104.04 102.14 30.12 Favored Pre-proline 0 CA--C 1.535 0.403 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -177.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_exo -53.99 170.9 0.41 Allowed 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 122.403 2.068 . . . . 0.0 112.913 177.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -63.66 157.86 22.91 Favored 'General case' 0 C--N 1.319 -0.717 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.57 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.33 161.95 33.36 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.943 0.402 . . . . 0.0 111.311 -179.202 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 5.7 p30 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 118.608 -0.71 . . . . 0.0 109.579 178.645 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 6.1 m . . . . . 0 N--CA 1.48 1.05 0 CA-C-O 120.665 0.269 . . . . 0.0 110.904 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 102' ' ' TRP . . . . . . . . . . . . . 35.2 p90 -147.77 147.67 30.12 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 103' ' ' GLU . . . . . 0.468 ' HB2' ' CD1' ' A' ' 27' ' ' TYR . 16.0 mp0 -91.72 -23.92 19.62 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.008 0.432 . . . . 0.0 110.698 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 1.4 m -136.93 147.61 46.49 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.299 -0.41 . . . . 0.0 109.939 179.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -116.39 -74.81 0.59 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.565 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -54.21 113.56 1.3 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.096 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 107' ' ' SER . . . . . 0.483 ' O ' ' HB2' ' A' ' 73' ' ' HIS . 3.6 m -140.31 66.76 1.38 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.133 -179.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 112.97 8.8 19.73 Favored Glycine 0 N--CA 1.449 -0.482 0 N-CA-C 111.671 -0.571 . . . . 0.0 111.671 -179.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 113.46 -156.43 15.63 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.991 -0.624 . . . . 0.0 111.943 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -135.33 60.84 1.68 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.298 0.57 . . . . 0.0 109.592 179.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 111' ' ' THR . . . . . 0.412 HG22 ' H ' ' B' ' 112' ' ' ARG . 0.2 OUTLIER -73.95 177.05 5.88 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.468 -179.413 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 112' ' ' ARG . . . . . 0.412 ' H ' HG22 ' B' ' 111' ' ' THR . 14.5 ptt180 -162.09 171.68 17.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.029 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . 0.493 ' OXT' ' HB2' ' A' ' 16' ' ' LYS . 3.3 mm? . . . . . 0 C--O 1.249 1.071 0 CA-C-O 117.752 -1.118 . . . . 0.0 110.074 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.691 0 N-CA-C 112.275 -0.33 . . . . 0.0 112.275 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -173.03 -179.07 43.47 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 121.131 -0.557 . . . . 0.0 111.737 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -139.16 -176.66 4.59 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 39.2 ttp 55.24 70.48 0.62 Allowed 'General case' 0 C--N 1.331 -0.223 0 O-C-N 123.514 0.508 . . . . 0.0 110.915 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.419 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.1 mpt_? -70.73 132.47 87.07 Favored Pre-proline 0 C--N 1.323 -0.558 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -87.28 109.58 0.74 Allowed 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.884 2.39 . . . . 0.0 113.15 -178.396 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 15.0 Cg_exo -69.16 124.22 11.11 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.183 1.922 . . . . 0.0 112.34 178.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.443 HD11 ' HA ' ' A' ' 54' ' ' LEU . 2.6 mt -88.49 109.43 19.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.166 -0.924 . . . . 0.0 108.784 178.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.42 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 4.2 mm -76.1 99.97 2.07 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.586 -178.519 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.506 HG21 ' HB3' ' A' ' 17' ' ' TYR . 4.8 mt -76.67 159.85 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 14.7 t-80 -137.98 109.67 7.08 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.358 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 47.2 ttt180 -63.58 104.32 0.64 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.59 -179.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.4 50.07 1.06 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.539 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.05 -37.86 2.85 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.289 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.5 ptpt -84.09 -86.63 0.12 Allowed 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.643 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 7.5 pttp -154.89 -174.4 4.97 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 121.116 -0.234 . . . . 0.0 111.374 -178.58 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . 0.686 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 19.8 m-85 -87.98 1.63 53.68 Favored 'General case' 0 C--O 1.224 -0.238 0 CA-C-O 121.019 0.438 . . . . 0.0 109.858 179.119 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.541 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 52.38 53.37 31.99 Favored Glycine 0 C--O 1.22 -0.766 0 N-CA-C 116.738 1.455 . . . . 0.0 116.738 176.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.49 ' HB3' HG21 ' A' ' 43' ' ' VAL . 9.3 p90 -165.49 144.88 6.51 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 122.409 1.099 . . . . 0.0 113.018 175.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.434 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 92.2 m -91.27 116.08 28.54 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 113.434 -1.712 . . . . 0.0 112.921 -178.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -90.34 82.15 5.98 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 121.063 0.459 . . . . 0.0 110.133 178.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.51 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 4.5 tpt180 -70.21 125.02 25.57 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.379 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.546 ' HA ' ' ND1' ' A' ' 38' ' ' HIS . . . -81.17 140.32 35.04 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.258 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.1 pt -141.02 139.9 33.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.235 0.541 . . . . 0.0 111.66 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 36.3 mtm180 -106.5 93.76 4.77 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.704 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.4 m -81.28 100.91 5.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.069 0.461 . . . . 0.0 110.574 179.131 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 24.8 m-85 -81.57 158.75 24.29 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.242 -0.436 . . . . 0.0 109.845 179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 99.7 mmm -93.88 55.66 2.16 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.176 0.512 . . . . 0.0 110.248 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 67.42 -126.01 24.51 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.63 -0.713 . . . . 0.0 112.012 -179.555 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -82.35 71.23 9.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.434 0.635 . . . . 0.0 109.574 179.303 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.1 m -161.76 149.41 14.7 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.483 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -78.84 -12.39 60.03 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.127 0.489 . . . . 0.0 111.416 -179.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 4.5 p -76.58 132.05 33.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.586 0.708 . . . . 0.0 110.784 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 27.8 p90 -150.29 148.5 28.94 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.56 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.15 128.99 48.41 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 178.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.9 t -81.59 96.41 3.25 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.049 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -110.06 -173.88 2.36 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.816 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.546 ' ND1' ' HA ' ' A' ' 23' ' ' ALA . 95.2 m-70 -149.7 166.29 29.82 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 48.4 ttm -153.19 138.17 17.22 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.515 HG11 ' CD2' ' A' ' 54' ' ' LEU . 2.6 p -71.6 102.52 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 CA-C-O 122.007 0.908 . . . . 0.0 108.871 178.848 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.51 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.1 t-105 -69.75 -41.16 75.59 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.814 -177.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' HIS . . . . . 0.46 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -154.59 128.09 8.55 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.076 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.541 HG21 ' O ' ' A' ' 18' ' ' GLY . 5.8 p -125.47 124.77 67.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 CA-C-O 121.834 0.826 . . . . 0.0 110.534 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.583 ' O ' ' HB2' ' A' ' 50' ' ' SER . 32.5 mt-10 -68.63 118.38 11.56 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 114.171 -1.377 . . . . 0.0 112.41 -178.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.601 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 14.7 p-10 -87.47 32.66 0.7 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.772 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -92.21 -22.66 29.16 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.866 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.518 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 174.85 -51.42 0.13 Allowed Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 119.534 -1.317 . . . . 0.0 114.281 -179.095 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -60.81 -131.13 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.401 2.734 . . . . 0.0 116.409 -179.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.686 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -42.12 -44.71 3.75 Favored 'General case' 0 N--CA 1.464 0.273 0 N-CA-C 114.644 1.35 . . . . 0.0 114.644 -176.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.601 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -62.12 -58.32 8.24 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -177.661 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.518 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 2.3 mm-40 -62.2 -24.68 67.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.213 0.53 . . . . 0.0 110.799 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -70.68 -24.58 62.7 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.267 178.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 136.31 -12.87 4.07 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.914 179.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.515 ' CD2' HG11 ' A' ' 40' ' ' VAL . 1.1 tt -69.29 116.29 9.55 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.623 0.725 . . . . 0.0 112.036 -179.201 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.494 ' N ' HD23 ' A' ' 54' ' ' LEU . 0.0 OUTLIER -97.86 125.71 42.88 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.587 177.883 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -50.87 141.76 12.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.894 0.378 . . . . 0.0 111.209 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 86.19 37.85 8.83 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.628 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.619 ' OD1' ' HB ' ' A' ' 91' ' ' THR . 1.9 t70 -120.52 142.73 49.04 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 179.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.481 HD11 ' O ' ' A' ' 38' ' ' HIS . 12.2 tp -89.72 128.1 36.05 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.89 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 4.0 mp -86.19 126.63 40.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.975 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 41.1 p -102.27 -41.27 6.42 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.871 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 59.3 m80 -138.94 160.24 40.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.176 -178.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.6 p -142.74 115.81 3.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.192 -0.458 . . . . 0.0 109.913 177.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 56.45 31.17 18.37 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.745 -0.662 . . . . 0.0 111.467 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.31 41.03 17.92 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.973 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.443 ' HA ' ' OE1' ' A' ' 66' ' ' GLU . 2.2 tp10 -152.15 108.48 2.82 Favored Pre-proline 0 N--CA 1.432 -1.373 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -48.48 134.61 26.48 Favored 'Trans proline' 0 N--CA 1.45 -1.061 0 C-N-CA 123.636 2.891 . . . . 0.0 111.066 178.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 32.9 m -87.57 -7.65 10.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-N 114.373 -1.285 . . . . 0.0 109.288 -178.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.9 m170 -55.59 96.12 0.02 OUTLIER 'General case' 0 N--CA 1.427 -1.591 0 CA-C-N 112.771 -2.013 . . . . 0.0 111.744 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.9 -12.56 27.1 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.291 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 31.1 mt -74.84 138.22 42.37 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.413 HG13 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -77.93 169.86 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.267 179.801 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -42.79 -48.9 5.76 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 123.76 0.824 . . . . 0.0 112.711 -179.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.1 p -84.52 -15.38 46.06 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.309 0.855 . . . . 0.0 113.309 -177.049 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.413 ' HG3' HG13 ' A' ' 72' ' ' VAL . 18.7 mt-10 -69.56 -43.39 73.0 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 121.096 -0.242 . . . . 0.0 111.35 -179.176 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.41 HG12 ' CD2' ' A' ' 38' ' ' HIS . 3.8 m -64.4 -45.23 96.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.26 0.552 . . . . 0.0 109.632 179.185 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.417 HG12 ' CD1' ' B' ' 113' ' ' LEU . 79.4 t -54.48 -48.28 69.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.877 177.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -59.56 -49.53 77.4 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.825 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.13 -41.31 62.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.605 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.407 HD12 ' HG ' ' B' ' 113' ' ' LEU . 16.0 mt -68.75 -52.88 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.972 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 46.4 mt -59.05 -37.5 77.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.201 0.524 . . . . 0.0 111.088 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -61.71 -38.62 88.53 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.928 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 40.4 t -52.76 -47.29 67.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.283 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 136.57 -135.39 7.7 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.122 -1.037 . . . . 0.0 112.921 179.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -79.6 1.76 24.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.132 0.491 . . . . 0.0 111.374 -179.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 10.9 pttp -159.67 175.46 13.15 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.173 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.42 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 12.2 p -167.55 147.18 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 O-C-N 123.567 0.542 . . . . 0.0 112.342 -179.105 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.43 93.84 7.9 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.867 179.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.418 HG21 ' O ' ' A' ' 8' ' ' ILE . 7.3 tt -88.3 113.59 25.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-O 121.055 0.455 . . . . 0.0 110.474 179.078 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -90.58 110.83 21.97 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.945 0.402 . . . . 0.0 111.235 -179.005 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.619 ' HB ' ' OD1' ' A' ' 58' ' ' ASP . 26.1 p -103.77 169.54 8.46 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.217 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.425 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 8.6 t -107.25 104.59 52.92 Favored Pre-proline 0 CA--C 1.534 0.342 0 C-N-CA 120.444 -0.502 . . . . 0.0 112.191 -178.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_exo -53.09 172.24 0.2 Allowed 'Trans proline' 0 C--N 1.351 0.669 0 C-N-CA 122.311 2.007 . . . . 0.0 113.039 178.099 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -64.28 163.39 13.0 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.048 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -156.72 177.98 10.86 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.4 -179.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 7.5 p30 . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.529 -0.748 . . . . 0.0 110.733 179.985 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 N--CA 1.478 0.971 0 CA-C-O 120.911 0.386 . . . . 0.0 110.354 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 102' ' ' TRP . . . . . 0.437 ' HH2' ' CH2' ' A' ' 41' ' ' TRP . 22.9 p90 -132.9 163.02 30.07 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.034 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -63.08 -73.09 0.12 Allowed 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.954 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -159.24 169.61 23.72 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.245 0.545 . . . . 0.0 111.466 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 8.0 t-160 -109.82 106.12 15.59 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.605 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 12.7 mptt -131.54 20.93 4.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.257 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 46.2 m -122.94 111.21 16.35 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.682 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 79.83 165.09 30.58 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.789 -0.719 . . . . 0.0 111.821 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -80.56 -109.52 0.29 Allowed Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.964 -0.636 . . . . 0.0 111.874 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -142.98 44.39 1.57 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.498 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 7.0 m -62.57 148.55 45.71 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.157 -0.929 . . . . 0.0 110.877 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 112' ' ' ARG . . . . . 0.412 ' CB ' ' HA ' ' A' ' 20' ' ' THR . 13.4 ptp180 -143.67 168.14 20.6 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.894 0.378 . . . . 0.0 110.692 -179.732 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . 0.643 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 3.3 mm? . . . . . 0 C--N 1.318 -0.764 0 CA-C-O 118.588 -0.72 . . . . 0.0 109.761 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.877 0 N-CA-C 111.92 -0.472 . . . . 0.0 111.92 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -149.13 169.42 29.51 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.159 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.6 m -135.4 157.84 45.87 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.38 -0.229 . . . . 0.0 110.38 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 93.4 mtp 61.23 75.75 0.4 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.148 0.499 . . . . 0.0 110.752 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.448 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.0 mpt_? -72.91 134.98 80.77 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.515 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.448 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 5.0 Cg_endo -92.24 116.02 0.37 Allowed 'Trans proline' 0 CA--C 1.531 0.355 0 C-N-CA 123.326 2.684 . . . . 0.0 113.408 -178.623 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.483 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 12.3 Cg_exo -73.88 124.22 9.02 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 122.439 2.093 . . . . 0.0 113.17 178.396 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.489 ' O ' HG22 ' A' ' 89' ' ' ILE . 1.1 mt -87.45 110.33 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.836 177.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.411 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 3.2 mm -78.16 97.91 2.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.569 -178.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.537 HG12 ' CB ' ' A' ' 49' ' ' ALA . 5.2 mt -77.35 162.08 4.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 177.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 53.0 t-80 -137.51 114.44 10.64 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 108.11 -1.071 . . . . 0.0 108.11 178.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 30.6 ttt180 -61.34 107.14 0.72 Allowed 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.675 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -80.68 50.68 1.37 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.432 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.34 23.54 74.97 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.638 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.516 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 9.8 ptpt -150.76 -80.6 0.11 Allowed 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.627 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 21.7 pttm -158.42 178.25 10.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.377 0.132 . . . . 0.0 110.822 -178.705 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . 0.478 ' HB3' HG21 ' A' ' 10' ' ' ILE . 6.4 m-85 -89.22 4.44 48.67 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-O 121.54 0.686 . . . . 0.0 109.536 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.16 -27.48 0.09 OUTLIER Glycine 0 C--N 1.335 0.528 0 N-CA-C 116.925 1.53 . . . . 0.0 116.925 177.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.559 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.4 p90 -81.7 147.64 29.38 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 122.445 1.117 . . . . 0.0 113.459 -176.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.431 ' HA ' ' HB2' ' B' ' 112' ' ' ARG . 87.5 m -97.0 112.55 24.26 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 113.344 -1.753 . . . . 0.0 111.575 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -85.37 86.78 7.35 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.316 178.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.498 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 5.5 tpt180 -68.71 146.13 53.23 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.472 179.697 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.518 ' O ' ' HA ' ' B' ' 105' ' ' HIS . . . -105.7 149.36 26.46 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.661 0.267 . . . . 0.0 111.177 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.5 pt -146.26 173.21 3.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.555 178.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 6.0 mtp180 -146.15 87.14 1.73 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.7 m -76.22 103.28 3.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.391 0.615 . . . . 0.0 111.673 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 23.3 m-85 -82.42 134.49 35.23 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.405 179.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 22.5 mmt -90.21 83.2 5.98 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.58 -161.37 44.45 Favored Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 -178.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -92.87 85.61 5.22 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -165.87 179.92 5.62 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.596 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -80.61 -6.58 58.51 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.749 0.309 . . . . 0.0 111.685 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.5 p -78.29 119.26 26.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.556 0.693 . . . . 0.0 110.764 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.0 p90 -159.93 148.59 17.36 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.974 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.83 130.21 55.0 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.958 0.409 . . . . 0.0 110.435 179.286 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 t -85.78 95.43 4.55 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.794 179.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 41.6 m-70 -104.94 -174.88 2.64 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.61 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.515 ' O ' HD11 ' A' ' 59' ' ' LEU . 99.1 m-70 -150.9 164.61 35.9 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -152.44 139.74 19.45 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.586 -178.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.459 HG13 HD21 ' A' ' 54' ' ' LEU . 1.9 p -73.64 105.51 3.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 121.808 0.813 . . . . 0.0 109.466 178.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.498 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 4.4 t-105 -69.87 -44.39 69.9 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.446 -1.252 . . . . 0.0 112.292 -177.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' HIS . . . . . 0.475 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 2.1 t60 -154.29 133.75 12.72 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.229 -0.896 . . . . 0.0 110.046 -178.332 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.559 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 3.0 p -126.87 129.16 71.36 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 CA-C-O 121.629 0.728 . . . . 0.0 110.859 179.238 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.422 ' O ' ' HB2' ' A' ' 50' ' ' SER . 15.5 mt-10 -66.05 119.79 12.01 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 114.74 -1.118 . . . . 0.0 111.583 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.556 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 9.4 p-10 -88.07 19.16 3.78 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.174 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.03 4.12 60.7 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.372 -0.918 . . . . 0.0 113.837 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 161.27 -55.74 0.31 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 118.795 -1.669 . . . . 0.0 115.187 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -60.57 -135.14 0.0 OUTLIER 'Trans proline' 0 CA--C 1.545 1.04 0 C-N-CA 123.043 2.495 . . . . 0.0 116.679 -178.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.537 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -43.17 -36.99 1.9 Allowed 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 115.208 1.558 . . . . 0.0 115.208 -176.582 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.556 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 1.9 m -62.29 -55.08 31.77 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 118.655 0.661 . . . . 0.0 111.546 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -63.5 -24.31 67.76 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.008 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.08 -24.79 60.71 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.905 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.54 -7.33 6.23 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.565 -0.826 . . . . 0.0 113.104 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.459 HD21 HG13 ' A' ' 40' ' ' VAL . 5.1 tt -70.59 113.81 8.07 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.044 0.45 . . . . 0.0 110.88 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.17 122.32 32.35 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.931 178.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.444 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 36.3 tt0 -49.49 131.73 20.88 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 120.905 0.383 . . . . 0.0 110.664 177.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.37 65.89 1.35 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.294 -178.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.495 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.7 t0 -144.84 148.31 33.84 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.515 HD11 ' O ' ' A' ' 38' ' ' HIS . 8.7 tp -92.5 127.78 38.12 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.22 -179.635 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 4.0 mp -87.05 125.18 40.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.704 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 52.8 p -102.07 -39.08 7.46 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.379 0.609 . . . . 0.0 110.599 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 59.0 m80 -139.31 155.26 47.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.089 -178.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.7 p -138.2 113.07 9.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.851 177.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.8 t30 56.46 32.84 21.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.786 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.12 43.22 22.02 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.12 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.44 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.5 tp10 -149.99 106.2 3.21 Favored Pre-proline 0 N--CA 1.44 -0.949 0 C-N-CA 122.578 0.351 . . . . 0.0 110.375 179.673 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.44 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.7 Cg_exo -45.09 129.51 10.16 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 123.71 2.94 . . . . 0.0 111.538 177.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 31.3 m -86.76 -9.56 11.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-N 114.419 -1.264 . . . . 0.0 109.18 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.3 m170 -54.51 97.64 0.02 OUTLIER 'General case' 0 N--CA 1.426 -1.633 0 CA-C-N 112.602 -2.09 . . . . 0.0 112.074 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 108.98 -11.02 34.44 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.63 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.6 mt -75.79 139.96 42.08 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -79.3 170.47 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.566 ' O ' HG21 ' A' ' 76' ' ' VAL . 55.4 t60 -44.37 -54.75 5.55 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.668 0.747 . . . . 0.0 112.417 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 27.6 p -73.14 -20.69 60.86 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.111 -0.949 . . . . 0.0 112.788 -177.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.4 mt-10 -69.21 -41.81 76.57 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 121.271 -0.171 . . . . 0.0 111.168 -179.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.566 HG21 ' O ' ' A' ' 73' ' ' HIS . 13.6 m -67.05 -46.95 83.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 C-N-CA 120.476 -0.49 . . . . 0.0 110.024 178.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.455 HG21 ' O ' ' A' ' 73' ' ' HIS . 40.6 t -53.13 -46.49 55.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.18 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -66.6 -42.48 86.82 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.836 179.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -54.04 -39.27 66.06 Favored 'General case' 0 C--N 1.327 -0.388 0 O-C-N 123.681 0.613 . . . . 0.0 109.801 178.076 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.463 HD12 ' HG ' ' B' ' 113' ' ' LEU . 16.4 mt -71.28 -51.91 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.494 179.472 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 82.5 mt -57.95 -32.69 68.08 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-O 121.104 0.478 . . . . 0.0 110.609 179.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 24.8 ttmt -58.67 -40.0 82.28 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.226 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 26.1 t -56.9 -55.04 39.65 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.745 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 134.99 -127.96 4.59 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.069 -1.063 . . . . 0.0 113.807 178.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -75.18 -2.9 29.95 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -178.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.4 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 18.5 pttp -159.77 175.33 13.25 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.249 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 9' ' ' ILE . 13.5 p -166.67 145.1 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.505 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.465 ' HB2' ' CB ' ' A' ' 7' ' ' PRO . . . -93.88 92.36 7.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.3 -0.864 . . . . 0.0 111.665 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.489 HG22 ' O ' ' A' ' 8' ' ' ILE . 6.8 tt -88.05 112.24 23.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-O 121.014 0.435 . . . . 0.0 110.346 179.262 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 1.0 OUTLIER -91.95 115.39 28.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.779 0.323 . . . . 0.0 111.326 -178.829 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.495 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 64.5 p -109.4 175.39 5.47 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.315 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.489 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 6.3 t -103.9 105.16 46.96 Favored Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 113.04 0.755 . . . . 0.0 113.04 -178.059 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -52.8 171.86 0.2 Allowed 'Trans proline' 0 C--O 1.236 0.421 0 C-N-CA 122.64 2.226 . . . . 0.0 112.928 177.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -66.47 159.16 27.74 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.796 179.532 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -155.47 160.31 40.49 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.218 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 10.8 p30 . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.47 -0.776 . . . . 0.0 110.516 -179.709 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 15.9 m . . . . . 0 N--CA 1.477 0.902 0 CA-C-O 120.566 0.222 . . . . 0.0 110.597 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 102' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -136.37 34.27 2.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.301 0.572 . . . . 0.0 109.877 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -74.61 -71.98 0.31 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.397 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 57.3 m -155.7 -160.03 0.98 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.193 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 105' ' ' HIS . . . . . 0.518 ' HA ' ' O ' ' A' ' 23' ' ' ALA . 4.5 p80 -73.01 82.31 1.23 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.343 0.592 . . . . 0.0 111.178 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 83.2 mttt -94.98 12.81 27.1 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.96 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.03 21.87 5.34 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.56 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.28 -123.95 1.17 Allowed Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.533 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -158.63 -128.78 1.02 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.057 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -117.43 33.15 5.77 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 122.79 -0.241 . . . . 0.0 111.317 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 111' ' ' THR . . . . . 0.401 ' HB ' ' CD2' ' A' ' 73' ' ' HIS . 25.8 m -72.45 93.67 1.57 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.438 0.637 . . . . 0.0 110.022 179.336 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 112' ' ' ARG . . . . . 0.431 ' HB2' ' HA ' ' A' ' 20' ' ' THR . 6.8 ptp85 -81.9 174.06 11.64 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.54 -0.755 . . . . 0.0 110.459 -179.567 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . 0.627 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 4.1 mm? . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.517 -0.754 . . . . 0.0 110.852 -179.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.452 ' HA2' ' HG3' ' A' ' 95' ' ' GLU . . . . . . . . 0 N--CA 1.482 1.72 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -112.45 -169.32 17.87 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.173 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 m -134.03 152.56 51.89 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.574 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 89.9 mtp 62.3 78.28 0.3 Allowed 'General case' 0 N--CA 1.463 0.192 0 O-C-N 123.715 0.635 . . . . 0.0 110.631 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.412 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.9 mpt_? -72.02 148.92 92.07 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.264 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 8.4 Cg_endo -95.43 113.06 0.15 Allowed 'Trans proline' 0 N--CA 1.461 -0.414 0 C-N-CA 123.742 2.961 . . . . 0.0 113.173 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.476 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 12.5 Cg_exo -72.86 122.87 8.51 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.463 2.109 . . . . 0.0 113.299 178.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.442 HG22 ' N ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -83.38 109.14 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.28 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.072 177.708 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.2 mm -77.36 97.31 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.174 -178.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.506 HG12 ' CB ' ' A' ' 49' ' ' ALA . 5.7 mt -76.89 159.1 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . 0.421 ' N ' HG23 ' A' ' 10' ' ' ILE . 47.3 t-80 -136.5 112.18 9.41 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 46.7 ttt180 -63.67 109.16 1.6 Allowed 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.728 -178.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -83.36 52.31 2.19 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.87 178.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.54 -49.65 4.21 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-N 115.767 -0.652 . . . . 0.0 112.243 -179.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.5 ptpt -71.76 -90.41 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.544 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 16.4 pttm -158.53 -171.56 3.5 Favored 'General case' 0 C--N 1.327 -0.4 0 O-C-N 122.434 -0.166 . . . . 0.0 111.092 -178.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . 0.462 ' HB3' HG21 ' A' ' 10' ' ' ILE . 12.2 m-85 -88.11 -1.76 58.2 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.517 0.675 . . . . 0.0 109.744 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.522 ' HA3' ' HB2' ' A' ' 44' ' ' GLU . . . 63.62 -19.34 0.09 OUTLIER Glycine 0 CA--C 1.519 0.342 0 N-CA-C 117.057 1.583 . . . . 0.0 117.057 177.507 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.57 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.4 p90 -85.44 146.89 26.75 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 122.505 1.145 . . . . 0.0 113.524 -177.253 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 86.1 m -94.65 113.55 25.37 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.601 -1.636 . . . . 0.0 112.364 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.49 81.5 6.54 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.931 0.396 . . . . 0.0 110.692 178.694 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.437 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 0.1 OUTLIER -69.87 134.42 48.44 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.259 179.417 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -103.37 141.63 35.61 Favored 'General case' 0 C--N 1.328 -0.344 0 O-C-N 123.011 0.195 . . . . 0.0 111.141 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -146.48 -171.92 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.758 179.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.423 ' HD2' ' OG ' ' B' ' 107' ' ' SER . 0.6 OUTLIER -150.08 118.69 6.53 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.26 0.552 . . . . 0.0 110.643 179.326 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.513 ' O ' ' HB2' ' A' ' 34' ' ' TYR . 14.3 m -84.19 -167.77 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.367 178.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -156.19 136.35 12.9 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.641 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 22.3 mmt -121.78 112.49 18.43 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 112.385 0.513 . . . . 0.0 112.385 -177.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.33 -156.7 45.43 Favored Glycine 0 N--CA 1.453 -0.2 0 CA-C-N 116.07 -0.513 . . . . 0.0 113.623 178.24 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -91.48 -19.79 22.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.035 0.445 . . . . 0.0 110.274 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.7 m -71.0 160.53 32.75 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.071 179.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.89 21.05 0.57 Allowed 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 3.9 p -81.35 131.06 34.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.416 0.627 . . . . 0.0 110.081 179.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . 0.513 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 54.1 p90 -147.37 156.06 42.55 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.626 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.48 ' O ' HG22 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -116.05 129.96 56.59 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.86 0.362 . . . . 0.0 110.861 179.209 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 9.4 t -81.01 102.37 6.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.401 ' NE2' ' HB ' ' A' ' 35' ' ' THR . 98.4 m-70 -108.48 -176.06 2.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.238 -179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.503 ' CD2' HG13 ' A' ' 76' ' ' VAL . 97.7 m-70 -148.46 168.5 22.51 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 3.1 mtm -157.05 137.76 13.24 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 120.61 0.243 . . . . 0.0 110.425 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.47 ' CG1' HD22 ' A' ' 54' ' ' LEU . 1.9 p -72.83 100.63 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-O 122.126 0.965 . . . . 0.0 108.817 178.625 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.437 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.2 t-105 -69.77 -41.08 75.61 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.025 -1.443 . . . . 0.0 112.711 -177.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' HIS . . . . . 0.453 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -156.39 127.19 6.81 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.374 -178.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.57 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 2.4 p -118.84 129.0 75.65 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 CA-C-O 121.251 0.548 . . . . 0.0 110.024 179.18 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.522 ' HB2' ' HA3' ' A' ' 18' ' ' GLY . 5.2 mt-10 -63.9 114.04 3.83 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 114.735 -1.121 . . . . 0.0 111.645 -178.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.476 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 11.8 p-10 -83.17 39.54 0.65 Allowed 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.92 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -122.75 11.88 8.83 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.407 -0.901 . . . . 0.0 113.935 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 156.75 -61.99 0.33 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 118.633 -1.746 . . . . 0.0 115.153 179.314 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . 0.415 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 51.2 Cg_exo -61.04 -133.41 0.0 OUTLIER 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 123.17 2.58 . . . . 0.0 116.958 -177.46 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.506 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -42.13 -35.36 0.91 Allowed 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 114.95 1.463 . . . . 0.0 114.95 -176.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.476 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -61.13 -59.61 5.07 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 118.33 0.513 . . . . 0.0 111.706 -178.921 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -63.61 -30.24 71.38 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.548 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.19 -29.28 70.26 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.673 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.3 -10.5 5.59 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.196 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.47 HD22 ' CG1' ' A' ' 40' ' ' VAL . 5.6 tt -66.85 114.45 5.71 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.849 0.357 . . . . 0.0 110.48 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.15 122.49 32.5 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.486 178.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.427 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 40.2 tt0 -51.34 138.0 22.17 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.989 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 83.14 47.35 5.82 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.222 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.578 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.3 t0 -127.24 149.23 50.1 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.493 HD11 ' O ' ' A' ' 38' ' ' HIS . 19.9 tp -93.03 125.8 37.8 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.149 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.8 mp -83.82 124.74 39.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.276 -179.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 57.8 p -99.51 -40.0 8.06 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.378 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -142.05 157.31 45.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.122 -178.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.67 115.21 8.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 177.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 59.62 31.1 20.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.418 -179.4 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 73.23 45.5 30.78 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.372 -178.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.4 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 1.5 tp10 -151.75 111.23 2.93 Favored Pre-proline 0 N--CA 1.433 -1.316 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 -179.246 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 4.7 Cg_endo -50.99 133.47 40.65 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 123.551 2.834 . . . . 0.0 111.257 178.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 35.1 m -90.01 -7.87 10.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.806 -178.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.8 m170 -55.41 95.06 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.54 0 CA-C-N 112.977 -1.919 . . . . 0.0 111.96 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.29 -9.37 24.59 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.394 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 32.2 mt -77.39 139.76 39.78 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -81.14 171.18 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.162 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.49 ' HB2' ' O ' ' B' ' 107' ' ' SER . 2.1 t60 -42.02 -49.02 4.71 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 123.682 0.793 . . . . 0.0 112.934 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 30.6 p -82.11 -21.14 36.88 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 -176.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -67.53 -40.83 85.06 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 121.082 -0.247 . . . . 0.0 111.38 -178.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.503 HG13 ' CD2' ' A' ' 38' ' ' HIS . 3.9 m -65.68 -46.85 88.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.267 0.556 . . . . 0.0 109.599 178.66 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.437 HG21 ' O ' ' A' ' 73' ' ' HIS . 58.4 t -54.79 -45.71 74.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.295 177.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -62.96 -45.12 93.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.942 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.53 -41.66 66.63 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.34 0.59 . . . . 0.0 110.041 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.401 HD12 ' HG ' ' B' ' 113' ' ' LEU . 12.0 mt -68.77 -50.66 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.964 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 65.9 mt -59.23 -39.54 83.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.252 0.549 . . . . 0.0 110.478 178.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -61.46 -36.58 80.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.69 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 44.3 t -53.76 -47.64 70.49 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.129 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 138.06 -124.45 2.96 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.264 -0.969 . . . . 0.0 113.295 179.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -93.65 7.07 46.16 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.265 0.555 . . . . 0.0 110.887 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 19.8 pttp -161.12 179.21 8.59 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.859 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.4 p -170.15 143.68 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 O-C-N 123.609 0.568 . . . . 0.0 112.439 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.09 90.44 6.4 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.649 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 5.0 tt -87.78 115.65 28.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-O 120.954 0.407 . . . . 0.0 110.553 179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 3.6 t -94.76 116.04 28.25 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.777 0.322 . . . . 0.0 111.395 -178.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.578 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 81.4 p -109.37 173.31 6.38 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.7 179.026 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.6 t -101.44 104.18 32.11 Favored Pre-proline 0 CA--C 1.536 0.414 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 91' ' ' THR . 77.1 Cg_exo -54.37 177.46 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.577 2.185 . . . . 0.0 113.015 177.609 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -62.55 156.47 23.0 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.396 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . 0.452 ' HG3' ' HA2' ' A' ' 1' ' ' GLY . 0.7 OUTLIER -158.78 160.29 36.12 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.764 -179.951 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 10.2 p30 . . . . . 0 C--O 1.251 1.162 0 CA-C-O 118.362 -0.828 . . . . 0.0 109.319 178.925 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 73.3 m . . . . . 0 N--CA 1.475 0.799 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 102' ' ' TRP . . . . . 0.442 ' H ' ' HA ' ' A' ' 26' ' ' VAL . 1.9 t90 66.26 49.17 1.51 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-O 121.75 0.786 . . . . 0.0 109.034 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 10.9 mp0 -74.66 -21.94 59.15 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.284 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 69.5 p -170.42 176.65 4.34 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.105 0.479 . . . . 0.0 111.617 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -113.01 27.42 9.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.381 178.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 57.2 mtpt -75.52 34.38 0.11 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.714 -178.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 107' ' ' SER . . . . . 0.49 ' O ' ' HB2' ' A' ' 73' ' ' HIS . 9.4 m -113.07 6.47 17.63 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.213 0.53 . . . . 0.0 109.751 178.838 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.29 -161.37 28.17 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.628 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -114.75 -92.59 1.88 Allowed Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.196 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -156.98 97.73 1.7 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 4.1 m -127.1 79.33 1.87 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.144 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 112' ' ' ARG . . . . . 0.404 HH11 ' HD3' ' B' ' 112' ' ' ARG . 7.2 ptt180 -67.8 162.8 23.16 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.537 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . 0.544 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 4.5 mm? . . . . . 0 C--O 1.25 1.099 0 CA-C-O 118.711 -0.662 . . . . 0.0 110.78 -178.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.782 0 N-CA-C 112.1 -0.4 . . . . 0.0 112.1 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -169.28 -171.25 34.78 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.899 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.7 m -147.19 158.22 43.87 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 110.386 -0.227 . . . . 0.0 110.386 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 77.4 mtp 63.41 78.94 0.27 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.183 0.516 . . . . 0.0 110.939 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 7.9 mpt_? -72.78 139.31 80.26 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.733 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -87.87 109.8 0.66 Allowed 'Trans proline' 0 C--O 1.236 0.418 0 C-N-CA 123.204 2.603 . . . . 0.0 112.826 -179.026 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.45 ' HA ' ' O ' ' A' ' 89' ' ' ILE . 12.0 Cg_exo -72.81 121.39 7.31 Favored 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 122.368 2.045 . . . . 0.0 113.041 179.02 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -83.0 110.86 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 CA-C-N 115.388 -0.824 . . . . 0.0 108.802 178.12 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.4 mm -77.16 100.75 2.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.75 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.488 HG21 ' HB3' ' A' ' 17' ' ' TYR . 6.0 mt -76.54 163.51 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' HIS . . . . . . . . . . . . . 29.0 t-80 -141.53 107.1 5.06 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.105 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 52.6 ttt-85 -62.19 110.31 1.58 Allowed 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.164 -178.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -81.72 46.47 0.98 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.774 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.79 -0.26 66.32 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 121.163 -0.541 . . . . 0.0 112.814 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.41 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 9.1 ptpt -119.65 -82.38 0.64 Allowed 'General case' 0 C--N 1.325 -0.458 0 O-C-N 122.891 -0.182 . . . . 0.0 111.277 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.508 ' HB2' ' OXT' ' B' ' 113' ' ' LEU . 17.1 pttt -155.14 -178.71 7.45 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.702 -178.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' TYR . . . . . 0.616 ' O ' ' HB3' ' A' ' 49' ' ' ALA . 16.9 m-85 -88.28 5.64 40.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.17 0.51 . . . . 0.0 110.223 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . 0.595 ' O ' HG21 ' A' ' 43' ' ' VAL . . . 53.27 48.99 58.18 Favored Glycine 0 C--O 1.217 -0.909 0 N-CA-C 116.744 1.458 . . . . 0.0 116.744 177.062 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.43 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 6.3 p90 -164.42 147.38 9.04 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 122.457 1.123 . . . . 0.0 112.977 176.304 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 97.9 m -92.39 115.31 27.97 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 113.42 -1.718 . . . . 0.0 112.414 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.22 84.48 6.51 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.74 0.305 . . . . 0.0 110.449 178.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.493 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 6.1 tpt180 -68.73 140.24 55.37 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.453 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.403 ' CB ' ' HD1' ' A' ' 73' ' ' HIS . . . -105.33 138.49 41.45 Favored 'General case' 0 C--N 1.328 -0.363 0 O-C-N 123.074 0.234 . . . . 0.0 110.462 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 4.3 pt -143.04 144.52 23.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-O 121.298 0.57 . . . . 0.0 111.765 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 91.0 mtt180 -115.56 90.51 3.35 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.446 179.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.2 m -75.69 118.03 21.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.12 -179.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 11.2 m-85 -78.19 156.55 29.77 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.256 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.0 mtm -136.41 80.15 1.8 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.789 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.18 -157.76 14.9 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.375 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -93.36 -19.22 21.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.921 0.391 . . . . 0.0 111.054 -179.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -73.69 172.08 12.09 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.163 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -81.22 22.16 0.68 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.417 0.627 . . . . 0.0 110.676 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.8 p -81.83 127.54 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 CA-C-O 121.455 0.645 . . . . 0.0 110.439 179.362 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 19.0 p90 -147.43 157.26 43.5 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.418 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.77 124.64 50.9 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.198 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 t -82.55 102.31 8.35 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.789 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 54.9 m-70 -115.41 -175.46 2.71 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.676 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.506 ' CD2' HG13 ' A' ' 76' ' ' VAL . 97.1 m-70 -148.79 153.3 37.95 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 48.3 mtm -148.68 141.02 24.15 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.033 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.428 HG13 HD21 ' A' ' 54' ' ' LEU . 2.3 p -72.55 104.78 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-O 121.784 0.802 . . . . 0.0 109.581 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . 0.493 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.2 t-105 -70.07 -42.55 72.65 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.476 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' HIS . . . . . 0.432 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 0.9 OUTLIER -155.08 132.56 11.18 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.158 -179.125 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.595 HG21 ' O ' ' A' ' 18' ' ' GLY . 4.0 p -127.75 130.08 70.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 121.575 0.702 . . . . 0.0 110.508 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.556 ' O ' ' HB2' ' A' ' 50' ' ' SER . 37.1 mt-10 -67.04 115.07 6.34 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 114.583 -1.19 . . . . 0.0 111.811 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.533 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 11.9 p-10 -84.19 35.72 0.55 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.649 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.94 -26.12 8.09 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.708 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -179.93 -54.4 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 119.439 -1.362 . . . . 0.0 114.688 -178.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -58.07 -129.57 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 0.975 0 C-N-CA 123.524 2.816 . . . . 0.0 116.68 -178.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.616 ' HB3' ' O ' ' A' ' 17' ' ' TYR . . . -43.36 -42.87 4.8 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -176.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.556 ' HB2' ' O ' ' A' ' 44' ' ' GLU . 0.4 OUTLIER -62.09 -62.25 1.91 Allowed 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 112.742 0.645 . . . . 0.0 112.742 -177.668 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -62.04 -22.69 65.94 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.02 0.438 . . . . 0.0 111.072 -178.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -71.06 -24.57 62.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.692 179.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.05 -15.05 3.76 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.75 -0.738 . . . . 0.0 113.03 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LEU . . . . . 0.428 HD21 HG13 ' A' ' 40' ' ' VAL . 5.1 tt -69.42 113.07 6.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.049 0.452 . . . . 0.0 110.787 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ARG . . . . . 0.511 ' HD3' ' O ' ' A' ' 55' ' ' ARG . 0.0 OUTLIER -93.74 123.73 37.27 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.573 178.313 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.432 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 37.0 tt0 -49.08 134.43 17.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.247 0.546 . . . . 0.0 111.31 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 89.77 60.79 1.4 Allowed Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.734 -0.745 . . . . 0.0 111.681 -179.222 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.607 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.4 t0 -140.75 155.25 46.48 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.495 HD11 ' O ' ' A' ' 38' ' ' HIS . 13.3 tp -102.75 125.27 49.42 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.931 -179.414 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.5 mp -82.68 122.75 37.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.276 -179.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.43 ' O ' HG22 ' A' ' 68' ' ' VAL . 44.8 p -100.59 -34.1 10.03 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.652 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 75.2 m80 -146.04 162.53 37.68 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.081 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.3 p -145.89 114.83 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.65 177.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 57.58 32.57 22.03 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.766 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 68.98 47.44 54.47 Favored Glycine 0 N--CA 1.444 -0.768 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -178.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -149.55 99.98 3.34 Favored Pre-proline 0 N--CA 1.442 -0.835 0 C-N-CA 122.834 0.454 . . . . 0.0 110.079 -179.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -36.37 124.36 0.35 Allowed 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 124.424 3.416 . . . . 0.0 112.564 177.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.43 HG22 ' O ' ' A' ' 61' ' ' THR . 27.0 m -86.68 -11.11 11.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.055 -179.411 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.5 m170 -56.57 98.14 0.03 OUTLIER 'General case' 0 N--CA 1.425 -1.688 0 CA-C-N 112.83 -1.986 . . . . 0.0 111.301 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 109.51 -6.41 31.71 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.441 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 25.0 mt -79.01 137.76 37.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.717 0.259 . . . . 0.0 110.517 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -79.92 170.05 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.28 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.485 ' O ' HG21 ' A' ' 76' ' ' VAL . 38.3 t60 -44.09 -54.4 5.56 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.643 0.735 . . . . 0.0 112.764 -179.452 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 21.1 p -73.53 -21.0 60.5 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 115.312 -0.858 . . . . 0.0 113.236 -176.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -68.4 -41.97 79.72 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 120.969 -0.292 . . . . 0.0 111.608 -179.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.506 HG13 ' CD2' ' A' ' 38' ' ' HIS . 3.4 m -66.39 -44.58 90.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.95 179.04 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.434 HG21 ' O ' ' A' ' 73' ' ' HIS . 50.2 t -53.68 -47.99 60.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.826 177.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 56.8 mt-10 -63.6 -45.2 91.45 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.894 178.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.41 -40.48 65.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.294 0.569 . . . . 0.0 109.822 178.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 21.8 mt -70.58 -53.21 23.39 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.775 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.267 179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 83.8 mt -57.57 -38.39 74.73 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 120.887 0.375 . . . . 0.0 111.294 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 17.8 ttmt -59.6 -37.96 79.95 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.753 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 34.8 t -56.25 -39.52 72.71 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.972 -179.286 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.63 -141.38 12.91 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.11 -1.043 . . . . 0.0 112.997 179.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 23.5 p30 -75.13 5.5 5.3 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -179.101 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 16.0 pttp -162.71 171.18 17.22 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.726 -0.215 . . . . 0.0 110.452 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 11.6 p -164.96 147.06 2.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.73 94.22 7.98 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.748 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.45 ' O ' ' HA ' ' A' ' 7' ' ' PRO . 4.5 tt -88.61 116.16 29.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.749 0.309 . . . . 0.0 110.492 179.277 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.436 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.1 OUTLIER -93.39 112.9 24.93 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.628 0.251 . . . . 0.0 111.508 -178.752 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.607 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 80.4 p -107.14 179.99 4.1 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 178.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.414 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 4.0 t -114.1 104.11 54.95 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-O 121.232 0.539 . . . . 0.0 112.322 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -56.31 175.53 0.25 Allowed 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.68 2.253 . . . . 0.0 113.344 178.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -65.32 162.33 17.74 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.476 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -160.3 154.73 23.66 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.143 179.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 12.8 p30 . . . . . 0 C--O 1.251 1.132 0 CA-C-O 118.532 -0.747 . . . . 0.0 110.535 -179.926 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.478 0.965 0 CA-C-O 120.636 0.255 . . . . 0.0 110.808 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 102' ' ' TRP . . . . . . . . . . . . . 6.5 t90 -174.76 115.68 0.17 Allowed 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.265 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -87.55 -85.58 0.17 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.884 178.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 5.3 m -138.7 -162.21 1.28 Allowed 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -115.03 97.25 6.11 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.171 0.51 . . . . 0.0 110.418 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 58.7 mttp -130.96 23.61 4.94 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.24 4.64 51.8 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.961 -179.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 151.42 -166.45 30.66 Favored Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.515 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -86.66 -143.02 7.37 Favored Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.192 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -131.53 39.36 3.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.192 0.52 . . . . 0.0 110.204 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 11.5 m -69.83 103.43 2.19 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.71 179.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 112' ' ' ARG . . . . . . . . . . . . . 6.1 ptm180 -95.39 168.09 10.93 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.969 -178.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . 0.508 ' OXT' ' HB2' ' A' ' 16' ' ' LYS . 3.4 mm? . . . . . 0 C--O 1.249 1.061 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.3 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 69.4 mtp 63.93 85.46 0.13 Allowed 'General case' 0 C--N 1.33 -0.241 0 O-C-N 123.869 0.731 . . . . 0.0 111.45 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.472 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 6.8 mpt_? -71.7 137.19 82.94 Favored Pre-proline 0 C--N 1.325 -0.485 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -88.05 113.94 0.84 Allowed 'Trans proline' 0 CA--C 1.53 0.304 0 C-N-CA 123.097 2.531 . . . . 0.0 113.134 -178.747 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.445 ' HA ' ' O ' ' A' ' 89' ' ' ILE . 13.0 Cg_exo -70.93 128.01 14.41 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.141 1.894 . . . . 0.0 112.681 178.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.66 HD13 ' HA ' ' A' ' 54' ' ' LEU . 3.1 mt -93.55 113.04 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.679 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mm -78.25 101.08 3.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.7 -178.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.674 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.4 mt -79.42 168.12 2.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 177.159 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' HIS . . . . . 0.57 ' N ' HG22 ' A' ' 10' ' ' ILE . 43.1 t-80 -145.88 114.38 6.75 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 178.41 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.9 ttt180 -66.48 99.57 0.58 Allowed 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.068 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.61 55.95 1.09 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.331 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.37 14.42 71.76 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.911 -0.586 . . . . 0.0 113.113 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.405 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 8.3 ptpt -140.48 -80.05 0.27 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 117.01 0.405 . . . . 0.0 111.777 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.405 ' H ' ' HG3' ' A' ' 15' ' ' LYS . 24.4 pttt -155.97 178.02 10.75 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.541 0.21 . . . . 0.0 111.192 -178.756 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' TYR . . . . . 0.674 ' HB3' HG21 ' A' ' 10' ' ' ILE . 23.2 m-85 -87.5 2.35 50.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.253 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.526 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 53.37 49.84 55.09 Favored Glycine 0 C--O 1.215 -1.083 0 N-CA-C 116.436 1.334 . . . . 0.0 116.436 176.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.499 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 11.4 p90 -163.91 146.53 9.48 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 122.34 1.067 . . . . 0.0 112.314 176.185 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.534 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 32.7 m -93.35 119.59 32.65 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 113.48 -1.691 . . . . 0.0 113.534 -178.242 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.561 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -92.63 84.16 5.0 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.783 0.325 . . . . 0.0 110.222 177.836 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.427 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 4.4 tpt180 . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.142 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 t . . . . . 0 C--O 1.235 0.293 0 CA-C-O 120.562 0.22 . . . . 0.0 110.685 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 13.5 m-70 -110.51 177.17 4.77 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.992 0.425 . . . . 0.0 110.752 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.64 ' CD2' HG11 ' A' ' 76' ' ' VAL . 98.5 m-70 -150.19 152.8 35.21 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.277 -0.874 . . . . 0.0 108.709 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' MET . . . . . 0.426 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 44.6 mtm -147.53 141.7 26.12 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -178.787 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.711 HG11 HD21 ' A' ' 54' ' ' LEU . 2.5 p -73.14 103.19 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.981 0.896 . . . . 0.0 109.693 179.58 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.427 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 4.7 t-105 -69.28 -37.32 77.81 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.209 -1.359 . . . . 0.0 111.638 -178.432 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' HIS . . . . . 0.498 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 2.5 t60 -158.75 125.54 4.75 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.295 -178.168 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.3 p -121.47 124.78 72.55 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 CA-C-O 121.475 0.655 . . . . 0.0 109.746 178.446 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -63.72 109.31 1.66 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.524 -1.216 . . . . 0.0 111.922 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.585 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 8.8 p-10 -82.3 49.37 1.41 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.635 0.731 . . . . 0.0 109.708 179.008 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -131.05 13.62 5.49 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.447 -179.191 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.49 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 157.22 -68.79 0.28 Allowed Glycine 0 CA--C 1.523 0.546 0 C-N-CA 119.085 -1.531 . . . . 0.0 115.176 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_exo -60.18 -129.92 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 0 C-N-CA 123.748 2.965 . . . . 0.0 117.341 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.491 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -41.86 -38.79 1.62 Allowed 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 114.625 1.343 . . . . 0.0 114.625 -176.542 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.585 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 1.0 OUTLIER -62.17 -56.18 21.25 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.722 -178.844 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.49 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 7.3 mm-40 -63.45 -28.58 70.07 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.306 0.574 . . . . 0.0 110.432 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.46 -28.72 69.86 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.567 178.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.43 -5.15 5.57 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.931 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.711 HD21 HG11 ' A' ' 40' ' ' VAL . 1.7 tt -71.14 112.28 7.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.257 0.551 . . . . 0.0 111.463 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.96 120.81 32.26 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.704 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.498 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 33.2 tt0 -49.76 140.87 10.87 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.002 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.45 13.78 57.98 Favored Glycine 0 CA--C 1.52 0.357 0 C-N-CA 121.032 -0.604 . . . . 0.0 113.125 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.533 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 2.2 t0 -94.81 151.64 19.07 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.978 0.418 . . . . 0.0 111.116 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.522 HD12 ' O ' ' A' ' 38' ' ' HIS . 4.6 tp -98.26 129.94 44.98 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.192 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.559 HG12 HD11 ' A' ' 89' ' ' ILE . 3.8 mp -86.81 124.21 40.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.055 -179.246 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 66.3 p -100.4 -37.81 8.69 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.774 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.421 ' HB2' ' CB ' ' A' ' 90' ' ' SER . 59.1 m80 -143.11 162.54 35.27 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.927 -178.688 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.491 HG21 HG13 ' A' ' 80' ' ' ILE . 9.8 p -143.45 116.13 3.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.998 177.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 58.58 24.33 11.88 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.386 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.82 41.75 8.62 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.538 -178.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.522 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.1 tp10 -151.4 109.49 2.97 Favored Pre-proline 0 N--CA 1.434 -1.246 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.522 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 1.0 OUTLIER -47.29 128.88 15.18 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 123.947 3.098 . . . . 0.0 111.921 178.923 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.1 m -87.43 -13.76 10.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.165 0 CA-C-N 114.359 -1.291 . . . . 0.0 109.203 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 9.1 m170 -57.47 95.08 0.02 OUTLIER 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 112.846 -1.979 . . . . 0.0 111.163 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 119.41 -14.18 10.92 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.08 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 43.3 mt -76.01 142.52 41.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.592 0.234 . . . . 0.0 110.577 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.504 HG13 ' H ' ' A' ' 74' ' ' THR . 0.3 OUTLIER -78.08 169.66 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.882 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -42.42 -48.18 5.12 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.907 0.883 . . . . 0.0 113.119 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.504 ' H ' HG13 ' A' ' 72' ' ' VAL . 12.0 p -88.21 -15.45 35.93 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.038 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -68.4 -42.45 79.01 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 122.361 -0.212 . . . . 0.0 111.212 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.64 HG11 ' CD2' ' A' ' 38' ' ' HIS . 9.6 m -64.16 -46.36 93.76 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.233 0 CA-C-O 121.198 0.523 . . . . 0.0 110.0 179.275 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.589 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 72.8 t -55.18 -48.96 75.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.268 177.555 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -61.63 -44.01 97.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.161 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.19 -39.45 63.68 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-O 121.263 0.554 . . . . 0.0 109.937 178.631 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.576 HG23 HG11 ' A' ' 87' ' ' VAL . 14.3 mt -72.27 -50.34 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.807 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.589 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 39.6 mt -58.33 -36.85 74.01 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-O 121.329 0.585 . . . . 0.0 110.515 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 24.0 ttmt -60.34 -39.94 88.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.634 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 43.4 t -54.69 -36.47 64.69 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.359 -0.837 . . . . 0.0 111.49 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 127.85 -130.42 6.7 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.207 -0.997 . . . . 0.0 112.637 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 25.0 p30 -92.07 13.87 17.6 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.208 0.528 . . . . 0.0 111.047 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 19.5 pttp -163.47 176.69 9.53 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.064 179.347 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.576 HG11 HG23 ' A' ' 80' ' ' ILE . 8.6 p -171.81 145.99 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -179.429 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.417 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -92.38 95.82 9.89 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.276 -0.874 . . . . 0.0 111.108 178.778 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.58 HG22 ' O ' ' A' ' 8' ' ' ILE . 11.2 tt -89.09 113.64 25.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 120.945 0.403 . . . . 0.0 111.06 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.421 ' CB ' ' HB2' ' A' ' 62' ' ' HIS . 0.2 OUTLIER -87.52 110.14 20.12 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.929 0.395 . . . . 0.0 110.911 -179.535 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.533 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 40.0 p -108.32 164.37 12.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.151 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.446 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 2.1 t -99.78 105.51 34.89 Favored Pre-proline 0 C--N 1.328 -0.356 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -177.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 91' ' ' THR . 52.6 Cg_exo -54.64 176.2 0.12 Allowed 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 122.328 2.018 . . . . 0.0 113.089 178.014 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.01 164.05 13.52 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.695 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.321 -0.673 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.341 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.5 m . . . . . 0 N--CA 1.452 -0.339 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 84.9 mtp 58.31 79.76 0.2 Allowed 'General case' 0 N--CA 1.463 0.2 0 O-C-N 123.685 0.616 . . . . 0.0 111.483 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.499 ' H ' ' HD2' ' A' ' 5' ' ' ARG . 3.4 mpt_? -72.26 132.5 84.11 Favored Pre-proline 0 C--N 1.325 -0.498 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.497 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 3.6 Cg_exo -83.46 114.33 2.1 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 123.059 2.506 . . . . 0.0 112.745 -178.63 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 13.6 Cg_exo -70.84 124.31 10.52 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.245 1.963 . . . . 0.0 112.381 178.764 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.587 ' O ' HG22 ' A' ' 89' ' ' ILE . 5.2 mt -91.46 111.02 23.28 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.079 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mm -77.79 101.45 3.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -177.41 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.552 HG12 ' CB ' ' A' ' 49' ' ' ALA . 5.3 mt -78.05 164.95 3.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 177.069 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' HIS . . . . . 0.533 ' N ' HG22 ' A' ' 10' ' ' ILE . 32.7 t-80 -142.78 114.29 7.95 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.8 ttt180 -63.39 114.09 3.65 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.401 0.62 . . . . 0.0 110.725 -179.504 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -84.67 43.82 1.01 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.185 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.55 3.95 83.9 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.735 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.3 ptpt -127.64 -82.65 0.6 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.699 0.285 . . . . 0.0 111.138 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.525 ' HE2' ' OE1' ' A' ' 44' ' ' GLU . 22.7 pttm -158.51 -179.55 8.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.924 -178.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' TYR . . . . . 0.516 ' HA ' ' HB3' ' A' ' 48' ' ' PRO . 12.8 m-85 -89.98 -0.41 57.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.524 0.678 . . . . 0.0 109.182 179.214 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.404 ' HA3' ' HB2' ' A' ' 44' ' ' GLU . . . 64.98 -24.92 0.11 Allowed Glycine 0 C--N 1.331 0.274 0 N-CA-C 116.704 1.442 . . . . 0.0 116.704 177.843 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.575 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.7 p90 -81.96 142.48 32.38 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 122.615 1.197 . . . . 0.0 113.636 -176.562 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 58.6 m -93.14 114.65 27.21 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 113.225 -1.807 . . . . 0.0 111.481 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.649 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -86.4 84.28 7.48 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 178.752 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.589 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 1.9 tpt180 . . . . . 0 C--N 1.327 -0.387 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.936 -179.454 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.6 t . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 120.898 0.38 . . . . 0.0 110.656 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 8.0 m-70 -108.63 -174.0 2.41 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.465 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.438 ' O ' HD12 ' A' ' 59' ' ' LEU . 99.1 m-70 -151.39 161.61 42.39 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -179.762 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' MET . . . . . 0.474 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 68.5 mtm -150.02 144.79 26.02 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.755 0.312 . . . . 0.0 110.488 -178.566 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.508 HG11 ' CD2' ' A' ' 54' ' ' LEU . 2.7 p -74.41 104.5 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-O 121.823 0.82 . . . . 0.0 109.67 179.202 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.589 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 5.3 t-105 -69.82 -40.09 76.1 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.659 -1.155 . . . . 0.0 112.167 -178.389 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' HIS . . . . . 0.511 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.8 t60 -158.91 127.82 5.39 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.329 -178.271 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.575 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 2.4 p -120.93 129.33 75.8 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.109 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.525 ' OE1' ' HE2' ' A' ' 16' ' ' LYS . 27.5 mt-10 -64.09 113.12 3.31 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.911 -179.049 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.65 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 9.4 p-10 -84.88 34.33 0.54 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.134 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -124.3 17.07 7.52 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.151 -1.024 . . . . 0.0 113.926 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.04 -64.99 0.28 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 118.884 -1.627 . . . . 0.0 115.049 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.516 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 49.6 Cg_exo -62.36 -133.33 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.316 2.677 . . . . 0.0 116.913 -177.79 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.552 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -43.33 -35.48 1.52 Allowed 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 -176.578 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.65 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 2.0 m -63.42 -53.32 54.21 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 118.399 0.545 . . . . 0.0 111.674 -178.844 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -63.2 -30.96 72.01 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-O 121.52 0.676 . . . . 0.0 109.807 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.15 -31.75 73.07 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.913 -1.039 . . . . 0.0 110.067 178.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.65 -5.87 5.52 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.551 179.749 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.582 HD11 HD13 ' A' ' 89' ' ' ILE . 1.1 tt -67.02 117.28 8.86 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.249 0.547 . . . . 0.0 111.44 -179.455 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.435 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -91.19 121.78 33.26 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.311 178.821 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -51.85 138.95 23.03 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.597 177.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.19 15.98 56.5 Favored Glycine 0 CA--C 1.52 0.399 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.713 -179.547 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.623 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 5.2 t0 -94.28 153.87 17.81 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.773 0.32 . . . . 0.0 110.553 179.581 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.474 ' HA ' ' HG2' ' A' ' 39' ' ' MET . 4.8 tp -101.02 128.46 47.05 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.589 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.505 ' CG1' HD11 ' A' ' 89' ' ' ILE . 4.0 mp -85.42 124.46 40.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.88 -179.652 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 64.6 p -101.88 -39.95 7.13 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.351 0.596 . . . . 0.0 110.519 179.528 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 62.0 m80 -139.75 157.19 46.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.969 -178.759 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.424 ' O ' HG13 ' A' ' 63' ' ' VAL . 7.6 p -139.82 109.73 3.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.562 178.004 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 61.73 30.64 18.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.654 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.38 45.44 18.8 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -178.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.481 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 4.0 tp10 -149.84 105.11 3.22 Favored Pre-proline 0 N--CA 1.436 -1.166 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.355 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.481 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.2 Cg_endo -49.97 127.85 20.43 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 123.474 2.783 . . . . 0.0 111.264 178.761 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.7 m -88.7 -11.25 10.49 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.644 -179.047 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -55.25 93.77 0.01 OUTLIER 'General case' 0 N--CA 1.427 -1.6 0 CA-C-N 113.029 -1.896 . . . . 0.0 111.806 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 114.41 -10.03 22.1 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.523 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 25.6 mt -75.66 145.05 41.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.783 0.325 . . . . 0.0 110.295 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.537 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.5 OUTLIER -77.91 166.48 2.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.727 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.415 ' O ' HG22 ' A' ' 76' ' ' VAL . 77.8 t60 -46.04 -52.74 11.39 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.966 0.888 . . . . 0.0 112.3 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.2 p -72.57 -19.71 61.45 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 114.986 -1.006 . . . . 0.0 112.868 -176.649 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.537 ' HG3' HG12 ' A' ' 72' ' ' VAL . 21.5 mt-10 -70.69 -42.97 69.98 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 121.218 -0.193 . . . . 0.0 110.97 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.649 HG21 ' HG ' ' A' ' 21' ' ' LEU . 15.5 m -64.8 -47.22 89.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.132 0 C-N-CA 120.354 -0.538 . . . . 0.0 109.764 179.273 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.536 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 48.6 t -54.71 -45.79 73.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.077 177.74 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.447 ' O ' ' HB2' ' A' ' 82' ' ' LYS . 17.9 mt-10 -63.15 -44.6 95.07 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.633 179.092 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -54.37 -41.14 68.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.207 0.527 . . . . 0.0 110.313 179.247 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.557 HG23 HG11 ' A' ' 87' ' ' VAL . 18.5 mt -69.3 -51.83 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.224 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 61.4 mt -59.74 -36.24 76.2 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.183 0.516 . . . . 0.0 110.477 179.095 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 78' ' ' GLU . 25.5 ttmt -59.37 -41.38 89.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.63 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 38.4 t -54.82 -36.47 65.03 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.527 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 127.01 -121.31 3.89 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 119.86 -1.162 . . . . 0.0 113.859 178.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -98.57 8.97 44.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.24 0.543 . . . . 0.0 110.893 -179.032 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 16.5 pttp -161.72 174.83 12.69 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.006 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.557 HG11 HG23 ' A' ' 80' ' ' ILE . 9.2 p -169.21 146.14 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.405 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -92.67 93.8 8.68 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.282 -0.872 . . . . 0.0 111.007 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.587 HG22 ' O ' ' A' ' 8' ' ' ILE . 9.3 tt -87.39 111.39 21.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 121.122 0.486 . . . . 0.0 110.659 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.438 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -89.43 106.9 18.76 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.716 0.293 . . . . 0.0 110.67 -179.291 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.623 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 81.5 p -104.51 169.13 8.65 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.839 179.396 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.451 HG22 ' HB3' ' A' ' 59' ' ' LEU . 8.6 t -100.01 107.24 45.89 Favored Pre-proline 0 CA--C 1.537 0.448 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 -177.264 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.418 ' HD3' ' O ' ' A' ' 91' ' ' THR . 76.3 Cg_exo -54.84 174.6 0.19 Allowed 'Trans proline' 0 C--N 1.352 0.715 0 C-N-CA 122.345 2.03 . . . . 0.0 113.012 177.135 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.48 167.72 8.36 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.17 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.326 -0.44 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.968 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.4 m . . . . . 0 C--O 1.233 0.191 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 91.1 mtp 60.23 78.34 0.28 Allowed 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.686 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.494 ' H ' ' HD2' ' A' ' 5' ' ' ARG . 4.6 mpt_? -71.25 137.46 84.21 Favored Pre-proline 0 C--N 1.323 -0.581 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 179.246 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 2.9 Cg_endo -84.57 112.67 1.6 Allowed 'Trans proline' 0 N--CA 1.462 -0.334 0 C-N-CA 122.92 2.414 . . . . 0.0 112.813 -178.825 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.464 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 17.4 Cg_exo -68.48 125.83 13.36 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.227 1.951 . . . . 0.0 112.526 178.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.573 ' O ' HG22 ' A' ' 89' ' ' ILE . 5.9 mt -92.85 115.82 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.712 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.5 mm -79.23 104.26 7.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 CA-C-N 116.191 -0.458 . . . . 0.0 112.208 -178.118 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.657 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.5 mt -80.14 160.73 4.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 176.341 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' HIS . . . . . 0.523 ' N ' HG22 ' A' ' 10' ' ' ILE . 39.8 t-80 -141.75 114.31 8.37 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.661 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 53.2 ttt180 -63.44 98.14 0.16 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.773 -179.678 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.89 55.77 2.17 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.357 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.28 7.56 77.96 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.826 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.456 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 10.9 ptpt -132.47 -87.73 0.45 Allowed 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.855 -0.203 . . . . 0.0 111.272 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.456 ' H ' ' HG3' ' A' ' 15' ' ' LYS . 32.1 pttt -155.5 -172.62 4.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.454 0.169 . . . . 0.0 110.717 -178.686 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' TYR . . . . . 0.657 ' HB3' HG21 ' A' ' 10' ' ' ILE . 21.0 m-85 -88.17 2.12 52.85 Favored 'General case' 0 CA--C 1.519 -0.236 0 CA-C-O 121.062 0.458 . . . . 0.0 109.925 179.443 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.505 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 52.2 49.79 48.86 Favored Glycine 0 C--O 1.219 -0.821 0 N-CA-C 116.728 1.451 . . . . 0.0 116.728 176.308 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.498 ' HB3' HG23 ' A' ' 43' ' ' VAL . 8.1 p90 -164.21 148.86 10.0 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-O 122.345 1.069 . . . . 0.0 112.477 176.292 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 42.3 m -94.63 113.99 25.88 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 113.722 -1.581 . . . . 0.0 112.806 -179.048 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.612 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -88.1 82.85 7.07 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.939 0.4 . . . . 0.0 109.941 178.294 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.542 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 3.6 tpt180 . . . . . 0 C--N 1.323 -0.555 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.727 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 t . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 -113.5 -179.06 3.53 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.28 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.569 ' CD2' HG11 ' A' ' 76' ' ' VAL . 94.4 m-70 -149.66 153.57 37.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' MET . . . . . 0.466 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 27.2 mtm -148.57 145.5 27.85 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -178.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.512 HG11 ' CD2' ' A' ' 54' ' ' LEU . 3.4 p -73.25 103.32 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 CA-C-O 122.006 0.908 . . . . 0.0 109.793 179.274 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.542 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.6 t-105 -70.65 -40.37 73.07 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.468 -1.242 . . . . 0.0 111.499 -178.682 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' HIS . . . . . 0.497 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 1.9 t60 -156.64 132.09 9.35 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.952 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 18' ' ' GLY . 5.1 p -127.96 125.48 64.81 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.012 0 CA-C-O 121.919 0.866 . . . . 0.0 110.348 178.837 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.484 ' O ' ' HB2' ' A' ' 50' ' ' SER . 28.3 mt-10 -65.24 114.09 4.47 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 114.284 -1.325 . . . . 0.0 112.117 -178.566 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.544 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 10.6 p-10 -83.65 46.07 1.12 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.646 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -119.44 -2.77 13.16 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.399 -0.905 . . . . 0.0 113.595 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.63 -59.09 0.27 Allowed Glycine 0 CA--C 1.521 0.411 0 C-N-CA 119.119 -1.515 . . . . 0.0 114.884 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -59.24 -130.98 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 0.98 0 C-N-CA 123.463 2.776 . . . . 0.0 116.593 -178.439 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.524 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -43.69 -40.81 4.43 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 114.382 1.253 . . . . 0.0 114.382 -176.751 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.544 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -60.03 -59.99 4.55 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -178.312 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -63.37 -28.62 70.12 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.064 0.459 . . . . 0.0 110.713 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.13 -29.99 70.72 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.947 178.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 135.69 -9.28 4.28 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.767 179.444 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.512 ' CD2' HG11 ' A' ' 40' ' ' VAL . 0.9 OUTLIER -68.34 117.76 10.54 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.374 0.607 . . . . 0.0 111.42 -179.615 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -92.85 121.24 34.03 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.726 178.419 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.497 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 37.1 tt0 -50.13 135.09 21.47 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.15 59.5 1.75 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.569 -0.824 . . . . 0.0 111.231 -178.68 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.429 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 3.4 t0 -142.81 147.58 35.71 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.496 HD12 ' O ' ' A' ' 38' ' ' HIS . 10.9 tp -92.95 131.28 38.09 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.408 -179.541 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.481 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.6 mp -89.13 125.35 42.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.9 p -101.87 -40.02 7.11 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.259 0.552 . . . . 0.0 110.799 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -139.76 158.44 44.09 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.591 -179.145 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 63' ' ' VAL . 7.6 p -141.62 110.4 2.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-O 121.11 0.481 . . . . 0.0 109.981 178.149 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.9 t30 59.49 33.91 22.37 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.093 179.399 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.0 42.26 25.27 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.17 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.502 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 5.6 tp10 -151.37 106.67 2.95 Favored Pre-proline 0 N--CA 1.434 -1.234 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.502 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.2 Cg_endo -50.4 129.1 25.09 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.557 2.838 . . . . 0.0 110.962 178.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 20.2 m -85.85 -13.31 11.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.258 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.0 m170 -56.6 96.98 0.02 OUTLIER 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 112.732 -2.031 . . . . 0.0 110.835 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.94 -12.88 26.93 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.405 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 21.7 mt -76.1 141.61 41.93 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.571 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -75.46 165.65 3.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.292 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -42.97 -55.19 3.87 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-O 121.765 0.793 . . . . 0.0 112.82 -179.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.0 p -74.53 -16.96 60.81 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 114.93 -1.032 . . . . 0.0 113.04 -176.502 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.571 ' HG3' HG12 ' A' ' 72' ' ' VAL . 24.3 mt-10 -70.57 -42.03 71.64 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 120.95 -0.3 . . . . 0.0 111.121 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.612 HG21 ' HG ' ' A' ' 21' ' ' LEU . 15.6 m -65.59 -46.44 89.54 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.471 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 60.9 t -53.05 -48.59 52.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.632 176.796 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -63.47 -44.44 94.45 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.847 179.266 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.38 -42.01 66.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.269 0.557 . . . . 0.0 109.933 178.568 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.568 HG23 HG11 ' A' ' 87' ' ' VAL . 22.7 mt -67.35 -48.83 76.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.621 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 50.2 mt -60.84 -39.4 88.94 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-O 121.032 0.444 . . . . 0.0 110.657 178.738 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 23.1 ttmt -60.35 -40.5 90.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.142 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 41.4 t -54.22 -31.79 54.16 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.714 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 129.52 -127.81 5.56 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.672 179.408 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -99.1 10.53 41.27 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.432 0.634 . . . . 0.0 110.413 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.415 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 17.3 pttp -161.99 172.51 15.85 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.862 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.568 HG11 HG23 ' A' ' 80' ' ' ILE . 8.5 p -168.03 149.82 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -178.326 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.464 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -93.37 97.66 10.72 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.309 178.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.573 HG22 ' O ' ' A' ' 8' ' ' ILE . 10.2 tt -89.62 112.91 25.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 120.884 0.373 . . . . 0.0 110.862 179.392 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.9 OUTLIER -88.67 105.02 17.4 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.729 0.3 . . . . 0.0 111.296 -179.008 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.502 ' O ' ' HD3' ' A' ' 93' ' ' PRO . 42.3 p -102.36 163.2 12.37 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.436 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 1.6 t -98.65 104.92 27.18 Favored Pre-proline 0 C--N 1.326 -0.439 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.286 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.502 ' HD3' ' O ' ' A' ' 91' ' ' THR . 73.2 Cg_exo -53.73 176.06 0.1 Allowed 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.503 2.135 . . . . 0.0 113.036 178.622 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -64.26 166.12 8.48 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.319 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.321 -0.657 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.899 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.452 -0.354 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 37.8 mtp 55.85 78.93 0.18 Allowed 'General case' 0 C--O 1.235 0.336 0 O-C-N 123.58 0.55 . . . . 0.0 111.471 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.475 ' H ' ' HD2' ' A' ' 5' ' ' ARG . 4.0 mpt_? -70.92 137.47 85.07 Favored Pre-proline 0 C--N 1.325 -0.464 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.0 OUTLIER -86.93 111.08 0.87 Allowed 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.795 2.33 . . . . 0.0 112.899 -178.284 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.532 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 15.5 Cg_exo -69.12 119.87 6.8 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 121.935 1.756 . . . . 0.0 112.15 178.616 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.616 ' O ' HG22 ' A' ' 89' ' ' ILE . 7.0 mt -87.85 110.94 21.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-N 115.07 -0.968 . . . . 0.0 108.967 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.2 mm -76.77 101.45 2.93 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.825 -0.625 . . . . 0.0 112.045 -178.045 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.676 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.2 mt -78.92 159.27 4.64 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.368 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 176.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' HIS . . . . . 0.506 ' N ' HG22 ' A' ' 10' ' ' ILE . 15.1 t-80 -135.44 109.98 8.54 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 178.604 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.1 ttt180 -64.64 100.71 0.4 Allowed 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.419 -0.81 . . . . 0.0 111.05 -179.335 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.95 55.68 1.81 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.275 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.7 -45.31 3.38 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.479 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.2 ptpt -79.23 -85.79 0.08 Allowed 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.381 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 23.7 pttt -157.29 -174.09 4.73 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.52 0.193 . . . . 0.0 111.52 -178.559 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' TYR . . . . . 0.676 ' HB3' HG21 ' A' ' 10' ' ' ILE . 21.4 m-85 -85.49 2.42 44.74 Favored 'General case' 0 CA--C 1.518 -0.25 0 CA-C-O 121.103 0.478 . . . . 0.0 109.757 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.559 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 51.04 53.54 26.6 Favored Glycine 0 C--O 1.215 -1.044 0 N-CA-C 116.124 1.21 . . . . 0.0 116.124 177.328 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.478 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 12.4 p90 -163.94 149.03 10.54 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 122.744 1.259 . . . . 0.0 112.965 176.156 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.502 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 40.5 m -95.16 117.48 30.29 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 112.904 -1.953 . . . . 0.0 113.109 -178.522 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.493 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.4 OUTLIER -94.45 80.78 3.91 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 178.286 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.509 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 1.6 tpt180 . . . . . 0 C--N 1.327 -0.376 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.995 -179.51 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.6 t . . . . . 0 N--CA 1.45 -0.46 0 CA-C-O 120.907 0.384 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 89.2 m-70 -125.43 -177.73 3.99 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.464 179.262 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.551 ' CD2' HG11 ' A' ' 76' ' ' VAL . 98.0 m-70 -147.71 154.7 40.9 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -179.269 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 35.4 mtm -149.13 146.56 27.74 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -178.611 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.585 HG11 HD21 ' A' ' 54' ' ' LEU . 2.6 p -74.0 101.75 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.976 0.893 . . . . 0.0 109.774 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.509 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 2.9 t-105 -70.39 -39.21 74.67 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.37 -178.598 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' HIS . . . . . 0.44 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -156.53 129.57 7.92 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.975 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.559 HG23 ' O ' ' A' ' 18' ' ' GLY . 3.8 p -124.28 127.06 73.02 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.555 0.693 . . . . 0.0 110.248 179.06 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -66.64 113.23 4.64 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 114.507 -1.224 . . . . 0.0 112.043 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.558 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 10.4 p-10 -81.5 40.2 0.57 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.918 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -108.15 -8.75 28.93 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.376 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.407 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 160.55 -49.91 0.37 Allowed Glycine 0 CA--C 1.526 0.761 0 C-N-CA 119.491 -1.338 . . . . 0.0 114.867 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -60.11 -128.98 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.09 0 C-N-CA 123.094 2.529 . . . . 0.0 116.233 -179.223 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.504 ' HA ' HG12 ' A' ' 10' ' ' ILE . . . -45.12 -39.97 6.49 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 114.195 1.183 . . . . 0.0 114.195 -177.113 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.558 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 5.5 m -57.34 -62.86 1.47 Allowed 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -179.158 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.407 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 9.5 mm-40 -63.25 -23.15 67.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.295 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.66 -26.16 66.07 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.256 178.899 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 130.21 -8.36 5.99 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.677 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.585 HD21 HG11 ' A' ' 40' ' ' VAL . 1.1 tt -70.0 117.99 12.28 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-O 121.435 0.636 . . . . 0.0 111.324 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.404 ' H ' ' HG3' ' A' ' 55' ' ' ARG . 0.0 OUTLIER -96.45 121.52 38.35 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.941 178.357 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.434 ' HB2' HG12 ' A' ' 43' ' ' VAL . 46.3 tt0 -50.45 141.14 12.59 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.771 0.319 . . . . 0.0 111.51 178.856 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.24 6.0 63.31 Favored Glycine 0 C--N 1.333 0.415 0 C-N-CA 121.239 -0.505 . . . . 0.0 113.231 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.537 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 2.0 t0 -89.9 155.71 18.95 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.032 0.444 . . . . 0.0 111.036 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.489 HD12 ' O ' ' A' ' 38' ' ' HIS . 2.5 tp -100.14 133.97 43.75 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.7 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.502 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.5 mp -91.26 122.74 42.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 26.2 p -99.7 -40.61 7.68 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.401 0.619 . . . . 0.0 110.361 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 72.7 m80 -138.28 157.21 46.71 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.761 -178.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.57 111.51 5.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.965 -0.562 . . . . 0.0 109.889 178.28 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 60.39 30.04 19.49 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.811 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.46 44.29 17.14 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.182 -179.036 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.472 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.1 tp10 -149.99 106.26 3.21 Favored Pre-proline 0 N--CA 1.437 -1.084 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 -179.066 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.472 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 4.4 Cg_endo -49.62 129.32 23.22 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.66 2.907 . . . . 0.0 111.124 178.776 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 22.3 m -86.82 -7.96 10.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 114.594 -1.185 . . . . 0.0 109.039 -178.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 22.1 m170 -55.17 101.01 0.04 OUTLIER 'General case' 0 N--CA 1.426 -1.629 0 CA-C-N 112.741 -2.027 . . . . 0.0 111.676 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.68 -6.77 49.07 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.842 179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 26.3 mt -78.29 141.41 38.53 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.669 0.271 . . . . 0.0 110.469 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.674 HG12 ' HG3' ' A' ' 75' ' ' GLU . 2.0 p -78.58 169.82 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 177.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.428 ' O ' HG23 ' A' ' 77' ' ' VAL . 8.6 t60 -48.19 -53.62 16.28 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.682 0.753 . . . . 0.0 112.352 -179.424 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 16.7 p -69.44 -22.66 63.64 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.192 -0.913 . . . . 0.0 112.456 -177.247 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.674 ' HG3' HG12 ' A' ' 72' ' ' VAL . 24.4 mt-10 -69.06 -43.28 74.94 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 121.224 -0.191 . . . . 0.0 111.476 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.551 HG11 ' CD2' ' A' ' 38' ' ' HIS . 10.0 m -66.24 -44.61 91.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.726 178.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 73' ' ' HIS . 54.0 t -56.57 -47.26 82.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.929 177.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -62.78 -43.46 98.73 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.55 178.374 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.38 -40.75 65.26 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.339 0.59 . . . . 0.0 109.915 178.444 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.633 HG23 HG11 ' A' ' 87' ' ' VAL . 28.1 mt -68.84 -51.58 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.889 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 64.1 mt -59.88 -36.03 76.08 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.1 0.476 . . . . 0.0 110.644 179.092 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -57.91 -39.15 77.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.231 -0.895 . . . . 0.0 111.58 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 34.0 t -56.21 -44.87 79.91 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.244 179.756 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 136.29 -116.61 1.48 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.323 -0.941 . . . . 0.0 113.71 178.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -102.85 9.1 39.1 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.475 0.655 . . . . 0.0 110.506 -178.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 10.1 pttp -161.36 173.53 14.82 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.499 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.633 HG11 HG23 ' A' ' 80' ' ' ILE . 10.4 p -167.76 145.13 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -179.583 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.532 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -91.15 96.22 10.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.37 178.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.616 HG22 ' O ' ' A' ' 8' ' ' ILE . 11.1 tt -88.72 111.08 22.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.196 0.522 . . . . 0.0 110.831 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.93 106.0 17.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.982 -179.089 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.537 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 64.6 p -102.33 170.86 7.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.21 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.428 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 4.9 t -104.85 99.95 21.41 Favored Pre-proline 0 CA--C 1.534 0.358 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -178.179 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' ' 91' ' ' THR . 74.6 Cg_exo -51.73 167.63 0.41 Allowed 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.487 2.125 . . . . 0.0 113.204 178.516 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.431 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.0 OUTLIER -63.75 158.71 21.01 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.953 -179.937 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.327 -0.392 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.529 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 53.2 m . . . . . 0 N--CA 1.453 -0.288 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 9.0 mtp 60.65 77.53 0.32 Allowed 'General case' 0 C--O 1.233 0.185 0 O-C-N 123.476 0.485 . . . . 0.0 111.619 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.455 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.0 mpt_? -73.26 136.86 78.6 Favored Pre-proline 0 C--N 1.326 -0.421 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 179.198 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.5 Cg_endo -89.22 110.02 0.48 Allowed 'Trans proline' 0 C--O 1.235 0.326 0 C-N-CA 123.196 2.597 . . . . 0.0 113.021 -179.108 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.488 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 16.9 Cg_exo -69.78 122.52 9.19 Favored 'Trans proline' 0 CA--C 1.515 -0.453 0 C-N-CA 122.327 2.018 . . . . 0.0 113.112 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.549 HD13 ' HA ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -87.42 112.0 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.258 0 CA-C-N 115.129 -0.941 . . . . 0.0 108.778 178.317 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.401 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 3.2 mm -77.5 101.42 3.37 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.336 -178.721 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.672 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.4 mt -77.81 162.65 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 N-CA-C 106.904 -1.517 . . . . 0.0 106.904 176.871 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' HIS . . . . . 0.544 ' N ' HG22 ' A' ' 10' ' ' ILE . 15.0 t-80 -140.79 113.15 7.97 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 47.2 ttt180 -63.39 101.7 0.34 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.995 -178.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.12 49.95 1.0 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.45 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.12 12.7 81.5 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 121.199 -0.524 . . . . 0.0 113.1 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 3.8 ptpt -136.51 -82.59 0.38 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.849 0.325 . . . . 0.0 111.12 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 8.6 pttt -156.16 -179.59 8.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.421 -178.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' TYR . . . . . 0.672 ' HB3' HG21 ' A' ' 10' ' ' ILE . 19.3 m-85 -86.58 5.34 36.14 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-O 121.245 0.545 . . . . 0.0 110.191 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.576 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 54.46 49.22 61.49 Favored Glycine 0 C--O 1.215 -1.069 0 N-CA-C 116.697 1.439 . . . . 0.0 116.697 176.697 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.482 ' HB2' HG23 ' A' ' 40' ' ' VAL . 9.3 p90 -165.6 149.23 8.07 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-O 122.345 1.069 . . . . 0.0 113.068 176.583 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.427 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 94.8 m -95.25 118.37 31.91 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 113.643 -1.617 . . . . 0.0 112.724 -179.161 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.559 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -89.91 84.86 6.24 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.802 0.334 . . . . 0.0 110.248 178.511 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.566 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 5.1 tpt180 . . . . . 0 C--N 1.328 -0.352 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.222 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 6.2 t . . . . . 0 C--O 1.234 0.28 0 CA-C-O 120.676 0.274 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -117.82 177.97 4.58 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.517 ' CD2' HG11 ' A' ' 76' ' ' VAL . 98.7 m-70 -148.15 153.35 38.71 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 -179.509 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.0 mtm -147.24 145.25 29.38 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.083 -178.66 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.564 HG11 ' CD2' ' A' ' 54' ' ' LEU . 3.4 p -73.33 102.52 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.71 0 CA-C-O 121.946 0.879 . . . . 0.0 109.576 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.566 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 2.5 t-105 -70.48 -39.36 74.26 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.699 -1.137 . . . . 0.0 111.89 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' HIS . . . . . 0.461 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 4.3 t60 -155.23 124.5 6.3 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.368 -178.598 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.2 p -122.04 124.92 72.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-O 121.575 0.702 . . . . 0.0 109.975 179.258 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.504 ' OE1' ' HA2' ' A' ' 18' ' ' GLY . 49.3 mt-10 -66.99 120.12 13.11 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 114.396 -1.275 . . . . 0.0 111.307 -179.391 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.555 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 14.7 p-10 -85.84 24.8 1.2 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.84 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -82.98 -23.4 55.54 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.959 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 170.92 -51.78 0.19 Allowed Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 119.568 -1.301 . . . . 0.0 114.745 -179.225 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -55.33 -128.45 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.085 0 C-N-CA 123.505 2.803 . . . . 0.0 116.92 -178.399 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.473 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -45.23 -40.01 6.97 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 -176.688 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.555 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -60.5 -61.08 2.85 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -177.956 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 5.5 mm-40 -61.01 -32.49 72.08 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.372 0.606 . . . . 0.0 110.781 -178.677 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -60.34 -29.84 69.14 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.677 179.269 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 136.8 -11.84 3.95 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.511 -0.852 . . . . 0.0 113.092 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.564 ' CD2' HG11 ' A' ' 40' ' ' VAL . 0.8 OUTLIER -68.08 116.04 8.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.406 0.622 . . . . 0.0 111.074 -179.642 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.44 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -93.77 125.56 38.45 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.026 178.975 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -51.42 140.18 18.14 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.876 0.37 . . . . 0.0 111.036 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.71 10.09 67.72 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.95 -0.643 . . . . 0.0 113.161 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.562 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 5.3 t0 -88.5 148.91 23.91 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.0 0.429 . . . . 0.0 110.659 179.59 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.432 HD12 ' O ' ' A' ' 38' ' ' HIS . 10.1 tp -95.91 130.03 42.99 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.726 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.504 HG12 HD11 ' A' ' 89' ' ' ILE . 3.6 mp -88.15 126.14 41.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.127 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 41.9 p -102.8 -38.62 7.35 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.646 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -141.23 159.49 42.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.922 -178.698 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.404 HG21 HG13 ' A' ' 80' ' ' ILE . 7.3 p -140.65 111.14 3.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.125 0.488 . . . . 0.0 110.208 178.238 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.409 ' HA ' ' HB3' ' A' ' 88' ' ' ALA . 2.8 t30 60.76 26.34 16.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.372 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.18 44.41 7.57 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.935 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.496 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.5 tp10 -153.19 110.5 2.64 Favored Pre-proline 0 N--CA 1.433 -1.312 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.519 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.496 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 3.7 Cg_endo -49.99 131.88 31.24 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 123.725 2.95 . . . . 0.0 111.407 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.5 m -88.23 -8.61 10.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.289 -178.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -56.75 94.85 0.01 OUTLIER 'General case' 0 N--CA 1.429 -1.51 0 CA-C-N 112.95 -1.932 . . . . 0.0 111.566 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 112.47 -11.82 25.91 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.435 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 29.7 mt -74.87 138.82 42.72 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 179.527 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.507 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.8 OUTLIER -77.79 167.19 2.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.276 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 48.2 t60 -44.75 -46.42 10.46 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.779 0.8 . . . . 0.0 112.939 -179.314 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.496 ' H ' HG13 ' A' ' 72' ' ' VAL . 19.3 p -80.51 -21.06 42.27 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.274 -0.875 . . . . 0.0 112.755 -176.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.507 ' HG3' HG12 ' A' ' 72' ' ' VAL . 25.5 mt-10 -70.23 -40.31 74.56 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 121.319 -0.153 . . . . 0.0 111.354 -179.626 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.559 HG21 ' HG ' ' A' ' 21' ' ' LEU . 4.5 m -65.45 -45.76 91.97 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.183 0 C-N-CA 120.251 -0.58 . . . . 0.0 109.597 178.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 99.5 t -55.24 -47.02 78.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.187 -0.915 . . . . 0.0 109.926 177.239 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -64.81 -43.97 91.41 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.607 179.288 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.48 -42.08 66.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.768 178.346 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.677 HG23 HG11 ' A' ' 87' ' ' VAL . 16.2 mt -67.81 -52.15 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.719 179.484 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 93.1 mt -59.95 -32.78 71.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.017 179.312 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 8.3 ttmm -61.55 -38.91 89.19 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.352 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 36.2 t -56.0 -52.99 62.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.961 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 137.73 -134.43 6.96 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 119.96 -1.114 . . . . 0.0 113.132 179.301 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -73.67 -2.01 21.37 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.853 0.358 . . . . 0.0 111.799 -179.085 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -159.93 175.26 13.26 Favored 'General case' 0 N--CA 1.444 -0.773 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.503 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.677 HG11 HG23 ' A' ' 80' ' ' ILE . 13.4 p -166.84 147.1 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 O-C-N 123.596 0.56 . . . . 0.0 112.465 -179.062 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.488 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -93.51 96.76 10.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.642 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.543 HG22 ' O ' ' A' ' 8' ' ' ILE . 6.9 tt -88.8 111.57 22.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 120.973 0.416 . . . . 0.0 110.255 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -89.11 112.25 23.19 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.825 0.345 . . . . 0.0 111.074 -178.908 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.562 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 61.3 p -109.76 171.73 7.27 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.306 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.9 t -104.21 105.48 49.34 Favored Pre-proline 0 CA--C 1.537 0.464 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.473 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -55.73 175.24 0.22 Allowed 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.622 2.215 . . . . 0.0 113.403 178.161 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.402 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.0 OUTLIER -63.71 159.95 18.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.287 -179.647 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.347 0 CA-C-O 121.073 0.463 . . . . 0.0 110.677 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.0 m . . . . . 0 N--CA 1.453 -0.276 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 28.6 mtp 57.06 74.05 0.43 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.008 0.432 . . . . 0.0 111.3 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.49 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.6 mpt_? -73.31 135.53 79.23 Favored Pre-proline 0 C--N 1.32 -0.692 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.49 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.9 Cg_endo -87.31 116.88 1.22 Allowed 'Trans proline' 0 N--CA 1.462 -0.371 0 C-N-CA 123.3 2.666 . . . . 0.0 112.842 -178.69 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.466 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 7.5 Cg_exo -75.12 122.08 6.93 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.078 1.852 . . . . 0.0 112.843 178.629 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.62 HD13 ' HA ' ' A' ' 54' ' ' LEU . 2.3 mt -86.71 112.41 22.91 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.356 178.616 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.8 mm -79.06 99.74 3.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.218 -0.446 . . . . 0.0 112.049 -178.273 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.695 HG21 ' HB3' ' A' ' 17' ' ' TYR . 4.3 mt -77.64 160.47 4.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 177.059 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' HIS . . . . . 0.523 ' N ' HG22 ' A' ' 10' ' ' ILE . 24.8 t-80 -138.17 111.59 8.06 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.01 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ARG . . . . . 0.422 HH11 ' HD3' ' A' ' 12' ' ' ARG . 30.8 ttt180 -62.89 103.71 0.47 Allowed 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.838 -179.009 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.77 47.7 0.76 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.482 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.17 -4.86 65.04 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.287 -0.482 . . . . 0.0 113.344 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.8 ptpt -120.61 -80.12 0.62 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.996 0.398 . . . . 0.0 111.44 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 20.5 pttt -155.76 -174.96 5.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.64 0.257 . . . . 0.0 110.558 -178.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' TYR . . . . . 0.695 ' HB3' HG21 ' A' ' 10' ' ' ILE . 18.4 m-85 -89.71 5.65 44.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.254 0.55 . . . . 0.0 109.661 179.521 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.521 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 54.26 48.31 64.49 Favored Glycine 0 C--O 1.219 -0.842 0 N-CA-C 116.423 1.329 . . . . 0.0 116.423 176.818 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.458 ' HB3' HG23 ' A' ' 43' ' ' VAL . 10.4 p90 -164.09 146.56 9.2 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-O 122.627 1.203 . . . . 0.0 112.836 176.627 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 91.8 m -93.64 114.83 27.24 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 113.46 -1.7 . . . . 0.0 112.51 -178.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.598 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -91.14 82.47 5.53 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-O 120.577 0.227 . . . . 0.0 111.218 179.119 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 1.3 tpt180 . . . . . 0 C--N 1.326 -0.431 0 CA-C-N 116.761 -0.2 . . . . 0.0 111.185 179.279 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t . . . . . 0 N--CA 1.453 -0.277 0 CA-C-O 120.586 0.231 . . . . 0.0 110.605 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.6 m-70 -112.86 179.65 3.91 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.18 -0.463 . . . . 0.0 109.953 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.501 ' O ' HD12 ' A' ' 59' ' ' LEU . 99.1 m-70 -148.92 152.43 36.38 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 41.0 mtm -148.07 146.15 28.73 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.573 HG11 ' CD2' ' A' ' 54' ' ' LEU . 2.7 p -72.28 102.89 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.989 0.9 . . . . 0.0 109.342 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 2.1 t-105 -68.86 -39.92 79.61 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.442 -178.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' HIS . . . . . 0.498 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 2.0 t60 -158.34 128.46 6.02 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.67 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.3 p -124.66 126.06 71.01 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-O 121.642 0.734 . . . . 0.0 110.422 179.426 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.508 ' O ' ' HB2' ' A' ' 50' ' ' SER . 5.7 mt-10 -68.69 123.06 19.85 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.279 -1.328 . . . . 0.0 111.914 -179.103 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.499 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 12.2 p-10 -86.11 20.3 2.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.925 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.36 -19.63 66.17 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 116.006 -0.543 . . . . 0.0 113.666 -179.116 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 168.18 -49.77 0.23 Allowed Glycine 0 CA--C 1.522 0.486 0 C-N-CA 119.134 -1.508 . . . . 0.0 114.733 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -60.33 -132.48 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.967 0 C-N-CA 123.117 2.544 . . . . 0.0 116.318 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.499 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -39.79 -41.63 1.15 Allowed 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 -176.703 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.508 ' HB2' ' O ' ' A' ' 44' ' ' GLU . 0.4 OUTLIER -63.07 -59.5 4.7 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 118.385 0.538 . . . . 0.0 112.227 -178.098 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -63.62 -21.93 66.63 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.272 0.558 . . . . 0.0 110.847 -179.132 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.2 -26.15 61.94 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.463 178.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 135.09 -12.95 4.41 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.204 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.62 ' HA ' HD13 ' A' ' 8' ' ' ILE . 1.2 tt -69.54 115.24 8.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.312 0.577 . . . . 0.0 111.646 -179.394 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.413 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.0 OUTLIER -93.86 123.53 37.27 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.666 178.035 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.498 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 34.4 tt0 -49.36 143.77 6.13 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.945 0.402 . . . . 0.0 111.893 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.6 5.66 74.54 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.951 -0.643 . . . . 0.0 112.737 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.487 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 6.3 t0 -86.61 144.07 27.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.854 0.359 . . . . 0.0 110.693 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.501 HD12 ' O ' ' A' ' 38' ' ' HIS . 4.0 tp -92.17 134.12 35.16 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.509 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.539 HG12 HD11 ' A' ' 89' ' ' ILE . 3.4 mp -91.45 125.23 44.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.042 -179.311 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 45.8 p -101.66 -37.56 8.3 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.386 0.612 . . . . 0.0 110.886 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 69.5 m80 -141.73 157.68 44.75 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.148 -178.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.446 HG21 HG13 ' A' ' 80' ' ' ILE . 12.2 p -144.29 122.07 5.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.008 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 56.78 27.06 12.23 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.611 -179.367 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.28 43.25 26.04 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.917 -0.659 . . . . 0.0 111.596 -178.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.458 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.8 tp10 -150.42 104.4 3.11 Favored Pre-proline 0 N--CA 1.433 -1.319 0 C-N-CA 122.949 0.5 . . . . 0.0 109.732 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 47.3 Cg_exo -41.48 128.41 3.42 Favored 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 124.114 3.21 . . . . 0.0 111.512 177.59 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 32.7 m -86.25 -11.32 11.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 114.675 -1.148 . . . . 0.0 109.321 -178.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -54.6 97.09 0.02 OUTLIER 'General case' 0 N--CA 1.424 -1.728 0 CA-C-N 112.697 -2.047 . . . . 0.0 111.667 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.03 -13.86 23.97 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.828 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 41.2 mt -74.54 145.13 43.69 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.693 0.246 . . . . 0.0 110.349 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.638 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -79.2 168.95 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 179.268 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -45.79 -50.19 14.28 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 121.45 0.643 . . . . 0.0 112.628 -179.234 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.478 ' H ' HG13 ' A' ' 72' ' ' VAL . 18.0 p -81.64 -14.54 56.56 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.84 -177.43 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.638 ' HG3' HG12 ' A' ' 72' ' ' VAL . 15.2 mt-10 -69.81 -42.6 73.48 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 121.25 -0.18 . . . . 0.0 111.286 -179.213 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.598 HG21 ' HG ' ' A' ' 21' ' ' LEU . 4.3 m -65.1 -44.56 95.63 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 CA-C-O 121.369 0.604 . . . . 0.0 109.43 179.006 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.433 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 83.5 t -53.14 -49.5 50.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 114.829 -1.078 . . . . 0.0 110.043 177.315 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -59.84 -45.33 92.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.005 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -54.16 -40.78 67.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.347 0.594 . . . . 0.0 110.216 178.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.754 HG23 HG11 ' A' ' 87' ' ' VAL . 14.5 mt -73.17 -49.75 36.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.091 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.433 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 91.1 mt -57.83 -41.67 82.75 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.837 0.351 . . . . 0.0 111.069 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 18.8 ttmt -60.58 -37.85 82.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.703 -0.68 . . . . 0.0 112.026 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 8.1 t -51.41 -45.81 62.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.456 -179.501 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.71 -132.49 7.95 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 119.879 -1.153 . . . . 0.0 114.023 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -73.14 -6.66 47.19 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 111.948 0.351 . . . . 0.0 111.948 -178.564 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.1 pttp -160.17 175.1 13.3 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-O 120.618 0.247 . . . . 0.0 110.985 -179.488 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.754 HG11 HG23 ' A' ' 80' ' ' ILE . 11.4 p -167.42 146.19 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.737 -0.665 . . . . 0.0 112.516 -179.037 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.466 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -92.87 98.57 11.46 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.886 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.55 HG22 ' O ' ' A' ' 8' ' ' ILE . 8.6 tt -92.62 113.32 27.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 120.81 0.338 . . . . 0.0 110.352 178.606 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.423 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -92.03 112.77 24.83 Favored 'General case' 0 C--N 1.323 -0.559 0 O-C-N 122.189 -0.32 . . . . 0.0 111.106 -179.052 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.487 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 77.6 p -108.41 175.68 5.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.525 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 4.1 t -104.04 102.14 30.12 Favored Pre-proline 0 CA--C 1.535 0.403 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -177.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.405 ' HD3' ' O ' ' A' ' 91' ' ' THR . 76.2 Cg_exo -53.99 170.9 0.41 Allowed 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 122.403 2.068 . . . . 0.0 112.913 177.637 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.409 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.0 OUTLIER -63.66 157.86 22.91 Favored 'General case' 0 C--N 1.319 -0.717 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.57 179.789 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.465 0 CA-C-O 120.943 0.402 . . . . 0.0 111.311 -179.202 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.45 -0.441 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 39.2 ttp 55.24 70.48 0.62 Allowed 'General case' 0 C--N 1.331 -0.223 0 O-C-N 123.514 0.508 . . . . 0.0 110.915 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.456 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.1 mpt_? -70.73 132.47 87.07 Favored Pre-proline 0 C--N 1.323 -0.558 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.456 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -87.28 109.58 0.74 Allowed 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.884 2.39 . . . . 0.0 113.15 -178.396 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 15.0 Cg_exo -69.16 124.22 11.11 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.183 1.922 . . . . 0.0 112.34 178.637 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.571 HD13 ' HA ' ' A' ' 54' ' ' LEU . 2.6 mt -88.49 109.43 19.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.166 -0.924 . . . . 0.0 108.784 178.752 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.416 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 4.2 mm -76.1 99.97 2.07 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.586 -178.519 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.703 HG21 ' HB3' ' A' ' 17' ' ' TYR . 4.8 mt -76.67 159.85 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.027 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' HIS . . . . . 0.533 ' N ' HG22 ' A' ' 10' ' ' ILE . 14.7 t-80 -137.98 109.67 7.08 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 47.2 ttt180 -63.58 104.32 0.64 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.59 -179.344 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.4 50.07 1.06 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.539 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.05 -37.86 2.85 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.289 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.5 ptpt -84.09 -86.63 0.12 Allowed 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.5 pttp -154.89 -174.4 4.97 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 121.116 -0.234 . . . . 0.0 111.374 -178.58 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' TYR . . . . . 0.703 ' HB3' HG21 ' A' ' 10' ' ' ILE . 19.8 m-85 -87.98 1.63 53.68 Favored 'General case' 0 C--O 1.224 -0.238 0 CA-C-O 121.019 0.438 . . . . 0.0 109.858 179.119 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 52.38 53.37 31.99 Favored Glycine 0 C--O 1.22 -0.766 0 N-CA-C 116.738 1.455 . . . . 0.0 116.738 176.827 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.562 ' HB3' HG23 ' A' ' 43' ' ' VAL . 9.3 p90 -165.49 144.88 6.51 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 122.409 1.099 . . . . 0.0 113.018 175.853 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 92.2 m -91.27 116.08 28.54 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 113.434 -1.712 . . . . 0.0 112.921 -178.744 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.598 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -90.34 82.15 5.98 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 121.063 0.459 . . . . 0.0 110.133 178.491 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.527 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 4.5 tpt180 . . . . . 0 C--N 1.325 -0.492 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.379 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.9 t . . . . . 0 N--CA 1.45 -0.456 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -110.06 -173.88 2.36 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.816 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.535 ' O ' HD12 ' A' ' 59' ' ' LEU . 95.2 m-70 -149.7 166.29 29.82 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 48.4 ttm -153.19 138.17 17.22 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.669 HG11 HD21 ' A' ' 54' ' ' LEU . 2.6 p -71.6 102.52 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 CA-C-O 122.007 0.908 . . . . 0.0 108.871 178.848 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.527 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.1 t-105 -69.75 -41.16 75.59 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.814 -177.867 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' HIS . . . . . 0.449 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -154.59 128.09 8.55 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.076 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.562 HG23 ' HB3' ' A' ' 19' ' ' PHE . 5.8 p -125.47 124.77 67.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 CA-C-O 121.834 0.826 . . . . 0.0 110.534 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.589 ' O ' ' HB2' ' A' ' 50' ' ' SER . 32.5 mt-10 -68.63 118.38 11.56 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 114.171 -1.377 . . . . 0.0 112.41 -178.756 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.609 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 14.7 p-10 -87.47 32.66 0.7 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.772 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -92.21 -22.66 29.16 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.866 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLY . . . . . 0.526 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 174.85 -51.42 0.13 Allowed Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 119.534 -1.317 . . . . 0.0 114.281 -179.095 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -60.81 -131.13 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.401 2.734 . . . . 0.0 116.409 -179.009 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.522 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -42.12 -44.71 3.75 Favored 'General case' 0 N--CA 1.464 0.273 0 N-CA-C 114.644 1.35 . . . . 0.0 114.644 -176.826 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.609 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -62.12 -58.32 8.24 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -177.661 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.526 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 2.3 mm-40 -62.2 -24.68 67.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.213 0.53 . . . . 0.0 110.799 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -70.68 -24.58 62.7 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.267 178.652 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 136.31 -12.87 4.07 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.914 179.103 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.669 HD21 HG11 ' A' ' 40' ' ' VAL . 1.1 tt -69.29 116.29 9.55 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.623 0.725 . . . . 0.0 112.036 -179.201 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.86 125.71 42.88 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.587 177.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -50.87 141.76 12.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.894 0.378 . . . . 0.0 111.209 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 86.19 37.85 8.83 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.628 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.633 ' OD1' ' HB ' ' A' ' 91' ' ' THR . 1.9 t70 -120.52 142.73 49.04 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 179.736 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.535 HD12 ' O ' ' A' ' 38' ' ' HIS . 12.2 tp -89.72 128.1 36.05 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.89 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.511 HG12 HD11 ' A' ' 89' ' ' ILE . 4.0 mp -86.19 126.63 40.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.975 -179.629 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 41.1 p -102.27 -41.27 6.42 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.871 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 59.3 m80 -138.94 160.24 40.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.176 -178.471 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.411 HG21 HG13 ' A' ' 80' ' ' ILE . 10.6 p -142.74 115.81 3.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.192 -0.458 . . . . 0.0 109.913 177.817 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 56.45 31.17 18.37 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.745 -0.662 . . . . 0.0 111.467 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.31 41.03 17.92 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.973 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.522 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.2 tp10 -152.15 108.48 2.82 Favored Pre-proline 0 N--CA 1.432 -1.373 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.522 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 1.3 Cg_endo -48.48 134.61 26.48 Favored 'Trans proline' 0 N--CA 1.45 -1.061 0 C-N-CA 123.636 2.891 . . . . 0.0 111.066 178.284 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 32.9 m -87.57 -7.65 10.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-N 114.373 -1.285 . . . . 0.0 109.288 -178.445 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.9 m170 -55.59 96.12 0.02 OUTLIER 'General case' 0 N--CA 1.427 -1.591 0 CA-C-N 112.771 -2.013 . . . . 0.0 111.744 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.9 -12.56 27.1 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.291 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 31.1 mt -74.84 138.22 42.37 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.641 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -77.93 169.86 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.267 179.801 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -42.79 -48.9 5.76 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 123.76 0.824 . . . . 0.0 112.711 -179.499 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.517 ' H ' HG13 ' A' ' 72' ' ' VAL . 25.1 p -84.52 -15.38 46.06 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.309 0.855 . . . . 0.0 113.309 -177.049 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.641 ' HG3' HG12 ' A' ' 72' ' ' VAL . 18.7 mt-10 -69.56 -43.39 73.0 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 121.096 -0.242 . . . . 0.0 111.35 -179.176 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.598 HG21 ' HG ' ' A' ' 21' ' ' LEU . 3.8 m -64.4 -45.23 96.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.26 0.552 . . . . 0.0 109.632 179.185 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.402 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 79.4 t -54.48 -48.28 69.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.877 177.43 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -59.56 -49.53 77.4 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.825 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.13 -41.31 62.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.605 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.702 HG23 HG11 ' A' ' 87' ' ' VAL . 16.0 mt -68.75 -52.88 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.972 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.402 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 46.4 mt -59.05 -37.5 77.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.201 0.524 . . . . 0.0 111.088 179.603 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -61.71 -38.62 88.53 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.928 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 40.4 t -52.76 -47.29 67.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.283 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 136.57 -135.39 7.7 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.122 -1.037 . . . . 0.0 112.921 179.146 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -79.6 1.76 24.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.132 0.491 . . . . 0.0 111.374 -179.16 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 10.9 pttp -159.67 175.46 13.15 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.173 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.702 HG11 HG23 ' A' ' 80' ' ' ILE . 12.2 p -167.55 147.18 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 O-C-N 123.567 0.542 . . . . 0.0 112.342 -179.105 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.43 93.84 7.9 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.867 179.585 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.511 HD11 HG12 ' A' ' 60' ' ' ILE . 7.3 tt -88.3 113.59 25.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-O 121.055 0.455 . . . . 0.0 110.474 179.078 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.463 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -90.58 110.83 21.97 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.945 0.402 . . . . 0.0 111.235 -179.005 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.633 ' HB ' ' OD1' ' A' ' 58' ' ' ASP . 26.1 p -103.77 169.54 8.46 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.217 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.432 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 8.6 t -107.25 104.59 52.92 Favored Pre-proline 0 CA--C 1.534 0.342 0 C-N-CA 120.444 -0.502 . . . . 0.0 112.191 -178.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_exo -53.09 172.24 0.2 Allowed 'Trans proline' 0 C--N 1.351 0.669 0 C-N-CA 122.311 2.007 . . . . 0.0 113.039 178.099 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -64.28 163.39 13.0 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.048 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.324 -0.529 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.4 -179.106 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.6 m . . . . . 0 C--O 1.234 0.273 0 N-CA-C 110.38 -0.229 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 93.4 mtp 61.23 75.75 0.4 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.148 0.499 . . . . 0.0 110.752 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.484 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.0 mpt_? -72.91 134.98 80.77 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.515 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 5.0 Cg_endo -92.24 116.02 0.37 Allowed 'Trans proline' 0 CA--C 1.531 0.355 0 C-N-CA 123.326 2.684 . . . . 0.0 113.408 -178.623 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.497 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 12.3 Cg_exo -73.88 124.22 9.02 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 122.439 2.093 . . . . 0.0 113.17 178.396 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.499 HD13 ' HA ' ' A' ' 54' ' ' LEU . 1.1 mt -87.45 110.33 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.836 177.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.414 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 3.2 mm -78.16 97.91 2.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.569 -178.634 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.639 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.2 mt -77.35 162.08 4.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 177.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' HIS . . . . . 0.52 ' N ' HG22 ' A' ' 10' ' ' ILE . 53.0 t-80 -137.51 114.44 10.64 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 108.11 -1.071 . . . . 0.0 108.11 178.536 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 30.6 ttt180 -61.34 107.14 0.72 Allowed 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.675 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -80.68 50.68 1.37 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.432 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.34 23.54 74.97 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.638 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' LYS . . . . . 0.497 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 9.8 ptpt -150.76 -80.6 0.11 Allowed 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.497 ' H ' ' HG3' ' A' ' 15' ' ' LYS . 21.7 pttm -158.42 178.25 10.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.377 0.132 . . . . 0.0 110.822 -178.705 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' TYR . . . . . 0.639 ' HB3' HG21 ' A' ' 10' ' ' ILE . 6.4 m-85 -89.22 4.44 48.67 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-O 121.54 0.686 . . . . 0.0 109.536 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.408 ' O ' ' HG3' ' A' ' 44' ' ' GLU . . . 64.16 -27.48 0.09 OUTLIER Glycine 0 C--N 1.335 0.528 0 N-CA-C 116.925 1.53 . . . . 0.0 116.925 177.249 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.579 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.4 p90 -81.7 147.64 29.38 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 122.445 1.117 . . . . 0.0 113.459 -176.568 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 87.5 m -97.0 112.55 24.26 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 113.344 -1.753 . . . . 0.0 111.575 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.652 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -85.37 86.78 7.35 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.316 178.985 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.516 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 5.5 tpt180 . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.472 179.697 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 t . . . . . 0 N--CA 1.45 -0.452 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 41.6 m-70 -104.94 -174.88 2.64 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.61 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.534 ' O ' HD12 ' A' ' 59' ' ' LEU . 99.1 m-70 -150.9 164.61 35.9 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -152.44 139.74 19.45 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.586 -178.388 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.874 HG11 HD21 ' A' ' 54' ' ' LEU . 1.9 p -73.64 105.51 3.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 121.808 0.813 . . . . 0.0 109.466 178.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.516 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 4.4 t-105 -69.87 -44.39 69.9 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.446 -1.252 . . . . 0.0 112.292 -177.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' HIS . . . . . 0.482 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 2.1 t60 -154.29 133.75 12.72 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.229 -0.896 . . . . 0.0 110.046 -178.332 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.579 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 3.0 p -126.87 129.16 71.36 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 CA-C-O 121.629 0.728 . . . . 0.0 110.859 179.238 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.419 ' O ' ' HB2' ' A' ' 50' ' ' SER . 15.5 mt-10 -66.05 119.79 12.01 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 114.74 -1.118 . . . . 0.0 111.583 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.567 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 9.4 p-10 -88.07 19.16 3.78 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.174 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.03 4.12 60.7 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.372 -0.918 . . . . 0.0 113.837 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 161.27 -55.74 0.31 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 118.795 -1.669 . . . . 0.0 115.187 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.406 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 50.5 Cg_exo -60.57 -135.14 0.0 OUTLIER 'Trans proline' 0 CA--C 1.545 1.04 0 C-N-CA 123.043 2.495 . . . . 0.0 116.679 -178.079 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.549 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -43.17 -36.99 1.9 Allowed 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 115.208 1.558 . . . . 0.0 115.208 -176.582 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.567 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 1.9 m -62.29 -55.08 31.77 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 118.655 0.661 . . . . 0.0 111.546 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -63.5 -24.31 67.76 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.008 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.08 -24.79 60.71 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.905 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.54 -7.33 6.23 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.565 -0.826 . . . . 0.0 113.104 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.874 HD21 HG11 ' A' ' 40' ' ' VAL . 5.1 tt -70.59 113.81 8.07 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.044 0.45 . . . . 0.0 110.88 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.17 122.32 32.35 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.931 178.17 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.455 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 36.3 tt0 -49.49 131.73 20.88 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 120.905 0.383 . . . . 0.0 110.664 177.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.37 65.89 1.35 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.294 -178.54 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.497 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.7 t0 -144.84 148.31 33.84 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.534 HD12 ' O ' ' A' ' 38' ' ' HIS . 8.7 tp -92.5 127.78 38.12 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.22 -179.635 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.443 ' CG1' HD11 ' A' ' 89' ' ' ILE . 4.0 mp -87.05 125.18 40.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.704 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 52.8 p -102.07 -39.08 7.46 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.379 0.609 . . . . 0.0 110.599 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 59.0 m80 -139.31 155.26 47.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.089 -178.765 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.565 HG21 HG13 ' A' ' 80' ' ' ILE . 7.7 p -138.2 113.07 9.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.851 177.743 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.8 t30 56.46 32.84 21.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.786 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.12 43.22 22.02 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.12 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.503 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.5 tp10 -149.99 106.2 3.21 Favored Pre-proline 0 N--CA 1.44 -0.949 0 C-N-CA 122.578 0.351 . . . . 0.0 110.375 179.673 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.503 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.7 Cg_exo -45.09 129.51 10.16 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 123.71 2.94 . . . . 0.0 111.538 177.724 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 31.3 m -86.76 -9.56 11.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-N 114.419 -1.264 . . . . 0.0 109.18 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.3 m170 -54.51 97.64 0.02 OUTLIER 'General case' 0 N--CA 1.426 -1.633 0 CA-C-N 112.602 -2.09 . . . . 0.0 112.074 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 108.98 -11.02 34.44 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.63 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.6 mt -75.79 139.96 42.08 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.655 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -79.3 170.47 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.632 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.466 ' O ' HG23 ' A' ' 77' ' ' VAL . 55.4 t60 -44.37 -54.75 5.55 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.668 0.747 . . . . 0.0 112.417 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 27.6 p -73.14 -20.69 60.86 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.111 -0.949 . . . . 0.0 112.788 -177.259 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.655 ' HG3' HG12 ' A' ' 72' ' ' VAL . 26.4 mt-10 -69.21 -41.81 76.57 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 121.271 -0.171 . . . . 0.0 111.168 -179.261 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.652 HG21 ' HG ' ' A' ' 21' ' ' LEU . 13.6 m -67.05 -46.95 83.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 C-N-CA 120.476 -0.49 . . . . 0.0 110.024 178.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.466 HG23 ' O ' ' A' ' 73' ' ' HIS . 40.6 t -53.13 -46.49 55.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.18 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -66.6 -42.48 86.82 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.836 179.302 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -54.04 -39.27 66.06 Favored 'General case' 0 C--N 1.327 -0.388 0 O-C-N 123.681 0.613 . . . . 0.0 109.801 178.076 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.675 HG23 HG11 ' A' ' 87' ' ' VAL . 16.4 mt -71.28 -51.91 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.494 179.472 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 82.5 mt -57.95 -32.69 68.08 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-O 121.104 0.478 . . . . 0.0 110.609 179.076 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 24.8 ttmt -58.67 -40.0 82.28 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.226 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 26.1 t -56.9 -55.04 39.65 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.745 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 134.99 -127.96 4.59 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.069 -1.063 . . . . 0.0 113.807 178.731 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -75.18 -2.9 29.95 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -178.575 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.422 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 18.5 pttp -159.77 175.33 13.25 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.249 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.675 HG11 HG23 ' A' ' 80' ' ' ILE . 13.5 p -166.67 145.1 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.505 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ALA . . . . . 0.472 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -93.88 92.36 7.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.3 -0.864 . . . . 0.0 111.665 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.449 HG22 ' O ' ' A' ' 8' ' ' ILE . 6.8 tt -88.05 112.24 23.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-O 121.014 0.435 . . . . 0.0 110.346 179.262 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 1.0 OUTLIER -91.95 115.39 28.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.779 0.323 . . . . 0.0 111.326 -178.829 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.497 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 64.5 p -109.4 175.39 5.47 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.315 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.499 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 6.3 t -103.9 105.16 46.96 Favored Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 113.04 0.755 . . . . 0.0 113.04 -178.059 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -52.8 171.86 0.2 Allowed 'Trans proline' 0 C--O 1.236 0.421 0 C-N-CA 122.64 2.226 . . . . 0.0 112.928 177.45 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -66.47 159.16 27.74 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.796 179.532 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.218 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 N--CA 1.451 -0.399 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 89.9 mtp 62.3 78.28 0.3 Allowed 'General case' 0 N--CA 1.463 0.192 0 O-C-N 123.715 0.635 . . . . 0.0 110.631 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.441 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.9 mpt_? -72.02 148.92 92.07 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.264 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 8.4 Cg_endo -95.43 113.06 0.15 Allowed 'Trans proline' 0 N--CA 1.461 -0.414 0 C-N-CA 123.742 2.961 . . . . 0.0 113.173 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 12.5 Cg_exo -72.86 122.87 8.51 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.463 2.109 . . . . 0.0 113.299 178.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.54 HG21 ' N ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -83.38 109.14 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.28 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.072 177.708 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.401 ' H ' HG12 ' A' ' 9' ' ' ILE . 3.2 mm -77.36 97.31 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.174 -178.78 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.539 HG12 ' HB2' ' A' ' 49' ' ' ALA . 5.7 mt -76.89 159.1 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' HIS . . . . . 0.494 ' N ' HG22 ' A' ' 10' ' ' ILE . 47.3 t-80 -136.5 112.18 9.41 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 46.7 ttt180 -63.67 109.16 1.6 Allowed 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.728 -178.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -83.36 52.31 2.19 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.87 178.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.54 -49.65 4.21 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-N 115.767 -0.652 . . . . 0.0 112.243 -179.388 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.5 ptpt -71.76 -90.41 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 16.4 pttm -158.53 -171.56 3.5 Favored 'General case' 0 C--N 1.327 -0.4 0 O-C-N 122.434 -0.166 . . . . 0.0 111.092 -178.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' TYR . . . . . 0.477 ' HB3' HG21 ' A' ' 10' ' ' ILE . 12.2 m-85 -88.11 -1.76 58.2 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.517 0.675 . . . . 0.0 109.744 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.558 ' HA3' ' HB2' ' A' ' 44' ' ' GLU . . . 63.62 -19.34 0.09 OUTLIER Glycine 0 CA--C 1.519 0.342 0 N-CA-C 117.057 1.583 . . . . 0.0 117.057 177.507 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.591 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.4 p90 -85.44 146.89 26.75 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 122.505 1.145 . . . . 0.0 113.524 -177.253 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.406 HG21 HH11 ' A' ' 22' ' ' ARG . 86.1 m -94.65 113.55 25.37 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.601 -1.636 . . . . 0.0 112.364 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.568 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -89.49 81.5 6.54 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.931 0.396 . . . . 0.0 110.692 178.694 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.452 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--N 1.323 -0.545 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.259 179.417 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 9.4 t . . . . . 0 N--CA 1.451 -0.403 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -108.48 -176.06 2.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.238 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.537 ' CD2' HG11 ' A' ' 76' ' ' VAL . 97.7 m-70 -148.46 168.5 22.51 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' MET . . . . . 0.411 ' HG2' ' O ' ' A' ' 58' ' ' ASP . 3.1 mtm -157.05 137.76 13.24 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 120.61 0.243 . . . . 0.0 110.425 -178.818 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.927 HG11 HD21 ' A' ' 54' ' ' LEU . 1.9 p -72.83 100.63 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-O 122.126 0.965 . . . . 0.0 108.817 178.625 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.452 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.2 t-105 -69.77 -41.08 75.61 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.025 -1.443 . . . . 0.0 112.711 -177.378 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' HIS . . . . . 0.463 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -156.39 127.19 6.81 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.374 -178.652 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.591 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 2.4 p -118.84 129.0 75.65 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 CA-C-O 121.251 0.548 . . . . 0.0 110.024 179.18 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.558 ' HB2' ' HA3' ' A' ' 18' ' ' GLY . 5.2 mt-10 -63.9 114.04 3.83 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 114.735 -1.121 . . . . 0.0 111.645 -178.78 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.485 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 11.8 p-10 -83.17 39.54 0.65 Allowed 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.92 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -122.75 11.88 8.83 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.407 -0.901 . . . . 0.0 113.935 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 156.75 -61.99 0.33 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 118.633 -1.746 . . . . 0.0 115.153 179.314 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' PRO . . . . . 0.466 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 51.2 Cg_exo -61.04 -133.41 0.0 OUTLIER 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 123.17 2.58 . . . . 0.0 116.958 -177.46 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.539 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -42.13 -35.36 0.91 Allowed 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 114.95 1.463 . . . . 0.0 114.95 -176.807 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.485 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -61.13 -59.61 5.07 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 118.33 0.513 . . . . 0.0 111.706 -178.921 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -63.61 -30.24 71.38 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.548 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.19 -29.28 70.26 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.673 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.3 -10.5 5.59 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.196 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.927 HD21 HG11 ' A' ' 40' ' ' VAL . 5.6 tt -66.85 114.45 5.71 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.849 0.357 . . . . 0.0 110.48 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.15 122.49 32.5 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.486 178.586 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.438 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 40.2 tt0 -51.34 138.0 22.17 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.989 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 83.14 47.35 5.82 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.222 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.582 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.3 t0 -127.24 149.23 50.1 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.507 HD12 ' O ' ' A' ' 38' ' ' HIS . 19.9 tp -93.03 125.8 37.8 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.149 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.451 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.8 mp -83.82 124.74 39.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.276 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 57.8 p -99.51 -40.0 8.06 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.378 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -142.05 157.31 45.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.122 -178.349 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.67 115.21 8.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 177.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 59.62 31.1 20.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.418 -179.4 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 73.23 45.5 30.78 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.372 -178.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.499 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 1.5 tp10 -151.75 111.23 2.93 Favored Pre-proline 0 N--CA 1.433 -1.316 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 -179.246 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.499 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 4.7 Cg_endo -50.99 133.47 40.65 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 123.551 2.834 . . . . 0.0 111.257 178.745 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 35.1 m -90.01 -7.87 10.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.806 -178.385 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.8 m170 -55.41 95.06 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.54 0 CA-C-N 112.977 -1.919 . . . . 0.0 111.96 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.29 -9.37 24.59 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.394 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 32.2 mt -77.39 139.76 39.78 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.505 HG13 ' H ' ' A' ' 74' ' ' THR . 0.6 OUTLIER -81.14 171.18 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.162 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -42.02 -49.02 4.71 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 123.682 0.793 . . . . 0.0 112.934 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.505 ' H ' HG13 ' A' ' 72' ' ' VAL . 30.6 p -82.11 -21.14 36.88 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 -176.586 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLU . . . . . 0.402 ' HG3' HG12 ' A' ' 72' ' ' VAL . 28.2 mt-10 -67.53 -40.83 85.06 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 121.082 -0.247 . . . . 0.0 111.38 -178.583 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.568 HG21 ' HG ' ' A' ' 21' ' ' LEU . 3.9 m -65.68 -46.85 88.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.267 0.556 . . . . 0.0 109.599 178.66 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 58.4 t -54.79 -45.71 74.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.295 177.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -62.96 -45.12 93.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.942 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.53 -41.66 66.63 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.34 0.59 . . . . 0.0 110.041 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.637 HG23 HG11 ' A' ' 87' ' ' VAL . 12.0 mt -68.77 -50.66 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.964 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 65.9 mt -59.23 -39.54 83.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.252 0.549 . . . . 0.0 110.478 178.908 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -61.46 -36.58 80.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.69 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 44.3 t -53.76 -47.64 70.49 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.129 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 138.06 -124.45 2.96 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.264 -0.969 . . . . 0.0 113.295 179.104 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -93.65 7.07 46.16 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.265 0.555 . . . . 0.0 110.887 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 19.8 pttp -161.12 179.21 8.59 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.859 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.637 HG11 HG23 ' A' ' 80' ' ' ILE . 11.4 p -170.15 143.68 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 O-C-N 123.609 0.568 . . . . 0.0 112.439 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.09 90.44 6.4 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.649 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.451 HD11 ' CG1' ' A' ' 60' ' ' ILE . 5.0 tt -87.78 115.65 28.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-O 120.954 0.407 . . . . 0.0 110.553 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 3.6 t -94.76 116.04 28.25 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.777 0.322 . . . . 0.0 111.395 -178.847 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.582 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 81.4 p -109.37 173.31 6.38 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.7 179.026 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.402 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 3.6 t -101.44 104.18 32.11 Favored Pre-proline 0 CA--C 1.536 0.414 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.705 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 91' ' ' THR . 77.1 Cg_exo -54.37 177.46 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.577 2.185 . . . . 0.0 113.015 177.609 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -62.55 156.47 23.0 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.396 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.321 -0.635 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.764 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.7 m . . . . . 0 N--CA 1.453 -0.305 0 N-CA-C 110.386 -0.227 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 77.4 mtp 63.41 78.94 0.27 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.183 0.516 . . . . 0.0 110.939 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.432 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.9 mpt_? -72.78 139.31 80.26 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.733 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -87.87 109.8 0.66 Allowed 'Trans proline' 0 C--O 1.236 0.418 0 C-N-CA 123.204 2.603 . . . . 0.0 112.826 -179.026 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.472 ' HA ' ' O ' ' A' ' 89' ' ' ILE . 12.0 Cg_exo -72.81 121.39 7.31 Favored 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 122.368 2.045 . . . . 0.0 113.041 179.02 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.466 HG21 ' N ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -83.0 110.86 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 CA-C-N 115.388 -0.824 . . . . 0.0 108.802 178.12 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.4 mm -77.16 100.75 2.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.75 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.698 HG21 ' HB3' ' A' ' 17' ' ' TYR . 6.0 mt -76.54 163.51 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.385 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' HIS . . . . . 0.55 ' N ' HG22 ' A' ' 10' ' ' ILE . 29.0 t-80 -141.53 107.1 5.06 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.105 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 52.6 ttt-85 -62.19 110.31 1.58 Allowed 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.164 -178.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -81.72 46.47 0.98 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.774 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.79 -0.26 66.32 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 121.163 -0.541 . . . . 0.0 112.814 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.1 ptpt -119.65 -82.38 0.64 Allowed 'General case' 0 C--N 1.325 -0.458 0 O-C-N 122.891 -0.182 . . . . 0.0 111.277 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.404 ' HE3' ' OE1' ' A' ' 44' ' ' GLU . 17.1 pttt -155.14 -178.71 7.45 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.702 -178.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' TYR . . . . . 0.698 ' HB3' HG21 ' A' ' 10' ' ' ILE . 16.9 m-85 -88.28 5.64 40.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.17 0.51 . . . . 0.0 110.223 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . 0.548 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 53.27 48.99 58.18 Favored Glycine 0 C--O 1.217 -0.909 0 N-CA-C 116.744 1.458 . . . . 0.0 116.744 177.062 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.499 ' HB3' HG23 ' A' ' 43' ' ' VAL . 6.3 p90 -164.42 147.38 9.04 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 122.457 1.123 . . . . 0.0 112.977 176.304 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 97.9 m -92.39 115.31 27.97 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 113.42 -1.718 . . . . 0.0 112.414 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' LEU . . . . . 0.665 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -89.22 84.48 6.51 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.74 0.305 . . . . 0.0 110.449 178.487 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.512 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 6.1 tpt180 . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.453 179.736 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 t . . . . . 0 N--CA 1.452 -0.344 0 CA-C-O 120.699 0.285 . . . . 0.0 110.789 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 54.9 m-70 -115.41 -175.46 2.71 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.676 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.529 ' CD2' HG11 ' A' ' 76' ' ' VAL . 97.1 m-70 -148.79 153.3 37.95 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 48.3 mtm -148.68 141.02 24.15 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.033 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.913 HG11 HD21 ' A' ' 54' ' ' LEU . 2.3 p -72.55 104.78 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-O 121.784 0.802 . . . . 0.0 109.581 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' TRP . . . . . 0.512 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.2 t-105 -70.07 -42.55 72.65 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.476 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' HIS . . . . . 0.442 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 0.9 OUTLIER -155.08 132.56 11.18 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.158 -179.125 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.0 p -127.75 130.08 70.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 121.575 0.702 . . . . 0.0 110.508 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.564 ' O ' ' HB2' ' A' ' 50' ' ' SER . 37.1 mt-10 -67.04 115.07 6.34 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 114.583 -1.19 . . . . 0.0 111.811 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ASP . . . . . 0.539 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 11.9 p-10 -84.19 35.72 0.55 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.649 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.94 -26.12 8.09 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.708 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -179.93 -54.4 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 119.439 -1.362 . . . . 0.0 114.688 -178.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -58.07 -129.57 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 0.975 0 C-N-CA 123.524 2.816 . . . . 0.0 116.68 -178.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.522 ' HB1' HD13 ' A' ' 54' ' ' LEU . . . -43.36 -42.87 4.8 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -176.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.564 ' HB2' ' O ' ' A' ' 44' ' ' GLU . 0.4 OUTLIER -62.09 -62.25 1.91 Allowed 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 112.742 0.645 . . . . 0.0 112.742 -177.668 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -62.04 -22.69 65.94 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.02 0.438 . . . . 0.0 111.072 -178.593 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -71.06 -24.57 62.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.692 179.131 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.05 -15.05 3.76 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.75 -0.738 . . . . 0.0 113.03 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LEU . . . . . 0.913 HD21 HG11 ' A' ' 40' ' ' VAL . 5.1 tt -69.42 113.07 6.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.049 0.452 . . . . 0.0 110.787 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ARG . . . . . 0.502 ' HD3' ' O ' ' A' ' 55' ' ' ARG . 0.0 OUTLIER -93.74 123.73 37.27 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.573 178.313 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.442 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 37.0 tt0 -49.08 134.43 17.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.247 0.546 . . . . 0.0 111.31 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 89.77 60.79 1.4 Allowed Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.734 -0.745 . . . . 0.0 111.681 -179.222 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.605 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.4 t0 -140.75 155.25 46.48 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 38' ' ' HIS . 13.3 tp -102.75 125.27 49.42 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.931 -179.414 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.433 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.5 mp -82.68 122.75 37.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.276 -179.386 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.435 ' O ' HG22 ' A' ' 68' ' ' VAL . 44.8 p -100.59 -34.1 10.03 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.652 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 75.2 m80 -146.04 162.53 37.68 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.081 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.3 p -145.89 114.83 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.65 177.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 57.58 32.57 22.03 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.766 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 68.98 47.44 54.47 Favored Glycine 0 N--CA 1.444 -0.768 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -178.852 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.41 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.9 tp10 -149.55 99.98 3.34 Favored Pre-proline 0 N--CA 1.442 -0.835 0 C-N-CA 122.834 0.454 . . . . 0.0 110.079 -179.077 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 80.4 Cg_exo -36.37 124.36 0.35 Allowed 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 124.424 3.416 . . . . 0.0 112.564 177.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 61' ' ' THR . 27.0 m -86.68 -11.11 11.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.055 -179.411 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.5 m170 -56.57 98.14 0.03 OUTLIER 'General case' 0 N--CA 1.425 -1.688 0 CA-C-N 112.83 -1.986 . . . . 0.0 111.301 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 109.51 -6.41 31.71 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.441 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 25.0 mt -79.01 137.76 37.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.717 0.259 . . . . 0.0 110.517 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -79.92 170.05 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.28 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 38.3 t60 -44.09 -54.4 5.56 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.643 0.735 . . . . 0.0 112.764 -179.452 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 21.1 p -73.53 -21.0 60.5 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 115.312 -0.858 . . . . 0.0 113.236 -176.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -68.4 -41.97 79.72 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 120.969 -0.292 . . . . 0.0 111.608 -179.051 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.665 HG21 ' HG ' ' A' ' 21' ' ' LEU . 3.4 m -66.39 -44.58 90.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.95 179.04 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 50.2 t -53.68 -47.99 60.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.826 177.465 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 56.8 mt-10 -63.6 -45.2 91.45 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.894 178.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.41 -40.48 65.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.294 0.569 . . . . 0.0 109.822 178.859 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.707 HG23 HG11 ' A' ' 87' ' ' VAL . 21.8 mt -70.58 -53.21 23.39 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.775 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.267 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 83.8 mt -57.57 -38.39 74.73 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 120.887 0.375 . . . . 0.0 111.294 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 17.8 ttmt -59.6 -37.96 79.95 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.753 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 34.8 t -56.25 -39.52 72.71 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.972 -179.286 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.63 -141.38 12.91 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.11 -1.043 . . . . 0.0 112.997 179.388 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 23.5 p30 -75.13 5.5 5.3 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -179.101 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 16.0 pttp -162.71 171.18 17.22 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.726 -0.215 . . . . 0.0 110.452 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.707 HG11 HG23 ' A' ' 80' ' ' ILE . 11.6 p -164.96 147.06 2.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.73 94.22 7.98 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.748 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.472 ' O ' ' HA ' ' A' ' 7' ' ' PRO . 4.5 tt -88.61 116.16 29.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.749 0.309 . . . . 0.0 110.492 179.277 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.1 OUTLIER -93.39 112.9 24.93 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.628 0.251 . . . . 0.0 111.508 -178.752 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.605 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 80.4 p -107.14 179.99 4.1 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 178.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.417 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 4.0 t -114.1 104.11 54.95 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-O 121.232 0.539 . . . . 0.0 112.322 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -56.31 175.53 0.25 Allowed 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.68 2.253 . . . . 0.0 113.344 178.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.436 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.1 OUTLIER -65.32 162.33 17.74 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.476 -179.715 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.327 -0.393 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.143 179.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.75 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.28 164.52 27.26 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 121.068 -0.586 . . . . 0.0 111.886 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m -125.9 146.33 49.88 Favored 'General case' 0 C--N 1.319 -0.735 0 O-C-N 122.78 -0.247 . . . . 0.0 110.42 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 69.4 mtp 63.93 85.46 0.13 Allowed 'General case' 0 C--N 1.33 -0.241 0 O-C-N 123.869 0.731 . . . . 0.0 111.45 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.472 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 6.8 mpt_? -71.7 137.19 82.94 Favored Pre-proline 0 C--N 1.325 -0.485 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -88.05 113.94 0.84 Allowed 'Trans proline' 0 CA--C 1.53 0.304 0 C-N-CA 123.097 2.531 . . . . 0.0 113.134 -178.747 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.445 ' HA ' ' O ' ' A' ' 89' ' ' ILE . 13.0 Cg_exo -70.93 128.01 14.41 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.141 1.894 . . . . 0.0 112.681 178.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.66 HD13 ' HA ' ' A' ' 54' ' ' LEU . 3.1 mt -93.55 113.04 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.679 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mm -78.25 101.08 3.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.7 -178.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.674 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.4 mt -79.42 168.12 2.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 177.159 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' HIS . . . . . 0.57 ' N ' HG22 ' A' ' 10' ' ' ILE . 43.1 t-80 -145.88 114.38 6.75 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 178.41 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.9 ttt180 -66.48 99.57 0.58 Allowed 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.068 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.61 55.95 1.09 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.331 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.37 14.42 71.76 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.911 -0.586 . . . . 0.0 113.113 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.405 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 8.3 ptpt -140.48 -80.05 0.27 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 117.01 0.405 . . . . 0.0 111.777 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.631 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 24.4 pttt -155.97 178.02 10.75 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.541 0.21 . . . . 0.0 111.192 -178.756 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' TYR . . . . . 0.674 ' HB3' HG21 ' A' ' 10' ' ' ILE . 23.2 m-85 -87.5 2.35 50.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.253 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.526 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 53.37 49.84 55.09 Favored Glycine 0 C--O 1.215 -1.083 0 N-CA-C 116.436 1.334 . . . . 0.0 116.436 176.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.499 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 11.4 p90 -163.91 146.53 9.48 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 122.34 1.067 . . . . 0.0 112.314 176.185 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.534 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 32.7 m -93.35 119.59 32.65 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 113.48 -1.691 . . . . 0.0 113.534 -178.242 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.561 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -92.63 84.16 5.0 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.783 0.325 . . . . 0.0 110.222 177.836 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.427 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 4.4 tpt180 -69.76 121.79 17.91 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.142 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.582 ' HA ' ' ND1' ' A' ' 38' ' ' HIS . . . -87.46 134.53 33.58 Favored 'General case' 0 C--N 1.328 -0.343 0 O-C-N 123.207 0.317 . . . . 0.0 110.846 179.338 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.492 HG21 ' CE3' ' B' ' 102' ' ' TRP . 1.5 pt -153.04 104.97 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 179.324 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 20.9 mtm180 -77.55 101.37 6.48 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 176.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.8 m -77.71 105.07 6.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.187 0.518 . . . . 0.0 112.217 -178.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 29.6 m-85 -78.02 151.56 33.48 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 18.3 mmt -89.58 -2.1 58.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.857 0.36 . . . . 0.0 110.875 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.41 -133.21 4.01 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.902 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -83.1 -18.04 40.98 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.051 0.453 . . . . 0.0 110.431 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.02 164.51 25.41 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.117 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -78.14 -3.51 42.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.147 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.7 p -77.46 126.56 38.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.729 0.776 . . . . 0.0 111.096 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -157.93 154.17 27.39 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.38 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -113.99 129.75 56.58 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.769 0.319 . . . . 0.0 110.205 178.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 t -82.17 97.75 4.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 116.644 -0.253 . . . . 0.0 110.685 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 13.5 m-70 -110.51 177.17 4.77 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.992 0.425 . . . . 0.0 110.752 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.64 ' CD2' HG11 ' A' ' 76' ' ' VAL . 98.5 m-70 -150.19 152.8 35.21 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.277 -0.874 . . . . 0.0 108.709 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' MET . . . . . 0.426 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 44.6 mtm -147.53 141.7 26.12 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -178.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.711 HG11 HD21 ' A' ' 54' ' ' LEU . 2.5 p -73.14 103.19 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.981 0.896 . . . . 0.0 109.693 179.58 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.427 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 4.7 t-105 -69.28 -37.32 77.81 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.209 -1.359 . . . . 0.0 111.638 -178.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' HIS . . . . . 0.498 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 2.5 t60 -158.75 125.54 4.75 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.295 -178.168 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.3 p -121.47 124.78 72.55 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 CA-C-O 121.475 0.655 . . . . 0.0 109.746 178.446 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -63.72 109.31 1.66 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.524 -1.216 . . . . 0.0 111.922 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.585 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 8.8 p-10 -82.3 49.37 1.41 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.635 0.731 . . . . 0.0 109.708 179.008 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -131.05 13.62 5.49 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.447 -179.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.49 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 157.22 -68.79 0.28 Allowed Glycine 0 CA--C 1.523 0.546 0 C-N-CA 119.085 -1.531 . . . . 0.0 115.176 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_exo -60.18 -129.92 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 0 C-N-CA 123.748 2.965 . . . . 0.0 117.341 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.491 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -41.86 -38.79 1.62 Allowed 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 114.625 1.343 . . . . 0.0 114.625 -176.542 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.585 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 1.0 OUTLIER -62.17 -56.18 21.25 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.722 -178.844 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.49 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 7.3 mm-40 -63.45 -28.58 70.07 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.306 0.574 . . . . 0.0 110.432 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.46 -28.72 69.86 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.567 178.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.43 -5.15 5.57 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.931 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.711 HD21 HG11 ' A' ' 40' ' ' VAL . 1.7 tt -71.14 112.28 7.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.257 0.551 . . . . 0.0 111.463 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.96 120.81 32.26 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.704 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.498 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 33.2 tt0 -49.76 140.87 10.87 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.002 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.45 13.78 57.98 Favored Glycine 0 CA--C 1.52 0.357 0 C-N-CA 121.032 -0.604 . . . . 0.0 113.125 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.533 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 2.2 t0 -94.81 151.64 19.07 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.978 0.418 . . . . 0.0 111.116 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.522 HD12 ' O ' ' A' ' 38' ' ' HIS . 4.6 tp -98.26 129.94 44.98 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.192 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.559 HG12 HD11 ' A' ' 89' ' ' ILE . 3.8 mp -86.81 124.21 40.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.055 -179.246 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 66.3 p -100.4 -37.81 8.69 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.774 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.421 ' HB2' ' CB ' ' A' ' 90' ' ' SER . 59.1 m80 -143.11 162.54 35.27 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.927 -178.688 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.491 HG21 HG13 ' A' ' 80' ' ' ILE . 9.8 p -143.45 116.13 3.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.998 177.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 58.58 24.33 11.88 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.386 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.82 41.75 8.62 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.538 -178.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.522 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.1 tp10 -151.4 109.49 2.97 Favored Pre-proline 0 N--CA 1.434 -1.246 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.522 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 1.0 OUTLIER -47.29 128.88 15.18 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 123.947 3.098 . . . . 0.0 111.921 178.923 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.1 m -87.43 -13.76 10.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.165 0 CA-C-N 114.359 -1.291 . . . . 0.0 109.203 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 9.1 m170 -57.47 95.08 0.02 OUTLIER 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 112.846 -1.979 . . . . 0.0 111.163 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 119.41 -14.18 10.92 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.08 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 43.3 mt -76.01 142.52 41.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.592 0.234 . . . . 0.0 110.577 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.504 HG13 ' H ' ' A' ' 74' ' ' THR . 0.3 OUTLIER -78.08 169.66 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.882 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -42.42 -48.18 5.12 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.907 0.883 . . . . 0.0 113.119 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.504 ' H ' HG13 ' A' ' 72' ' ' VAL . 12.0 p -88.21 -15.45 35.93 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.038 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -68.4 -42.45 79.01 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 122.361 -0.212 . . . . 0.0 111.212 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.64 HG11 ' CD2' ' A' ' 38' ' ' HIS . 9.6 m -64.16 -46.36 93.76 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.233 0 CA-C-O 121.198 0.523 . . . . 0.0 110.0 179.275 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.589 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 72.8 t -55.18 -48.96 75.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.268 177.555 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -61.63 -44.01 97.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.161 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.19 -39.45 63.68 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-O 121.263 0.554 . . . . 0.0 109.937 178.631 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.576 HG23 HG11 ' A' ' 87' ' ' VAL . 14.3 mt -72.27 -50.34 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.807 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.589 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 39.6 mt -58.33 -36.85 74.01 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-O 121.329 0.585 . . . . 0.0 110.515 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 24.0 ttmt -60.34 -39.94 88.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.634 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 43.4 t -54.69 -36.47 64.69 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.359 -0.837 . . . . 0.0 111.49 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 127.85 -130.42 6.7 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.207 -0.997 . . . . 0.0 112.637 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 25.0 p30 -92.07 13.87 17.6 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.208 0.528 . . . . 0.0 111.047 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 19.5 pttp -163.47 176.69 9.53 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.064 179.347 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.576 HG11 HG23 ' A' ' 80' ' ' ILE . 8.6 p -171.81 145.99 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -179.429 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.417 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -92.38 95.82 9.89 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.276 -0.874 . . . . 0.0 111.108 178.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.58 HG22 ' O ' ' A' ' 8' ' ' ILE . 11.2 tt -89.09 113.64 25.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 120.945 0.403 . . . . 0.0 111.06 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.421 ' CB ' ' HB2' ' A' ' 62' ' ' HIS . 0.2 OUTLIER -87.52 110.14 20.12 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.929 0.395 . . . . 0.0 110.911 -179.535 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.533 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 40.0 p -108.32 164.37 12.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.151 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.446 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 2.1 t -99.78 105.51 34.89 Favored Pre-proline 0 C--N 1.328 -0.356 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -177.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 91' ' ' THR . 52.6 Cg_exo -54.64 176.2 0.12 Allowed 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 122.328 2.018 . . . . 0.0 113.089 178.014 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.01 164.05 13.52 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.695 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -163.32 159.45 22.56 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.341 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 5.5 p30 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.576 -0.726 . . . . 0.0 110.256 179.981 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.6 m . . . . . 0 N--CA 1.478 0.961 0 N-CA-C 110.669 -0.123 . . . . 0.0 110.669 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 102' ' ' TRP . . . . . 0.492 ' CE3' HG21 ' A' ' 24' ' ' ILE . 35.8 t-105 72.16 113.88 0.06 Allowed 'General case' 0 N--CA 1.47 0.528 0 O-C-N 123.764 0.665 . . . . 0.0 110.67 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 8.7 tm-20 -155.82 -46.67 0.08 Allowed 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 -178.155 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.88 22.76 0.37 Allowed 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 114.076 1.139 . . . . 0.0 114.076 -176.596 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 40.9 p-80 -67.04 -26.49 66.78 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.233 0.54 . . . . 0.0 109.756 179.253 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 106' ' ' LYS . . . . . 0.414 ' HD3' ' N ' ' B' ' 107' ' ' SER . 0.0 OUTLIER -111.05 -19.91 12.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.817 178.203 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 107' ' ' SER . . . . . 0.414 ' N ' ' HD3' ' B' ' 106' ' ' LYS . 1.4 m -80.91 89.98 5.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.68 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 125.47 -11.59 7.55 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.643 -179.193 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 93.18 -141.48 15.55 Favored Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.483 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -139.85 47.01 1.85 Allowed 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 7.0 m -64.02 135.63 56.6 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.016 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 112' ' ' ARG . . . . . 0.523 ' NH2' ' HD2' ' A' ' 16' ' ' LYS . 8.7 ptm180 -131.57 171.29 13.61 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.123 -179.361 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 113' ' ' LEU . . . . . 0.631 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 3.3 mm? . . . . . 0 C--O 1.243 0.735 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.03 -179.546 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.75 0 N-CA-C 112.009 -0.437 . . . . 0.0 112.009 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -155.24 166.77 32.73 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.787 -0.72 . . . . 0.0 111.853 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.5 m -134.83 155.59 50.38 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 84.9 mtp 58.31 79.76 0.2 Allowed 'General case' 0 N--CA 1.463 0.2 0 O-C-N 123.685 0.616 . . . . 0.0 111.483 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.499 ' H ' ' HD2' ' A' ' 5' ' ' ARG . 3.4 mpt_? -72.26 132.5 84.11 Favored Pre-proline 0 C--N 1.325 -0.498 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.497 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 3.6 Cg_exo -83.46 114.33 2.1 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 123.059 2.506 . . . . 0.0 112.745 -178.63 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 13.6 Cg_exo -70.84 124.31 10.52 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.245 1.963 . . . . 0.0 112.381 178.764 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.587 ' O ' HG22 ' A' ' 89' ' ' ILE . 5.2 mt -91.46 111.02 23.28 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.079 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mm -77.79 101.45 3.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -177.41 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.552 HG12 ' CB ' ' A' ' 49' ' ' ALA . 5.3 mt -78.05 164.95 3.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 177.069 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' HIS . . . . . 0.533 ' N ' HG22 ' A' ' 10' ' ' ILE . 32.7 t-80 -142.78 114.29 7.95 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.8 ttt180 -63.39 114.09 3.65 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.401 0.62 . . . . 0.0 110.725 -179.504 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -84.67 43.82 1.01 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.185 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.55 3.95 83.9 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.735 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.3 ptpt -127.64 -82.65 0.6 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.699 0.285 . . . . 0.0 111.138 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.525 ' HE2' ' OE1' ' A' ' 44' ' ' GLU . 22.7 pttm -158.51 -179.55 8.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.924 -178.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' TYR . . . . . 0.516 ' HA ' ' HB3' ' A' ' 48' ' ' PRO . 12.8 m-85 -89.98 -0.41 57.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.524 0.678 . . . . 0.0 109.182 179.214 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.404 ' HA3' ' HB2' ' A' ' 44' ' ' GLU . . . 64.98 -24.92 0.11 Allowed Glycine 0 C--N 1.331 0.274 0 N-CA-C 116.704 1.442 . . . . 0.0 116.704 177.843 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.575 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.7 p90 -81.96 142.48 32.38 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 122.615 1.197 . . . . 0.0 113.636 -176.562 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 58.6 m -93.14 114.65 27.21 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 113.225 -1.807 . . . . 0.0 111.481 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.649 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -86.4 84.28 7.48 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 178.752 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.589 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 1.9 tpt180 -66.07 135.93 55.3 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.936 -179.454 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.558 ' HB2' ' HD1' ' A' ' 73' ' ' HIS . . . -90.92 132.58 35.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.651 0.262 . . . . 0.0 110.841 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.486 HG22 ' CZ2' ' B' ' 102' ' ' TRP . 18.4 pt -137.29 166.95 24.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.977 0.418 . . . . 0.0 111.226 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -140.15 91.72 2.48 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.698 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 1.7 m -79.4 123.36 36.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.639 -179.383 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -81.15 146.07 30.72 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.822 0.344 . . . . 0.0 110.079 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 90.5 mtp -124.79 45.13 2.61 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.824 -178.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.76 -167.06 31.52 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.387 -0.911 . . . . 0.0 112.989 179.397 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -84.44 -34.28 23.5 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.857 0.36 . . . . 0.0 110.668 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.418 ' C ' ' H ' ' A' ' 33' ' ' VAL . 2.4 m -71.67 -178.33 2.2 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.602 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -77.62 30.42 0.16 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 121.011 0.434 . . . . 0.0 111.225 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.418 ' H ' ' C ' ' A' ' 31' ' ' SER . 2.2 p -85.95 120.14 35.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.478 0.656 . . . . 0.0 110.332 179.255 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -149.82 149.74 30.95 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.484 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.49 128.12 52.34 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.844 178.792 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.6 t -80.63 94.94 2.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-O 120.898 0.38 . . . . 0.0 110.656 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 51.3 m170 -108.63 -174.0 2.41 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.465 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.501 ' ND1' ' HA ' ' A' ' 23' ' ' ALA . 99.1 m-70 -151.39 161.61 42.39 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -179.762 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' MET . . . . . 0.474 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 68.5 mtm -150.02 144.79 26.02 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.755 0.312 . . . . 0.0 110.488 -178.566 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.508 HG11 ' CD2' ' A' ' 54' ' ' LEU . 2.7 p -74.41 104.5 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-O 121.823 0.82 . . . . 0.0 109.67 179.202 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.589 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 5.3 t-105 -69.82 -40.09 76.1 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.659 -1.155 . . . . 0.0 112.167 -178.389 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' HIS . . . . . 0.511 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.8 t60 -158.91 127.82 5.39 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.329 -178.271 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.575 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 2.4 p -120.93 129.33 75.8 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.109 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.525 ' OE1' ' HE2' ' A' ' 16' ' ' LYS . 27.5 mt-10 -64.09 113.12 3.31 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.911 -179.049 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.65 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 9.4 p-10 -84.88 34.33 0.54 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.134 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -124.3 17.07 7.52 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.151 -1.024 . . . . 0.0 113.926 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.04 -64.99 0.28 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 118.884 -1.627 . . . . 0.0 115.049 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.516 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 49.6 Cg_exo -62.36 -133.33 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.316 2.677 . . . . 0.0 116.913 -177.79 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.552 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -43.33 -35.48 1.52 Allowed 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 -176.578 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.65 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 2.0 m -63.42 -53.32 54.21 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 118.399 0.545 . . . . 0.0 111.674 -178.844 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -63.2 -30.96 72.01 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-O 121.52 0.676 . . . . 0.0 109.807 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.15 -31.75 73.07 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.913 -1.039 . . . . 0.0 110.067 178.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.65 -5.87 5.52 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.551 179.749 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.582 HD11 HD13 ' A' ' 89' ' ' ILE . 1.1 tt -67.02 117.28 8.86 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.249 0.547 . . . . 0.0 111.44 -179.455 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.435 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -91.19 121.78 33.26 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.311 178.821 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -51.85 138.95 23.03 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.597 177.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.19 15.98 56.5 Favored Glycine 0 CA--C 1.52 0.399 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.713 -179.547 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.623 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 5.2 t0 -94.28 153.87 17.81 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.773 0.32 . . . . 0.0 110.553 179.581 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.474 ' HA ' ' HG2' ' A' ' 39' ' ' MET . 4.8 tp -101.02 128.46 47.05 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.589 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.505 ' CG1' HD11 ' A' ' 89' ' ' ILE . 4.0 mp -85.42 124.46 40.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.88 -179.652 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 64.6 p -101.88 -39.95 7.13 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.351 0.596 . . . . 0.0 110.519 179.528 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 62.0 m80 -139.75 157.19 46.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.969 -178.759 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.424 ' O ' HG13 ' A' ' 63' ' ' VAL . 7.6 p -139.82 109.73 3.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.562 178.004 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 61.73 30.64 18.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.654 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.38 45.44 18.8 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -178.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.481 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 4.0 tp10 -149.84 105.11 3.22 Favored Pre-proline 0 N--CA 1.436 -1.166 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.355 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.481 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.2 Cg_endo -49.97 127.85 20.43 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 123.474 2.783 . . . . 0.0 111.264 178.761 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.7 m -88.7 -11.25 10.49 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.644 -179.047 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -55.25 93.77 0.01 OUTLIER 'General case' 0 N--CA 1.427 -1.6 0 CA-C-N 113.029 -1.896 . . . . 0.0 111.806 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 114.41 -10.03 22.1 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.523 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 25.6 mt -75.66 145.05 41.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.783 0.325 . . . . 0.0 110.295 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.537 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.5 OUTLIER -77.91 166.48 2.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.727 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.558 ' HD1' ' HB2' ' A' ' 23' ' ' ALA . 77.8 t60 -46.04 -52.74 11.39 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.966 0.888 . . . . 0.0 112.3 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.2 p -72.57 -19.71 61.45 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 114.986 -1.006 . . . . 0.0 112.868 -176.649 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.537 ' HG3' HG12 ' A' ' 72' ' ' VAL . 21.5 mt-10 -70.69 -42.97 69.98 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 121.218 -0.193 . . . . 0.0 110.97 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.649 HG21 ' HG ' ' A' ' 21' ' ' LEU . 15.5 m -64.8 -47.22 89.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.132 0 C-N-CA 120.354 -0.538 . . . . 0.0 109.764 179.273 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.536 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 48.6 t -54.71 -45.79 73.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.077 177.74 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.447 ' O ' ' HB2' ' A' ' 82' ' ' LYS . 17.9 mt-10 -63.15 -44.6 95.07 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.633 179.092 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -54.37 -41.14 68.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.207 0.527 . . . . 0.0 110.313 179.247 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.557 HG23 HG11 ' A' ' 87' ' ' VAL . 18.5 mt -69.3 -51.83 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.224 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 61.4 mt -59.74 -36.24 76.2 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.183 0.516 . . . . 0.0 110.477 179.095 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 78' ' ' GLU . 25.5 ttmt -59.37 -41.38 89.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.63 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 38.4 t -54.82 -36.47 65.03 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.527 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 127.01 -121.31 3.89 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 119.86 -1.162 . . . . 0.0 113.859 178.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -98.57 8.97 44.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.24 0.543 . . . . 0.0 110.893 -179.032 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 16.5 pttp -161.72 174.83 12.69 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.006 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.557 HG11 HG23 ' A' ' 80' ' ' ILE . 9.2 p -169.21 146.14 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.405 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -92.67 93.8 8.68 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.282 -0.872 . . . . 0.0 111.007 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.587 HG22 ' O ' ' A' ' 8' ' ' ILE . 9.3 tt -87.39 111.39 21.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 121.122 0.486 . . . . 0.0 110.659 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.438 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -89.43 106.9 18.76 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.716 0.293 . . . . 0.0 110.67 -179.291 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.623 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 81.5 p -104.51 169.13 8.65 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.839 179.396 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.451 HG22 ' HB3' ' A' ' 59' ' ' LEU . 8.6 t -100.01 107.24 45.89 Favored Pre-proline 0 CA--C 1.537 0.448 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 -177.264 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.418 ' HD3' ' O ' ' A' ' 91' ' ' THR . 76.3 Cg_exo -54.84 174.6 0.19 Allowed 'Trans proline' 0 C--N 1.352 0.715 0 C-N-CA 122.345 2.03 . . . . 0.0 113.012 177.135 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.48 167.72 8.36 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.17 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -156.15 161.79 40.29 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.968 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 8.6 p30 . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.77 -0.633 . . . . 0.0 110.83 -179.579 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 5.0 m . . . . . 0 N--CA 1.476 0.832 0 CA-C-O 121.109 0.481 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 102' ' ' TRP . . . . . 0.486 ' CZ2' HG22 ' A' ' 24' ' ' ILE . 23.3 t90 -137.98 127.06 24.25 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.23 179.672 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -79.97 -87.79 0.07 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.288 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -144.4 -166.61 2.42 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.184 -179.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 9.9 m80 -61.5 122.0 14.12 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.201 0.524 . . . . 0.0 111.778 -179.277 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -132.02 9.7 4.53 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -114.22 151.63 32.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.891 -179.609 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -87.89 136.37 13.76 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.851 -179.571 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 99.05 136.22 9.26 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.654 179.4 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 110' ' ' GLU . . . . . 0.577 ' OE1' ' HD2' ' A' ' 22' ' ' ARG . 4.5 mm-40 -154.51 75.31 0.98 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.197 0.522 . . . . 0.0 110.695 178.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 111' ' ' THR . . . . . 0.43 HG22 ' NE2' ' A' ' 73' ' ' HIS . 5.1 t -108.68 177.61 4.73 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 112' ' ' ARG . . . . . 0.561 ' HG2' ' N ' ' B' ' 113' ' ' LEU . 0.0 OUTLIER -132.14 151.38 51.82 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.83 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 113' ' ' LEU . . . . . 0.561 ' N ' ' HG2' ' B' ' 112' ' ' ARG . 3.8 mm? . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.442 -0.789 . . . . 0.0 110.434 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.742 0 N-CA-C 112.138 -0.385 . . . . 0.0 112.138 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.88 -178.92 45.12 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.873 -0.68 . . . . 0.0 111.796 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.4 m -155.97 155.3 32.53 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 91.1 mtp 60.23 78.34 0.28 Allowed 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.686 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.494 ' H ' ' HD2' ' A' ' 5' ' ' ARG . 4.6 mpt_? -71.25 137.46 84.21 Favored Pre-proline 0 C--N 1.323 -0.581 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 179.246 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 2.9 Cg_endo -84.57 112.67 1.6 Allowed 'Trans proline' 0 N--CA 1.462 -0.334 0 C-N-CA 122.92 2.414 . . . . 0.0 112.813 -178.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.464 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 17.4 Cg_exo -68.48 125.83 13.36 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.227 1.951 . . . . 0.0 112.526 178.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.573 ' O ' HG22 ' A' ' 89' ' ' ILE . 5.9 mt -92.85 115.82 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.5 mm -79.23 104.26 7.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 CA-C-N 116.191 -0.458 . . . . 0.0 112.208 -178.118 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.657 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.5 mt -80.14 160.73 4.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 176.341 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' HIS . . . . . 0.523 ' N ' HG22 ' A' ' 10' ' ' ILE . 39.8 t-80 -141.75 114.31 8.37 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.661 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 53.2 ttt180 -63.44 98.14 0.16 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.773 -179.678 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.89 55.77 2.17 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.357 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.28 7.56 77.96 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.826 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.456 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 10.9 ptpt -132.47 -87.73 0.45 Allowed 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.855 -0.203 . . . . 0.0 111.272 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.572 ' HB2' ' OXT' ' B' ' 113' ' ' LEU . 32.1 pttt -155.5 -172.62 4.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.454 0.169 . . . . 0.0 110.717 -178.686 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' TYR . . . . . 0.657 ' HB3' HG21 ' A' ' 10' ' ' ILE . 21.0 m-85 -88.17 2.12 52.85 Favored 'General case' 0 CA--C 1.519 -0.236 0 CA-C-O 121.062 0.458 . . . . 0.0 109.925 179.443 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.505 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 52.2 49.79 48.86 Favored Glycine 0 C--O 1.219 -0.821 0 N-CA-C 116.728 1.451 . . . . 0.0 116.728 176.308 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.498 ' HB3' HG23 ' A' ' 43' ' ' VAL . 8.1 p90 -164.21 148.86 10.0 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-O 122.345 1.069 . . . . 0.0 112.477 176.292 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 42.3 m -94.63 113.99 25.88 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 113.722 -1.581 . . . . 0.0 112.806 -179.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.612 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -88.1 82.85 7.07 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.939 0.4 . . . . 0.0 109.941 178.294 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.542 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 3.6 tpt180 -67.99 129.53 40.21 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.727 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.477 ' HB2' ' HD1' ' A' ' 73' ' ' HIS . . . -94.38 136.16 34.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.794 -0.185 . . . . 0.0 110.582 179.66 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.431 HD11 ' HG3' ' A' ' 39' ' ' MET . 3.2 pt -149.46 122.71 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.101 0.477 . . . . 0.0 111.437 179.372 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.475 ' HD2' ' CE2' ' A' ' 34' ' ' TYR . 82.1 mtm180 -96.38 99.8 11.46 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 1.6 m -76.09 110.5 11.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.201 0.524 . . . . 0.0 111.519 -179.129 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 48.4 m-85 -79.8 99.23 7.39 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.377 178.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.7 mtm -127.36 126.37 42.38 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.493 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 131.54 168.57 12.17 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -69.3 -46.55 66.89 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 117.006 0.403 . . . . 0.0 110.59 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.412 ' C ' ' H ' ' A' ' 33' ' ' VAL . 0.8 OUTLIER -76.81 -177.87 4.55 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.702 179.833 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.5 32.94 0.2 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.108 0.48 . . . . 0.0 110.681 179.819 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.412 ' H ' ' C ' ' A' ' 31' ' ' SER . 3.6 p -80.8 138.81 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-O 121.353 0.597 . . . . 0.0 110.313 -179.561 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.475 ' CE2' ' HD2' ' A' ' 25' ' ' ARG . 43.5 p90 -145.29 152.95 40.73 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.352 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -110.58 125.05 52.98 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.679 -0.409 . . . . 0.0 110.162 178.428 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 t -81.55 100.41 5.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.992 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 -113.5 -179.06 3.53 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.28 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.569 ' CD2' HG11 ' A' ' 76' ' ' VAL . 94.4 m-70 -149.66 153.57 37.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' MET . . . . . 0.466 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 27.2 mtm -148.57 145.5 27.85 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -178.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.512 HG11 ' CD2' ' A' ' 54' ' ' LEU . 3.4 p -73.25 103.32 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 CA-C-O 122.006 0.908 . . . . 0.0 109.793 179.274 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.542 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.6 t-105 -70.65 -40.37 73.07 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.468 -1.242 . . . . 0.0 111.499 -178.682 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' HIS . . . . . 0.497 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 1.9 t60 -156.64 132.09 9.35 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.952 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 18' ' ' GLY . 5.1 p -127.96 125.48 64.81 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.012 0 CA-C-O 121.919 0.866 . . . . 0.0 110.348 178.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.484 ' O ' ' HB2' ' A' ' 50' ' ' SER . 28.3 mt-10 -65.24 114.09 4.47 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 114.284 -1.325 . . . . 0.0 112.117 -178.566 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.544 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 10.6 p-10 -83.65 46.07 1.12 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.646 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -119.44 -2.77 13.16 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.399 -0.905 . . . . 0.0 113.595 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.63 -59.09 0.27 Allowed Glycine 0 CA--C 1.521 0.411 0 C-N-CA 119.119 -1.515 . . . . 0.0 114.884 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -59.24 -130.98 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 0.98 0 C-N-CA 123.463 2.776 . . . . 0.0 116.593 -178.439 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.524 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -43.69 -40.81 4.43 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 114.382 1.253 . . . . 0.0 114.382 -176.751 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.544 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -60.03 -59.99 4.55 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -178.312 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -63.37 -28.62 70.12 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.064 0.459 . . . . 0.0 110.713 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.13 -29.99 70.72 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.947 178.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 135.69 -9.28 4.28 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.767 179.444 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.512 ' CD2' HG11 ' A' ' 40' ' ' VAL . 0.9 OUTLIER -68.34 117.76 10.54 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.374 0.607 . . . . 0.0 111.42 -179.615 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -92.85 121.24 34.03 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.726 178.419 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.497 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 37.1 tt0 -50.13 135.09 21.47 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.15 59.5 1.75 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.569 -0.824 . . . . 0.0 111.231 -178.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.429 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 3.4 t0 -142.81 147.58 35.71 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.496 HD12 ' O ' ' A' ' 38' ' ' HIS . 10.9 tp -92.95 131.28 38.09 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.408 -179.541 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.481 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.6 mp -89.13 125.35 42.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.9 p -101.87 -40.02 7.11 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.259 0.552 . . . . 0.0 110.799 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -139.76 158.44 44.09 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.591 -179.145 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 63' ' ' VAL . 7.6 p -141.62 110.4 2.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-O 121.11 0.481 . . . . 0.0 109.981 178.149 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.9 t30 59.49 33.91 22.37 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.093 179.399 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.0 42.26 25.27 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.17 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.502 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 5.6 tp10 -151.37 106.67 2.95 Favored Pre-proline 0 N--CA 1.434 -1.234 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.502 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.2 Cg_endo -50.4 129.1 25.09 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.557 2.838 . . . . 0.0 110.962 178.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 20.2 m -85.85 -13.31 11.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.258 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.0 m170 -56.6 96.98 0.02 OUTLIER 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 112.732 -2.031 . . . . 0.0 110.835 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.94 -12.88 26.93 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.405 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 21.7 mt -76.1 141.61 41.93 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.571 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -75.46 165.65 3.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.292 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.477 ' HD1' ' HB2' ' A' ' 23' ' ' ALA . 83.2 t60 -42.97 -55.19 3.87 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-O 121.765 0.793 . . . . 0.0 112.82 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.0 p -74.53 -16.96 60.81 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 114.93 -1.032 . . . . 0.0 113.04 -176.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.571 ' HG3' HG12 ' A' ' 72' ' ' VAL . 24.3 mt-10 -70.57 -42.03 71.64 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 120.95 -0.3 . . . . 0.0 111.121 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.612 HG21 ' HG ' ' A' ' 21' ' ' LEU . 15.6 m -65.59 -46.44 89.54 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.471 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 60.9 t -53.05 -48.59 52.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.632 176.796 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -63.47 -44.44 94.45 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.847 179.266 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.38 -42.01 66.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.269 0.557 . . . . 0.0 109.933 178.568 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.568 HG23 HG11 ' A' ' 87' ' ' VAL . 22.7 mt -67.35 -48.83 76.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.621 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 50.2 mt -60.84 -39.4 88.94 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-O 121.032 0.444 . . . . 0.0 110.657 178.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 23.1 ttmt -60.35 -40.5 90.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.142 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 41.4 t -54.22 -31.79 54.16 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.714 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 129.52 -127.81 5.56 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.672 179.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -99.1 10.53 41.27 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.432 0.634 . . . . 0.0 110.413 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.415 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 17.3 pttp -161.99 172.51 15.85 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.862 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.568 HG11 HG23 ' A' ' 80' ' ' ILE . 8.5 p -168.03 149.82 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -178.326 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.464 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -93.37 97.66 10.72 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.309 178.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.573 HG22 ' O ' ' A' ' 8' ' ' ILE . 10.2 tt -89.62 112.91 25.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 120.884 0.373 . . . . 0.0 110.862 179.392 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.9 OUTLIER -88.67 105.02 17.4 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.729 0.3 . . . . 0.0 111.296 -179.008 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.502 ' O ' ' HD3' ' A' ' 93' ' ' PRO . 42.3 p -102.36 163.2 12.37 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.436 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 1.6 t -98.65 104.92 27.18 Favored Pre-proline 0 C--N 1.326 -0.439 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.286 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.502 ' HD3' ' O ' ' A' ' 91' ' ' THR . 73.2 Cg_exo -53.73 176.06 0.1 Allowed 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.503 2.135 . . . . 0.0 113.036 178.622 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -64.26 166.12 8.48 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.319 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -161.67 173.42 14.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.899 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 4.7 p30 . . . . . 0 C--O 1.252 1.232 0 CA-C-O 118.826 -0.607 . . . . 0.0 110.358 179.547 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.479 1.023 0 CA-C-O 120.602 0.239 . . . . 0.0 111.087 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 102' ' ' TRP . . . . . 0.423 ' HH2' ' CH2' ' A' ' 41' ' ' TRP . 13.6 t90 -117.55 88.9 3.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.332 0.586 . . . . 0.0 110.295 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 20.2 mp0 -94.32 -36.98 11.71 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.395 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 29.8 m -153.74 -170.25 3.52 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.029 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 13.6 m80 -70.78 69.76 0.45 Allowed 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.135 0.493 . . . . 0.0 110.592 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 51.5 mttt -81.88 62.07 5.5 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.071 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.1 p -157.07 -70.68 0.1 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.636 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 111.95 113.68 3.33 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.144 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 121.4 136.17 4.96 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.794 -0.717 . . . . 0.0 113.002 179.402 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -125.11 17.85 8.42 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.781 0.324 . . . . 0.0 110.184 179.114 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 1.4 m -59.36 149.97 27.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.488 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 112' ' ' ARG . . . . . 0.401 ' HD3' ' O ' ' B' ' 113' ' ' LEU . 0.1 OUTLIER -135.74 170.71 15.55 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.823 -179.493 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 113' ' ' LEU . . . . . 0.572 ' OXT' ' HB2' ' A' ' 16' ' ' LYS . 3.3 mm? . . . . . 0 C--O 1.253 1.265 0 CA-C-O 118.111 -0.947 . . . . 0.0 109.219 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.503 ' HA2' ' HG3' ' A' ' 95' ' ' GLU . . . . . . . . 0 N--CA 1.481 1.7 0 N-CA-C 112.104 -0.398 . . . . 0.0 112.104 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -119.86 -157.47 10.27 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.159 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.6 t -158.13 162.83 38.01 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 37.8 mtp 55.85 78.93 0.18 Allowed 'General case' 0 C--O 1.235 0.336 0 O-C-N 123.58 0.55 . . . . 0.0 111.471 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.475 ' H ' ' HD2' ' A' ' 5' ' ' ARG . 4.0 mpt_? -70.92 137.47 85.07 Favored Pre-proline 0 C--N 1.325 -0.464 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.0 OUTLIER -86.93 111.08 0.87 Allowed 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.795 2.33 . . . . 0.0 112.899 -178.284 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.532 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 15.5 Cg_exo -69.12 119.87 6.8 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 121.935 1.756 . . . . 0.0 112.15 178.616 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.616 ' O ' HG22 ' A' ' 89' ' ' ILE . 7.0 mt -87.85 110.94 21.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-N 115.07 -0.968 . . . . 0.0 108.967 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.2 mm -76.77 101.45 2.93 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.825 -0.625 . . . . 0.0 112.045 -178.045 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.676 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.2 mt -78.92 159.27 4.64 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.368 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 176.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' HIS . . . . . 0.506 ' N ' HG22 ' A' ' 10' ' ' ILE . 15.1 t-80 -135.44 109.98 8.54 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 178.604 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.1 ttt180 -64.64 100.71 0.4 Allowed 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.419 -0.81 . . . . 0.0 111.05 -179.335 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.95 55.68 1.81 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.275 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.7 -45.31 3.38 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.479 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.2 ptpt -79.23 -85.79 0.08 Allowed 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.381 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.63 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 23.7 pttt -157.29 -174.09 4.73 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.52 0.193 . . . . 0.0 111.52 -178.559 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' TYR . . . . . 0.676 ' HB3' HG21 ' A' ' 10' ' ' ILE . 21.4 m-85 -85.49 2.42 44.74 Favored 'General case' 0 CA--C 1.518 -0.25 0 CA-C-O 121.103 0.478 . . . . 0.0 109.757 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.559 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 51.04 53.54 26.6 Favored Glycine 0 C--O 1.215 -1.044 0 N-CA-C 116.124 1.21 . . . . 0.0 116.124 177.328 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.478 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 12.4 p90 -163.94 149.03 10.54 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 122.744 1.259 . . . . 0.0 112.965 176.156 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.529 ' HA ' ' HB2' ' B' ' 112' ' ' ARG . 40.5 m -95.16 117.48 30.29 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 112.904 -1.953 . . . . 0.0 113.109 -178.522 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.493 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.4 OUTLIER -94.45 80.78 3.91 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 178.286 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.509 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 1.6 tpt180 -65.26 140.78 58.75 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.995 -179.51 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.42 ' CB ' ' HD1' ' A' ' 73' ' ' HIS . . . -103.7 129.01 50.98 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.882 -179.404 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.495 HG21 ' CZ3' ' B' ' 102' ' ' TRP . 3.4 pt -140.22 165.83 20.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.013 0.435 . . . . 0.0 111.061 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.417 ' O ' ' HB2' ' B' ' 103' ' ' GLU . 0.1 OUTLIER -135.87 111.38 9.22 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.336 0.589 . . . . 0.0 110.43 -179.373 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.935 HG12 ' H ' ' B' ' 102' ' ' TRP . 8.9 m -84.84 115.86 27.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.726 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -79.6 106.3 11.53 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.624 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -81.9 -0.63 44.62 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.789 -178.434 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -158.54 163.42 33.02 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.21 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -81.84 62.7 5.76 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.547 0.689 . . . . 0.0 109.903 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.414 ' HB2' HG12 ' A' ' 33' ' ' VAL . 49.0 m -163.51 -160.03 0.56 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.942 -179.216 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.03 7.81 8.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.823 0.344 . . . . 0.0 111.426 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.414 HG12 ' HB2' ' A' ' 31' ' ' SER . 2.2 p -82.24 123.89 38.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.404 0.621 . . . . 0.0 111.341 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -158.8 150.75 21.14 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.919 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -112.27 129.71 56.18 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.918 0.39 . . . . 0.0 110.248 178.797 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.6 t -83.92 117.0 28.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.895 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 55.3 m80 -125.43 -177.73 3.99 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.464 179.262 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.551 ' CD2' HG11 ' A' ' 76' ' ' VAL . 98.0 m-70 -147.71 154.7 40.9 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -179.269 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 35.4 mtm -149.13 146.56 27.74 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -178.611 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.585 HG11 HD21 ' A' ' 54' ' ' LEU . 2.6 p -74.0 101.75 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.976 0.893 . . . . 0.0 109.774 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.509 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 2.9 t-105 -70.39 -39.21 74.67 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.37 -178.598 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' HIS . . . . . 0.44 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -156.53 129.57 7.92 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.975 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.559 HG23 ' O ' ' A' ' 18' ' ' GLY . 3.8 p -124.28 127.06 73.02 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.555 0.693 . . . . 0.0 110.248 179.06 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -66.64 113.23 4.64 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 114.507 -1.224 . . . . 0.0 112.043 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.558 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 10.4 p-10 -81.5 40.2 0.57 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.918 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -108.15 -8.75 28.93 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.376 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.407 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 160.55 -49.91 0.37 Allowed Glycine 0 CA--C 1.526 0.761 0 C-N-CA 119.491 -1.338 . . . . 0.0 114.867 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -60.11 -128.98 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.09 0 C-N-CA 123.094 2.529 . . . . 0.0 116.233 -179.223 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.504 ' HA ' HG12 ' A' ' 10' ' ' ILE . . . -45.12 -39.97 6.49 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 114.195 1.183 . . . . 0.0 114.195 -177.113 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.558 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 5.5 m -57.34 -62.86 1.47 Allowed 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -179.158 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.407 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 9.5 mm-40 -63.25 -23.15 67.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.295 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.66 -26.16 66.07 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.256 178.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 130.21 -8.36 5.99 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.677 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.585 HD21 HG11 ' A' ' 40' ' ' VAL . 1.1 tt -70.0 117.99 12.28 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-O 121.435 0.636 . . . . 0.0 111.324 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.404 ' H ' ' HG3' ' A' ' 55' ' ' ARG . 0.0 OUTLIER -96.45 121.52 38.35 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.941 178.357 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.434 ' HB2' HG12 ' A' ' 43' ' ' VAL . 46.3 tt0 -50.45 141.14 12.59 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.771 0.319 . . . . 0.0 111.51 178.856 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.24 6.0 63.31 Favored Glycine 0 C--N 1.333 0.415 0 C-N-CA 121.239 -0.505 . . . . 0.0 113.231 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.537 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 2.0 t0 -89.9 155.71 18.95 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.032 0.444 . . . . 0.0 111.036 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.489 HD12 ' O ' ' A' ' 38' ' ' HIS . 2.5 tp -100.14 133.97 43.75 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.7 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.502 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.5 mp -91.26 122.74 42.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 26.2 p -99.7 -40.61 7.68 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.401 0.619 . . . . 0.0 110.361 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 72.7 m80 -138.28 157.21 46.71 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.761 -178.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.57 111.51 5.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.965 -0.562 . . . . 0.0 109.889 178.28 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 60.39 30.04 19.49 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.811 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.46 44.29 17.14 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.182 -179.036 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.472 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.1 tp10 -149.99 106.26 3.21 Favored Pre-proline 0 N--CA 1.437 -1.084 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 -179.066 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.472 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 4.4 Cg_endo -49.62 129.32 23.22 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.66 2.907 . . . . 0.0 111.124 178.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 22.3 m -86.82 -7.96 10.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 114.594 -1.185 . . . . 0.0 109.039 -178.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 22.1 m170 -55.17 101.01 0.04 OUTLIER 'General case' 0 N--CA 1.426 -1.629 0 CA-C-N 112.741 -2.027 . . . . 0.0 111.676 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.68 -6.77 49.07 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.842 179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 26.3 mt -78.29 141.41 38.53 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.669 0.271 . . . . 0.0 110.469 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.674 HG12 ' HG3' ' A' ' 75' ' ' GLU . 2.0 p -78.58 169.82 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 177.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' B' ' 110' ' ' GLU . 8.6 t60 -48.19 -53.62 16.28 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.682 0.753 . . . . 0.0 112.352 -179.424 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 16.7 p -69.44 -22.66 63.64 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.192 -0.913 . . . . 0.0 112.456 -177.247 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.674 ' HG3' HG12 ' A' ' 72' ' ' VAL . 24.4 mt-10 -69.06 -43.28 74.94 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 121.224 -0.191 . . . . 0.0 111.476 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.551 HG11 ' CD2' ' A' ' 38' ' ' HIS . 10.0 m -66.24 -44.61 91.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.726 178.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.458 HG13 HD23 ' B' ' 113' ' ' LEU . 54.0 t -56.57 -47.26 82.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.929 177.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -62.78 -43.46 98.73 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.55 178.374 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.38 -40.75 65.26 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.339 0.59 . . . . 0.0 109.915 178.444 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.633 HG23 HG11 ' A' ' 87' ' ' VAL . 28.1 mt -68.84 -51.58 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.889 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 64.1 mt -59.88 -36.03 76.08 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.1 0.476 . . . . 0.0 110.644 179.092 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -57.91 -39.15 77.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.231 -0.895 . . . . 0.0 111.58 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 34.0 t -56.21 -44.87 79.91 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.244 179.756 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 136.29 -116.61 1.48 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.323 -0.941 . . . . 0.0 113.71 178.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -102.85 9.1 39.1 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.475 0.655 . . . . 0.0 110.506 -178.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 10.1 pttp -161.36 173.53 14.82 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.499 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.633 HG11 HG23 ' A' ' 80' ' ' ILE . 10.4 p -167.76 145.13 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -179.583 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.532 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -91.15 96.22 10.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.37 178.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.616 HG22 ' O ' ' A' ' 8' ' ' ILE . 11.1 tt -88.72 111.08 22.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.196 0.522 . . . . 0.0 110.831 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.93 106.0 17.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.982 -179.089 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.537 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 64.6 p -102.33 170.86 7.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.21 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.428 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 4.9 t -104.85 99.95 21.41 Favored Pre-proline 0 CA--C 1.534 0.358 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -178.179 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' ' 91' ' ' THR . 74.6 Cg_exo -51.73 167.63 0.41 Allowed 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.487 2.125 . . . . 0.0 113.204 178.516 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.431 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.0 OUTLIER -63.75 158.71 21.01 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.953 -179.937 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLU . . . . . 0.503 ' HG3' ' HA2' ' A' ' 1' ' ' GLY . 0.0 OUTLIER -159.7 167.13 29.07 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.529 -179.716 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 8.3 p30 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.497 -0.763 . . . . 0.0 111.043 -179.934 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 101' ' ' SER . . . . . 0.408 ' O ' ' HB3' ' B' ' 102' ' ' TRP . 0.8 OUTLIER . . . . . 0 N--CA 1.476 0.847 0 N-CA-C 110.581 -0.155 . . . . 0.0 110.581 . . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 102' ' ' TRP . . . . . 0.935 ' H ' HG12 ' A' ' 26' ' ' VAL . 65.0 t-105 72.25 150.23 0.1 Allowed 'General case' 0 N--CA 1.466 0.348 0 O-C-N 123.718 0.636 . . . . 0.0 111.796 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 103' ' ' GLU . . . . . 0.417 ' HB2' ' O ' ' A' ' 25' ' ' ARG . 0.0 OUTLIER -158.96 172.05 18.92 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.765 179.448 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 3.4 p -70.43 168.77 15.41 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.803 179.81 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -72.66 122.08 20.85 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.327 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -116.83 -155.62 0.59 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.003 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.5 m -50.21 132.93 24.07 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-O 121.086 0.47 . . . . 0.0 111.698 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 134.61 -41.46 1.45 Allowed Glycine 0 N--CA 1.445 -0.744 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.656 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 79.73 -151.03 33.49 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.424 179.678 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 110' ' ' GLU . . . . . 0.462 ' HA ' ' CE1' ' A' ' 73' ' ' HIS . 2.6 mm-40 -141.16 111.16 6.62 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -179.714 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 20.2 m -131.92 88.94 2.62 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.234 0.54 . . . . 0.0 109.915 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 112' ' ' ARG . . . . . 0.529 ' HB2' ' HA ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -83.06 150.08 26.54 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.954 -179.084 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 113' ' ' LEU . . . . . 0.63 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 0.3 OUTLIER . . . . . 0 C--O 1.244 0.787 0 CA-C-O 118.48 -0.772 . . . . 0.0 110.297 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.428 ' HA2' ' HG3' ' A' ' 95' ' ' GLU . . . . . . . . 0 N--CA 1.479 1.549 0 N-CA-C 112.171 -0.372 . . . . 0.0 112.171 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 159.88 -173.47 36.57 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 121.078 -0.582 . . . . 0.0 111.702 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 53.2 m -148.59 169.88 19.35 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 9.0 mtp 60.65 77.53 0.32 Allowed 'General case' 0 C--O 1.233 0.185 0 O-C-N 123.476 0.485 . . . . 0.0 111.619 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.455 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.0 mpt_? -73.26 136.86 78.6 Favored Pre-proline 0 C--N 1.326 -0.421 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 179.198 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.5 Cg_endo -89.22 110.02 0.48 Allowed 'Trans proline' 0 C--O 1.235 0.326 0 C-N-CA 123.196 2.597 . . . . 0.0 113.021 -179.108 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.488 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 16.9 Cg_exo -69.78 122.52 9.19 Favored 'Trans proline' 0 CA--C 1.515 -0.453 0 C-N-CA 122.327 2.018 . . . . 0.0 113.112 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.549 HD13 ' HA ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -87.42 112.0 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.258 0 CA-C-N 115.129 -0.941 . . . . 0.0 108.778 178.317 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.401 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 3.2 mm -77.5 101.42 3.37 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.336 -178.721 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.672 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.4 mt -77.81 162.65 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 N-CA-C 106.904 -1.517 . . . . 0.0 106.904 176.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' HIS . . . . . 0.544 ' N ' HG22 ' A' ' 10' ' ' ILE . 15.0 t-80 -140.79 113.15 7.97 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 47.2 ttt180 -63.39 101.7 0.34 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.995 -178.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.12 49.95 1.0 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.45 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.12 12.7 81.5 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 121.199 -0.524 . . . . 0.0 113.1 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 3.8 ptpt -136.51 -82.59 0.38 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.849 0.325 . . . . 0.0 111.12 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.522 ' HB2' ' OXT' ' B' ' 113' ' ' LEU . 8.6 pttt -156.16 -179.59 8.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.421 -178.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' TYR . . . . . 0.672 ' HB3' HG21 ' A' ' 10' ' ' ILE . 19.3 m-85 -86.58 5.34 36.14 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-O 121.245 0.545 . . . . 0.0 110.191 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.576 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 54.46 49.22 61.49 Favored Glycine 0 C--O 1.215 -1.069 0 N-CA-C 116.697 1.439 . . . . 0.0 116.697 176.697 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.482 ' HB2' HG23 ' A' ' 40' ' ' VAL . 9.3 p90 -165.6 149.23 8.07 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-O 122.345 1.069 . . . . 0.0 113.068 176.583 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.427 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 94.8 m -95.25 118.37 31.91 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 113.643 -1.617 . . . . 0.0 112.724 -179.161 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.559 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -89.91 84.86 6.24 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.802 0.334 . . . . 0.0 110.248 178.511 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.566 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 5.1 tpt180 -68.74 142.66 54.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.222 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.593 ' HB2' ' HD1' ' A' ' 73' ' ' HIS . . . -108.55 144.8 35.75 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 110.679 -0.119 . . . . 0.0 110.679 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 2.7 pt -148.29 141.0 18.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 CA-C-O 120.828 0.347 . . . . 0.0 111.389 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 11.6 mtm180 -105.93 93.6 4.72 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' A' ' 34' ' ' TYR . 10.9 m -81.43 114.29 22.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.508 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.465 ' HE1' ' HG ' ' B' ' 104' ' ' SER . 4.5 m-85 -82.83 121.91 27.54 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 36.6 mmt -84.8 93.58 8.51 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.898 -179.2 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.72 -146.7 18.34 Favored Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.008 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -100.09 -14.02 18.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.11 0.481 . . . . 0.0 110.643 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.516 ' HB2' HG12 ' A' ' 33' ' ' VAL . 0.7 OUTLIER -72.3 169.53 16.05 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.959 -179.836 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.77 9.72 4.88 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.516 HG12 ' HB2' ' A' ' 31' ' ' SER . 3.6 p -78.75 130.02 36.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.425 0.631 . . . . 0.0 110.204 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.443 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 51.2 p90 -142.21 146.69 35.49 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.786 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -107.69 133.8 51.59 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 178.404 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 6.2 t -84.91 108.7 17.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.893 -179.52 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 45.4 m80 -117.82 177.97 4.58 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.517 ' CD2' HG11 ' A' ' 76' ' ' VAL . 98.7 m-70 -148.15 153.35 38.71 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 -179.509 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.0 mtm -147.24 145.25 29.38 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.083 -178.66 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.564 HG11 ' CD2' ' A' ' 54' ' ' LEU . 3.4 p -73.33 102.52 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.71 0 CA-C-O 121.946 0.879 . . . . 0.0 109.576 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.566 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 2.5 t-105 -70.48 -39.36 74.26 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.699 -1.137 . . . . 0.0 111.89 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' HIS . . . . . 0.461 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 4.3 t60 -155.23 124.5 6.3 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.368 -178.598 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.2 p -122.04 124.92 72.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-O 121.575 0.702 . . . . 0.0 109.975 179.258 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.504 ' OE1' ' HA2' ' A' ' 18' ' ' GLY . 49.3 mt-10 -66.99 120.12 13.11 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 114.396 -1.275 . . . . 0.0 111.307 -179.391 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.555 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 14.7 p-10 -85.84 24.8 1.2 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.84 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -82.98 -23.4 55.54 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.959 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 170.92 -51.78 0.19 Allowed Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 119.568 -1.301 . . . . 0.0 114.745 -179.225 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -55.33 -128.45 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.085 0 C-N-CA 123.505 2.803 . . . . 0.0 116.92 -178.399 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.473 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -45.23 -40.01 6.97 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 -176.688 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.555 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -60.5 -61.08 2.85 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -177.956 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 5.5 mm-40 -61.01 -32.49 72.08 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.372 0.606 . . . . 0.0 110.781 -178.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -60.34 -29.84 69.14 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.677 179.269 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 136.8 -11.84 3.95 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.511 -0.852 . . . . 0.0 113.092 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.564 ' CD2' HG11 ' A' ' 40' ' ' VAL . 0.8 OUTLIER -68.08 116.04 8.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.406 0.622 . . . . 0.0 111.074 -179.642 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.44 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -93.77 125.56 38.45 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.026 178.975 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -51.42 140.18 18.14 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.876 0.37 . . . . 0.0 111.036 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.71 10.09 67.72 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.95 -0.643 . . . . 0.0 113.161 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.562 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 5.3 t0 -88.5 148.91 23.91 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.0 0.429 . . . . 0.0 110.659 179.59 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.432 HD12 ' O ' ' A' ' 38' ' ' HIS . 10.1 tp -95.91 130.03 42.99 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.726 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.504 HG12 HD11 ' A' ' 89' ' ' ILE . 3.6 mp -88.15 126.14 41.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.127 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 41.9 p -102.8 -38.62 7.35 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.646 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -141.23 159.49 42.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.922 -178.698 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.404 HG21 HG13 ' A' ' 80' ' ' ILE . 7.3 p -140.65 111.14 3.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.125 0.488 . . . . 0.0 110.208 178.238 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.409 ' HA ' ' HB3' ' A' ' 88' ' ' ALA . 2.8 t30 60.76 26.34 16.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.372 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.18 44.41 7.57 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.935 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.496 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.5 tp10 -153.19 110.5 2.64 Favored Pre-proline 0 N--CA 1.433 -1.312 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.519 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.496 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 3.7 Cg_endo -49.99 131.88 31.24 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 123.725 2.95 . . . . 0.0 111.407 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.5 m -88.23 -8.61 10.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.289 -178.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -56.75 94.85 0.01 OUTLIER 'General case' 0 N--CA 1.429 -1.51 0 CA-C-N 112.95 -1.932 . . . . 0.0 111.566 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 112.47 -11.82 25.91 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.435 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 29.7 mt -74.87 138.82 42.72 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 179.527 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.507 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.8 OUTLIER -77.79 167.19 2.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.276 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.593 ' HD1' ' HB2' ' A' ' 23' ' ' ALA . 48.2 t60 -44.75 -46.42 10.46 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.779 0.8 . . . . 0.0 112.939 -179.314 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.496 ' H ' HG13 ' A' ' 72' ' ' VAL . 19.3 p -80.51 -21.06 42.27 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.274 -0.875 . . . . 0.0 112.755 -176.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.507 ' HG3' HG12 ' A' ' 72' ' ' VAL . 25.5 mt-10 -70.23 -40.31 74.56 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 121.319 -0.153 . . . . 0.0 111.354 -179.626 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.559 HG21 ' HG ' ' A' ' 21' ' ' LEU . 4.5 m -65.45 -45.76 91.97 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.183 0 C-N-CA 120.251 -0.58 . . . . 0.0 109.597 178.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.485 HG13 ' CD1' ' B' ' 113' ' ' LEU . 99.5 t -55.24 -47.02 78.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.187 -0.915 . . . . 0.0 109.926 177.239 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -64.81 -43.97 91.41 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.607 179.288 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.48 -42.08 66.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.768 178.346 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.677 HG23 HG11 ' A' ' 87' ' ' VAL . 16.2 mt -67.81 -52.15 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.719 179.484 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 93.1 mt -59.95 -32.78 71.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.017 179.312 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 8.3 ttmm -61.55 -38.91 89.19 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.352 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 36.2 t -56.0 -52.99 62.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.961 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 137.73 -134.43 6.96 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 119.96 -1.114 . . . . 0.0 113.132 179.301 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -73.67 -2.01 21.37 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.853 0.358 . . . . 0.0 111.799 -179.085 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -159.93 175.26 13.26 Favored 'General case' 0 N--CA 1.444 -0.773 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.503 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.677 HG11 HG23 ' A' ' 80' ' ' ILE . 13.4 p -166.84 147.1 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 O-C-N 123.596 0.56 . . . . 0.0 112.465 -179.062 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.488 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -93.51 96.76 10.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.642 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.543 HG22 ' O ' ' A' ' 8' ' ' ILE . 6.9 tt -88.8 111.57 22.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 120.973 0.416 . . . . 0.0 110.255 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -89.11 112.25 23.19 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.825 0.345 . . . . 0.0 111.074 -178.908 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.562 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 61.3 p -109.76 171.73 7.27 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.306 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.9 t -104.21 105.48 49.34 Favored Pre-proline 0 CA--C 1.537 0.464 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.473 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -55.73 175.24 0.22 Allowed 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.622 2.215 . . . . 0.0 113.403 178.161 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.402 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.0 OUTLIER -63.71 159.95 18.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.287 -179.647 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLU . . . . . 0.428 ' HG3' ' HA2' ' A' ' 1' ' ' GLY . 0.0 OUTLIER -157.05 157.19 34.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.073 0.463 . . . . 0.0 110.677 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 8.1 p30 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 118.504 -0.76 . . . . 0.0 110.891 -179.586 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.2 m . . . . . 0 N--CA 1.48 1.042 0 CA-C-O 120.658 0.266 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 102' ' ' TRP . . . . . . . . . . . . . 4.3 t-105 179.2 83.93 0.01 OUTLIER 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 8.5 mp0 -106.93 -76.46 0.61 Allowed 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.44 -177.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 104' ' ' SER . . . . . 0.465 ' HG ' ' HE1' ' A' ' 27' ' ' TYR . 0.7 OUTLIER -99.99 144.88 28.51 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.796 0.332 . . . . 0.0 111.098 -179.438 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 3.4 t60 -108.9 -14.4 14.58 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.109 0.481 . . . . 0.0 110.592 179.596 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -67.42 97.3 0.56 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.792 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -156.58 25.83 0.34 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.29 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 147.65 -98.08 0.19 Allowed Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 121.066 -0.588 . . . . 0.0 111.945 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -175.71 -129.59 1.23 Allowed Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.939 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -130.71 35.83 3.97 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.208 0.528 . . . . 0.0 110.11 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 8.4 m -71.14 98.3 1.66 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.218 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 112' ' ' ARG . . . . . 0.406 ' CB ' ' HA ' ' A' ' 20' ' ' THR . 6.1 ptm180 -91.28 173.58 7.84 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.542 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 113' ' ' LEU . . . . . 0.522 ' OXT' ' HB2' ' A' ' 16' ' ' LYS . 3.4 mm? . . . . . 0 C--O 1.249 1.063 0 CA-C-O 117.907 -1.044 . . . . 0.0 109.223 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.671 0 N-CA-C 112.029 -0.428 . . . . 0.0 112.029 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -127.73 177.58 17.47 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 121.078 -0.582 . . . . 0.0 111.725 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.0 m -128.09 -178.93 4.73 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 28.6 mtp 57.06 74.05 0.43 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.008 0.432 . . . . 0.0 111.3 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.49 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.6 mpt_? -73.31 135.53 79.23 Favored Pre-proline 0 C--N 1.32 -0.692 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.49 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.9 Cg_endo -87.31 116.88 1.22 Allowed 'Trans proline' 0 N--CA 1.462 -0.371 0 C-N-CA 123.3 2.666 . . . . 0.0 112.842 -178.69 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.466 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 7.5 Cg_exo -75.12 122.08 6.93 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.078 1.852 . . . . 0.0 112.843 178.629 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.62 HD13 ' HA ' ' A' ' 54' ' ' LEU . 2.3 mt -86.71 112.41 22.91 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.356 178.616 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.8 mm -79.06 99.74 3.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.218 -0.446 . . . . 0.0 112.049 -178.273 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.695 HG21 ' HB3' ' A' ' 17' ' ' TYR . 4.3 mt -77.64 160.47 4.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 177.059 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' HIS . . . . . 0.523 ' N ' HG22 ' A' ' 10' ' ' ILE . 24.8 t-80 -138.17 111.59 8.06 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.01 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ARG . . . . . 0.422 HH11 ' HD3' ' A' ' 12' ' ' ARG . 30.8 ttt180 -62.89 103.71 0.47 Allowed 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.838 -179.009 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.77 47.7 0.76 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.482 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.17 -4.86 65.04 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.287 -0.482 . . . . 0.0 113.344 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.8 ptpt -120.61 -80.12 0.62 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.996 0.398 . . . . 0.0 111.44 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.503 ' HB2' ' OXT' ' B' ' 113' ' ' LEU . 20.5 pttt -155.76 -174.96 5.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.64 0.257 . . . . 0.0 110.558 -178.811 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' TYR . . . . . 0.695 ' HB3' HG21 ' A' ' 10' ' ' ILE . 18.4 m-85 -89.71 5.65 44.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.254 0.55 . . . . 0.0 109.661 179.521 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.521 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 54.26 48.31 64.49 Favored Glycine 0 C--O 1.219 -0.842 0 N-CA-C 116.423 1.329 . . . . 0.0 116.423 176.818 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.458 ' HB3' HG23 ' A' ' 43' ' ' VAL . 10.4 p90 -164.09 146.56 9.2 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-O 122.627 1.203 . . . . 0.0 112.836 176.627 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 91.8 m -93.64 114.83 27.24 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 113.46 -1.7 . . . . 0.0 112.51 -178.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.598 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -91.14 82.47 5.53 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-O 120.577 0.227 . . . . 0.0 111.218 179.119 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 1.3 tpt180 -73.22 144.63 46.68 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.761 -0.2 . . . . 0.0 111.185 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -100.66 146.08 27.63 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.039 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.5 pt -145.25 139.74 22.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 178.613 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.473 ' HB3' ' CD1' ' A' ' 34' ' ' TYR . 29.7 mtt180 -111.09 101.7 10.21 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.734 0.302 . . . . 0.0 110.998 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.3 m -84.3 115.47 26.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.696 179.081 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.483 ' CD1' ' HB2' ' B' ' 103' ' ' GLU . 8.6 m-85 -80.22 148.08 30.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.482 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 48.3 mtt -87.18 62.82 7.5 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.9 -134.05 16.46 Favored Glycine 0 N--CA 1.447 -0.623 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -90.47 86.08 6.33 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 178.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.0 p -163.32 162.29 25.03 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.858 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -81.63 -17.16 49.11 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.454 0.645 . . . . 0.0 110.615 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.7 p -79.75 138.78 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 CA-C-N 115.434 -0.803 . . . . 0.0 110.879 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.473 ' CD1' ' HB3' ' A' ' 25' ' ' ARG . 51.3 p90 -149.71 155.96 41.07 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.827 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -103.78 128.53 51.19 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.021 0.439 . . . . 0.0 110.138 179.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t -86.3 107.17 16.35 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.605 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.6 m-70 -112.86 179.65 3.91 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.18 -0.463 . . . . 0.0 109.953 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.501 ' O ' HD12 ' A' ' 59' ' ' LEU . 99.1 m-70 -148.92 152.43 36.38 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 41.0 mtm -148.07 146.15 28.73 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.573 HG11 ' CD2' ' A' ' 54' ' ' LEU . 2.7 p -72.28 102.89 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.989 0.9 . . . . 0.0 109.342 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 2.1 t-105 -68.86 -39.92 79.61 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.442 -178.395 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' HIS . . . . . 0.498 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 2.0 t60 -158.34 128.46 6.02 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.67 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.3 p -124.66 126.06 71.01 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-O 121.642 0.734 . . . . 0.0 110.422 179.426 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.508 ' O ' ' HB2' ' A' ' 50' ' ' SER . 5.7 mt-10 -68.69 123.06 19.85 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.279 -1.328 . . . . 0.0 111.914 -179.103 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.499 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 12.2 p-10 -86.11 20.3 2.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.925 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.36 -19.63 66.17 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 116.006 -0.543 . . . . 0.0 113.666 -179.116 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 168.18 -49.77 0.23 Allowed Glycine 0 CA--C 1.522 0.486 0 C-N-CA 119.134 -1.508 . . . . 0.0 114.733 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -60.33 -132.48 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.967 0 C-N-CA 123.117 2.544 . . . . 0.0 116.318 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.499 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -39.79 -41.63 1.15 Allowed 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 -176.703 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.508 ' HB2' ' O ' ' A' ' 44' ' ' GLU . 0.4 OUTLIER -63.07 -59.5 4.7 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 118.385 0.538 . . . . 0.0 112.227 -178.098 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -63.62 -21.93 66.63 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.272 0.558 . . . . 0.0 110.847 -179.132 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.2 -26.15 61.94 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.463 178.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 135.09 -12.95 4.41 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.204 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.62 ' HA ' HD13 ' A' ' 8' ' ' ILE . 1.2 tt -69.54 115.24 8.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.312 0.577 . . . . 0.0 111.646 -179.394 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.413 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.0 OUTLIER -93.86 123.53 37.27 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.666 178.035 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.498 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 34.4 tt0 -49.36 143.77 6.13 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.945 0.402 . . . . 0.0 111.893 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.6 5.66 74.54 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.951 -0.643 . . . . 0.0 112.737 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.487 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 6.3 t0 -86.61 144.07 27.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.854 0.359 . . . . 0.0 110.693 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.501 HD12 ' O ' ' A' ' 38' ' ' HIS . 4.0 tp -92.17 134.12 35.16 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.509 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.539 HG12 HD11 ' A' ' 89' ' ' ILE . 3.4 mp -91.45 125.23 44.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.042 -179.311 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 45.8 p -101.66 -37.56 8.3 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.386 0.612 . . . . 0.0 110.886 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 69.5 m80 -141.73 157.68 44.75 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.148 -178.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.446 HG21 HG13 ' A' ' 80' ' ' ILE . 12.2 p -144.29 122.07 5.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.008 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 56.78 27.06 12.23 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.611 -179.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.28 43.25 26.04 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.917 -0.659 . . . . 0.0 111.596 -178.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.458 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.8 tp10 -150.42 104.4 3.11 Favored Pre-proline 0 N--CA 1.433 -1.319 0 C-N-CA 122.949 0.5 . . . . 0.0 109.732 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 47.3 Cg_exo -41.48 128.41 3.42 Favored 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 124.114 3.21 . . . . 0.0 111.512 177.59 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 32.7 m -86.25 -11.32 11.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 114.675 -1.148 . . . . 0.0 109.321 -178.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -54.6 97.09 0.02 OUTLIER 'General case' 0 N--CA 1.424 -1.728 0 CA-C-N 112.697 -2.047 . . . . 0.0 111.667 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.03 -13.86 23.97 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.828 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 41.2 mt -74.54 145.13 43.69 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.693 0.246 . . . . 0.0 110.349 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.638 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -79.2 168.95 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 179.268 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.503 ' HB2' ' O ' ' B' ' 107' ' ' SER . 2.2 t60 -45.79 -50.19 14.28 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 121.45 0.643 . . . . 0.0 112.628 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.478 ' H ' HG13 ' A' ' 72' ' ' VAL . 18.0 p -81.64 -14.54 56.56 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.84 -177.43 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.638 ' HG3' HG12 ' A' ' 72' ' ' VAL . 15.2 mt-10 -69.81 -42.6 73.48 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 121.25 -0.18 . . . . 0.0 111.286 -179.213 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.598 HG21 ' HG ' ' A' ' 21' ' ' LEU . 4.3 m -65.1 -44.56 95.63 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 CA-C-O 121.369 0.604 . . . . 0.0 109.43 179.006 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.433 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 83.5 t -53.14 -49.5 50.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 114.829 -1.078 . . . . 0.0 110.043 177.315 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -59.84 -45.33 92.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.005 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -54.16 -40.78 67.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.347 0.594 . . . . 0.0 110.216 178.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.754 HG23 HG11 ' A' ' 87' ' ' VAL . 14.5 mt -73.17 -49.75 36.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.091 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.433 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 91.1 mt -57.83 -41.67 82.75 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.837 0.351 . . . . 0.0 111.069 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 18.8 ttmt -60.58 -37.85 82.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.703 -0.68 . . . . 0.0 112.026 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 8.1 t -51.41 -45.81 62.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.456 -179.501 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.71 -132.49 7.95 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 119.879 -1.153 . . . . 0.0 114.023 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -73.14 -6.66 47.19 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 111.948 0.351 . . . . 0.0 111.948 -178.564 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.1 pttp -160.17 175.1 13.3 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-O 120.618 0.247 . . . . 0.0 110.985 -179.488 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.754 HG11 HG23 ' A' ' 80' ' ' ILE . 11.4 p -167.42 146.19 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.737 -0.665 . . . . 0.0 112.516 -179.037 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.466 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -92.87 98.57 11.46 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.886 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.55 HG22 ' O ' ' A' ' 8' ' ' ILE . 8.6 tt -92.62 113.32 27.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 120.81 0.338 . . . . 0.0 110.352 178.606 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.423 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -92.03 112.77 24.83 Favored 'General case' 0 C--N 1.323 -0.559 0 O-C-N 122.189 -0.32 . . . . 0.0 111.106 -179.052 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.487 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 77.6 p -108.41 175.68 5.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.525 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 4.1 t -104.04 102.14 30.12 Favored Pre-proline 0 CA--C 1.535 0.403 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -177.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.405 ' HD3' ' O ' ' A' ' 91' ' ' THR . 76.2 Cg_exo -53.99 170.9 0.41 Allowed 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 122.403 2.068 . . . . 0.0 112.913 177.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.409 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.0 OUTLIER -63.66 157.86 22.91 Favored 'General case' 0 C--N 1.319 -0.717 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.57 179.789 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.33 161.95 33.36 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.943 0.402 . . . . 0.0 111.311 -179.202 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 5.7 p30 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 118.608 -0.71 . . . . 0.0 109.579 178.645 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 6.1 m . . . . . 0 N--CA 1.48 1.05 0 CA-C-O 120.665 0.269 . . . . 0.0 110.904 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 102' ' ' TRP . . . . . . . . . . . . . 35.2 p90 -147.77 147.67 30.12 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 103' ' ' GLU . . . . . 0.483 ' HB2' ' CD1' ' A' ' 27' ' ' TYR . 16.0 mp0 -91.72 -23.92 19.62 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.008 0.432 . . . . 0.0 110.698 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 1.4 m -136.93 147.61 46.49 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.299 -0.41 . . . . 0.0 109.939 179.141 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -116.39 -74.81 0.59 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.565 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -54.21 113.56 1.3 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.096 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 107' ' ' SER . . . . . 0.503 ' O ' ' HB2' ' A' ' 73' ' ' HIS . 3.6 m -140.31 66.76 1.38 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.133 -179.633 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 112.97 8.8 19.73 Favored Glycine 0 N--CA 1.449 -0.482 0 N-CA-C 111.671 -0.571 . . . . 0.0 111.671 -179.38 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 113.46 -156.43 15.63 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.991 -0.624 . . . . 0.0 111.943 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -135.33 60.84 1.68 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.298 0.57 . . . . 0.0 109.592 179.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 111' ' ' THR . . . . . 0.42 HG22 ' H ' ' B' ' 112' ' ' ARG . 0.2 OUTLIER -73.95 177.05 5.88 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.468 -179.413 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 112' ' ' ARG . . . . . 0.42 ' H ' HG22 ' B' ' 111' ' ' THR . 14.5 ptt180 -162.09 171.68 17.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.029 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 113' ' ' LEU . . . . . 0.503 ' OXT' ' HB2' ' A' ' 16' ' ' LYS . 3.3 mm? . . . . . 0 C--O 1.249 1.071 0 CA-C-O 117.752 -1.118 . . . . 0.0 110.074 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.691 0 N-CA-C 112.275 -0.33 . . . . 0.0 112.275 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -173.03 -179.07 43.47 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 121.131 -0.557 . . . . 0.0 111.737 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -139.16 -176.66 4.59 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 39.2 ttp 55.24 70.48 0.62 Allowed 'General case' 0 C--N 1.331 -0.223 0 O-C-N 123.514 0.508 . . . . 0.0 110.915 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.456 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.1 mpt_? -70.73 132.47 87.07 Favored Pre-proline 0 C--N 1.323 -0.558 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.456 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -87.28 109.58 0.74 Allowed 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.884 2.39 . . . . 0.0 113.15 -178.396 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 15.0 Cg_exo -69.16 124.22 11.11 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.183 1.922 . . . . 0.0 112.34 178.637 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.571 HD13 ' HA ' ' A' ' 54' ' ' LEU . 2.6 mt -88.49 109.43 19.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.166 -0.924 . . . . 0.0 108.784 178.752 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.416 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 4.2 mm -76.1 99.97 2.07 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.586 -178.519 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.703 HG21 ' HB3' ' A' ' 17' ' ' TYR . 4.8 mt -76.67 159.85 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.027 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' HIS . . . . . 0.533 ' N ' HG22 ' A' ' 10' ' ' ILE . 14.7 t-80 -137.98 109.67 7.08 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 47.2 ttt180 -63.58 104.32 0.64 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.59 -179.344 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.4 50.07 1.06 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.539 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.05 -37.86 2.85 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.289 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.5 ptpt -84.09 -86.63 0.12 Allowed 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.654 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 7.5 pttp -154.89 -174.4 4.97 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 121.116 -0.234 . . . . 0.0 111.374 -178.58 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' TYR . . . . . 0.703 ' HB3' HG21 ' A' ' 10' ' ' ILE . 19.8 m-85 -87.98 1.63 53.68 Favored 'General case' 0 C--O 1.224 -0.238 0 CA-C-O 121.019 0.438 . . . . 0.0 109.858 179.119 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 52.38 53.37 31.99 Favored Glycine 0 C--O 1.22 -0.766 0 N-CA-C 116.738 1.455 . . . . 0.0 116.738 176.827 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.562 ' HB3' HG23 ' A' ' 43' ' ' VAL . 9.3 p90 -165.49 144.88 6.51 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 122.409 1.099 . . . . 0.0 113.018 175.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 92.2 m -91.27 116.08 28.54 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 113.434 -1.712 . . . . 0.0 112.921 -178.744 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.598 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -90.34 82.15 5.98 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 121.063 0.459 . . . . 0.0 110.133 178.491 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.527 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 4.5 tpt180 -70.21 125.02 25.57 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.379 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.552 ' HA ' ' ND1' ' A' ' 38' ' ' HIS . . . -81.17 140.32 35.04 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.258 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.1 pt -141.02 139.9 33.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.235 0.541 . . . . 0.0 111.66 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 36.3 mtm180 -106.5 93.76 4.77 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.704 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.4 m -81.28 100.91 5.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.069 0.461 . . . . 0.0 110.574 179.131 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' TYR . . . . . 0.402 ' CD2' ' HB3' ' A' ' 34' ' ' TYR . 24.8 m-85 -81.57 158.75 24.29 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.242 -0.436 . . . . 0.0 109.845 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 99.7 mmm -93.88 55.66 2.16 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.176 0.512 . . . . 0.0 110.248 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 67.42 -126.01 24.51 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.63 -0.713 . . . . 0.0 112.012 -179.555 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -82.35 71.23 9.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.434 0.635 . . . . 0.0 109.574 179.303 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.412 ' HB3' HG12 ' A' ' 33' ' ' VAL . 49.1 m -161.76 149.41 14.7 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.483 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -78.84 -12.39 60.03 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.127 0.489 . . . . 0.0 111.416 -179.43 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.412 HG12 ' HB3' ' A' ' 31' ' ' SER . 4.5 p -76.58 132.05 33.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.586 0.708 . . . . 0.0 110.784 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.402 ' HB3' ' CD2' ' A' ' 27' ' ' TYR . 27.8 p90 -150.29 148.5 28.94 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.56 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.15 128.99 48.41 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 178.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.9 t -81.59 96.41 3.25 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.049 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -110.06 -173.88 2.36 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.816 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.552 ' ND1' ' HA ' ' A' ' 23' ' ' ALA . 95.2 m-70 -149.7 166.29 29.82 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 48.4 ttm -153.19 138.17 17.22 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.669 HG11 HD21 ' A' ' 54' ' ' LEU . 2.6 p -71.6 102.52 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 CA-C-O 122.007 0.908 . . . . 0.0 108.871 178.848 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.527 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.1 t-105 -69.75 -41.16 75.59 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.814 -177.867 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' HIS . . . . . 0.449 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -154.59 128.09 8.55 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.076 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.562 HG23 ' HB3' ' A' ' 19' ' ' PHE . 5.8 p -125.47 124.77 67.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 CA-C-O 121.834 0.826 . . . . 0.0 110.534 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.589 ' O ' ' HB2' ' A' ' 50' ' ' SER . 32.5 mt-10 -68.63 118.38 11.56 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 114.171 -1.377 . . . . 0.0 112.41 -178.756 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.609 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 14.7 p-10 -87.47 32.66 0.7 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.772 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -92.21 -22.66 29.16 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.866 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.526 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 174.85 -51.42 0.13 Allowed Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 119.534 -1.317 . . . . 0.0 114.281 -179.095 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -60.81 -131.13 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.401 2.734 . . . . 0.0 116.409 -179.009 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.522 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -42.12 -44.71 3.75 Favored 'General case' 0 N--CA 1.464 0.273 0 N-CA-C 114.644 1.35 . . . . 0.0 114.644 -176.826 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.609 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -62.12 -58.32 8.24 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -177.661 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.526 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 2.3 mm-40 -62.2 -24.68 67.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.213 0.53 . . . . 0.0 110.799 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -70.68 -24.58 62.7 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.267 178.652 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 136.31 -12.87 4.07 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.914 179.103 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.669 HD21 HG11 ' A' ' 40' ' ' VAL . 1.1 tt -69.29 116.29 9.55 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.623 0.725 . . . . 0.0 112.036 -179.201 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.86 125.71 42.88 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.587 177.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -50.87 141.76 12.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.894 0.378 . . . . 0.0 111.209 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 86.19 37.85 8.83 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.628 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.633 ' OD1' ' HB ' ' A' ' 91' ' ' THR . 1.9 t70 -120.52 142.73 49.04 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 179.736 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.535 HD12 ' O ' ' A' ' 38' ' ' HIS . 12.2 tp -89.72 128.1 36.05 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.89 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.511 HG12 HD11 ' A' ' 89' ' ' ILE . 4.0 mp -86.19 126.63 40.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.975 -179.629 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 41.1 p -102.27 -41.27 6.42 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.871 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 59.3 m80 -138.94 160.24 40.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.176 -178.471 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.411 HG21 HG13 ' A' ' 80' ' ' ILE . 10.6 p -142.74 115.81 3.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.192 -0.458 . . . . 0.0 109.913 177.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 56.45 31.17 18.37 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.745 -0.662 . . . . 0.0 111.467 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.31 41.03 17.92 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.973 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.522 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.2 tp10 -152.15 108.48 2.82 Favored Pre-proline 0 N--CA 1.432 -1.373 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.522 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 1.3 Cg_endo -48.48 134.61 26.48 Favored 'Trans proline' 0 N--CA 1.45 -1.061 0 C-N-CA 123.636 2.891 . . . . 0.0 111.066 178.284 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 32.9 m -87.57 -7.65 10.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-N 114.373 -1.285 . . . . 0.0 109.288 -178.445 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.9 m170 -55.59 96.12 0.02 OUTLIER 'General case' 0 N--CA 1.427 -1.591 0 CA-C-N 112.771 -2.013 . . . . 0.0 111.744 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.9 -12.56 27.1 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.291 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 31.1 mt -74.84 138.22 42.37 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.641 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -77.93 169.86 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.267 179.801 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -42.79 -48.9 5.76 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 123.76 0.824 . . . . 0.0 112.711 -179.499 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.517 ' H ' HG13 ' A' ' 72' ' ' VAL . 25.1 p -84.52 -15.38 46.06 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.309 0.855 . . . . 0.0 113.309 -177.049 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.641 ' HG3' HG12 ' A' ' 72' ' ' VAL . 18.7 mt-10 -69.56 -43.39 73.0 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 121.096 -0.242 . . . . 0.0 111.35 -179.176 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.598 HG21 ' HG ' ' A' ' 21' ' ' LEU . 3.8 m -64.4 -45.23 96.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.26 0.552 . . . . 0.0 109.632 179.185 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.41 HG13 ' CD1' ' B' ' 113' ' ' LEU . 79.4 t -54.48 -48.28 69.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.877 177.43 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -59.56 -49.53 77.4 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.825 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.13 -41.31 62.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.605 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.702 HG23 HG11 ' A' ' 87' ' ' VAL . 16.0 mt -68.75 -52.88 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.972 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.402 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 46.4 mt -59.05 -37.5 77.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.201 0.524 . . . . 0.0 111.088 179.603 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -61.71 -38.62 88.53 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.928 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 40.4 t -52.76 -47.29 67.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.283 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 136.57 -135.39 7.7 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.122 -1.037 . . . . 0.0 112.921 179.146 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -79.6 1.76 24.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.132 0.491 . . . . 0.0 111.374 -179.16 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 10.9 pttp -159.67 175.46 13.15 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.173 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.702 HG11 HG23 ' A' ' 80' ' ' ILE . 12.2 p -167.55 147.18 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 O-C-N 123.567 0.542 . . . . 0.0 112.342 -179.105 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.43 93.84 7.9 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.867 179.585 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.511 HD11 HG12 ' A' ' 60' ' ' ILE . 7.3 tt -88.3 113.59 25.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-O 121.055 0.455 . . . . 0.0 110.474 179.078 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.463 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -90.58 110.83 21.97 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.945 0.402 . . . . 0.0 111.235 -179.005 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.633 ' HB ' ' OD1' ' A' ' 58' ' ' ASP . 26.1 p -103.77 169.54 8.46 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.217 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.432 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 8.6 t -107.25 104.59 52.92 Favored Pre-proline 0 CA--C 1.534 0.342 0 C-N-CA 120.444 -0.502 . . . . 0.0 112.191 -178.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_exo -53.09 172.24 0.2 Allowed 'Trans proline' 0 C--N 1.351 0.669 0 C-N-CA 122.311 2.007 . . . . 0.0 113.039 178.099 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -64.28 163.39 13.0 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.048 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -156.72 177.98 10.86 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.4 -179.106 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 7.5 p30 . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.529 -0.748 . . . . 0.0 110.733 179.985 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 N--CA 1.478 0.971 0 CA-C-O 120.911 0.386 . . . . 0.0 110.354 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 102' ' ' TRP . . . . . 0.443 ' HH2' ' CH2' ' A' ' 41' ' ' TRP . 22.9 p90 -132.9 163.02 30.07 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.034 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -63.08 -73.09 0.12 Allowed 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.954 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -159.24 169.61 23.72 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.245 0.545 . . . . 0.0 111.466 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 8.0 t-160 -109.82 106.12 15.59 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.605 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 12.7 mptt -131.54 20.93 4.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.257 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 46.2 m -122.94 111.21 16.35 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.682 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 79.83 165.09 30.58 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.789 -0.719 . . . . 0.0 111.821 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -80.56 -109.52 0.29 Allowed Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.964 -0.636 . . . . 0.0 111.874 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -142.98 44.39 1.57 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.498 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 7.0 m -62.57 148.55 45.71 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.157 -0.929 . . . . 0.0 110.877 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 112' ' ' ARG . . . . . . . . . . . . . 13.4 ptp180 -143.67 168.14 20.6 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.894 0.378 . . . . 0.0 110.692 -179.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 113' ' ' LEU . . . . . 0.654 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 3.3 mm? . . . . . 0 C--N 1.318 -0.764 0 CA-C-O 118.588 -0.72 . . . . 0.0 109.761 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.877 0 N-CA-C 111.92 -0.472 . . . . 0.0 111.92 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -149.13 169.42 29.51 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.159 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.6 m -135.4 157.84 45.87 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.38 -0.229 . . . . 0.0 110.38 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 93.4 mtp 61.23 75.75 0.4 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.148 0.499 . . . . 0.0 110.752 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.484 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.0 mpt_? -72.91 134.98 80.77 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.515 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 5.0 Cg_endo -92.24 116.02 0.37 Allowed 'Trans proline' 0 CA--C 1.531 0.355 0 C-N-CA 123.326 2.684 . . . . 0.0 113.408 -178.623 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.497 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 12.3 Cg_exo -73.88 124.22 9.02 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 122.439 2.093 . . . . 0.0 113.17 178.396 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.499 HD13 ' HA ' ' A' ' 54' ' ' LEU . 1.1 mt -87.45 110.33 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.836 177.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.414 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 3.2 mm -78.16 97.91 2.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.569 -178.634 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.639 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.2 mt -77.35 162.08 4.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 177.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' HIS . . . . . 0.52 ' N ' HG22 ' A' ' 10' ' ' ILE . 53.0 t-80 -137.51 114.44 10.64 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 108.11 -1.071 . . . . 0.0 108.11 178.536 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 30.6 ttt180 -61.34 107.14 0.72 Allowed 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.675 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -80.68 50.68 1.37 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.432 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.34 23.54 74.97 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.638 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.497 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 9.8 ptpt -150.76 -80.6 0.11 Allowed 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.642 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 21.7 pttm -158.42 178.25 10.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.377 0.132 . . . . 0.0 110.822 -178.705 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' TYR . . . . . 0.639 ' HB3' HG21 ' A' ' 10' ' ' ILE . 6.4 m-85 -89.22 4.44 48.67 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-O 121.54 0.686 . . . . 0.0 109.536 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.408 ' O ' ' HG3' ' A' ' 44' ' ' GLU . . . 64.16 -27.48 0.09 OUTLIER Glycine 0 C--N 1.335 0.528 0 N-CA-C 116.925 1.53 . . . . 0.0 116.925 177.249 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.579 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.4 p90 -81.7 147.64 29.38 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 122.445 1.117 . . . . 0.0 113.459 -176.568 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.435 ' HA ' ' HB2' ' B' ' 112' ' ' ARG . 87.5 m -97.0 112.55 24.26 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 113.344 -1.753 . . . . 0.0 111.575 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.652 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -85.37 86.78 7.35 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.316 178.985 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.516 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 5.5 tpt180 -68.71 146.13 53.23 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.472 179.697 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.729 ' HB2' ' HD1' ' A' ' 73' ' ' HIS . . . -105.7 149.36 26.46 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.661 0.267 . . . . 0.0 111.177 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.5 pt -146.26 173.21 3.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.555 178.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 6.0 mtp180 -146.15 87.14 1.73 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.7 m -76.22 103.28 3.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.391 0.615 . . . . 0.0 111.673 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 23.3 m-85 -82.42 134.49 35.23 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.405 179.208 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 22.5 mmt -90.21 83.2 5.98 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.58 -161.37 44.45 Favored Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 -178.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -92.87 85.61 5.22 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -165.87 179.92 5.62 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.596 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -80.61 -6.58 58.51 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.749 0.309 . . . . 0.0 111.685 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.5 p -78.29 119.26 26.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.556 0.693 . . . . 0.0 110.764 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.0 p90 -159.93 148.59 17.36 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.974 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.83 130.21 55.0 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.958 0.409 . . . . 0.0 110.435 179.286 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 t -85.78 95.43 4.55 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.794 179.635 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 41.6 m-70 -104.94 -174.88 2.64 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.61 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.534 ' O ' HD12 ' A' ' 59' ' ' LEU . 99.1 m-70 -150.9 164.61 35.9 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -152.44 139.74 19.45 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.586 -178.388 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.874 HG11 HD21 ' A' ' 54' ' ' LEU . 1.9 p -73.64 105.51 3.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 121.808 0.813 . . . . 0.0 109.466 178.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.516 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 4.4 t-105 -69.87 -44.39 69.9 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.446 -1.252 . . . . 0.0 112.292 -177.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' HIS . . . . . 0.482 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 2.1 t60 -154.29 133.75 12.72 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.229 -0.896 . . . . 0.0 110.046 -178.332 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.579 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 3.0 p -126.87 129.16 71.36 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 CA-C-O 121.629 0.728 . . . . 0.0 110.859 179.238 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.419 ' O ' ' HB2' ' A' ' 50' ' ' SER . 15.5 mt-10 -66.05 119.79 12.01 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 114.74 -1.118 . . . . 0.0 111.583 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.567 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 9.4 p-10 -88.07 19.16 3.78 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.174 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.03 4.12 60.7 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.372 -0.918 . . . . 0.0 113.837 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 161.27 -55.74 0.31 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 118.795 -1.669 . . . . 0.0 115.187 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.406 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 50.5 Cg_exo -60.57 -135.14 0.0 OUTLIER 'Trans proline' 0 CA--C 1.545 1.04 0 C-N-CA 123.043 2.495 . . . . 0.0 116.679 -178.079 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.549 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -43.17 -36.99 1.9 Allowed 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 115.208 1.558 . . . . 0.0 115.208 -176.582 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.567 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 1.9 m -62.29 -55.08 31.77 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 118.655 0.661 . . . . 0.0 111.546 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -63.5 -24.31 67.76 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.008 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.08 -24.79 60.71 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.905 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.54 -7.33 6.23 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.565 -0.826 . . . . 0.0 113.104 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.874 HD21 HG11 ' A' ' 40' ' ' VAL . 5.1 tt -70.59 113.81 8.07 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.044 0.45 . . . . 0.0 110.88 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.17 122.32 32.35 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.931 178.17 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.455 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 36.3 tt0 -49.49 131.73 20.88 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 120.905 0.383 . . . . 0.0 110.664 177.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.37 65.89 1.35 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.294 -178.54 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.497 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.7 t0 -144.84 148.31 33.84 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.534 HD12 ' O ' ' A' ' 38' ' ' HIS . 8.7 tp -92.5 127.78 38.12 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.22 -179.635 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.443 ' CG1' HD11 ' A' ' 89' ' ' ILE . 4.0 mp -87.05 125.18 40.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.704 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 52.8 p -102.07 -39.08 7.46 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.379 0.609 . . . . 0.0 110.599 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 59.0 m80 -139.31 155.26 47.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.089 -178.765 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.565 HG21 HG13 ' A' ' 80' ' ' ILE . 7.7 p -138.2 113.07 9.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.851 177.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.8 t30 56.46 32.84 21.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.786 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.12 43.22 22.02 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.12 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.503 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.5 tp10 -149.99 106.2 3.21 Favored Pre-proline 0 N--CA 1.44 -0.949 0 C-N-CA 122.578 0.351 . . . . 0.0 110.375 179.673 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.503 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.7 Cg_exo -45.09 129.51 10.16 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 123.71 2.94 . . . . 0.0 111.538 177.724 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 31.3 m -86.76 -9.56 11.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-N 114.419 -1.264 . . . . 0.0 109.18 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.3 m170 -54.51 97.64 0.02 OUTLIER 'General case' 0 N--CA 1.426 -1.633 0 CA-C-N 112.602 -2.09 . . . . 0.0 112.074 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 108.98 -11.02 34.44 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.63 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.6 mt -75.79 139.96 42.08 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.655 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -79.3 170.47 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.632 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.729 ' HD1' ' HB2' ' A' ' 23' ' ' ALA . 55.4 t60 -44.37 -54.75 5.55 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.668 0.747 . . . . 0.0 112.417 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 27.6 p -73.14 -20.69 60.86 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.111 -0.949 . . . . 0.0 112.788 -177.259 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.655 ' HG3' HG12 ' A' ' 72' ' ' VAL . 26.4 mt-10 -69.21 -41.81 76.57 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 121.271 -0.171 . . . . 0.0 111.168 -179.261 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.652 HG21 ' HG ' ' A' ' 21' ' ' LEU . 13.6 m -67.05 -46.95 83.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 C-N-CA 120.476 -0.49 . . . . 0.0 110.024 178.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.466 HG23 ' O ' ' A' ' 73' ' ' HIS . 40.6 t -53.13 -46.49 55.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.18 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -66.6 -42.48 86.82 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.836 179.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -54.04 -39.27 66.06 Favored 'General case' 0 C--N 1.327 -0.388 0 O-C-N 123.681 0.613 . . . . 0.0 109.801 178.076 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.675 HG23 HG11 ' A' ' 87' ' ' VAL . 16.4 mt -71.28 -51.91 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.494 179.472 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 82.5 mt -57.95 -32.69 68.08 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-O 121.104 0.478 . . . . 0.0 110.609 179.076 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 24.8 ttmt -58.67 -40.0 82.28 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.226 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 26.1 t -56.9 -55.04 39.65 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.745 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 134.99 -127.96 4.59 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.069 -1.063 . . . . 0.0 113.807 178.731 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -75.18 -2.9 29.95 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -178.575 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.422 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 18.5 pttp -159.77 175.33 13.25 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.249 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.675 HG11 HG23 ' A' ' 80' ' ' ILE . 13.5 p -166.67 145.1 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.505 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.472 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -93.88 92.36 7.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.3 -0.864 . . . . 0.0 111.665 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.449 HG22 ' O ' ' A' ' 8' ' ' ILE . 6.8 tt -88.05 112.24 23.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-O 121.014 0.435 . . . . 0.0 110.346 179.262 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 1.0 OUTLIER -91.95 115.39 28.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.779 0.323 . . . . 0.0 111.326 -178.829 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.497 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 64.5 p -109.4 175.39 5.47 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.315 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.499 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 6.3 t -103.9 105.16 46.96 Favored Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 113.04 0.755 . . . . 0.0 113.04 -178.059 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -52.8 171.86 0.2 Allowed 'Trans proline' 0 C--O 1.236 0.421 0 C-N-CA 122.64 2.226 . . . . 0.0 112.928 177.45 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -66.47 159.16 27.74 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.796 179.532 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -155.47 160.31 40.49 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.218 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 10.8 p30 . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.47 -0.776 . . . . 0.0 110.516 -179.709 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 15.9 m . . . . . 0 N--CA 1.477 0.902 0 CA-C-O 120.566 0.222 . . . . 0.0 110.597 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 102' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -136.37 34.27 2.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.301 0.572 . . . . 0.0 109.877 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -74.61 -71.98 0.31 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.397 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 57.3 m -155.7 -160.03 0.98 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.193 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 105' ' ' HIS . . . . . 0.528 ' HA ' ' O ' ' A' ' 23' ' ' ALA . 4.5 p80 -73.01 82.31 1.23 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.343 0.592 . . . . 0.0 111.178 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 83.2 mttt -94.98 12.81 27.1 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.96 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.03 21.87 5.34 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.56 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.28 -123.95 1.17 Allowed Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.533 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -158.63 -128.78 1.02 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.057 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -117.43 33.15 5.77 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 122.79 -0.241 . . . . 0.0 111.317 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 111' ' ' THR . . . . . 0.402 ' HB ' ' CD2' ' A' ' 73' ' ' HIS . 25.8 m -72.45 93.67 1.57 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.438 0.637 . . . . 0.0 110.022 179.336 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 112' ' ' ARG . . . . . 0.435 ' HB2' ' HA ' ' A' ' 20' ' ' THR . 6.8 ptp85 -81.9 174.06 11.64 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.54 -0.755 . . . . 0.0 110.459 -179.567 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 113' ' ' LEU . . . . . 0.642 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 4.1 mm? . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.517 -0.754 . . . . 0.0 110.852 -179.179 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.458 ' HA2' ' HG3' ' A' ' 95' ' ' GLU . . . . . . . . 0 N--CA 1.482 1.72 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -112.45 -169.32 17.87 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.173 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 m -134.03 152.56 51.89 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.574 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 89.9 mtp 62.3 78.28 0.3 Allowed 'General case' 0 N--CA 1.463 0.192 0 O-C-N 123.715 0.635 . . . . 0.0 110.631 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.441 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.9 mpt_? -72.02 148.92 92.07 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.264 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 8.4 Cg_endo -95.43 113.06 0.15 Allowed 'Trans proline' 0 N--CA 1.461 -0.414 0 C-N-CA 123.742 2.961 . . . . 0.0 113.173 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 12.5 Cg_exo -72.86 122.87 8.51 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.463 2.109 . . . . 0.0 113.299 178.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.54 HG21 ' N ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -83.38 109.14 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.28 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.072 177.708 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.401 ' H ' HG12 ' A' ' 9' ' ' ILE . 3.2 mm -77.36 97.31 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.174 -178.78 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.539 HG12 ' HB2' ' A' ' 49' ' ' ALA . 5.7 mt -76.89 159.1 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' HIS . . . . . 0.494 ' N ' HG22 ' A' ' 10' ' ' ILE . 47.3 t-80 -136.5 112.18 9.41 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 46.7 ttt180 -63.67 109.16 1.6 Allowed 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.728 -178.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -83.36 52.31 2.19 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.87 178.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.54 -49.65 4.21 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-N 115.767 -0.652 . . . . 0.0 112.243 -179.388 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.5 ptpt -71.76 -90.41 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.547 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 16.4 pttm -158.53 -171.56 3.5 Favored 'General case' 0 C--N 1.327 -0.4 0 O-C-N 122.434 -0.166 . . . . 0.0 111.092 -178.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' TYR . . . . . 0.477 ' HB3' HG21 ' A' ' 10' ' ' ILE . 12.2 m-85 -88.11 -1.76 58.2 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.517 0.675 . . . . 0.0 109.744 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.558 ' HA3' ' HB2' ' A' ' 44' ' ' GLU . . . 63.62 -19.34 0.09 OUTLIER Glycine 0 CA--C 1.519 0.342 0 N-CA-C 117.057 1.583 . . . . 0.0 117.057 177.507 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.591 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.4 p90 -85.44 146.89 26.75 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 122.505 1.145 . . . . 0.0 113.524 -177.253 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.406 HG21 HH11 ' A' ' 22' ' ' ARG . 86.1 m -94.65 113.55 25.37 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.601 -1.636 . . . . 0.0 112.364 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.568 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -89.49 81.5 6.54 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.931 0.396 . . . . 0.0 110.692 178.694 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.452 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 0.1 OUTLIER -69.87 134.42 48.44 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.259 179.417 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.429 ' HB3' ' HD1' ' A' ' 73' ' ' HIS . . . -103.37 141.63 35.61 Favored 'General case' 0 C--N 1.328 -0.344 0 O-C-N 123.011 0.195 . . . . 0.0 111.141 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -146.48 -171.92 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.758 179.709 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.43 ' HD2' ' OG ' ' B' ' 107' ' ' SER . 0.6 OUTLIER -150.08 118.69 6.53 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.26 0.552 . . . . 0.0 110.643 179.326 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.532 ' O ' ' HB2' ' A' ' 34' ' ' TYR . 14.3 m -84.19 -167.77 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.367 178.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -156.19 136.35 12.9 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.641 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 22.3 mmt -121.78 112.49 18.43 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 112.385 0.513 . . . . 0.0 112.385 -177.762 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.33 -156.7 45.43 Favored Glycine 0 N--CA 1.453 -0.2 0 CA-C-N 116.07 -0.513 . . . . 0.0 113.623 178.24 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -91.48 -19.79 22.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.035 0.445 . . . . 0.0 110.274 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.7 m -71.0 160.53 32.75 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.071 179.381 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.89 21.05 0.57 Allowed 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.817 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 3.9 p -81.35 131.06 34.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.416 0.627 . . . . 0.0 110.081 179.469 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' TYR . . . . . 0.532 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 54.1 p90 -147.37 156.06 42.55 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.626 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.474 ' O ' HG22 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -116.05 129.96 56.59 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.86 0.362 . . . . 0.0 110.861 179.209 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 9.4 t -81.01 102.37 6.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.403 ' NE2' ' HB ' ' A' ' 35' ' ' THR . 98.4 m-70 -108.48 -176.06 2.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.238 -179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.537 ' CD2' HG11 ' A' ' 76' ' ' VAL . 97.7 m-70 -148.46 168.5 22.51 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' MET . . . . . 0.411 ' HG2' ' O ' ' A' ' 58' ' ' ASP . 3.1 mtm -157.05 137.76 13.24 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 120.61 0.243 . . . . 0.0 110.425 -178.818 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.927 HG11 HD21 ' A' ' 54' ' ' LEU . 1.9 p -72.83 100.63 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-O 122.126 0.965 . . . . 0.0 108.817 178.625 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.452 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.2 t-105 -69.77 -41.08 75.61 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.025 -1.443 . . . . 0.0 112.711 -177.378 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' HIS . . . . . 0.463 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -156.39 127.19 6.81 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.374 -178.652 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.591 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 2.4 p -118.84 129.0 75.65 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 CA-C-O 121.251 0.548 . . . . 0.0 110.024 179.18 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.558 ' HB2' ' HA3' ' A' ' 18' ' ' GLY . 5.2 mt-10 -63.9 114.04 3.83 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 114.735 -1.121 . . . . 0.0 111.645 -178.78 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.485 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 11.8 p-10 -83.17 39.54 0.65 Allowed 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.92 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -122.75 11.88 8.83 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.407 -0.901 . . . . 0.0 113.935 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 156.75 -61.99 0.33 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 118.633 -1.746 . . . . 0.0 115.153 179.314 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' PRO . . . . . 0.466 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 51.2 Cg_exo -61.04 -133.41 0.0 OUTLIER 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 123.17 2.58 . . . . 0.0 116.958 -177.46 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.539 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -42.13 -35.36 0.91 Allowed 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 114.95 1.463 . . . . 0.0 114.95 -176.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.485 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -61.13 -59.61 5.07 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 118.33 0.513 . . . . 0.0 111.706 -178.921 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -63.61 -30.24 71.38 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.548 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.19 -29.28 70.26 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.673 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.3 -10.5 5.59 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.196 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.927 HD21 HG11 ' A' ' 40' ' ' VAL . 5.6 tt -66.85 114.45 5.71 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.849 0.357 . . . . 0.0 110.48 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.15 122.49 32.5 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.486 178.586 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.438 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 40.2 tt0 -51.34 138.0 22.17 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.989 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 83.14 47.35 5.82 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.222 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.582 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.3 t0 -127.24 149.23 50.1 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.507 HD12 ' O ' ' A' ' 38' ' ' HIS . 19.9 tp -93.03 125.8 37.8 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.149 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.451 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.8 mp -83.82 124.74 39.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.276 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 57.8 p -99.51 -40.0 8.06 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.378 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -142.05 157.31 45.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.122 -178.349 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.67 115.21 8.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 177.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 59.62 31.1 20.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.418 -179.4 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 73.23 45.5 30.78 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.372 -178.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.499 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 1.5 tp10 -151.75 111.23 2.93 Favored Pre-proline 0 N--CA 1.433 -1.316 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 -179.246 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.499 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 4.7 Cg_endo -50.99 133.47 40.65 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 123.551 2.834 . . . . 0.0 111.257 178.745 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 35.1 m -90.01 -7.87 10.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.806 -178.385 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.8 m170 -55.41 95.06 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.54 0 CA-C-N 112.977 -1.919 . . . . 0.0 111.96 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.29 -9.37 24.59 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.394 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 32.2 mt -77.39 139.76 39.78 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.505 HG13 ' H ' ' A' ' 74' ' ' THR . 0.6 OUTLIER -81.14 171.18 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.162 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.508 ' HB2' ' O ' ' B' ' 107' ' ' SER . 2.1 t60 -42.02 -49.02 4.71 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 123.682 0.793 . . . . 0.0 112.934 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.505 ' H ' HG13 ' A' ' 72' ' ' VAL . 30.6 p -82.11 -21.14 36.88 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 -176.586 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.402 ' HG3' HG12 ' A' ' 72' ' ' VAL . 28.2 mt-10 -67.53 -40.83 85.06 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 121.082 -0.247 . . . . 0.0 111.38 -178.583 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.568 HG21 ' HG ' ' A' ' 21' ' ' LEU . 3.9 m -65.68 -46.85 88.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.267 0.556 . . . . 0.0 109.599 178.66 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.42 HG13 HD13 ' B' ' 113' ' ' LEU . 58.4 t -54.79 -45.71 74.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.295 177.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -62.96 -45.12 93.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.942 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.53 -41.66 66.63 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.34 0.59 . . . . 0.0 110.041 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.637 HG23 HG11 ' A' ' 87' ' ' VAL . 12.0 mt -68.77 -50.66 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.964 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 65.9 mt -59.23 -39.54 83.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.252 0.549 . . . . 0.0 110.478 178.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -61.46 -36.58 80.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.69 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 44.3 t -53.76 -47.64 70.49 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.129 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 138.06 -124.45 2.96 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.264 -0.969 . . . . 0.0 113.295 179.104 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -93.65 7.07 46.16 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.265 0.555 . . . . 0.0 110.887 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 19.8 pttp -161.12 179.21 8.59 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.859 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.637 HG11 HG23 ' A' ' 80' ' ' ILE . 11.4 p -170.15 143.68 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 O-C-N 123.609 0.568 . . . . 0.0 112.439 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.09 90.44 6.4 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.649 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.451 HD11 ' CG1' ' A' ' 60' ' ' ILE . 5.0 tt -87.78 115.65 28.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-O 120.954 0.407 . . . . 0.0 110.553 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 3.6 t -94.76 116.04 28.25 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.777 0.322 . . . . 0.0 111.395 -178.847 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.582 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 81.4 p -109.37 173.31 6.38 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.7 179.026 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.402 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 3.6 t -101.44 104.18 32.11 Favored Pre-proline 0 CA--C 1.536 0.414 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.705 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 91' ' ' THR . 77.1 Cg_exo -54.37 177.46 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.577 2.185 . . . . 0.0 113.015 177.609 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -62.55 156.47 23.0 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.396 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLU . . . . . 0.458 ' HG3' ' HA2' ' A' ' 1' ' ' GLY . 0.7 OUTLIER -158.78 160.29 36.12 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.764 -179.951 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 10.2 p30 . . . . . 0 C--O 1.251 1.162 0 CA-C-O 118.362 -0.828 . . . . 0.0 109.319 178.925 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 73.3 m . . . . . 0 N--CA 1.475 0.799 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 102' ' ' TRP . . . . . 0.455 ' H ' ' HA ' ' A' ' 26' ' ' VAL . 1.9 t90 66.26 49.17 1.51 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-O 121.75 0.786 . . . . 0.0 109.034 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 10.9 mp0 -74.66 -21.94 59.15 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.284 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 69.5 p -170.42 176.65 4.34 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.105 0.479 . . . . 0.0 111.617 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -113.01 27.42 9.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.381 178.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 57.2 mtpt -75.52 34.38 0.11 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.714 -178.251 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 107' ' ' SER . . . . . 0.508 ' O ' ' HB2' ' A' ' 73' ' ' HIS . 9.4 m -113.07 6.47 17.63 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.213 0.53 . . . . 0.0 109.751 178.838 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.29 -161.37 28.17 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.628 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -114.75 -92.59 1.88 Allowed Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.196 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -156.98 97.73 1.7 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 4.1 m -127.1 79.33 1.87 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.144 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 112' ' ' ARG . . . . . 0.42 HH11 ' HD3' ' B' ' 112' ' ' ARG . 7.2 ptt180 -67.8 162.8 23.16 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.537 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 113' ' ' LEU . . . . . 0.547 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 4.5 mm? . . . . . 0 C--O 1.25 1.099 0 CA-C-O 118.711 -0.662 . . . . 0.0 110.78 -178.827 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.782 0 N-CA-C 112.1 -0.4 . . . . 0.0 112.1 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -169.28 -171.25 34.78 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.899 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.7 m -147.19 158.22 43.87 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 110.386 -0.227 . . . . 0.0 110.386 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 77.4 mtp 63.41 78.94 0.27 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.183 0.516 . . . . 0.0 110.939 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.432 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.9 mpt_? -72.78 139.31 80.26 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.733 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -87.87 109.8 0.66 Allowed 'Trans proline' 0 C--O 1.236 0.418 0 C-N-CA 123.204 2.603 . . . . 0.0 112.826 -179.026 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.472 ' HA ' ' O ' ' A' ' 89' ' ' ILE . 12.0 Cg_exo -72.81 121.39 7.31 Favored 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 122.368 2.045 . . . . 0.0 113.041 179.02 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.466 HG21 ' N ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -83.0 110.86 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 CA-C-N 115.388 -0.824 . . . . 0.0 108.802 178.12 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.4 mm -77.16 100.75 2.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.75 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.698 HG21 ' HB3' ' A' ' 17' ' ' TYR . 6.0 mt -76.54 163.51 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.385 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' HIS . . . . . 0.55 ' N ' HG22 ' A' ' 10' ' ' ILE . 29.0 t-80 -141.53 107.1 5.06 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.105 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 52.6 ttt-85 -62.19 110.31 1.58 Allowed 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.164 -178.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -81.72 46.47 0.98 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.774 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.79 -0.26 66.32 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 121.163 -0.541 . . . . 0.0 112.814 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.1 ptpt -119.65 -82.38 0.64 Allowed 'General case' 0 C--N 1.325 -0.458 0 O-C-N 122.891 -0.182 . . . . 0.0 111.277 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.516 ' HB2' ' OXT' ' B' ' 113' ' ' LEU . 17.1 pttt -155.14 -178.71 7.45 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.702 -178.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' TYR . . . . . 0.698 ' HB3' HG21 ' A' ' 10' ' ' ILE . 16.9 m-85 -88.28 5.64 40.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.17 0.51 . . . . 0.0 110.223 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . 0.548 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 53.27 48.99 58.18 Favored Glycine 0 C--O 1.217 -0.909 0 N-CA-C 116.744 1.458 . . . . 0.0 116.744 177.062 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.499 ' HB3' HG23 ' A' ' 43' ' ' VAL . 6.3 p90 -164.42 147.38 9.04 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 122.457 1.123 . . . . 0.0 112.977 176.304 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 97.9 m -92.39 115.31 27.97 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 113.42 -1.718 . . . . 0.0 112.414 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' LEU . . . . . 0.665 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -89.22 84.48 6.51 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.74 0.305 . . . . 0.0 110.449 178.487 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.512 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 6.1 tpt180 -68.73 140.24 55.37 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.453 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.44 ' CB ' ' HD1' ' A' ' 73' ' ' HIS . . . -105.33 138.49 41.45 Favored 'General case' 0 C--N 1.328 -0.363 0 O-C-N 123.074 0.234 . . . . 0.0 110.462 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 4.3 pt -143.04 144.52 23.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-O 121.298 0.57 . . . . 0.0 111.765 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 91.0 mtt180 -115.56 90.51 3.35 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.446 179.208 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.2 m -75.69 118.03 21.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.12 -179.193 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 11.2 m-85 -78.19 156.55 29.77 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.256 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.0 mtm -136.41 80.15 1.8 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.789 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.18 -157.76 14.9 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.375 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -93.36 -19.22 21.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.921 0.391 . . . . 0.0 111.054 -179.618 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -73.69 172.08 12.09 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.163 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -81.22 22.16 0.68 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.417 0.627 . . . . 0.0 110.676 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.8 p -81.83 127.54 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 CA-C-O 121.455 0.645 . . . . 0.0 110.439 179.362 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 19.0 p90 -147.43 157.26 43.5 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.418 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.77 124.64 50.9 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.198 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 t -82.55 102.31 8.35 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.789 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 54.9 m-70 -115.41 -175.46 2.71 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.676 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.529 ' CD2' HG11 ' A' ' 76' ' ' VAL . 97.1 m-70 -148.79 153.3 37.95 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 48.3 mtm -148.68 141.02 24.15 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.033 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.913 HG11 HD21 ' A' ' 54' ' ' LEU . 2.3 p -72.55 104.78 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-O 121.784 0.802 . . . . 0.0 109.581 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' TRP . . . . . 0.512 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.2 t-105 -70.07 -42.55 72.65 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.476 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' HIS . . . . . 0.442 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 0.9 OUTLIER -155.08 132.56 11.18 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.158 -179.125 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.0 p -127.75 130.08 70.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 121.575 0.702 . . . . 0.0 110.508 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.564 ' O ' ' HB2' ' A' ' 50' ' ' SER . 37.1 mt-10 -67.04 115.07 6.34 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 114.583 -1.19 . . . . 0.0 111.811 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.539 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 11.9 p-10 -84.19 35.72 0.55 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.649 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.94 -26.12 8.09 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.708 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -179.93 -54.4 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 119.439 -1.362 . . . . 0.0 114.688 -178.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -58.07 -129.57 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 0.975 0 C-N-CA 123.524 2.816 . . . . 0.0 116.68 -178.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.522 ' HB1' HD13 ' A' ' 54' ' ' LEU . . . -43.36 -42.87 4.8 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -176.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.564 ' HB2' ' O ' ' A' ' 44' ' ' GLU . 0.4 OUTLIER -62.09 -62.25 1.91 Allowed 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 112.742 0.645 . . . . 0.0 112.742 -177.668 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -62.04 -22.69 65.94 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.02 0.438 . . . . 0.0 111.072 -178.593 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -71.06 -24.57 62.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.692 179.131 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.05 -15.05 3.76 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.75 -0.738 . . . . 0.0 113.03 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LEU . . . . . 0.913 HD21 HG11 ' A' ' 40' ' ' VAL . 5.1 tt -69.42 113.07 6.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.049 0.452 . . . . 0.0 110.787 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ARG . . . . . 0.502 ' HD3' ' O ' ' A' ' 55' ' ' ARG . 0.0 OUTLIER -93.74 123.73 37.27 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.573 178.313 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.442 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 37.0 tt0 -49.08 134.43 17.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.247 0.546 . . . . 0.0 111.31 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 89.77 60.79 1.4 Allowed Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.734 -0.745 . . . . 0.0 111.681 -179.222 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.605 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.4 t0 -140.75 155.25 46.48 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 38' ' ' HIS . 13.3 tp -102.75 125.27 49.42 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.931 -179.414 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.433 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.5 mp -82.68 122.75 37.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.276 -179.386 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.435 ' O ' HG22 ' A' ' 68' ' ' VAL . 44.8 p -100.59 -34.1 10.03 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.652 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 75.2 m80 -146.04 162.53 37.68 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.081 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.3 p -145.89 114.83 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.65 177.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 57.58 32.57 22.03 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.766 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 68.98 47.44 54.47 Favored Glycine 0 N--CA 1.444 -0.768 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -178.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.41 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.9 tp10 -149.55 99.98 3.34 Favored Pre-proline 0 N--CA 1.442 -0.835 0 C-N-CA 122.834 0.454 . . . . 0.0 110.079 -179.077 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 80.4 Cg_exo -36.37 124.36 0.35 Allowed 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 124.424 3.416 . . . . 0.0 112.564 177.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 61' ' ' THR . 27.0 m -86.68 -11.11 11.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.055 -179.411 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.5 m170 -56.57 98.14 0.03 OUTLIER 'General case' 0 N--CA 1.425 -1.688 0 CA-C-N 112.83 -1.986 . . . . 0.0 111.301 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 109.51 -6.41 31.71 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.441 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 25.0 mt -79.01 137.76 37.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.717 0.259 . . . . 0.0 110.517 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -79.92 170.05 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.28 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.44 ' HD1' ' CB ' ' A' ' 23' ' ' ALA . 38.3 t60 -44.09 -54.4 5.56 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.643 0.735 . . . . 0.0 112.764 -179.452 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 21.1 p -73.53 -21.0 60.5 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 115.312 -0.858 . . . . 0.0 113.236 -176.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -68.4 -41.97 79.72 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 120.969 -0.292 . . . . 0.0 111.608 -179.051 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.665 HG21 ' HG ' ' A' ' 21' ' ' LEU . 3.4 m -66.39 -44.58 90.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.95 179.04 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.425 HG13 ' CD1' ' B' ' 113' ' ' LEU . 50.2 t -53.68 -47.99 60.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.826 177.465 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 56.8 mt-10 -63.6 -45.2 91.45 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.894 178.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.41 -40.48 65.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.294 0.569 . . . . 0.0 109.822 178.859 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.707 HG23 HG11 ' A' ' 87' ' ' VAL . 21.8 mt -70.58 -53.21 23.39 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.775 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.267 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 83.8 mt -57.57 -38.39 74.73 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 120.887 0.375 . . . . 0.0 111.294 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 17.8 ttmt -59.6 -37.96 79.95 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.753 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 34.8 t -56.25 -39.52 72.71 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.972 -179.286 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.63 -141.38 12.91 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.11 -1.043 . . . . 0.0 112.997 179.388 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 23.5 p30 -75.13 5.5 5.3 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -179.101 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 16.0 pttp -162.71 171.18 17.22 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.726 -0.215 . . . . 0.0 110.452 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.707 HG11 HG23 ' A' ' 80' ' ' ILE . 11.6 p -164.96 147.06 2.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.73 94.22 7.98 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.748 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.472 ' O ' ' HA ' ' A' ' 7' ' ' PRO . 4.5 tt -88.61 116.16 29.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.749 0.309 . . . . 0.0 110.492 179.277 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.1 OUTLIER -93.39 112.9 24.93 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.628 0.251 . . . . 0.0 111.508 -178.752 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.605 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 80.4 p -107.14 179.99 4.1 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 178.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.417 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 4.0 t -114.1 104.11 54.95 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-O 121.232 0.539 . . . . 0.0 112.322 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -56.31 175.53 0.25 Allowed 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.68 2.253 . . . . 0.0 113.344 178.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.436 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.1 OUTLIER -65.32 162.33 17.74 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.476 -179.715 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -160.3 154.73 23.66 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.143 179.57 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 12.8 p30 . . . . . 0 C--O 1.251 1.132 0 CA-C-O 118.532 -0.747 . . . . 0.0 110.535 -179.926 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.478 0.965 0 CA-C-O 120.636 0.255 . . . . 0.0 110.808 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 102' ' ' TRP . . . . . . . . . . . . . 6.5 t90 -174.76 115.68 0.17 Allowed 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.265 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -87.55 -85.58 0.17 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.884 178.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 5.3 m -138.7 -162.21 1.28 Allowed 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.209 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -115.03 97.25 6.11 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.171 0.51 . . . . 0.0 110.418 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 58.7 mttp -130.96 23.61 4.94 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.499 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.24 4.64 51.8 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.961 -179.68 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 151.42 -166.45 30.66 Favored Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.515 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -86.66 -143.02 7.37 Favored Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.192 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -131.53 39.36 3.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.192 0.52 . . . . 0.0 110.204 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 11.5 m -69.83 103.43 2.19 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.71 179.291 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 112' ' ' ARG . . . . . . . . . . . . . 6.1 ptm180 -95.39 168.09 10.93 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.969 -178.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 113' ' ' LEU . . . . . 0.516 ' OXT' ' HB2' ' A' ' 16' ' ' LYS . 3.4 mm? . . . . . 0 C--O 1.249 1.061 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.3 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 69.4 mtp 63.93 85.46 0.13 Allowed 'General case' 0 C--N 1.33 -0.241 0 O-C-N 123.869 0.731 . . . . 0.0 111.45 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.472 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 6.8 mpt_? -71.7 137.19 82.94 Favored Pre-proline 0 C--N 1.325 -0.485 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -88.05 113.94 0.84 Allowed 'Trans proline' 0 CA--C 1.53 0.304 0 C-N-CA 123.097 2.531 . . . . 0.0 113.134 -178.747 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.445 ' HA ' ' O ' ' A' ' 89' ' ' ILE . 13.0 Cg_exo -70.93 128.01 14.41 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.141 1.894 . . . . 0.0 112.681 178.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.66 HD13 ' HA ' ' A' ' 54' ' ' LEU . 3.1 mt -93.55 113.04 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.679 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mm -78.25 101.08 3.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.7 -178.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.674 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.4 mt -79.42 168.12 2.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 177.159 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . 0.57 ' N ' HG22 ' A' ' 10' ' ' ILE . 43.1 t-80 -145.88 114.38 6.75 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 178.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.9 ttt180 -66.48 99.57 0.58 Allowed 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.068 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.61 55.95 1.09 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.331 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.37 14.42 71.76 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.911 -0.586 . . . . 0.0 113.113 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.405 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 8.3 ptpt -140.48 -80.05 0.27 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 117.01 0.405 . . . . 0.0 111.777 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.405 ' H ' ' HG3' ' A' ' 15' ' ' LYS . 24.4 pttt -155.97 178.02 10.75 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.541 0.21 . . . . 0.0 111.192 -178.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . 0.674 ' HB3' HG21 ' A' ' 10' ' ' ILE . 23.2 m-85 -87.5 2.35 50.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.253 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.526 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 53.37 49.84 55.09 Favored Glycine 0 C--O 1.215 -1.083 0 N-CA-C 116.436 1.334 . . . . 0.0 116.436 176.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.499 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 11.4 p90 -163.91 146.53 9.48 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 122.34 1.067 . . . . 0.0 112.314 176.185 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.534 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 32.7 m -93.35 119.59 32.65 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 113.48 -1.691 . . . . 0.0 113.534 -178.242 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.561 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -92.63 84.16 5.0 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.783 0.325 . . . . 0.0 110.222 177.836 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.427 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 4.4 tpt180 . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.142 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 t . . . . . 0 C--O 1.235 0.293 0 CA-C-O 120.562 0.22 . . . . 0.0 110.685 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 13.5 m-70 -110.51 177.17 4.77 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.992 0.425 . . . . 0.0 110.752 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.64 ' CD2' HG11 ' A' ' 76' ' ' VAL . 98.5 m-70 -150.19 152.8 35.21 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.277 -0.874 . . . . 0.0 108.709 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . 0.426 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 44.6 mtm -147.53 141.7 26.12 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -178.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.711 HG11 HD21 ' A' ' 54' ' ' LEU . 2.5 p -73.14 103.19 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.981 0.896 . . . . 0.0 109.693 179.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.427 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 4.7 t-105 -69.28 -37.32 77.81 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.209 -1.359 . . . . 0.0 111.638 -178.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' HIS . . . . . 0.498 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 2.5 t60 -158.75 125.54 4.75 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.295 -178.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.3 p -121.47 124.78 72.55 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 CA-C-O 121.475 0.655 . . . . 0.0 109.746 178.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -63.72 109.31 1.66 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.524 -1.216 . . . . 0.0 111.922 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.585 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 8.8 p-10 -82.3 49.37 1.41 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.635 0.731 . . . . 0.0 109.708 179.008 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -131.05 13.62 5.49 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.447 -179.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.49 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 157.22 -68.79 0.28 Allowed Glycine 0 CA--C 1.523 0.546 0 C-N-CA 119.085 -1.531 . . . . 0.0 115.176 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_exo -60.18 -129.92 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 0 C-N-CA 123.748 2.965 . . . . 0.0 117.341 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.491 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -41.86 -38.79 1.62 Allowed 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 114.625 1.343 . . . . 0.0 114.625 -176.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.585 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 1.0 OUTLIER -62.17 -56.18 21.25 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.722 -178.844 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.49 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 7.3 mm-40 -63.45 -28.58 70.07 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.306 0.574 . . . . 0.0 110.432 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.46 -28.72 69.86 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.567 178.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.43 -5.15 5.57 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.931 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.711 HD21 HG11 ' A' ' 40' ' ' VAL . 1.7 tt -71.14 112.28 7.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.257 0.551 . . . . 0.0 111.463 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.96 120.81 32.26 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.704 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.498 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 33.2 tt0 -49.76 140.87 10.87 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.002 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.45 13.78 57.98 Favored Glycine 0 CA--C 1.52 0.357 0 C-N-CA 121.032 -0.604 . . . . 0.0 113.125 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.533 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 2.2 t0 -94.81 151.64 19.07 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.978 0.418 . . . . 0.0 111.116 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.522 HD12 ' O ' ' A' ' 38' ' ' HIS . 4.6 tp -98.26 129.94 44.98 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.192 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.559 HG12 HD11 ' A' ' 89' ' ' ILE . 3.8 mp -86.81 124.21 40.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.055 -179.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 66.3 p -100.4 -37.81 8.69 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.774 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.421 ' HB2' ' CB ' ' A' ' 90' ' ' SER . 59.1 m80 -143.11 162.54 35.27 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.927 -178.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.491 HG21 HG13 ' A' ' 80' ' ' ILE . 9.8 p -143.45 116.13 3.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.998 177.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 58.58 24.33 11.88 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.386 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.82 41.75 8.62 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.538 -178.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.522 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.1 tp10 -151.4 109.49 2.97 Favored Pre-proline 0 N--CA 1.434 -1.246 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.522 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 1.0 OUTLIER -47.29 128.88 15.18 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 123.947 3.098 . . . . 0.0 111.921 178.923 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.1 m -87.43 -13.76 10.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.165 0 CA-C-N 114.359 -1.291 . . . . 0.0 109.203 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 9.1 m170 -57.47 95.08 0.02 OUTLIER 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 112.846 -1.979 . . . . 0.0 111.163 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 119.41 -14.18 10.92 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.08 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 43.3 mt -76.01 142.52 41.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.592 0.234 . . . . 0.0 110.577 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.504 HG13 ' H ' ' A' ' 74' ' ' THR . 0.3 OUTLIER -78.08 169.66 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.882 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -42.42 -48.18 5.12 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.907 0.883 . . . . 0.0 113.119 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.504 ' H ' HG13 ' A' ' 72' ' ' VAL . 12.0 p -88.21 -15.45 35.93 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.038 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -68.4 -42.45 79.01 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 122.361 -0.212 . . . . 0.0 111.212 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.64 HG11 ' CD2' ' A' ' 38' ' ' HIS . 9.6 m -64.16 -46.36 93.76 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.233 0 CA-C-O 121.198 0.523 . . . . 0.0 110.0 179.275 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.589 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 72.8 t -55.18 -48.96 75.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.268 177.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -61.63 -44.01 97.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.161 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.19 -39.45 63.68 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-O 121.263 0.554 . . . . 0.0 109.937 178.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.576 HG23 HG11 ' A' ' 87' ' ' VAL . 14.3 mt -72.27 -50.34 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.807 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.589 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 39.6 mt -58.33 -36.85 74.01 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-O 121.329 0.585 . . . . 0.0 110.515 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 24.0 ttmt -60.34 -39.94 88.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.634 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 43.4 t -54.69 -36.47 64.69 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.359 -0.837 . . . . 0.0 111.49 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 127.85 -130.42 6.7 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.207 -0.997 . . . . 0.0 112.637 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 25.0 p30 -92.07 13.87 17.6 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.208 0.528 . . . . 0.0 111.047 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 19.5 pttp -163.47 176.69 9.53 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.064 179.347 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.576 HG11 HG23 ' A' ' 80' ' ' ILE . 8.6 p -171.81 145.99 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -179.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.417 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -92.38 95.82 9.89 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.276 -0.874 . . . . 0.0 111.108 178.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.58 HG22 ' O ' ' A' ' 8' ' ' ILE . 11.2 tt -89.09 113.64 25.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 120.945 0.403 . . . . 0.0 111.06 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.421 ' CB ' ' HB2' ' A' ' 62' ' ' HIS . 0.2 OUTLIER -87.52 110.14 20.12 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.929 0.395 . . . . 0.0 110.911 -179.535 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.533 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 40.0 p -108.32 164.37 12.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.151 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.446 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 2.1 t -99.78 105.51 34.89 Favored Pre-proline 0 C--N 1.328 -0.356 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -177.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 91' ' ' THR . 52.6 Cg_exo -54.64 176.2 0.12 Allowed 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 122.328 2.018 . . . . 0.0 113.089 178.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.01 164.05 13.52 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.695 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.321 -0.673 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.341 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.5 m . . . . . 0 N--CA 1.452 -0.339 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 84.9 mtp 58.31 79.76 0.2 Allowed 'General case' 0 N--CA 1.463 0.2 0 O-C-N 123.685 0.616 . . . . 0.0 111.483 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.499 ' HD2' ' H ' ' A' ' 5' ' ' ARG . 3.4 mpt_? -72.26 132.5 84.11 Favored Pre-proline 0 C--N 1.325 -0.498 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.497 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 3.6 Cg_exo -83.46 114.33 2.1 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 123.059 2.506 . . . . 0.0 112.745 -178.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 13.6 Cg_exo -70.84 124.31 10.52 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.245 1.963 . . . . 0.0 112.381 178.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.587 ' O ' HG22 ' A' ' 89' ' ' ILE . 5.2 mt -91.46 111.02 23.28 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.079 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mm -77.79 101.45 3.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -177.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.552 HG12 ' CB ' ' A' ' 49' ' ' ALA . 5.3 mt -78.05 164.95 3.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 177.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . 0.533 ' N ' HG22 ' A' ' 10' ' ' ILE . 32.7 t-80 -142.78 114.29 7.95 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.8 ttt180 -63.39 114.09 3.65 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.401 0.62 . . . . 0.0 110.725 -179.504 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -84.67 43.82 1.01 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.185 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.55 3.95 83.9 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.735 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.3 ptpt -127.64 -82.65 0.6 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.699 0.285 . . . . 0.0 111.138 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.525 ' HE2' ' OE1' ' A' ' 44' ' ' GLU . 22.7 pttm -158.51 -179.55 8.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.924 -178.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . 0.516 ' HA ' ' HB3' ' A' ' 48' ' ' PRO . 12.8 m-85 -89.98 -0.41 57.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.524 0.678 . . . . 0.0 109.182 179.214 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.404 ' HA3' ' HB2' ' A' ' 44' ' ' GLU . . . 64.98 -24.92 0.11 Allowed Glycine 0 C--N 1.331 0.274 0 N-CA-C 116.704 1.442 . . . . 0.0 116.704 177.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.575 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.7 p90 -81.96 142.48 32.38 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 122.615 1.197 . . . . 0.0 113.636 -176.562 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 58.6 m -93.14 114.65 27.21 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 113.225 -1.807 . . . . 0.0 111.481 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.649 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -86.4 84.28 7.48 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 178.752 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.589 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 1.9 tpt180 . . . . . 0 C--N 1.327 -0.387 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.936 -179.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.6 t . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 120.898 0.38 . . . . 0.0 110.656 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 8.0 m-70 -108.63 -174.0 2.41 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.465 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.438 ' O ' HD12 ' A' ' 59' ' ' LEU . 99.1 m-70 -151.39 161.61 42.39 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -179.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . 0.474 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 68.5 mtm -150.02 144.79 26.02 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.755 0.312 . . . . 0.0 110.488 -178.566 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.508 HG11 ' CD2' ' A' ' 54' ' ' LEU . 2.7 p -74.41 104.5 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-O 121.823 0.82 . . . . 0.0 109.67 179.202 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.589 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 5.3 t-105 -69.82 -40.09 76.1 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.659 -1.155 . . . . 0.0 112.167 -178.389 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' HIS . . . . . 0.511 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.8 t60 -158.91 127.82 5.39 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.329 -178.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.575 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 2.4 p -120.93 129.33 75.8 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.109 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.525 ' OE1' ' HE2' ' A' ' 16' ' ' LYS . 27.5 mt-10 -64.09 113.12 3.31 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.911 -179.049 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.65 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 9.4 p-10 -84.88 34.33 0.54 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.134 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -124.3 17.07 7.52 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.151 -1.024 . . . . 0.0 113.926 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.04 -64.99 0.28 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 118.884 -1.627 . . . . 0.0 115.049 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.516 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 49.6 Cg_exo -62.36 -133.33 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.316 2.677 . . . . 0.0 116.913 -177.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.552 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -43.33 -35.48 1.52 Allowed 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 -176.578 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.65 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 2.0 m -63.42 -53.32 54.21 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 118.399 0.545 . . . . 0.0 111.674 -178.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -63.2 -30.96 72.01 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-O 121.52 0.676 . . . . 0.0 109.807 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.15 -31.75 73.07 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.913 -1.039 . . . . 0.0 110.067 178.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.65 -5.87 5.52 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.551 179.749 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.582 HD11 HD13 ' A' ' 89' ' ' ILE . 1.1 tt -67.02 117.28 8.86 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.249 0.547 . . . . 0.0 111.44 -179.455 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.435 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -91.19 121.78 33.26 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.311 178.821 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -51.85 138.95 23.03 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.597 177.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.19 15.98 56.5 Favored Glycine 0 CA--C 1.52 0.399 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.713 -179.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.623 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 5.2 t0 -94.28 153.87 17.81 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.773 0.32 . . . . 0.0 110.553 179.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.474 ' HA ' ' HG2' ' A' ' 39' ' ' MET . 4.8 tp -101.02 128.46 47.05 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.589 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.505 ' CG1' HD11 ' A' ' 89' ' ' ILE . 4.0 mp -85.42 124.46 40.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.88 -179.652 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 64.6 p -101.88 -39.95 7.13 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.351 0.596 . . . . 0.0 110.519 179.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 62.0 m80 -139.75 157.19 46.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.969 -178.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.424 ' O ' HG13 ' A' ' 63' ' ' VAL . 7.6 p -139.82 109.73 3.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.562 178.004 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 61.73 30.64 18.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.654 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.38 45.44 18.8 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -178.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.481 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 4.0 tp10 -149.84 105.11 3.22 Favored Pre-proline 0 N--CA 1.436 -1.166 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.481 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.2 Cg_endo -49.97 127.85 20.43 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 123.474 2.783 . . . . 0.0 111.264 178.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.7 m -88.7 -11.25 10.49 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.644 -179.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -55.25 93.77 0.01 OUTLIER 'General case' 0 N--CA 1.427 -1.6 0 CA-C-N 113.029 -1.896 . . . . 0.0 111.806 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 114.41 -10.03 22.1 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.523 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 25.6 mt -75.66 145.05 41.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.783 0.325 . . . . 0.0 110.295 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.537 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.5 OUTLIER -77.91 166.48 2.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.727 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.415 ' O ' HG22 ' A' ' 76' ' ' VAL . 77.8 t60 -46.04 -52.74 11.39 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.966 0.888 . . . . 0.0 112.3 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.2 p -72.57 -19.71 61.45 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 114.986 -1.006 . . . . 0.0 112.868 -176.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.537 ' HG3' HG12 ' A' ' 72' ' ' VAL . 21.5 mt-10 -70.69 -42.97 69.98 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 121.218 -0.193 . . . . 0.0 110.97 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.649 HG21 ' HG ' ' A' ' 21' ' ' LEU . 15.5 m -64.8 -47.22 89.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.132 0 C-N-CA 120.354 -0.538 . . . . 0.0 109.764 179.273 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.536 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 48.6 t -54.71 -45.79 73.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.077 177.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.447 ' O ' ' HB2' ' A' ' 82' ' ' LYS . 17.9 mt-10 -63.15 -44.6 95.07 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.633 179.092 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -54.37 -41.14 68.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.207 0.527 . . . . 0.0 110.313 179.247 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.557 HG23 HG11 ' A' ' 87' ' ' VAL . 18.5 mt -69.3 -51.83 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.224 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 61.4 mt -59.74 -36.24 76.2 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.183 0.516 . . . . 0.0 110.477 179.095 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 78' ' ' GLU . 25.5 ttmt -59.37 -41.38 89.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.63 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 38.4 t -54.82 -36.47 65.03 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.527 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 127.01 -121.31 3.89 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 119.86 -1.162 . . . . 0.0 113.859 178.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -98.57 8.97 44.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.24 0.543 . . . . 0.0 110.893 -179.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 16.5 pttp -161.72 174.83 12.69 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.006 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.557 HG11 HG23 ' A' ' 80' ' ' ILE . 9.2 p -169.21 146.14 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.405 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -92.67 93.8 8.68 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.282 -0.872 . . . . 0.0 111.007 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.587 HG22 ' O ' ' A' ' 8' ' ' ILE . 9.3 tt -87.39 111.39 21.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 121.122 0.486 . . . . 0.0 110.659 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.438 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -89.43 106.9 18.76 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.716 0.293 . . . . 0.0 110.67 -179.291 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.623 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 81.5 p -104.51 169.13 8.65 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.839 179.396 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.451 HG22 ' HB3' ' A' ' 59' ' ' LEU . 8.6 t -100.01 107.24 45.89 Favored Pre-proline 0 CA--C 1.537 0.448 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 -177.264 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.418 ' HD3' ' O ' ' A' ' 91' ' ' THR . 76.3 Cg_exo -54.84 174.6 0.19 Allowed 'Trans proline' 0 C--N 1.352 0.715 0 C-N-CA 122.345 2.03 . . . . 0.0 113.012 177.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.48 167.72 8.36 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.17 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.326 -0.44 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.968 179.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.4 m . . . . . 0 C--O 1.233 0.191 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 91.1 mtp 60.23 78.34 0.28 Allowed 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.686 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.494 ' HD2' ' H ' ' A' ' 5' ' ' ARG . 4.6 mpt_? -71.25 137.46 84.21 Favored Pre-proline 0 C--N 1.323 -0.581 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 179.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 2.9 Cg_endo -84.57 112.67 1.6 Allowed 'Trans proline' 0 N--CA 1.462 -0.334 0 C-N-CA 122.92 2.414 . . . . 0.0 112.813 -178.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.464 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 17.4 Cg_exo -68.48 125.83 13.36 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.227 1.951 . . . . 0.0 112.526 178.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.573 ' O ' HG22 ' A' ' 89' ' ' ILE . 5.9 mt -92.85 115.82 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.5 mm -79.23 104.26 7.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 CA-C-N 116.191 -0.458 . . . . 0.0 112.208 -178.118 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.657 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.5 mt -80.14 160.73 4.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 176.341 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . 0.523 ' N ' HG22 ' A' ' 10' ' ' ILE . 39.8 t-80 -141.75 114.31 8.37 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.661 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 53.2 ttt180 -63.44 98.14 0.16 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.773 -179.678 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.89 55.77 2.17 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.357 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.28 7.56 77.96 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.826 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.456 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 10.9 ptpt -132.47 -87.73 0.45 Allowed 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.855 -0.203 . . . . 0.0 111.272 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.456 ' H ' ' HG3' ' A' ' 15' ' ' LYS . 32.1 pttt -155.5 -172.62 4.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.454 0.169 . . . . 0.0 110.717 -178.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . 0.657 ' HB3' HG21 ' A' ' 10' ' ' ILE . 21.0 m-85 -88.17 2.12 52.85 Favored 'General case' 0 CA--C 1.519 -0.236 0 CA-C-O 121.062 0.458 . . . . 0.0 109.925 179.443 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.505 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 52.2 49.79 48.86 Favored Glycine 0 C--O 1.219 -0.821 0 N-CA-C 116.728 1.451 . . . . 0.0 116.728 176.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.498 ' HB3' HG23 ' A' ' 43' ' ' VAL . 8.1 p90 -164.21 148.86 10.0 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-O 122.345 1.069 . . . . 0.0 112.477 176.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 42.3 m -94.63 113.99 25.88 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 113.722 -1.581 . . . . 0.0 112.806 -179.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.612 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -88.1 82.85 7.07 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.939 0.4 . . . . 0.0 109.941 178.294 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.542 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 3.6 tpt180 . . . . . 0 C--N 1.323 -0.555 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.727 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 t . . . . . 0 N--CA 1.454 -0.269 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 -113.5 -179.06 3.53 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.28 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.569 ' CD2' HG11 ' A' ' 76' ' ' VAL . 94.4 m-70 -149.66 153.57 37.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . 0.466 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 27.2 mtm -148.57 145.5 27.85 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -178.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.512 HG11 ' CD2' ' A' ' 54' ' ' LEU . 3.4 p -73.25 103.32 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 CA-C-O 122.006 0.908 . . . . 0.0 109.793 179.274 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.542 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.6 t-105 -70.65 -40.37 73.07 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.468 -1.242 . . . . 0.0 111.499 -178.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' HIS . . . . . 0.497 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 1.9 t60 -156.64 132.09 9.35 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.952 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 18' ' ' GLY . 5.1 p -127.96 125.48 64.81 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.012 0 CA-C-O 121.919 0.866 . . . . 0.0 110.348 178.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.484 ' O ' ' HB2' ' A' ' 50' ' ' SER . 28.3 mt-10 -65.24 114.09 4.47 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 114.284 -1.325 . . . . 0.0 112.117 -178.566 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.544 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 10.6 p-10 -83.65 46.07 1.12 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.646 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -119.44 -2.77 13.16 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.399 -0.905 . . . . 0.0 113.595 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.63 -59.09 0.27 Allowed Glycine 0 CA--C 1.521 0.411 0 C-N-CA 119.119 -1.515 . . . . 0.0 114.884 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -59.24 -130.98 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 0.98 0 C-N-CA 123.463 2.776 . . . . 0.0 116.593 -178.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.524 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -43.69 -40.81 4.43 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 114.382 1.253 . . . . 0.0 114.382 -176.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.544 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -60.03 -59.99 4.55 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -178.312 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -63.37 -28.62 70.12 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.064 0.459 . . . . 0.0 110.713 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.13 -29.99 70.72 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.947 178.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 135.69 -9.28 4.28 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.767 179.444 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.512 ' CD2' HG11 ' A' ' 40' ' ' VAL . 0.9 OUTLIER -68.34 117.76 10.54 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.374 0.607 . . . . 0.0 111.42 -179.615 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -92.85 121.24 34.03 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.726 178.419 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.497 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 37.1 tt0 -50.13 135.09 21.47 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.15 59.5 1.75 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.569 -0.824 . . . . 0.0 111.231 -178.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.429 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 3.4 t0 -142.81 147.58 35.71 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.496 HD12 ' O ' ' A' ' 38' ' ' HIS . 10.9 tp -92.95 131.28 38.09 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.408 -179.541 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.481 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.6 mp -89.13 125.35 42.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.9 p -101.87 -40.02 7.11 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.259 0.552 . . . . 0.0 110.799 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -139.76 158.44 44.09 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.591 -179.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 63' ' ' VAL . 7.6 p -141.62 110.4 2.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-O 121.11 0.481 . . . . 0.0 109.981 178.149 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.9 t30 59.49 33.91 22.37 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.093 179.399 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.0 42.26 25.27 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.17 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.502 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 5.6 tp10 -151.37 106.67 2.95 Favored Pre-proline 0 N--CA 1.434 -1.234 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.502 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.2 Cg_endo -50.4 129.1 25.09 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.557 2.838 . . . . 0.0 110.962 178.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 20.2 m -85.85 -13.31 11.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.258 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.0 m170 -56.6 96.98 0.02 OUTLIER 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 112.732 -2.031 . . . . 0.0 110.835 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.94 -12.88 26.93 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.405 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 21.7 mt -76.1 141.61 41.93 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.571 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -75.46 165.65 3.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.292 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -42.97 -55.19 3.87 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-O 121.765 0.793 . . . . 0.0 112.82 -179.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.0 p -74.53 -16.96 60.81 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 114.93 -1.032 . . . . 0.0 113.04 -176.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.571 ' HG3' HG12 ' A' ' 72' ' ' VAL . 24.3 mt-10 -70.57 -42.03 71.64 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 120.95 -0.3 . . . . 0.0 111.121 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.612 HG21 ' HG ' ' A' ' 21' ' ' LEU . 15.6 m -65.59 -46.44 89.54 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.471 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 60.9 t -53.05 -48.59 52.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.632 176.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -63.47 -44.44 94.45 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.847 179.266 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.38 -42.01 66.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.269 0.557 . . . . 0.0 109.933 178.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.568 HG23 HG11 ' A' ' 87' ' ' VAL . 22.7 mt -67.35 -48.83 76.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.621 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 50.2 mt -60.84 -39.4 88.94 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-O 121.032 0.444 . . . . 0.0 110.657 178.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 23.1 ttmt -60.35 -40.5 90.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.142 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 41.4 t -54.22 -31.79 54.16 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.714 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 129.52 -127.81 5.56 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.672 179.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -99.1 10.53 41.27 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.432 0.634 . . . . 0.0 110.413 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.415 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 17.3 pttp -161.99 172.51 15.85 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.862 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.568 HG11 HG23 ' A' ' 80' ' ' ILE . 8.5 p -168.03 149.82 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -178.326 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.464 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -93.37 97.66 10.72 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.309 178.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.573 HG22 ' O ' ' A' ' 8' ' ' ILE . 10.2 tt -89.62 112.91 25.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 120.884 0.373 . . . . 0.0 110.862 179.392 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.9 OUTLIER -88.67 105.02 17.4 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.729 0.3 . . . . 0.0 111.296 -179.008 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.502 ' O ' ' HD3' ' A' ' 93' ' ' PRO . 42.3 p -102.36 163.2 12.37 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.436 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 1.6 t -98.65 104.92 27.18 Favored Pre-proline 0 C--N 1.326 -0.439 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.502 ' HD3' ' O ' ' A' ' 91' ' ' THR . 73.2 Cg_exo -53.73 176.06 0.1 Allowed 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.503 2.135 . . . . 0.0 113.036 178.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -64.26 166.12 8.48 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.319 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.321 -0.657 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.899 -179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.452 -0.354 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 37.8 mtp 55.85 78.93 0.18 Allowed 'General case' 0 C--O 1.235 0.336 0 O-C-N 123.58 0.55 . . . . 0.0 111.471 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.475 ' HD2' ' H ' ' A' ' 5' ' ' ARG . 4.0 mpt_? -70.92 137.47 85.07 Favored Pre-proline 0 C--N 1.325 -0.464 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.0 OUTLIER -86.93 111.08 0.87 Allowed 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.795 2.33 . . . . 0.0 112.899 -178.284 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.532 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 15.5 Cg_exo -69.12 119.87 6.8 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 121.935 1.756 . . . . 0.0 112.15 178.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.616 ' O ' HG22 ' A' ' 89' ' ' ILE . 7.0 mt -87.85 110.94 21.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-N 115.07 -0.968 . . . . 0.0 108.967 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.2 mm -76.77 101.45 2.93 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.825 -0.625 . . . . 0.0 112.045 -178.045 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.676 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.2 mt -78.92 159.27 4.64 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.368 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 176.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . 0.506 ' N ' HG22 ' A' ' 10' ' ' ILE . 15.1 t-80 -135.44 109.98 8.54 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 178.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.1 ttt180 -64.64 100.71 0.4 Allowed 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.419 -0.81 . . . . 0.0 111.05 -179.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.95 55.68 1.81 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.275 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.7 -45.31 3.38 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.479 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.2 ptpt -79.23 -85.79 0.08 Allowed 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 23.7 pttt -157.29 -174.09 4.73 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.52 0.193 . . . . 0.0 111.52 -178.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . 0.676 ' HB3' HG21 ' A' ' 10' ' ' ILE . 21.4 m-85 -85.49 2.42 44.74 Favored 'General case' 0 CA--C 1.518 -0.25 0 CA-C-O 121.103 0.478 . . . . 0.0 109.757 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.559 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 51.04 53.54 26.6 Favored Glycine 0 C--O 1.215 -1.044 0 N-CA-C 116.124 1.21 . . . . 0.0 116.124 177.328 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.478 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 12.4 p90 -163.94 149.03 10.54 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 122.744 1.259 . . . . 0.0 112.965 176.156 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.502 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 40.5 m -95.16 117.48 30.29 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 112.904 -1.953 . . . . 0.0 113.109 -178.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.493 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.4 OUTLIER -94.45 80.78 3.91 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 178.286 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.509 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 1.6 tpt180 . . . . . 0 C--N 1.327 -0.376 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.995 -179.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.6 t . . . . . 0 N--CA 1.45 -0.46 0 CA-C-O 120.907 0.384 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 89.2 m-70 -125.43 -177.73 3.99 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.464 179.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.551 ' CD2' HG11 ' A' ' 76' ' ' VAL . 98.0 m-70 -147.71 154.7 40.9 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -179.269 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 35.4 mtm -149.13 146.56 27.74 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -178.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.585 HG11 HD21 ' A' ' 54' ' ' LEU . 2.6 p -74.0 101.75 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.976 0.893 . . . . 0.0 109.774 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.509 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 2.9 t-105 -70.39 -39.21 74.67 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.37 -178.598 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' HIS . . . . . 0.44 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -156.53 129.57 7.92 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.975 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.559 HG23 ' O ' ' A' ' 18' ' ' GLY . 3.8 p -124.28 127.06 73.02 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.555 0.693 . . . . 0.0 110.248 179.06 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -66.64 113.23 4.64 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 114.507 -1.224 . . . . 0.0 112.043 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.558 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 10.4 p-10 -81.5 40.2 0.57 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.918 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -108.15 -8.75 28.93 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.376 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.407 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 160.55 -49.91 0.37 Allowed Glycine 0 CA--C 1.526 0.761 0 C-N-CA 119.491 -1.338 . . . . 0.0 114.867 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -60.11 -128.98 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.09 0 C-N-CA 123.094 2.529 . . . . 0.0 116.233 -179.223 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.504 ' HA ' HG12 ' A' ' 10' ' ' ILE . . . -45.12 -39.97 6.49 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 114.195 1.183 . . . . 0.0 114.195 -177.113 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.558 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 5.5 m -57.34 -62.86 1.47 Allowed 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -179.158 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.407 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 9.5 mm-40 -63.25 -23.15 67.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.295 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.66 -26.16 66.07 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.256 178.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 130.21 -8.36 5.99 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.677 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.585 HD21 HG11 ' A' ' 40' ' ' VAL . 1.1 tt -70.0 117.99 12.28 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-O 121.435 0.636 . . . . 0.0 111.324 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.404 ' H ' ' HG3' ' A' ' 55' ' ' ARG . 0.0 OUTLIER -96.45 121.52 38.35 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.941 178.357 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.434 ' HB2' HG12 ' A' ' 43' ' ' VAL . 46.3 tt0 -50.45 141.14 12.59 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.771 0.319 . . . . 0.0 111.51 178.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.24 6.0 63.31 Favored Glycine 0 C--N 1.333 0.415 0 C-N-CA 121.239 -0.505 . . . . 0.0 113.231 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.537 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 2.0 t0 -89.9 155.71 18.95 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.032 0.444 . . . . 0.0 111.036 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.489 HD12 ' O ' ' A' ' 38' ' ' HIS . 2.5 tp -100.14 133.97 43.75 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.7 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.502 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.5 mp -91.26 122.74 42.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 26.2 p -99.7 -40.61 7.68 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.401 0.619 . . . . 0.0 110.361 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 72.7 m80 -138.28 157.21 46.71 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.761 -178.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.57 111.51 5.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.965 -0.562 . . . . 0.0 109.889 178.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 60.39 30.04 19.49 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.811 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.46 44.29 17.14 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.182 -179.036 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.472 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.1 tp10 -149.99 106.26 3.21 Favored Pre-proline 0 N--CA 1.437 -1.084 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 -179.066 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.472 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 4.4 Cg_endo -49.62 129.32 23.22 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.66 2.907 . . . . 0.0 111.124 178.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 22.3 m -86.82 -7.96 10.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 114.594 -1.185 . . . . 0.0 109.039 -178.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 22.1 m170 -55.17 101.01 0.04 OUTLIER 'General case' 0 N--CA 1.426 -1.629 0 CA-C-N 112.741 -2.027 . . . . 0.0 111.676 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.68 -6.77 49.07 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.842 179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 26.3 mt -78.29 141.41 38.53 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.669 0.271 . . . . 0.0 110.469 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.674 HG12 ' HG3' ' A' ' 75' ' ' GLU . 2.0 p -78.58 169.82 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 177.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.428 ' O ' HG23 ' A' ' 77' ' ' VAL . 8.6 t60 -48.19 -53.62 16.28 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.682 0.753 . . . . 0.0 112.352 -179.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 16.7 p -69.44 -22.66 63.64 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.192 -0.913 . . . . 0.0 112.456 -177.247 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.674 ' HG3' HG12 ' A' ' 72' ' ' VAL . 24.4 mt-10 -69.06 -43.28 74.94 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 121.224 -0.191 . . . . 0.0 111.476 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.551 HG11 ' CD2' ' A' ' 38' ' ' HIS . 10.0 m -66.24 -44.61 91.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.726 178.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 73' ' ' HIS . 54.0 t -56.57 -47.26 82.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.929 177.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -62.78 -43.46 98.73 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.55 178.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.38 -40.75 65.26 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.339 0.59 . . . . 0.0 109.915 178.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.633 HG23 HG11 ' A' ' 87' ' ' VAL . 28.1 mt -68.84 -51.58 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.889 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 64.1 mt -59.88 -36.03 76.08 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.1 0.476 . . . . 0.0 110.644 179.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -57.91 -39.15 77.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.231 -0.895 . . . . 0.0 111.58 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 34.0 t -56.21 -44.87 79.91 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.244 179.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 136.29 -116.61 1.48 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.323 -0.941 . . . . 0.0 113.71 178.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -102.85 9.1 39.1 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.475 0.655 . . . . 0.0 110.506 -178.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 10.1 pttp -161.36 173.53 14.82 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.499 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.633 HG11 HG23 ' A' ' 80' ' ' ILE . 10.4 p -167.76 145.13 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -179.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.532 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -91.15 96.22 10.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.37 178.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.616 HG22 ' O ' ' A' ' 8' ' ' ILE . 11.1 tt -88.72 111.08 22.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.196 0.522 . . . . 0.0 110.831 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.93 106.0 17.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.982 -179.089 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.537 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 64.6 p -102.33 170.86 7.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.21 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.428 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 4.9 t -104.85 99.95 21.41 Favored Pre-proline 0 CA--C 1.534 0.358 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -178.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' ' 91' ' ' THR . 74.6 Cg_exo -51.73 167.63 0.41 Allowed 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.487 2.125 . . . . 0.0 113.204 178.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.431 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.0 OUTLIER -63.75 158.71 21.01 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.953 -179.937 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.327 -0.392 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.529 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 53.2 m . . . . . 0 N--CA 1.453 -0.288 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 9.0 mtp 60.65 77.53 0.32 Allowed 'General case' 0 C--O 1.233 0.185 0 O-C-N 123.476 0.485 . . . . 0.0 111.619 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.455 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.0 mpt_? -73.26 136.86 78.6 Favored Pre-proline 0 C--N 1.326 -0.421 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 179.198 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.5 Cg_endo -89.22 110.02 0.48 Allowed 'Trans proline' 0 C--O 1.235 0.326 0 C-N-CA 123.196 2.597 . . . . 0.0 113.021 -179.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.488 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 16.9 Cg_exo -69.78 122.52 9.19 Favored 'Trans proline' 0 CA--C 1.515 -0.453 0 C-N-CA 122.327 2.018 . . . . 0.0 113.112 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.549 HD13 ' HA ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -87.42 112.0 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.258 0 CA-C-N 115.129 -0.941 . . . . 0.0 108.778 178.317 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.401 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 3.2 mm -77.5 101.42 3.37 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.336 -178.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.672 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.4 mt -77.81 162.65 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 N-CA-C 106.904 -1.517 . . . . 0.0 106.904 176.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . 0.544 ' N ' HG22 ' A' ' 10' ' ' ILE . 15.0 t-80 -140.79 113.15 7.97 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 47.2 ttt180 -63.39 101.7 0.34 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.995 -178.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.12 49.95 1.0 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.45 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.12 12.7 81.5 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 121.199 -0.524 . . . . 0.0 113.1 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 3.8 ptpt -136.51 -82.59 0.38 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.849 0.325 . . . . 0.0 111.12 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 8.6 pttt -156.16 -179.59 8.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.421 -178.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . 0.672 ' HB3' HG21 ' A' ' 10' ' ' ILE . 19.3 m-85 -86.58 5.34 36.14 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-O 121.245 0.545 . . . . 0.0 110.191 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.576 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 54.46 49.22 61.49 Favored Glycine 0 C--O 1.215 -1.069 0 N-CA-C 116.697 1.439 . . . . 0.0 116.697 176.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.482 ' HB2' HG23 ' A' ' 40' ' ' VAL . 9.3 p90 -165.6 149.23 8.07 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-O 122.345 1.069 . . . . 0.0 113.068 176.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.427 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 94.8 m -95.25 118.37 31.91 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 113.643 -1.617 . . . . 0.0 112.724 -179.161 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.559 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -89.91 84.86 6.24 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.802 0.334 . . . . 0.0 110.248 178.511 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.566 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 5.1 tpt180 . . . . . 0 C--N 1.328 -0.352 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.222 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 6.2 t . . . . . 0 C--O 1.234 0.28 0 CA-C-O 120.676 0.274 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -117.82 177.97 4.58 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.517 ' CD2' HG11 ' A' ' 76' ' ' VAL . 98.7 m-70 -148.15 153.35 38.71 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 -179.509 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.0 mtm -147.24 145.25 29.38 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.083 -178.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.564 HG11 ' CD2' ' A' ' 54' ' ' LEU . 3.4 p -73.33 102.52 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.71 0 CA-C-O 121.946 0.879 . . . . 0.0 109.576 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.566 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 2.5 t-105 -70.48 -39.36 74.26 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.699 -1.137 . . . . 0.0 111.89 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' HIS . . . . . 0.461 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 4.3 t60 -155.23 124.5 6.3 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.368 -178.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.2 p -122.04 124.92 72.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-O 121.575 0.702 . . . . 0.0 109.975 179.258 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.504 ' OE1' ' HA2' ' A' ' 18' ' ' GLY . 49.3 mt-10 -66.99 120.12 13.11 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 114.396 -1.275 . . . . 0.0 111.307 -179.391 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.555 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 14.7 p-10 -85.84 24.8 1.2 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.84 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -82.98 -23.4 55.54 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.959 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 170.92 -51.78 0.19 Allowed Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 119.568 -1.301 . . . . 0.0 114.745 -179.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -55.33 -128.45 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.085 0 C-N-CA 123.505 2.803 . . . . 0.0 116.92 -178.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.473 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -45.23 -40.01 6.97 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 -176.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.555 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -60.5 -61.08 2.85 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -177.956 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 5.5 mm-40 -61.01 -32.49 72.08 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.372 0.606 . . . . 0.0 110.781 -178.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -60.34 -29.84 69.14 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.677 179.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 136.8 -11.84 3.95 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.511 -0.852 . . . . 0.0 113.092 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.564 ' CD2' HG11 ' A' ' 40' ' ' VAL . 0.8 OUTLIER -68.08 116.04 8.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.406 0.622 . . . . 0.0 111.074 -179.642 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.44 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -93.77 125.56 38.45 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.026 178.975 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -51.42 140.18 18.14 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.876 0.37 . . . . 0.0 111.036 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.71 10.09 67.72 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.95 -0.643 . . . . 0.0 113.161 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.562 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 5.3 t0 -88.5 148.91 23.91 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.0 0.429 . . . . 0.0 110.659 179.59 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.432 HD12 ' O ' ' A' ' 38' ' ' HIS . 10.1 tp -95.91 130.03 42.99 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.726 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.504 HG12 HD11 ' A' ' 89' ' ' ILE . 3.6 mp -88.15 126.14 41.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.127 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 41.9 p -102.8 -38.62 7.35 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.646 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -141.23 159.49 42.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.922 -178.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.404 HG21 HG13 ' A' ' 80' ' ' ILE . 7.3 p -140.65 111.14 3.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.125 0.488 . . . . 0.0 110.208 178.238 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.409 ' HA ' ' HB3' ' A' ' 88' ' ' ALA . 2.8 t30 60.76 26.34 16.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.372 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.18 44.41 7.57 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.935 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.496 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.5 tp10 -153.19 110.5 2.64 Favored Pre-proline 0 N--CA 1.433 -1.312 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.519 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.496 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 3.7 Cg_endo -49.99 131.88 31.24 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 123.725 2.95 . . . . 0.0 111.407 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.5 m -88.23 -8.61 10.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.289 -178.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -56.75 94.85 0.01 OUTLIER 'General case' 0 N--CA 1.429 -1.51 0 CA-C-N 112.95 -1.932 . . . . 0.0 111.566 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 112.47 -11.82 25.91 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.435 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 29.7 mt -74.87 138.82 42.72 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 179.527 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.507 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.8 OUTLIER -77.79 167.19 2.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.276 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 48.2 t60 -44.75 -46.42 10.46 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.779 0.8 . . . . 0.0 112.939 -179.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.496 ' H ' HG13 ' A' ' 72' ' ' VAL . 19.3 p -80.51 -21.06 42.27 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.274 -0.875 . . . . 0.0 112.755 -176.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.507 ' HG3' HG12 ' A' ' 72' ' ' VAL . 25.5 mt-10 -70.23 -40.31 74.56 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 121.319 -0.153 . . . . 0.0 111.354 -179.626 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.559 HG21 ' HG ' ' A' ' 21' ' ' LEU . 4.5 m -65.45 -45.76 91.97 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.183 0 C-N-CA 120.251 -0.58 . . . . 0.0 109.597 178.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 99.5 t -55.24 -47.02 78.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.187 -0.915 . . . . 0.0 109.926 177.239 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -64.81 -43.97 91.41 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.607 179.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.48 -42.08 66.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.768 178.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.677 HG23 HG11 ' A' ' 87' ' ' VAL . 16.2 mt -67.81 -52.15 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.719 179.484 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 93.1 mt -59.95 -32.78 71.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.017 179.312 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 8.3 ttmm -61.55 -38.91 89.19 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.352 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 36.2 t -56.0 -52.99 62.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.961 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 137.73 -134.43 6.96 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 119.96 -1.114 . . . . 0.0 113.132 179.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -73.67 -2.01 21.37 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.853 0.358 . . . . 0.0 111.799 -179.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -159.93 175.26 13.26 Favored 'General case' 0 N--CA 1.444 -0.773 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.503 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.677 HG11 HG23 ' A' ' 80' ' ' ILE . 13.4 p -166.84 147.1 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 O-C-N 123.596 0.56 . . . . 0.0 112.465 -179.062 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.488 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -93.51 96.76 10.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.642 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.543 HG22 ' O ' ' A' ' 8' ' ' ILE . 6.9 tt -88.8 111.57 22.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 120.973 0.416 . . . . 0.0 110.255 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -89.11 112.25 23.19 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.825 0.345 . . . . 0.0 111.074 -178.908 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.562 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 61.3 p -109.76 171.73 7.27 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.306 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.9 t -104.21 105.48 49.34 Favored Pre-proline 0 CA--C 1.537 0.464 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -55.73 175.24 0.22 Allowed 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.622 2.215 . . . . 0.0 113.403 178.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.402 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.0 OUTLIER -63.71 159.95 18.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.287 -179.647 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.347 0 CA-C-O 121.073 0.463 . . . . 0.0 110.677 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.0 m . . . . . 0 N--CA 1.453 -0.276 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 28.6 mtp 57.06 74.05 0.43 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.008 0.432 . . . . 0.0 111.3 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.49 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.6 mpt_? -73.31 135.53 79.23 Favored Pre-proline 0 C--N 1.32 -0.692 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.49 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.9 Cg_endo -87.31 116.88 1.22 Allowed 'Trans proline' 0 N--CA 1.462 -0.371 0 C-N-CA 123.3 2.666 . . . . 0.0 112.842 -178.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.466 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 7.5 Cg_exo -75.12 122.08 6.93 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.078 1.852 . . . . 0.0 112.843 178.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.62 HD13 ' HA ' ' A' ' 54' ' ' LEU . 2.3 mt -86.71 112.41 22.91 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.356 178.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.8 mm -79.06 99.74 3.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.218 -0.446 . . . . 0.0 112.049 -178.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.695 HG21 ' HB3' ' A' ' 17' ' ' TYR . 4.3 mt -77.64 160.47 4.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 177.059 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . 0.523 ' N ' HG22 ' A' ' 10' ' ' ILE . 24.8 t-80 -138.17 111.59 8.06 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.01 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . 0.422 HH11 ' HD3' ' A' ' 12' ' ' ARG . 30.8 ttt180 -62.89 103.71 0.47 Allowed 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.838 -179.009 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.77 47.7 0.76 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.482 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.17 -4.86 65.04 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.287 -0.482 . . . . 0.0 113.344 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.8 ptpt -120.61 -80.12 0.62 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.996 0.398 . . . . 0.0 111.44 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 20.5 pttt -155.76 -174.96 5.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.64 0.257 . . . . 0.0 110.558 -178.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . 0.695 ' HB3' HG21 ' A' ' 10' ' ' ILE . 18.4 m-85 -89.71 5.65 44.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.254 0.55 . . . . 0.0 109.661 179.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.521 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 54.26 48.31 64.49 Favored Glycine 0 C--O 1.219 -0.842 0 N-CA-C 116.423 1.329 . . . . 0.0 116.423 176.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.458 ' HB3' HG23 ' A' ' 43' ' ' VAL . 10.4 p90 -164.09 146.56 9.2 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-O 122.627 1.203 . . . . 0.0 112.836 176.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 91.8 m -93.64 114.83 27.24 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 113.46 -1.7 . . . . 0.0 112.51 -178.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.598 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -91.14 82.47 5.53 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-O 120.577 0.227 . . . . 0.0 111.218 179.119 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 1.3 tpt180 . . . . . 0 C--N 1.326 -0.431 0 CA-C-N 116.761 -0.2 . . . . 0.0 111.185 179.279 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t . . . . . 0 N--CA 1.453 -0.277 0 CA-C-O 120.586 0.231 . . . . 0.0 110.605 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.6 m-70 -112.86 179.65 3.91 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.18 -0.463 . . . . 0.0 109.953 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.501 ' O ' HD12 ' A' ' 59' ' ' LEU . 99.1 m-70 -148.92 152.43 36.38 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 41.0 mtm -148.07 146.15 28.73 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.573 HG11 ' CD2' ' A' ' 54' ' ' LEU . 2.7 p -72.28 102.89 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.989 0.9 . . . . 0.0 109.342 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 2.1 t-105 -68.86 -39.92 79.61 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.442 -178.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' HIS . . . . . 0.498 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 2.0 t60 -158.34 128.46 6.02 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.67 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.3 p -124.66 126.06 71.01 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-O 121.642 0.734 . . . . 0.0 110.422 179.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.508 ' O ' ' HB2' ' A' ' 50' ' ' SER . 5.7 mt-10 -68.69 123.06 19.85 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.279 -1.328 . . . . 0.0 111.914 -179.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.499 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 12.2 p-10 -86.11 20.3 2.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.925 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.36 -19.63 66.17 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 116.006 -0.543 . . . . 0.0 113.666 -179.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 168.18 -49.77 0.23 Allowed Glycine 0 CA--C 1.522 0.486 0 C-N-CA 119.134 -1.508 . . . . 0.0 114.733 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -60.33 -132.48 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.967 0 C-N-CA 123.117 2.544 . . . . 0.0 116.318 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.499 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -39.79 -41.63 1.15 Allowed 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 -176.703 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.508 ' HB2' ' O ' ' A' ' 44' ' ' GLU . 0.4 OUTLIER -63.07 -59.5 4.7 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 118.385 0.538 . . . . 0.0 112.227 -178.098 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -63.62 -21.93 66.63 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.272 0.558 . . . . 0.0 110.847 -179.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.2 -26.15 61.94 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.463 178.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 135.09 -12.95 4.41 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.204 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.62 ' HA ' HD13 ' A' ' 8' ' ' ILE . 1.2 tt -69.54 115.24 8.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.312 0.577 . . . . 0.0 111.646 -179.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.413 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.0 OUTLIER -93.86 123.53 37.27 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.666 178.035 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.498 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 34.4 tt0 -49.36 143.77 6.13 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.945 0.402 . . . . 0.0 111.893 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.6 5.66 74.54 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.951 -0.643 . . . . 0.0 112.737 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.487 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 6.3 t0 -86.61 144.07 27.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.854 0.359 . . . . 0.0 110.693 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.501 HD12 ' O ' ' A' ' 38' ' ' HIS . 4.0 tp -92.17 134.12 35.16 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.509 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.539 HG12 HD11 ' A' ' 89' ' ' ILE . 3.4 mp -91.45 125.23 44.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.042 -179.311 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 45.8 p -101.66 -37.56 8.3 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.386 0.612 . . . . 0.0 110.886 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 69.5 m80 -141.73 157.68 44.75 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.148 -178.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.446 HG21 HG13 ' A' ' 80' ' ' ILE . 12.2 p -144.29 122.07 5.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.008 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 56.78 27.06 12.23 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.611 -179.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.28 43.25 26.04 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.917 -0.659 . . . . 0.0 111.596 -178.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.458 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.8 tp10 -150.42 104.4 3.11 Favored Pre-proline 0 N--CA 1.433 -1.319 0 C-N-CA 122.949 0.5 . . . . 0.0 109.732 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 47.3 Cg_exo -41.48 128.41 3.42 Favored 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 124.114 3.21 . . . . 0.0 111.512 177.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 32.7 m -86.25 -11.32 11.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 114.675 -1.148 . . . . 0.0 109.321 -178.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -54.6 97.09 0.02 OUTLIER 'General case' 0 N--CA 1.424 -1.728 0 CA-C-N 112.697 -2.047 . . . . 0.0 111.667 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.03 -13.86 23.97 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.828 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 41.2 mt -74.54 145.13 43.69 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.693 0.246 . . . . 0.0 110.349 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.638 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -79.2 168.95 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 179.268 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -45.79 -50.19 14.28 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 121.45 0.643 . . . . 0.0 112.628 -179.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.478 ' H ' HG13 ' A' ' 72' ' ' VAL . 18.0 p -81.64 -14.54 56.56 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.84 -177.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.638 ' HG3' HG12 ' A' ' 72' ' ' VAL . 15.2 mt-10 -69.81 -42.6 73.48 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 121.25 -0.18 . . . . 0.0 111.286 -179.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.598 HG21 ' HG ' ' A' ' 21' ' ' LEU . 4.3 m -65.1 -44.56 95.63 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 CA-C-O 121.369 0.604 . . . . 0.0 109.43 179.006 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.433 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 83.5 t -53.14 -49.5 50.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 114.829 -1.078 . . . . 0.0 110.043 177.315 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -59.84 -45.33 92.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.005 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -54.16 -40.78 67.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.347 0.594 . . . . 0.0 110.216 178.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.754 HG23 HG11 ' A' ' 87' ' ' VAL . 14.5 mt -73.17 -49.75 36.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.091 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.433 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 91.1 mt -57.83 -41.67 82.75 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.837 0.351 . . . . 0.0 111.069 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 18.8 ttmt -60.58 -37.85 82.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.703 -0.68 . . . . 0.0 112.026 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 8.1 t -51.41 -45.81 62.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.456 -179.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.71 -132.49 7.95 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 119.879 -1.153 . . . . 0.0 114.023 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -73.14 -6.66 47.19 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 111.948 0.351 . . . . 0.0 111.948 -178.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.1 pttp -160.17 175.1 13.3 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-O 120.618 0.247 . . . . 0.0 110.985 -179.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.754 HG11 HG23 ' A' ' 80' ' ' ILE . 11.4 p -167.42 146.19 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.737 -0.665 . . . . 0.0 112.516 -179.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.466 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -92.87 98.57 11.46 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.886 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.55 HG22 ' O ' ' A' ' 8' ' ' ILE . 8.6 tt -92.62 113.32 27.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 120.81 0.338 . . . . 0.0 110.352 178.606 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.423 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -92.03 112.77 24.83 Favored 'General case' 0 C--N 1.323 -0.559 0 O-C-N 122.189 -0.32 . . . . 0.0 111.106 -179.052 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.487 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 77.6 p -108.41 175.68 5.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.525 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 4.1 t -104.04 102.14 30.12 Favored Pre-proline 0 CA--C 1.535 0.403 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -177.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.405 ' HD3' ' O ' ' A' ' 91' ' ' THR . 76.2 Cg_exo -53.99 170.9 0.41 Allowed 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 122.403 2.068 . . . . 0.0 112.913 177.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.409 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.0 OUTLIER -63.66 157.86 22.91 Favored 'General case' 0 C--N 1.319 -0.717 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.57 179.789 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.465 0 CA-C-O 120.943 0.402 . . . . 0.0 111.311 -179.202 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.45 -0.441 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 39.2 ttp 55.24 70.48 0.62 Allowed 'General case' 0 C--N 1.331 -0.223 0 O-C-N 123.514 0.508 . . . . 0.0 110.915 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.456 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.1 mpt_? -70.73 132.47 87.07 Favored Pre-proline 0 C--N 1.323 -0.558 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.456 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -87.28 109.58 0.74 Allowed 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.884 2.39 . . . . 0.0 113.15 -178.396 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 15.0 Cg_exo -69.16 124.22 11.11 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.183 1.922 . . . . 0.0 112.34 178.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.571 HD13 ' HA ' ' A' ' 54' ' ' LEU . 2.6 mt -88.49 109.43 19.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.166 -0.924 . . . . 0.0 108.784 178.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.416 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 4.2 mm -76.1 99.97 2.07 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.586 -178.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.703 HG21 ' HB3' ' A' ' 17' ' ' TYR . 4.8 mt -76.67 159.85 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . 0.533 ' N ' HG22 ' A' ' 10' ' ' ILE . 14.7 t-80 -137.98 109.67 7.08 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 47.2 ttt180 -63.58 104.32 0.64 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.59 -179.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.4 50.07 1.06 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.539 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.05 -37.86 2.85 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.289 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.5 ptpt -84.09 -86.63 0.12 Allowed 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 7.5 pttp -154.89 -174.4 4.97 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 121.116 -0.234 . . . . 0.0 111.374 -178.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . 0.703 ' HB3' HG21 ' A' ' 10' ' ' ILE . 19.8 m-85 -87.98 1.63 53.68 Favored 'General case' 0 C--O 1.224 -0.238 0 CA-C-O 121.019 0.438 . . . . 0.0 109.858 179.119 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 52.38 53.37 31.99 Favored Glycine 0 C--O 1.22 -0.766 0 N-CA-C 116.738 1.455 . . . . 0.0 116.738 176.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.562 ' HB3' HG23 ' A' ' 43' ' ' VAL . 9.3 p90 -165.49 144.88 6.51 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 122.409 1.099 . . . . 0.0 113.018 175.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 92.2 m -91.27 116.08 28.54 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 113.434 -1.712 . . . . 0.0 112.921 -178.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.598 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -90.34 82.15 5.98 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 121.063 0.459 . . . . 0.0 110.133 178.491 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.527 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 4.5 tpt180 . . . . . 0 C--N 1.325 -0.492 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.379 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.9 t . . . . . 0 N--CA 1.45 -0.456 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -110.06 -173.88 2.36 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.816 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.535 ' O ' HD12 ' A' ' 59' ' ' LEU . 95.2 m-70 -149.7 166.29 29.82 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 48.4 ttm -153.19 138.17 17.22 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.669 HG11 HD21 ' A' ' 54' ' ' LEU . 2.6 p -71.6 102.52 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 CA-C-O 122.007 0.908 . . . . 0.0 108.871 178.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.527 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.1 t-105 -69.75 -41.16 75.59 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.814 -177.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' HIS . . . . . 0.449 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -154.59 128.09 8.55 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.076 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.562 HG23 ' HB3' ' A' ' 19' ' ' PHE . 5.8 p -125.47 124.77 67.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 CA-C-O 121.834 0.826 . . . . 0.0 110.534 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.589 ' O ' ' HB2' ' A' ' 50' ' ' SER . 32.5 mt-10 -68.63 118.38 11.56 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 114.171 -1.377 . . . . 0.0 112.41 -178.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.609 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 14.7 p-10 -87.47 32.66 0.7 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.772 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -92.21 -22.66 29.16 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.866 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . 0.526 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 174.85 -51.42 0.13 Allowed Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 119.534 -1.317 . . . . 0.0 114.281 -179.095 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -60.81 -131.13 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.401 2.734 . . . . 0.0 116.409 -179.009 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.522 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -42.12 -44.71 3.75 Favored 'General case' 0 N--CA 1.464 0.273 0 N-CA-C 114.644 1.35 . . . . 0.0 114.644 -176.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.609 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -62.12 -58.32 8.24 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -177.661 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.526 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 2.3 mm-40 -62.2 -24.68 67.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.213 0.53 . . . . 0.0 110.799 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -70.68 -24.58 62.7 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.267 178.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 136.31 -12.87 4.07 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.914 179.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.669 HD21 HG11 ' A' ' 40' ' ' VAL . 1.1 tt -69.29 116.29 9.55 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.623 0.725 . . . . 0.0 112.036 -179.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.86 125.71 42.88 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.587 177.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -50.87 141.76 12.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.894 0.378 . . . . 0.0 111.209 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 86.19 37.85 8.83 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.628 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.633 ' OD1' ' HB ' ' A' ' 91' ' ' THR . 1.9 t70 -120.52 142.73 49.04 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 179.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.535 HD12 ' O ' ' A' ' 38' ' ' HIS . 12.2 tp -89.72 128.1 36.05 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.89 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.511 HG12 HD11 ' A' ' 89' ' ' ILE . 4.0 mp -86.19 126.63 40.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.975 -179.629 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 41.1 p -102.27 -41.27 6.42 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.871 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 59.3 m80 -138.94 160.24 40.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.176 -178.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.411 HG21 HG13 ' A' ' 80' ' ' ILE . 10.6 p -142.74 115.81 3.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.192 -0.458 . . . . 0.0 109.913 177.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 56.45 31.17 18.37 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.745 -0.662 . . . . 0.0 111.467 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.31 41.03 17.92 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.973 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.522 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.2 tp10 -152.15 108.48 2.82 Favored Pre-proline 0 N--CA 1.432 -1.373 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.522 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 1.3 Cg_endo -48.48 134.61 26.48 Favored 'Trans proline' 0 N--CA 1.45 -1.061 0 C-N-CA 123.636 2.891 . . . . 0.0 111.066 178.284 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 32.9 m -87.57 -7.65 10.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-N 114.373 -1.285 . . . . 0.0 109.288 -178.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.9 m170 -55.59 96.12 0.02 OUTLIER 'General case' 0 N--CA 1.427 -1.591 0 CA-C-N 112.771 -2.013 . . . . 0.0 111.744 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.9 -12.56 27.1 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.291 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 31.1 mt -74.84 138.22 42.37 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.641 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -77.93 169.86 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.267 179.801 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -42.79 -48.9 5.76 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 123.76 0.824 . . . . 0.0 112.711 -179.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.517 ' H ' HG13 ' A' ' 72' ' ' VAL . 25.1 p -84.52 -15.38 46.06 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.309 0.855 . . . . 0.0 113.309 -177.049 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.641 ' HG3' HG12 ' A' ' 72' ' ' VAL . 18.7 mt-10 -69.56 -43.39 73.0 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 121.096 -0.242 . . . . 0.0 111.35 -179.176 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.598 HG21 ' HG ' ' A' ' 21' ' ' LEU . 3.8 m -64.4 -45.23 96.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.26 0.552 . . . . 0.0 109.632 179.185 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.402 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 79.4 t -54.48 -48.28 69.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.877 177.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -59.56 -49.53 77.4 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.825 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.13 -41.31 62.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.605 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.702 HG23 HG11 ' A' ' 87' ' ' VAL . 16.0 mt -68.75 -52.88 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.972 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.402 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 46.4 mt -59.05 -37.5 77.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.201 0.524 . . . . 0.0 111.088 179.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -61.71 -38.62 88.53 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.928 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 40.4 t -52.76 -47.29 67.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.283 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 136.57 -135.39 7.7 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.122 -1.037 . . . . 0.0 112.921 179.146 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -79.6 1.76 24.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.132 0.491 . . . . 0.0 111.374 -179.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 10.9 pttp -159.67 175.46 13.15 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.173 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.702 HG11 HG23 ' A' ' 80' ' ' ILE . 12.2 p -167.55 147.18 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 O-C-N 123.567 0.542 . . . . 0.0 112.342 -179.105 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.43 93.84 7.9 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.867 179.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.511 HD11 HG12 ' A' ' 60' ' ' ILE . 7.3 tt -88.3 113.59 25.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-O 121.055 0.455 . . . . 0.0 110.474 179.078 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.463 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -90.58 110.83 21.97 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.945 0.402 . . . . 0.0 111.235 -179.005 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.633 ' HB ' ' OD1' ' A' ' 58' ' ' ASP . 26.1 p -103.77 169.54 8.46 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.217 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.432 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 8.6 t -107.25 104.59 52.92 Favored Pre-proline 0 CA--C 1.534 0.342 0 C-N-CA 120.444 -0.502 . . . . 0.0 112.191 -178.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_exo -53.09 172.24 0.2 Allowed 'Trans proline' 0 C--N 1.351 0.669 0 C-N-CA 122.311 2.007 . . . . 0.0 113.039 178.099 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -64.28 163.39 13.0 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.048 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.324 -0.529 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.4 -179.106 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.6 m . . . . . 0 C--O 1.234 0.273 0 N-CA-C 110.38 -0.229 . . . . 0.0 110.38 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 93.4 mtp 61.23 75.75 0.4 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.148 0.499 . . . . 0.0 110.752 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.484 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.0 mpt_? -72.91 134.98 80.77 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.515 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 5.0 Cg_endo -92.24 116.02 0.37 Allowed 'Trans proline' 0 CA--C 1.531 0.355 0 C-N-CA 123.326 2.684 . . . . 0.0 113.408 -178.623 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.497 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 12.3 Cg_exo -73.88 124.22 9.02 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 122.439 2.093 . . . . 0.0 113.17 178.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.499 HD13 ' HA ' ' A' ' 54' ' ' LEU . 1.1 mt -87.45 110.33 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.836 177.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.414 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 3.2 mm -78.16 97.91 2.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.569 -178.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.639 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.2 mt -77.35 162.08 4.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 177.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . 0.52 ' N ' HG22 ' A' ' 10' ' ' ILE . 53.0 t-80 -137.51 114.44 10.64 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 108.11 -1.071 . . . . 0.0 108.11 178.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 30.6 ttt180 -61.34 107.14 0.72 Allowed 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.675 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -80.68 50.68 1.37 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.432 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.34 23.54 74.97 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.638 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . 0.497 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 9.8 ptpt -150.76 -80.6 0.11 Allowed 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.497 ' H ' ' HG3' ' A' ' 15' ' ' LYS . 21.7 pttm -158.42 178.25 10.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.377 0.132 . . . . 0.0 110.822 -178.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . 0.639 ' HB3' HG21 ' A' ' 10' ' ' ILE . 6.4 m-85 -89.22 4.44 48.67 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-O 121.54 0.686 . . . . 0.0 109.536 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.408 ' O ' ' HG3' ' A' ' 44' ' ' GLU . . . 64.16 -27.48 0.09 OUTLIER Glycine 0 C--N 1.335 0.528 0 N-CA-C 116.925 1.53 . . . . 0.0 116.925 177.249 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.579 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.4 p90 -81.7 147.64 29.38 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 122.445 1.117 . . . . 0.0 113.459 -176.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 87.5 m -97.0 112.55 24.26 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 113.344 -1.753 . . . . 0.0 111.575 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.652 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -85.37 86.78 7.35 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.316 178.985 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.516 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 5.5 tpt180 . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.472 179.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 t . . . . . 0 N--CA 1.45 -0.452 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 41.6 m-70 -104.94 -174.88 2.64 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.61 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.534 ' O ' HD12 ' A' ' 59' ' ' LEU . 99.1 m-70 -150.9 164.61 35.9 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -152.44 139.74 19.45 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.586 -178.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.874 HG11 HD21 ' A' ' 54' ' ' LEU . 1.9 p -73.64 105.51 3.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 121.808 0.813 . . . . 0.0 109.466 178.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.516 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 4.4 t-105 -69.87 -44.39 69.9 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.446 -1.252 . . . . 0.0 112.292 -177.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' HIS . . . . . 0.482 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 2.1 t60 -154.29 133.75 12.72 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.229 -0.896 . . . . 0.0 110.046 -178.332 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.579 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 3.0 p -126.87 129.16 71.36 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 CA-C-O 121.629 0.728 . . . . 0.0 110.859 179.238 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.419 ' O ' ' HB2' ' A' ' 50' ' ' SER . 15.5 mt-10 -66.05 119.79 12.01 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 114.74 -1.118 . . . . 0.0 111.583 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.567 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 9.4 p-10 -88.07 19.16 3.78 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.174 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.03 4.12 60.7 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.372 -0.918 . . . . 0.0 113.837 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 161.27 -55.74 0.31 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 118.795 -1.669 . . . . 0.0 115.187 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.406 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 50.5 Cg_exo -60.57 -135.14 0.0 OUTLIER 'Trans proline' 0 CA--C 1.545 1.04 0 C-N-CA 123.043 2.495 . . . . 0.0 116.679 -178.079 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.549 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -43.17 -36.99 1.9 Allowed 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 115.208 1.558 . . . . 0.0 115.208 -176.582 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.567 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 1.9 m -62.29 -55.08 31.77 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 118.655 0.661 . . . . 0.0 111.546 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -63.5 -24.31 67.76 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.008 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.08 -24.79 60.71 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.905 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.54 -7.33 6.23 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.565 -0.826 . . . . 0.0 113.104 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.874 HD21 HG11 ' A' ' 40' ' ' VAL . 5.1 tt -70.59 113.81 8.07 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.044 0.45 . . . . 0.0 110.88 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.17 122.32 32.35 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.931 178.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.455 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 36.3 tt0 -49.49 131.73 20.88 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 120.905 0.383 . . . . 0.0 110.664 177.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.37 65.89 1.35 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.294 -178.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.497 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.7 t0 -144.84 148.31 33.84 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.534 HD12 ' O ' ' A' ' 38' ' ' HIS . 8.7 tp -92.5 127.78 38.12 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.22 -179.635 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.443 ' CG1' HD11 ' A' ' 89' ' ' ILE . 4.0 mp -87.05 125.18 40.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.704 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 52.8 p -102.07 -39.08 7.46 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.379 0.609 . . . . 0.0 110.599 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 59.0 m80 -139.31 155.26 47.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.089 -178.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.565 HG21 HG13 ' A' ' 80' ' ' ILE . 7.7 p -138.2 113.07 9.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.851 177.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.8 t30 56.46 32.84 21.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.786 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.12 43.22 22.02 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.12 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.503 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.5 tp10 -149.99 106.2 3.21 Favored Pre-proline 0 N--CA 1.44 -0.949 0 C-N-CA 122.578 0.351 . . . . 0.0 110.375 179.673 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.503 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.7 Cg_exo -45.09 129.51 10.16 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 123.71 2.94 . . . . 0.0 111.538 177.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 31.3 m -86.76 -9.56 11.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-N 114.419 -1.264 . . . . 0.0 109.18 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.3 m170 -54.51 97.64 0.02 OUTLIER 'General case' 0 N--CA 1.426 -1.633 0 CA-C-N 112.602 -2.09 . . . . 0.0 112.074 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 108.98 -11.02 34.44 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.63 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.6 mt -75.79 139.96 42.08 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.655 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -79.3 170.47 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.632 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.466 ' O ' HG23 ' A' ' 77' ' ' VAL . 55.4 t60 -44.37 -54.75 5.55 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.668 0.747 . . . . 0.0 112.417 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 27.6 p -73.14 -20.69 60.86 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.111 -0.949 . . . . 0.0 112.788 -177.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.655 ' HG3' HG12 ' A' ' 72' ' ' VAL . 26.4 mt-10 -69.21 -41.81 76.57 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 121.271 -0.171 . . . . 0.0 111.168 -179.261 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.652 HG21 ' HG ' ' A' ' 21' ' ' LEU . 13.6 m -67.05 -46.95 83.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 C-N-CA 120.476 -0.49 . . . . 0.0 110.024 178.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.466 HG23 ' O ' ' A' ' 73' ' ' HIS . 40.6 t -53.13 -46.49 55.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.18 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -66.6 -42.48 86.82 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.836 179.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -54.04 -39.27 66.06 Favored 'General case' 0 C--N 1.327 -0.388 0 O-C-N 123.681 0.613 . . . . 0.0 109.801 178.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.675 HG23 HG11 ' A' ' 87' ' ' VAL . 16.4 mt -71.28 -51.91 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.494 179.472 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 82.5 mt -57.95 -32.69 68.08 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-O 121.104 0.478 . . . . 0.0 110.609 179.076 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 24.8 ttmt -58.67 -40.0 82.28 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.226 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 26.1 t -56.9 -55.04 39.65 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.745 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 134.99 -127.96 4.59 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.069 -1.063 . . . . 0.0 113.807 178.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -75.18 -2.9 29.95 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -178.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.422 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 18.5 pttp -159.77 175.33 13.25 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.249 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.675 HG11 HG23 ' A' ' 80' ' ' ILE . 13.5 p -166.67 145.1 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.505 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . 0.472 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -93.88 92.36 7.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.3 -0.864 . . . . 0.0 111.665 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.449 HG22 ' O ' ' A' ' 8' ' ' ILE . 6.8 tt -88.05 112.24 23.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-O 121.014 0.435 . . . . 0.0 110.346 179.262 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 1.0 OUTLIER -91.95 115.39 28.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.779 0.323 . . . . 0.0 111.326 -178.829 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.497 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 64.5 p -109.4 175.39 5.47 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.315 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.499 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 6.3 t -103.9 105.16 46.96 Favored Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 113.04 0.755 . . . . 0.0 113.04 -178.059 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -52.8 171.86 0.2 Allowed 'Trans proline' 0 C--O 1.236 0.421 0 C-N-CA 122.64 2.226 . . . . 0.0 112.928 177.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -66.47 159.16 27.74 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.796 179.532 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.218 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 N--CA 1.451 -0.399 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 89.9 mtp 62.3 78.28 0.3 Allowed 'General case' 0 N--CA 1.463 0.192 0 O-C-N 123.715 0.635 . . . . 0.0 110.631 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.441 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.9 mpt_? -72.02 148.92 92.07 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.264 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 8.4 Cg_endo -95.43 113.06 0.15 Allowed 'Trans proline' 0 N--CA 1.461 -0.414 0 C-N-CA 123.742 2.961 . . . . 0.0 113.173 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 12.5 Cg_exo -72.86 122.87 8.51 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.463 2.109 . . . . 0.0 113.299 178.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.54 HG21 ' N ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -83.38 109.14 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.28 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.072 177.708 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.401 ' H ' HG12 ' A' ' 9' ' ' ILE . 3.2 mm -77.36 97.31 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.174 -178.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.539 HG12 ' HB2' ' A' ' 49' ' ' ALA . 5.7 mt -76.89 159.1 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . 0.494 ' N ' HG22 ' A' ' 10' ' ' ILE . 47.3 t-80 -136.5 112.18 9.41 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 46.7 ttt180 -63.67 109.16 1.6 Allowed 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.728 -178.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -83.36 52.31 2.19 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.87 178.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.54 -49.65 4.21 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-N 115.767 -0.652 . . . . 0.0 112.243 -179.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.5 ptpt -71.76 -90.41 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 16.4 pttm -158.53 -171.56 3.5 Favored 'General case' 0 C--N 1.327 -0.4 0 O-C-N 122.434 -0.166 . . . . 0.0 111.092 -178.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . 0.477 ' HB3' HG21 ' A' ' 10' ' ' ILE . 12.2 m-85 -88.11 -1.76 58.2 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.517 0.675 . . . . 0.0 109.744 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.558 ' HA3' ' HB2' ' A' ' 44' ' ' GLU . . . 63.62 -19.34 0.09 OUTLIER Glycine 0 CA--C 1.519 0.342 0 N-CA-C 117.057 1.583 . . . . 0.0 117.057 177.507 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.591 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.4 p90 -85.44 146.89 26.75 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 122.505 1.145 . . . . 0.0 113.524 -177.253 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.406 HG21 HH11 ' A' ' 22' ' ' ARG . 86.1 m -94.65 113.55 25.37 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.601 -1.636 . . . . 0.0 112.364 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.568 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -89.49 81.5 6.54 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.931 0.396 . . . . 0.0 110.692 178.694 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.452 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--N 1.323 -0.545 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.259 179.417 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 9.4 t . . . . . 0 N--CA 1.451 -0.403 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -108.48 -176.06 2.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.238 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.537 ' CD2' HG11 ' A' ' 76' ' ' VAL . 97.7 m-70 -148.46 168.5 22.51 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . 0.411 ' HG2' ' O ' ' A' ' 58' ' ' ASP . 3.1 mtm -157.05 137.76 13.24 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 120.61 0.243 . . . . 0.0 110.425 -178.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.927 HG11 HD21 ' A' ' 54' ' ' LEU . 1.9 p -72.83 100.63 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-O 122.126 0.965 . . . . 0.0 108.817 178.625 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.452 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.2 t-105 -69.77 -41.08 75.61 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.025 -1.443 . . . . 0.0 112.711 -177.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' HIS . . . . . 0.463 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -156.39 127.19 6.81 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.374 -178.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.591 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 2.4 p -118.84 129.0 75.65 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 CA-C-O 121.251 0.548 . . . . 0.0 110.024 179.18 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.558 ' HB2' ' HA3' ' A' ' 18' ' ' GLY . 5.2 mt-10 -63.9 114.04 3.83 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 114.735 -1.121 . . . . 0.0 111.645 -178.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.485 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 11.8 p-10 -83.17 39.54 0.65 Allowed 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.92 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -122.75 11.88 8.83 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.407 -0.901 . . . . 0.0 113.935 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 156.75 -61.99 0.33 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 118.633 -1.746 . . . . 0.0 115.153 179.314 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . 0.466 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 51.2 Cg_exo -61.04 -133.41 0.0 OUTLIER 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 123.17 2.58 . . . . 0.0 116.958 -177.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.539 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -42.13 -35.36 0.91 Allowed 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 114.95 1.463 . . . . 0.0 114.95 -176.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.485 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -61.13 -59.61 5.07 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 118.33 0.513 . . . . 0.0 111.706 -178.921 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -63.61 -30.24 71.38 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.548 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.19 -29.28 70.26 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.673 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.3 -10.5 5.59 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.196 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.927 HD21 HG11 ' A' ' 40' ' ' VAL . 5.6 tt -66.85 114.45 5.71 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.849 0.357 . . . . 0.0 110.48 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.15 122.49 32.5 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.486 178.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.438 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 40.2 tt0 -51.34 138.0 22.17 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.989 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 83.14 47.35 5.82 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.222 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.582 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.3 t0 -127.24 149.23 50.1 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.507 HD12 ' O ' ' A' ' 38' ' ' HIS . 19.9 tp -93.03 125.8 37.8 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.149 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.451 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.8 mp -83.82 124.74 39.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.276 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 57.8 p -99.51 -40.0 8.06 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.378 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -142.05 157.31 45.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.122 -178.349 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.67 115.21 8.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 177.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 59.62 31.1 20.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.418 -179.4 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 73.23 45.5 30.78 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.372 -178.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.499 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 1.5 tp10 -151.75 111.23 2.93 Favored Pre-proline 0 N--CA 1.433 -1.316 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 -179.246 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.499 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 4.7 Cg_endo -50.99 133.47 40.65 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 123.551 2.834 . . . . 0.0 111.257 178.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 35.1 m -90.01 -7.87 10.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.806 -178.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.8 m170 -55.41 95.06 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.54 0 CA-C-N 112.977 -1.919 . . . . 0.0 111.96 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.29 -9.37 24.59 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.394 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 32.2 mt -77.39 139.76 39.78 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.505 HG13 ' H ' ' A' ' 74' ' ' THR . 0.6 OUTLIER -81.14 171.18 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.162 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.1 t60 -42.02 -49.02 4.71 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 123.682 0.793 . . . . 0.0 112.934 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.505 ' H ' HG13 ' A' ' 72' ' ' VAL . 30.6 p -82.11 -21.14 36.88 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 -176.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . 0.402 ' HG3' HG12 ' A' ' 72' ' ' VAL . 28.2 mt-10 -67.53 -40.83 85.06 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 121.082 -0.247 . . . . 0.0 111.38 -178.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.568 HG21 ' HG ' ' A' ' 21' ' ' LEU . 3.9 m -65.68 -46.85 88.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.267 0.556 . . . . 0.0 109.599 178.66 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 58.4 t -54.79 -45.71 74.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.295 177.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -62.96 -45.12 93.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.942 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.53 -41.66 66.63 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.34 0.59 . . . . 0.0 110.041 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.637 HG23 HG11 ' A' ' 87' ' ' VAL . 12.0 mt -68.77 -50.66 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.964 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 65.9 mt -59.23 -39.54 83.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.252 0.549 . . . . 0.0 110.478 178.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -61.46 -36.58 80.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.69 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 44.3 t -53.76 -47.64 70.49 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.129 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 138.06 -124.45 2.96 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.264 -0.969 . . . . 0.0 113.295 179.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -93.65 7.07 46.16 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.265 0.555 . . . . 0.0 110.887 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 19.8 pttp -161.12 179.21 8.59 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.859 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.637 HG11 HG23 ' A' ' 80' ' ' ILE . 11.4 p -170.15 143.68 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 O-C-N 123.609 0.568 . . . . 0.0 112.439 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.09 90.44 6.4 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.649 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.451 HD11 ' CG1' ' A' ' 60' ' ' ILE . 5.0 tt -87.78 115.65 28.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-O 120.954 0.407 . . . . 0.0 110.553 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 3.6 t -94.76 116.04 28.25 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.777 0.322 . . . . 0.0 111.395 -178.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.582 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 81.4 p -109.37 173.31 6.38 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.7 179.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.402 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 3.6 t -101.44 104.18 32.11 Favored Pre-proline 0 CA--C 1.536 0.414 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 91' ' ' THR . 77.1 Cg_exo -54.37 177.46 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.577 2.185 . . . . 0.0 113.015 177.609 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -62.55 156.47 23.0 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.396 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.321 -0.635 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.764 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.7 m . . . . . 0 N--CA 1.453 -0.305 0 N-CA-C 110.386 -0.227 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 77.4 mtp 63.41 78.94 0.27 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.183 0.516 . . . . 0.0 110.939 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.432 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.9 mpt_? -72.78 139.31 80.26 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.733 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -87.87 109.8 0.66 Allowed 'Trans proline' 0 C--O 1.236 0.418 0 C-N-CA 123.204 2.603 . . . . 0.0 112.826 -179.026 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.472 ' HA ' ' O ' ' A' ' 89' ' ' ILE . 12.0 Cg_exo -72.81 121.39 7.31 Favored 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 122.368 2.045 . . . . 0.0 113.041 179.02 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.466 HG21 ' N ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -83.0 110.86 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 CA-C-N 115.388 -0.824 . . . . 0.0 108.802 178.12 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.4 mm -77.16 100.75 2.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.75 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.698 HG21 ' HB3' ' A' ' 17' ' ' TYR . 6.0 mt -76.54 163.51 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' HIS . . . . . 0.55 ' N ' HG22 ' A' ' 10' ' ' ILE . 29.0 t-80 -141.53 107.1 5.06 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.105 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 52.6 ttt-85 -62.19 110.31 1.58 Allowed 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.164 -178.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -81.72 46.47 0.98 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.774 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.79 -0.26 66.32 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 121.163 -0.541 . . . . 0.0 112.814 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.1 ptpt -119.65 -82.38 0.64 Allowed 'General case' 0 C--N 1.325 -0.458 0 O-C-N 122.891 -0.182 . . . . 0.0 111.277 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.404 ' HE3' ' OE1' ' A' ' 44' ' ' GLU . 17.1 pttt -155.14 -178.71 7.45 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.702 -178.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' TYR . . . . . 0.698 ' HB3' HG21 ' A' ' 10' ' ' ILE . 16.9 m-85 -88.28 5.64 40.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.17 0.51 . . . . 0.0 110.223 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . 0.548 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 53.27 48.99 58.18 Favored Glycine 0 C--O 1.217 -0.909 0 N-CA-C 116.744 1.458 . . . . 0.0 116.744 177.062 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.499 ' HB3' HG23 ' A' ' 43' ' ' VAL . 6.3 p90 -164.42 147.38 9.04 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 122.457 1.123 . . . . 0.0 112.977 176.304 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 97.9 m -92.39 115.31 27.97 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 113.42 -1.718 . . . . 0.0 112.414 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' LEU . . . . . 0.665 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -89.22 84.48 6.51 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.74 0.305 . . . . 0.0 110.449 178.487 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.512 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 6.1 tpt180 . . . . . 0 C--N 1.325 -0.498 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.453 179.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 t . . . . . 0 N--CA 1.452 -0.344 0 CA-C-O 120.699 0.285 . . . . 0.0 110.789 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 54.9 m-70 -115.41 -175.46 2.71 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.676 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.529 ' CD2' HG11 ' A' ' 76' ' ' VAL . 97.1 m-70 -148.79 153.3 37.95 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 48.3 mtm -148.68 141.02 24.15 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.033 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.913 HG11 HD21 ' A' ' 54' ' ' LEU . 2.3 p -72.55 104.78 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-O 121.784 0.802 . . . . 0.0 109.581 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . 0.512 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.2 t-105 -70.07 -42.55 72.65 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.476 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' HIS . . . . . 0.442 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 0.9 OUTLIER -155.08 132.56 11.18 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.158 -179.125 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.0 p -127.75 130.08 70.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 121.575 0.702 . . . . 0.0 110.508 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.564 ' O ' ' HB2' ' A' ' 50' ' ' SER . 37.1 mt-10 -67.04 115.07 6.34 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 114.583 -1.19 . . . . 0.0 111.811 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . 0.539 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 11.9 p-10 -84.19 35.72 0.55 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.649 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.94 -26.12 8.09 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.708 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -179.93 -54.4 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 119.439 -1.362 . . . . 0.0 114.688 -178.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -58.07 -129.57 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 0.975 0 C-N-CA 123.524 2.816 . . . . 0.0 116.68 -178.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.522 ' HB1' HD13 ' A' ' 54' ' ' LEU . . . -43.36 -42.87 4.8 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -176.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.564 ' HB2' ' O ' ' A' ' 44' ' ' GLU . 0.4 OUTLIER -62.09 -62.25 1.91 Allowed 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 112.742 0.645 . . . . 0.0 112.742 -177.668 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -62.04 -22.69 65.94 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.02 0.438 . . . . 0.0 111.072 -178.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -71.06 -24.57 62.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.692 179.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.05 -15.05 3.76 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.75 -0.738 . . . . 0.0 113.03 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LEU . . . . . 0.913 HD21 HG11 ' A' ' 40' ' ' VAL . 5.1 tt -69.42 113.07 6.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.049 0.452 . . . . 0.0 110.787 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ARG . . . . . 0.502 ' HD3' ' O ' ' A' ' 55' ' ' ARG . 0.0 OUTLIER -93.74 123.73 37.27 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.573 178.313 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.442 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 37.0 tt0 -49.08 134.43 17.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.247 0.546 . . . . 0.0 111.31 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 89.77 60.79 1.4 Allowed Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.734 -0.745 . . . . 0.0 111.681 -179.222 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.605 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.4 t0 -140.75 155.25 46.48 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 38' ' ' HIS . 13.3 tp -102.75 125.27 49.42 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.931 -179.414 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.433 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.5 mp -82.68 122.75 37.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.276 -179.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.435 ' O ' HG22 ' A' ' 68' ' ' VAL . 44.8 p -100.59 -34.1 10.03 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.652 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 75.2 m80 -146.04 162.53 37.68 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.081 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.3 p -145.89 114.83 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.65 177.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 57.58 32.57 22.03 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.766 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 68.98 47.44 54.47 Favored Glycine 0 N--CA 1.444 -0.768 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -178.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.41 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.9 tp10 -149.55 99.98 3.34 Favored Pre-proline 0 N--CA 1.442 -0.835 0 C-N-CA 122.834 0.454 . . . . 0.0 110.079 -179.077 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 80.4 Cg_exo -36.37 124.36 0.35 Allowed 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 124.424 3.416 . . . . 0.0 112.564 177.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 61' ' ' THR . 27.0 m -86.68 -11.11 11.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.055 -179.411 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.5 m170 -56.57 98.14 0.03 OUTLIER 'General case' 0 N--CA 1.425 -1.688 0 CA-C-N 112.83 -1.986 . . . . 0.0 111.301 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 109.51 -6.41 31.71 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.441 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 25.0 mt -79.01 137.76 37.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.717 0.259 . . . . 0.0 110.517 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -79.92 170.05 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.28 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 38.3 t60 -44.09 -54.4 5.56 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.643 0.735 . . . . 0.0 112.764 -179.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 21.1 p -73.53 -21.0 60.5 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 115.312 -0.858 . . . . 0.0 113.236 -176.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -68.4 -41.97 79.72 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 120.969 -0.292 . . . . 0.0 111.608 -179.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.665 HG21 ' HG ' ' A' ' 21' ' ' LEU . 3.4 m -66.39 -44.58 90.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.95 179.04 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 50.2 t -53.68 -47.99 60.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.826 177.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 56.8 mt-10 -63.6 -45.2 91.45 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.894 178.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.41 -40.48 65.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.294 0.569 . . . . 0.0 109.822 178.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.707 HG23 HG11 ' A' ' 87' ' ' VAL . 21.8 mt -70.58 -53.21 23.39 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.775 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.267 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 83.8 mt -57.57 -38.39 74.73 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 120.887 0.375 . . . . 0.0 111.294 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 17.8 ttmt -59.6 -37.96 79.95 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.753 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 34.8 t -56.25 -39.52 72.71 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.972 -179.286 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.63 -141.38 12.91 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.11 -1.043 . . . . 0.0 112.997 179.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 23.5 p30 -75.13 5.5 5.3 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -179.101 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 16.0 pttp -162.71 171.18 17.22 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.726 -0.215 . . . . 0.0 110.452 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.707 HG11 HG23 ' A' ' 80' ' ' ILE . 11.6 p -164.96 147.06 2.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.73 94.22 7.98 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.748 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.472 ' O ' ' HA ' ' A' ' 7' ' ' PRO . 4.5 tt -88.61 116.16 29.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.749 0.309 . . . . 0.0 110.492 179.277 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.1 OUTLIER -93.39 112.9 24.93 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.628 0.251 . . . . 0.0 111.508 -178.752 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.605 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 80.4 p -107.14 179.99 4.1 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 178.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.417 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 4.0 t -114.1 104.11 54.95 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-O 121.232 0.539 . . . . 0.0 112.322 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -56.31 175.53 0.25 Allowed 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.68 2.253 . . . . 0.0 113.344 178.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.436 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.1 OUTLIER -65.32 162.33 17.74 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.476 -179.715 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.327 -0.393 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.143 179.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.75 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -143.28 164.52 27.26 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 121.068 -0.586 . . . . 0.0 111.886 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 m -125.9 146.33 49.88 Favored 'General case' 0 C--N 1.319 -0.735 0 O-C-N 122.78 -0.247 . . . . 0.0 110.42 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 69.4 mtp 63.93 85.46 0.13 Allowed 'General case' 0 C--N 1.33 -0.241 0 O-C-N 123.869 0.731 . . . . 0.0 111.45 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.472 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 6.8 mpt_? -71.7 137.19 82.94 Favored Pre-proline 0 C--N 1.325 -0.485 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -88.05 113.94 0.84 Allowed 'Trans proline' 0 CA--C 1.53 0.304 0 C-N-CA 123.097 2.531 . . . . 0.0 113.134 -178.747 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.445 ' HA ' ' O ' ' A' ' 89' ' ' ILE . 13.0 Cg_exo -70.93 128.01 14.41 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.141 1.894 . . . . 0.0 112.681 178.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.66 HD13 ' HA ' ' A' ' 54' ' ' LEU . 3.1 mt -93.55 113.04 27.59 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.679 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.7 mm -78.25 101.08 3.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.014 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.7 -178.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.674 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.4 mt -79.42 168.12 2.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 177.159 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . 0.57 ' N ' HG22 ' A' ' 10' ' ' ILE . 43.1 t-80 -145.88 114.38 6.75 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 178.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.9 ttt180 -66.48 99.57 0.58 Allowed 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.068 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -76.61 55.95 1.09 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.331 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 70.37 14.42 71.76 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.911 -0.586 . . . . 0.0 113.113 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.405 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 8.3 ptpt -140.48 -80.05 0.27 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 117.01 0.405 . . . . 0.0 111.777 -179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.631 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 24.4 pttt -155.97 178.02 10.75 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.541 0.21 . . . . 0.0 111.192 -178.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . 0.674 ' HB3' HG21 ' A' ' 10' ' ' ILE . 23.2 m-85 -87.5 2.35 50.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.253 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.526 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 53.37 49.84 55.09 Favored Glycine 0 C--O 1.215 -1.083 0 N-CA-C 116.436 1.334 . . . . 0.0 116.436 176.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.499 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 11.4 p90 -163.91 146.53 9.48 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 122.34 1.067 . . . . 0.0 112.314 176.185 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.534 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 32.7 m -93.35 119.59 32.65 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 113.48 -1.691 . . . . 0.0 113.534 -178.242 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.561 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -92.63 84.16 5.0 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.783 0.325 . . . . 0.0 110.222 177.836 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.427 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 4.4 tpt180 -69.76 121.79 17.91 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.142 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.582 ' HA ' ' ND1' ' A' ' 38' ' ' HIS . . . -87.46 134.53 33.58 Favored 'General case' 0 C--N 1.328 -0.343 0 O-C-N 123.207 0.317 . . . . 0.0 110.846 179.338 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.492 HG21 ' CE3' ' B' ' 102' ' ' TRP . 1.5 pt -153.04 104.97 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.16 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 179.324 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 20.9 mtm180 -77.55 101.37 6.48 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 176.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.8 m -77.71 105.07 6.23 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-O 121.187 0.518 . . . . 0.0 112.217 -178.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 29.6 m-85 -78.02 151.56 33.48 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 18.3 mmt -89.58 -2.1 58.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.857 0.36 . . . . 0.0 110.875 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.41 -133.21 4.01 Favored Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.823 -0.703 . . . . 0.0 111.902 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -83.1 -18.04 40.98 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.051 0.453 . . . . 0.0 110.431 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.02 164.51 25.41 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.117 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -78.14 -3.51 42.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.068 -0.515 . . . . 0.0 112.147 -178.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.7 p -77.46 126.56 38.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.729 0.776 . . . . 0.0 111.096 -179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -157.93 154.17 27.39 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.38 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -113.99 129.75 56.58 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.769 0.319 . . . . 0.0 110.205 178.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 t -82.17 97.75 4.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-N 116.644 -0.253 . . . . 0.0 110.685 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 13.5 m-70 -110.51 177.17 4.77 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 120.992 0.425 . . . . 0.0 110.752 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.64 ' CD2' HG11 ' A' ' 76' ' ' VAL . 98.5 m-70 -150.19 152.8 35.21 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.277 -0.874 . . . . 0.0 108.709 -179.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . 0.426 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 44.6 mtm -147.53 141.7 26.12 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -178.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.711 HG11 HD21 ' A' ' 54' ' ' LEU . 2.5 p -73.14 103.19 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.981 0.896 . . . . 0.0 109.693 179.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.427 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 4.7 t-105 -69.28 -37.32 77.81 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.209 -1.359 . . . . 0.0 111.638 -178.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' HIS . . . . . 0.498 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 2.5 t60 -158.75 125.54 4.75 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.295 -178.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.3 p -121.47 124.78 72.55 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 CA-C-O 121.475 0.655 . . . . 0.0 109.746 178.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -63.72 109.31 1.66 Allowed 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.524 -1.216 . . . . 0.0 111.922 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.585 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 8.8 p-10 -82.3 49.37 1.41 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.635 0.731 . . . . 0.0 109.708 179.008 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -131.05 13.62 5.49 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.624 -0.798 . . . . 0.0 113.447 -179.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.49 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 157.22 -68.79 0.28 Allowed Glycine 0 CA--C 1.523 0.546 0 C-N-CA 119.085 -1.531 . . . . 0.0 115.176 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_exo -60.18 -129.92 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 0 C-N-CA 123.748 2.965 . . . . 0.0 117.341 -177.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.491 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -41.86 -38.79 1.62 Allowed 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 114.625 1.343 . . . . 0.0 114.625 -176.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.585 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 1.0 OUTLIER -62.17 -56.18 21.25 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.722 -178.844 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.49 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 7.3 mm-40 -63.45 -28.58 70.07 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.306 0.574 . . . . 0.0 110.432 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.46 -28.72 69.86 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.567 178.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.43 -5.15 5.57 Favored Glycine 0 N--CA 1.446 -0.677 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.931 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.711 HD21 HG11 ' A' ' 40' ' ' VAL . 1.7 tt -71.14 112.28 7.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.257 0.551 . . . . 0.0 111.463 -179.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.96 120.81 32.26 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.704 178.61 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.498 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 33.2 tt0 -49.76 140.87 10.87 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.159 -0.473 . . . . 0.0 112.002 179.156 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 91.45 13.78 57.98 Favored Glycine 0 CA--C 1.52 0.357 0 C-N-CA 121.032 -0.604 . . . . 0.0 113.125 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.533 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 2.2 t0 -94.81 151.64 19.07 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.978 0.418 . . . . 0.0 111.116 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.522 HD12 ' O ' ' A' ' 38' ' ' HIS . 4.6 tp -98.26 129.94 44.98 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.192 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.559 HG12 HD11 ' A' ' 89' ' ' ILE . 3.8 mp -86.81 124.21 40.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.055 -179.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 66.3 p -100.4 -37.81 8.69 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.774 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.421 ' HB2' ' CB ' ' A' ' 90' ' ' SER . 59.1 m80 -143.11 162.54 35.27 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.927 -178.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.491 HG21 HG13 ' A' ' 80' ' ' ILE . 9.8 p -143.45 116.13 3.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.998 177.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 58.58 24.33 11.88 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.386 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.82 41.75 8.62 Favored Glycine 0 N--CA 1.446 -0.682 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.538 -178.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.522 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.1 tp10 -151.4 109.49 2.97 Favored Pre-proline 0 N--CA 1.434 -1.246 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.522 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 1.0 OUTLIER -47.29 128.88 15.18 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 123.947 3.098 . . . . 0.0 111.921 178.923 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.1 m -87.43 -13.76 10.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.165 0 CA-C-N 114.359 -1.291 . . . . 0.0 109.203 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 9.1 m170 -57.47 95.08 0.02 OUTLIER 'General case' 0 N--CA 1.428 -1.572 0 CA-C-N 112.846 -1.979 . . . . 0.0 111.163 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 119.41 -14.18 10.92 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.08 -179.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 43.3 mt -76.01 142.52 41.86 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.592 0.234 . . . . 0.0 110.577 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.504 HG13 ' H ' ' A' ' 74' ' ' THR . 0.3 OUTLIER -78.08 169.66 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.882 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.4 t60 -42.42 -48.18 5.12 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.907 0.883 . . . . 0.0 113.119 -179.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.504 ' H ' HG13 ' A' ' 72' ' ' VAL . 12.0 p -88.21 -15.45 35.93 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 -177.038 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -68.4 -42.45 79.01 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 122.361 -0.212 . . . . 0.0 111.212 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.64 HG11 ' CD2' ' A' ' 38' ' ' HIS . 9.6 m -64.16 -46.36 93.76 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.233 0 CA-C-O 121.198 0.523 . . . . 0.0 110.0 179.275 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.589 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 72.8 t -55.18 -48.96 75.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.268 177.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -61.63 -44.01 97.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.161 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.19 -39.45 63.68 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-O 121.263 0.554 . . . . 0.0 109.937 178.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.576 HG23 HG11 ' A' ' 87' ' ' VAL . 14.3 mt -72.27 -50.34 36.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.807 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.589 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 39.6 mt -58.33 -36.85 74.01 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-O 121.329 0.585 . . . . 0.0 110.515 179.225 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 24.0 ttmt -60.34 -39.94 88.87 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.634 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 43.4 t -54.69 -36.47 64.69 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.359 -0.837 . . . . 0.0 111.49 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 127.85 -130.42 6.7 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 120.207 -0.997 . . . . 0.0 112.637 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 25.0 p30 -92.07 13.87 17.6 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.208 0.528 . . . . 0.0 111.047 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.414 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 19.5 pttp -163.47 176.69 9.53 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.064 179.347 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.576 HG11 HG23 ' A' ' 80' ' ' ILE . 8.6 p -171.81 145.99 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -179.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.417 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -92.38 95.82 9.89 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.276 -0.874 . . . . 0.0 111.108 178.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.58 HG22 ' O ' ' A' ' 8' ' ' ILE . 11.2 tt -89.09 113.64 25.98 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-O 120.945 0.403 . . . . 0.0 111.06 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.421 ' CB ' ' HB2' ' A' ' 62' ' ' HIS . 0.2 OUTLIER -87.52 110.14 20.12 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.929 0.395 . . . . 0.0 110.911 -179.535 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.533 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 40.0 p -108.32 164.37 12.38 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.151 179.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.446 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 2.1 t -99.78 105.51 34.89 Favored Pre-proline 0 C--N 1.328 -0.356 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -177.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 91' ' ' THR . 52.6 Cg_exo -54.64 176.2 0.12 Allowed 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 122.328 2.018 . . . . 0.0 113.089 178.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.01 164.05 13.52 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.695 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -163.32 159.45 22.56 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.341 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 5.5 p30 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.576 -0.726 . . . . 0.0 110.256 179.981 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.6 m . . . . . 0 N--CA 1.478 0.961 0 N-CA-C 110.669 -0.123 . . . . 0.0 110.669 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 102' ' ' TRP . . . . . 0.492 ' CE3' HG21 ' A' ' 24' ' ' ILE . 35.8 t-105 72.16 113.88 0.06 Allowed 'General case' 0 N--CA 1.47 0.528 0 O-C-N 123.764 0.665 . . . . 0.0 110.67 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 8.7 tm-20 -155.82 -46.67 0.08 Allowed 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 -178.155 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -78.88 22.76 0.37 Allowed 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 114.076 1.139 . . . . 0.0 114.076 -176.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 40.9 p-80 -67.04 -26.49 66.78 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.233 0.54 . . . . 0.0 109.756 179.253 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 106' ' ' LYS . . . . . 0.414 ' HD3' ' N ' ' B' ' 107' ' ' SER . 0.0 OUTLIER -111.05 -19.91 12.58 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.817 178.203 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . 0.414 ' N ' ' HD3' ' B' ' 106' ' ' LYS . 1.4 m -80.91 89.98 5.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.68 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 125.47 -11.59 7.55 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.643 -179.193 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 93.18 -141.48 15.55 Favored Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.933 -0.651 . . . . 0.0 112.483 179.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -139.85 47.01 1.85 Allowed 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 7.0 m -64.02 135.63 56.6 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.016 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 112' ' ' ARG . . . . . 0.523 ' NH2' ' HD2' ' A' ' 16' ' ' LYS . 8.7 ptm180 -131.57 171.29 13.61 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.123 -179.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . 0.631 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 3.3 mm? . . . . . 0 C--O 1.243 0.735 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.03 -179.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.75 0 N-CA-C 112.009 -0.437 . . . . 0.0 112.009 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -155.24 166.77 32.73 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.787 -0.72 . . . . 0.0 111.853 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.5 m -134.83 155.59 50.38 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 84.9 mtp 58.31 79.76 0.2 Allowed 'General case' 0 N--CA 1.463 0.2 0 O-C-N 123.685 0.616 . . . . 0.0 111.483 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.499 ' HD2' ' H ' ' A' ' 5' ' ' ARG . 3.4 mpt_? -72.26 132.5 84.11 Favored Pre-proline 0 C--N 1.325 -0.498 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.497 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 3.6 Cg_exo -83.46 114.33 2.1 Favored 'Trans proline' 0 N--CA 1.461 -0.397 0 C-N-CA 123.059 2.506 . . . . 0.0 112.745 -178.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 13.6 Cg_exo -70.84 124.31 10.52 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 C-N-CA 122.245 1.963 . . . . 0.0 112.381 178.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.587 ' O ' HG22 ' A' ' 89' ' ' ILE . 5.2 mt -91.46 111.02 23.28 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.079 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.9 mm -77.79 101.45 3.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -177.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.552 HG12 ' CB ' ' A' ' 49' ' ' ALA . 5.3 mt -78.05 164.95 3.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 177.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . 0.533 ' N ' HG22 ' A' ' 10' ' ' ILE . 32.7 t-80 -142.78 114.29 7.95 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.8 ttt180 -63.39 114.09 3.65 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.401 0.62 . . . . 0.0 110.725 -179.504 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -84.67 43.82 1.01 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.185 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.55 3.95 83.9 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.735 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 6.3 ptpt -127.64 -82.65 0.6 Allowed 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.699 0.285 . . . . 0.0 111.138 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.525 ' HE2' ' OE1' ' A' ' 44' ' ' GLU . 22.7 pttm -158.51 -179.55 8.19 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.924 -178.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . 0.516 ' HA ' ' HB3' ' A' ' 48' ' ' PRO . 12.8 m-85 -89.98 -0.41 57.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.524 0.678 . . . . 0.0 109.182 179.214 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.404 ' HA3' ' HB2' ' A' ' 44' ' ' GLU . . . 64.98 -24.92 0.11 Allowed Glycine 0 C--N 1.331 0.274 0 N-CA-C 116.704 1.442 . . . . 0.0 116.704 177.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.575 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.7 p90 -81.96 142.48 32.38 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 122.615 1.197 . . . . 0.0 113.636 -176.562 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 58.6 m -93.14 114.65 27.21 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 113.225 -1.807 . . . . 0.0 111.481 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.649 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -86.4 84.28 7.48 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 178.752 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.589 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 1.9 tpt180 -66.07 135.93 55.3 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.936 -179.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.558 ' HB2' ' HD1' ' A' ' 73' ' ' HIS . . . -90.92 132.58 35.85 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.651 0.262 . . . . 0.0 110.841 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.486 HG22 ' CZ2' ' B' ' 102' ' ' TRP . 18.4 pt -137.29 166.95 24.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.977 0.418 . . . . 0.0 111.226 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -140.15 91.72 2.48 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.698 179.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 1.7 m -79.4 123.36 36.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.639 -179.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -81.15 146.07 30.72 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.822 0.344 . . . . 0.0 110.079 179.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 90.5 mtp -124.79 45.13 2.61 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.824 -178.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.76 -167.06 31.52 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.387 -0.911 . . . . 0.0 112.989 179.397 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -84.44 -34.28 23.5 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.857 0.36 . . . . 0.0 110.668 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.418 ' C ' ' H ' ' A' ' 33' ' ' VAL . 2.4 m -71.67 -178.33 2.2 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.602 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -77.62 30.42 0.16 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 121.011 0.434 . . . . 0.0 111.225 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.418 ' H ' ' C ' ' A' ' 31' ' ' SER . 2.2 p -85.95 120.14 35.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.478 0.656 . . . . 0.0 110.332 179.255 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -149.82 149.74 30.95 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.484 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.49 128.12 52.34 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.844 178.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 12.6 t -80.63 94.94 2.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-O 120.898 0.38 . . . . 0.0 110.656 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 8.0 m-70 -108.63 -174.0 2.41 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.465 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.501 ' ND1' ' HA ' ' A' ' 23' ' ' ALA . 99.1 m-70 -151.39 161.61 42.39 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 -179.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . 0.474 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 68.5 mtm -150.02 144.79 26.02 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.755 0.312 . . . . 0.0 110.488 -178.566 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.508 HG11 ' CD2' ' A' ' 54' ' ' LEU . 2.7 p -74.41 104.5 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-O 121.823 0.82 . . . . 0.0 109.67 179.202 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.589 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 5.3 t-105 -69.82 -40.09 76.1 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.659 -1.155 . . . . 0.0 112.167 -178.389 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' HIS . . . . . 0.511 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.8 t60 -158.91 127.82 5.39 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.329 -178.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.575 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 2.4 p -120.93 129.33 75.8 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.109 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.525 ' OE1' ' HE2' ' A' ' 16' ' ' LYS . 27.5 mt-10 -64.09 113.12 3.31 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.911 -179.049 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.65 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 9.4 p-10 -84.88 34.33 0.54 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.405 -0.816 . . . . 0.0 111.134 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -124.3 17.07 7.52 Favored Glycine 0 N--CA 1.445 -0.753 0 C-N-CA 120.151 -1.024 . . . . 0.0 113.926 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 160.04 -64.99 0.28 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 118.884 -1.627 . . . . 0.0 115.049 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.516 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 49.6 Cg_exo -62.36 -133.33 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.316 2.677 . . . . 0.0 116.913 -177.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.552 ' CB ' HG12 ' A' ' 10' ' ' ILE . . . -43.33 -35.48 1.52 Allowed 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 114.971 1.471 . . . . 0.0 114.971 -176.578 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.65 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 2.0 m -63.42 -53.32 54.21 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 118.399 0.545 . . . . 0.0 111.674 -178.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.6 mm-40 -63.2 -30.96 72.01 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-O 121.52 0.676 . . . . 0.0 109.807 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -64.15 -31.75 73.07 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.913 -1.039 . . . . 0.0 110.067 178.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.65 -5.87 5.52 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.551 179.749 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.582 HD11 HD13 ' A' ' 89' ' ' ILE . 1.1 tt -67.02 117.28 8.86 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.249 0.547 . . . . 0.0 111.44 -179.455 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.435 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -91.19 121.78 33.26 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.311 178.821 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 51.2 tt0 -51.85 138.95 23.03 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.597 177.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.19 15.98 56.5 Favored Glycine 0 CA--C 1.52 0.399 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.713 -179.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.623 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 5.2 t0 -94.28 153.87 17.81 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.773 0.32 . . . . 0.0 110.553 179.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.474 ' HA ' ' HG2' ' A' ' 39' ' ' MET . 4.8 tp -101.02 128.46 47.05 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.589 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.505 ' CG1' HD11 ' A' ' 89' ' ' ILE . 4.0 mp -85.42 124.46 40.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.88 -179.652 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 64.6 p -101.88 -39.95 7.13 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.351 0.596 . . . . 0.0 110.519 179.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 62.0 m80 -139.75 157.19 46.16 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.969 -178.759 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.424 ' O ' HG13 ' A' ' 63' ' ' VAL . 7.6 p -139.82 109.73 3.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.562 178.004 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 61.73 30.64 18.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.654 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.38 45.44 18.8 Favored Glycine 0 N--CA 1.443 -0.844 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -178.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.481 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 4.0 tp10 -149.84 105.11 3.22 Favored Pre-proline 0 N--CA 1.436 -1.166 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.481 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.2 Cg_endo -49.97 127.85 20.43 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 123.474 2.783 . . . . 0.0 111.264 178.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.7 m -88.7 -11.25 10.49 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.129 0 CA-C-N 114.549 -1.205 . . . . 0.0 109.644 -179.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.4 m170 -55.25 93.77 0.01 OUTLIER 'General case' 0 N--CA 1.427 -1.6 0 CA-C-N 113.029 -1.896 . . . . 0.0 111.806 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 114.41 -10.03 22.1 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.523 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 25.6 mt -75.66 145.05 41.31 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.783 0.325 . . . . 0.0 110.295 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.537 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.5 OUTLIER -77.91 166.48 2.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.727 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.558 ' HD1' ' HB2' ' A' ' 23' ' ' ALA . 77.8 t60 -46.04 -52.74 11.39 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.966 0.888 . . . . 0.0 112.3 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.2 p -72.57 -19.71 61.45 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 114.986 -1.006 . . . . 0.0 112.868 -176.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.537 ' HG3' HG12 ' A' ' 72' ' ' VAL . 21.5 mt-10 -70.69 -42.97 69.98 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 121.218 -0.193 . . . . 0.0 110.97 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.649 HG21 ' HG ' ' A' ' 21' ' ' LEU . 15.5 m -64.8 -47.22 89.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.132 0 C-N-CA 120.354 -0.538 . . . . 0.0 109.764 179.273 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.536 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 48.6 t -54.71 -45.79 73.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.077 177.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.447 ' O ' ' HB2' ' A' ' 82' ' ' LYS . 17.9 mt-10 -63.15 -44.6 95.07 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.633 179.092 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -54.37 -41.14 68.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.207 0.527 . . . . 0.0 110.313 179.247 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.557 HG23 HG11 ' A' ' 87' ' ' VAL . 18.5 mt -69.3 -51.83 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.224 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 61.4 mt -59.74 -36.24 76.2 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.183 0.516 . . . . 0.0 110.477 179.095 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 78' ' ' GLU . 25.5 ttmt -59.37 -41.38 89.19 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.63 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 38.4 t -54.82 -36.47 65.03 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.527 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 127.01 -121.31 3.89 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 119.86 -1.162 . . . . 0.0 113.859 178.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 7.9 p30 -98.57 8.97 44.25 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.24 0.543 . . . . 0.0 110.893 -179.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 16.5 pttp -161.72 174.83 12.69 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.006 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.557 HG11 HG23 ' A' ' 80' ' ' ILE . 9.2 p -169.21 146.14 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.405 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -92.67 93.8 8.68 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.282 -0.872 . . . . 0.0 111.007 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.587 HG22 ' O ' ' A' ' 8' ' ' ILE . 9.3 tt -87.39 111.39 21.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 CA-C-O 121.122 0.486 . . . . 0.0 110.659 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.438 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -89.43 106.9 18.76 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.716 0.293 . . . . 0.0 110.67 -179.291 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.623 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 81.5 p -104.51 169.13 8.65 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.839 179.396 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.451 HG22 ' HB3' ' A' ' 59' ' ' LEU . 8.6 t -100.01 107.24 45.89 Favored Pre-proline 0 CA--C 1.537 0.448 0 N-CA-C 113.267 0.84 . . . . 0.0 113.267 -177.264 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.418 ' HD3' ' O ' ' A' ' 91' ' ' THR . 76.3 Cg_exo -54.84 174.6 0.19 Allowed 'Trans proline' 0 C--N 1.352 0.715 0 C-N-CA 122.345 2.03 . . . . 0.0 113.012 177.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -65.48 167.72 8.36 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.17 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -156.15 161.79 40.29 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.742 -0.663 . . . . 0.0 109.968 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 8.6 p30 . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.77 -0.633 . . . . 0.0 110.83 -179.579 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 5.0 m . . . . . 0 N--CA 1.476 0.832 0 CA-C-O 121.109 0.481 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 102' ' ' TRP . . . . . 0.486 ' CZ2' HG22 ' A' ' 24' ' ' ILE . 23.3 t90 -137.98 127.06 24.25 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.23 179.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -79.97 -87.79 0.07 Allowed 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.288 179.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -144.4 -166.61 2.42 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.184 -179.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 9.9 m80 -61.5 122.0 14.12 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.201 0.524 . . . . 0.0 111.778 -179.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -132.02 9.7 4.53 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -114.22 151.63 32.49 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.891 -179.609 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . -87.89 136.37 13.76 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.851 -179.571 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 99.05 136.22 9.26 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.034 -0.603 . . . . 0.0 112.654 179.4 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . 0.577 ' OE1' ' HD2' ' A' ' 22' ' ' ARG . 4.5 mm-40 -154.51 75.31 0.98 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.197 0.522 . . . . 0.0 110.695 178.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 111' ' ' THR . . . . . 0.43 HG22 ' NE2' ' A' ' 73' ' ' HIS . 5.1 t -108.68 177.61 4.73 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 112' ' ' ARG . . . . . 0.561 ' HG2' ' N ' ' B' ' 113' ' ' LEU . 0.0 OUTLIER -132.14 151.38 51.82 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 -179.83 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . 0.561 ' N ' ' HG2' ' B' ' 112' ' ' ARG . 3.8 mm? . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.442 -0.789 . . . . 0.0 110.434 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.742 0 N-CA-C 112.138 -0.385 . . . . 0.0 112.138 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.88 -178.92 45.12 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.873 -0.68 . . . . 0.0 111.796 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.4 m -155.97 155.3 32.53 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 91.1 mtp 60.23 78.34 0.28 Allowed 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.686 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.494 ' HD2' ' H ' ' A' ' 5' ' ' ARG . 4.6 mpt_? -71.25 137.46 84.21 Favored Pre-proline 0 C--N 1.323 -0.581 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 179.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 2.9 Cg_endo -84.57 112.67 1.6 Allowed 'Trans proline' 0 N--CA 1.462 -0.334 0 C-N-CA 122.92 2.414 . . . . 0.0 112.813 -178.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.464 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 17.4 Cg_exo -68.48 125.83 13.36 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.227 1.951 . . . . 0.0 112.526 178.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.573 ' O ' HG22 ' A' ' 89' ' ' ILE . 5.9 mt -92.85 115.82 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.106 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.5 mm -79.23 104.26 7.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.122 0 CA-C-N 116.191 -0.458 . . . . 0.0 112.208 -178.118 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.657 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.5 mt -80.14 160.73 4.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 176.341 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . 0.523 ' N ' HG22 ' A' ' 10' ' ' ILE . 39.8 t-80 -141.75 114.31 8.37 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.661 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 53.2 ttt180 -63.44 98.14 0.16 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.773 -179.678 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.89 55.77 2.17 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.357 -179.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.28 7.56 77.96 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.826 179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.456 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 10.9 ptpt -132.47 -87.73 0.45 Allowed 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.855 -0.203 . . . . 0.0 111.272 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.572 ' HB2' ' OXT' ' B' ' 113' ' ' LEU . 32.1 pttt -155.5 -172.62 4.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.454 0.169 . . . . 0.0 110.717 -178.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . 0.657 ' HB3' HG21 ' A' ' 10' ' ' ILE . 21.0 m-85 -88.17 2.12 52.85 Favored 'General case' 0 CA--C 1.519 -0.236 0 CA-C-O 121.062 0.458 . . . . 0.0 109.925 179.443 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.505 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 52.2 49.79 48.86 Favored Glycine 0 C--O 1.219 -0.821 0 N-CA-C 116.728 1.451 . . . . 0.0 116.728 176.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.498 ' HB3' HG23 ' A' ' 43' ' ' VAL . 8.1 p90 -164.21 148.86 10.0 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-O 122.345 1.069 . . . . 0.0 112.477 176.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 42.3 m -94.63 113.99 25.88 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 113.722 -1.581 . . . . 0.0 112.806 -179.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.612 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -88.1 82.85 7.07 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.939 0.4 . . . . 0.0 109.941 178.294 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.542 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 3.6 tpt180 -67.99 129.53 40.21 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.727 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.477 ' HB2' ' HD1' ' A' ' 73' ' ' HIS . . . -94.38 136.16 34.99 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.794 -0.185 . . . . 0.0 110.582 179.66 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.431 HD11 ' HG3' ' A' ' 39' ' ' MET . 3.2 pt -149.46 122.71 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.101 0.477 . . . . 0.0 111.437 179.372 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.475 ' HD2' ' CE2' ' A' ' 34' ' ' TYR . 82.1 mtm180 -96.38 99.8 11.46 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 1.6 m -76.09 110.5 11.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.201 0.524 . . . . 0.0 111.519 -179.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 48.4 m-85 -79.8 99.23 7.39 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.377 178.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 72.7 mtm -127.36 126.37 42.38 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.493 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 131.54 168.57 12.17 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -69.3 -46.55 66.89 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 117.006 0.403 . . . . 0.0 110.59 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.412 ' C ' ' H ' ' A' ' 33' ' ' VAL . 0.8 OUTLIER -76.81 -177.87 4.55 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.702 179.833 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.5 32.94 0.2 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.108 0.48 . . . . 0.0 110.681 179.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.412 ' H ' ' C ' ' A' ' 31' ' ' SER . 3.6 p -80.8 138.81 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 CA-C-O 121.353 0.597 . . . . 0.0 110.313 -179.561 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.475 ' CE2' ' HD2' ' A' ' 25' ' ' ARG . 43.5 p90 -145.29 152.95 40.73 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.352 -179.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -110.58 125.05 52.98 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.679 -0.409 . . . . 0.0 110.162 178.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.6 t -81.55 100.41 5.52 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.765 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.992 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.3 m-70 -113.5 -179.06 3.53 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.28 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.569 ' CD2' HG11 ' A' ' 76' ' ' VAL . 94.4 m-70 -149.66 153.57 37.22 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.498 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . 0.466 ' HG2' ' HA ' ' A' ' 59' ' ' LEU . 27.2 mtm -148.57 145.5 27.85 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 -178.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.512 HG11 ' CD2' ' A' ' 54' ' ' LEU . 3.4 p -73.25 103.32 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.54 0 CA-C-O 122.006 0.908 . . . . 0.0 109.793 179.274 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.542 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.6 t-105 -70.65 -40.37 73.07 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.468 -1.242 . . . . 0.0 111.499 -178.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' HIS . . . . . 0.497 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 1.9 t60 -156.64 132.09 9.35 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 114.938 -1.028 . . . . 0.0 109.952 -178.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.505 HG23 ' O ' ' A' ' 18' ' ' GLY . 5.1 p -127.96 125.48 64.81 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.012 0 CA-C-O 121.919 0.866 . . . . 0.0 110.348 178.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.484 ' O ' ' HB2' ' A' ' 50' ' ' SER . 28.3 mt-10 -65.24 114.09 4.47 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 114.284 -1.325 . . . . 0.0 112.117 -178.566 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.544 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 10.6 p-10 -83.65 46.07 1.12 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.564 -0.743 . . . . 0.0 110.646 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -119.44 -2.77 13.16 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.399 -0.905 . . . . 0.0 113.595 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.63 -59.09 0.27 Allowed Glycine 0 CA--C 1.521 0.411 0 C-N-CA 119.119 -1.515 . . . . 0.0 114.884 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 78.4 Cg_exo -59.24 -130.98 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 0.98 0 C-N-CA 123.463 2.776 . . . . 0.0 116.593 -178.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.524 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -43.69 -40.81 4.43 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 114.382 1.253 . . . . 0.0 114.382 -176.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.544 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -60.03 -59.99 4.55 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -178.312 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -63.37 -28.62 70.12 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.064 0.459 . . . . 0.0 110.713 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.13 -29.99 70.72 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.947 178.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 135.69 -9.28 4.28 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.767 179.444 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.512 ' CD2' HG11 ' A' ' 40' ' ' VAL . 0.9 OUTLIER -68.34 117.76 10.54 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.374 0.607 . . . . 0.0 111.42 -179.615 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -92.85 121.24 34.03 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.726 178.419 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.497 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 37.1 tt0 -50.13 135.09 21.47 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 177.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.15 59.5 1.75 Allowed Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.569 -0.824 . . . . 0.0 111.231 -178.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.429 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 3.4 t0 -142.81 147.58 35.71 Favored 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.496 HD12 ' O ' ' A' ' 38' ' ' HIS . 10.9 tp -92.95 131.28 38.09 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.408 -179.541 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.481 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.6 mp -89.13 125.35 42.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 28.9 p -101.87 -40.02 7.11 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.259 0.552 . . . . 0.0 110.799 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -139.76 158.44 44.09 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.591 -179.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 63' ' ' VAL . 7.6 p -141.62 110.4 2.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-O 121.11 0.481 . . . . 0.0 109.981 178.149 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 8.9 t30 59.49 33.91 22.37 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.629 -0.714 . . . . 0.0 111.093 179.399 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.0 42.26 25.27 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.17 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.502 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 5.6 tp10 -151.37 106.67 2.95 Favored Pre-proline 0 N--CA 1.434 -1.234 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.502 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.2 Cg_endo -50.4 129.1 25.09 Favored 'Trans proline' 0 N--CA 1.454 -0.843 0 C-N-CA 123.557 2.838 . . . . 0.0 110.962 178.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 20.2 m -85.85 -13.31 11.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.258 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.0 m170 -56.6 96.98 0.02 OUTLIER 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 112.732 -2.031 . . . . 0.0 110.835 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.94 -12.88 26.93 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.405 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 21.7 mt -76.1 141.61 41.93 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.571 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -75.46 165.65 3.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 179.292 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.477 ' HD1' ' HB2' ' A' ' 23' ' ' ALA . 83.2 t60 -42.97 -55.19 3.87 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-O 121.765 0.793 . . . . 0.0 112.82 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.0 p -74.53 -16.96 60.81 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 114.93 -1.032 . . . . 0.0 113.04 -176.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.571 ' HG3' HG12 ' A' ' 72' ' ' VAL . 24.3 mt-10 -70.57 -42.03 71.64 Favored 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 120.95 -0.3 . . . . 0.0 111.121 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.612 HG21 ' HG ' ' A' ' 21' ' ' LEU . 15.6 m -65.59 -46.44 89.54 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.125 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.471 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 60.9 t -53.05 -48.59 52.62 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.632 176.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -63.47 -44.44 94.45 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.847 179.266 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.38 -42.01 66.48 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.269 0.557 . . . . 0.0 109.933 178.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.568 HG23 HG11 ' A' ' 87' ' ' VAL . 22.7 mt -67.35 -48.83 76.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.621 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.471 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 50.2 mt -60.84 -39.4 88.94 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-O 121.032 0.444 . . . . 0.0 110.657 178.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 23.1 ttmt -60.35 -40.5 90.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.142 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 41.4 t -54.22 -31.79 54.16 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.714 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 129.52 -127.81 5.56 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.672 179.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -99.1 10.53 41.27 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 121.432 0.634 . . . . 0.0 110.413 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.415 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 17.3 pttp -161.99 172.51 15.85 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.862 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.568 HG11 HG23 ' A' ' 80' ' ' ILE . 8.5 p -168.03 149.82 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 112.962 0.727 . . . . 0.0 112.962 -178.326 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.464 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -93.37 97.66 10.72 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.309 178.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.573 HG22 ' O ' ' A' ' 8' ' ' ILE . 10.2 tt -89.62 112.91 25.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-O 120.884 0.373 . . . . 0.0 110.862 179.392 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.9 OUTLIER -88.67 105.02 17.4 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.729 0.3 . . . . 0.0 111.296 -179.008 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.502 ' O ' ' HD3' ' A' ' 93' ' ' PRO . 42.3 p -102.36 163.2 12.37 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.436 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 1.6 t -98.65 104.92 27.18 Favored Pre-proline 0 C--N 1.326 -0.439 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.502 ' HD3' ' O ' ' A' ' 91' ' ' THR . 73.2 Cg_exo -53.73 176.06 0.1 Allowed 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 122.503 2.135 . . . . 0.0 113.036 178.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -64.26 166.12 8.48 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.33 -0.85 . . . . 0.0 111.319 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -161.67 173.42 14.72 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.899 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 4.7 p30 . . . . . 0 C--O 1.252 1.232 0 CA-C-O 118.826 -0.607 . . . . 0.0 110.358 179.547 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.479 1.023 0 CA-C-O 120.602 0.239 . . . . 0.0 111.087 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 102' ' ' TRP . . . . . 0.423 ' HH2' ' CH2' ' A' ' 41' ' ' TRP . 13.6 t90 -117.55 88.9 3.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.332 0.586 . . . . 0.0 110.295 179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 20.2 mp0 -94.32 -36.98 11.71 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.395 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 29.8 m -153.74 -170.25 3.52 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.029 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 13.6 m80 -70.78 69.76 0.45 Allowed 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.135 0.493 . . . . 0.0 110.592 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 51.5 mttt -81.88 62.07 5.5 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.071 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 3.1 p -157.07 -70.68 0.1 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.636 -179.092 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 111.95 113.68 3.33 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.144 -179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 121.4 136.17 4.96 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.794 -0.717 . . . . 0.0 113.002 179.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -125.11 17.85 8.42 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.781 0.324 . . . . 0.0 110.184 179.114 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 1.4 m -59.36 149.97 27.56 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.488 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 112' ' ' ARG . . . . . 0.401 ' HD3' ' O ' ' B' ' 113' ' ' LEU . 0.1 OUTLIER -135.74 170.71 15.55 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.823 -179.493 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . 0.572 ' OXT' ' HB2' ' A' ' 16' ' ' LYS . 3.3 mm? . . . . . 0 C--O 1.253 1.265 0 CA-C-O 118.111 -0.947 . . . . 0.0 109.219 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.503 ' HA2' ' HG3' ' A' ' 95' ' ' GLU . . . . . . . . 0 N--CA 1.481 1.7 0 N-CA-C 112.104 -0.398 . . . . 0.0 112.104 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -119.86 -157.47 10.27 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.159 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.6 t -158.13 162.83 38.01 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 37.8 mtp 55.85 78.93 0.18 Allowed 'General case' 0 C--O 1.235 0.336 0 O-C-N 123.58 0.55 . . . . 0.0 111.471 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.475 ' HD2' ' H ' ' A' ' 5' ' ' ARG . 4.0 mpt_? -70.92 137.47 85.07 Favored Pre-proline 0 C--N 1.325 -0.464 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.0 OUTLIER -86.93 111.08 0.87 Allowed 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 122.795 2.33 . . . . 0.0 112.899 -178.284 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.532 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 15.5 Cg_exo -69.12 119.87 6.8 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 121.935 1.756 . . . . 0.0 112.15 178.616 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.616 ' O ' HG22 ' A' ' 89' ' ' ILE . 7.0 mt -87.85 110.94 21.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-N 115.07 -0.968 . . . . 0.0 108.967 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 3.2 mm -76.77 101.45 2.93 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 CA-C-N 115.825 -0.625 . . . . 0.0 112.045 -178.045 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.676 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.2 mt -78.92 159.27 4.64 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.368 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 176.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . 0.506 ' N ' HG22 ' A' ' 10' ' ' ILE . 15.1 t-80 -135.44 109.98 8.54 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 178.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 34.1 ttt180 -64.64 100.71 0.4 Allowed 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 115.419 -0.81 . . . . 0.0 111.05 -179.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.95 55.68 1.81 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.275 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.7 -45.31 3.38 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 121.062 -0.59 . . . . 0.0 112.479 -179.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 7.2 ptpt -79.23 -85.79 0.08 Allowed 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.63 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 23.7 pttt -157.29 -174.09 4.73 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 111.52 0.193 . . . . 0.0 111.52 -178.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . 0.676 ' HB3' HG21 ' A' ' 10' ' ' ILE . 21.4 m-85 -85.49 2.42 44.74 Favored 'General case' 0 CA--C 1.518 -0.25 0 CA-C-O 121.103 0.478 . . . . 0.0 109.757 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.559 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 51.04 53.54 26.6 Favored Glycine 0 C--O 1.215 -1.044 0 N-CA-C 116.124 1.21 . . . . 0.0 116.124 177.328 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.478 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 12.4 p90 -163.94 149.03 10.54 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 122.744 1.259 . . . . 0.0 112.965 176.156 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.529 ' HA ' ' HB2' ' B' ' 112' ' ' ARG . 40.5 m -95.16 117.48 30.29 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 112.904 -1.953 . . . . 0.0 113.109 -178.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.493 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.4 OUTLIER -94.45 80.78 3.91 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 178.286 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.509 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 1.6 tpt180 -65.26 140.78 58.75 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.995 -179.51 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.42 ' CB ' ' HD1' ' A' ' 73' ' ' HIS . . . -103.7 129.01 50.98 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.882 -179.404 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.495 HG21 ' CZ3' ' B' ' 102' ' ' TRP . 3.4 pt -140.22 165.83 20.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.013 0.435 . . . . 0.0 111.061 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.417 ' O ' ' HB2' ' B' ' 103' ' ' GLU . 0.1 OUTLIER -135.87 111.38 9.22 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.336 0.589 . . . . 0.0 110.43 -179.373 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.935 HG12 ' H ' ' B' ' 102' ' ' TRP . 8.9 m -84.84 115.86 27.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.726 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -79.6 106.3 11.53 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -81.9 -0.63 44.62 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.789 -178.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -158.54 163.42 33.02 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.21 179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -81.84 62.7 5.76 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.547 0.689 . . . . 0.0 109.903 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.414 ' HB2' HG12 ' A' ' 33' ' ' VAL . 49.0 m -163.51 -160.03 0.56 Allowed 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.942 -179.216 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.03 7.81 8.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.823 0.344 . . . . 0.0 111.426 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.414 HG12 ' HB2' ' A' ' 31' ' ' SER . 2.2 p -82.24 123.89 38.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 121.404 0.621 . . . . 0.0 111.341 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 51.9 p90 -158.8 150.75 21.14 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.919 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -112.27 129.71 56.18 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.918 0.39 . . . . 0.0 110.248 178.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.6 t -83.92 117.0 28.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.895 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 89.2 m-70 -125.43 -177.73 3.99 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.464 179.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.551 ' CD2' HG11 ' A' ' 76' ' ' VAL . 98.0 m-70 -147.71 154.7 40.9 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -179.269 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 35.4 mtm -149.13 146.56 27.74 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -178.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.585 HG11 HD21 ' A' ' 54' ' ' LEU . 2.6 p -74.0 101.75 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.976 0.893 . . . . 0.0 109.774 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.509 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 2.9 t-105 -70.39 -39.21 74.67 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.37 -178.598 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' HIS . . . . . 0.44 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -156.53 129.57 7.92 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.176 -0.92 . . . . 0.0 110.975 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.559 HG23 ' O ' ' A' ' 18' ' ' GLY . 3.8 p -124.28 127.06 73.02 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.555 0.693 . . . . 0.0 110.248 179.06 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -66.64 113.23 4.64 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 114.507 -1.224 . . . . 0.0 112.043 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.558 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 10.4 p-10 -81.5 40.2 0.57 Allowed 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.918 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -108.15 -8.75 28.93 Favored Glycine 0 N--CA 1.447 -0.604 0 C-N-CA 120.714 -0.755 . . . . 0.0 113.376 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.407 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 160.55 -49.91 0.37 Allowed Glycine 0 CA--C 1.526 0.761 0 C-N-CA 119.491 -1.338 . . . . 0.0 114.867 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_exo -60.11 -128.98 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.09 0 C-N-CA 123.094 2.529 . . . . 0.0 116.233 -179.223 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.504 ' HA ' HG12 ' A' ' 10' ' ' ILE . . . -45.12 -39.97 6.49 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 114.195 1.183 . . . . 0.0 114.195 -177.113 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.558 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 5.5 m -57.34 -62.86 1.47 Allowed 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 111.791 0.293 . . . . 0.0 111.791 -179.158 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.407 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 9.5 mm-40 -63.25 -23.15 67.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.295 -179.27 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.66 -26.16 66.07 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.256 178.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 130.21 -8.36 5.99 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.677 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.585 HD21 HG11 ' A' ' 40' ' ' VAL . 1.1 tt -70.0 117.99 12.28 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-O 121.435 0.636 . . . . 0.0 111.324 -179.576 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.404 ' H ' ' HG3' ' A' ' 55' ' ' ARG . 0.0 OUTLIER -96.45 121.52 38.35 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.941 178.357 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.434 ' HB2' HG12 ' A' ' 43' ' ' VAL . 46.3 tt0 -50.45 141.14 12.59 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.771 0.319 . . . . 0.0 111.51 178.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 93.24 6.0 63.31 Favored Glycine 0 C--N 1.333 0.415 0 C-N-CA 121.239 -0.505 . . . . 0.0 113.231 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.537 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 2.0 t0 -89.9 155.71 18.95 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.032 0.444 . . . . 0.0 111.036 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.489 HD12 ' O ' ' A' ' 38' ' ' HIS . 2.5 tp -100.14 133.97 43.75 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.7 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.502 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.5 mp -91.26 122.74 42.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 26.2 p -99.7 -40.61 7.68 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.401 0.619 . . . . 0.0 110.361 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 72.7 m80 -138.28 157.21 46.71 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.761 -178.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.57 111.51 5.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.965 -0.562 . . . . 0.0 109.889 178.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 60.39 30.04 19.49 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.811 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.46 44.29 17.14 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.182 -179.036 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.472 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.1 tp10 -149.99 106.26 3.21 Favored Pre-proline 0 N--CA 1.437 -1.084 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 -179.066 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.472 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 4.4 Cg_endo -49.62 129.32 23.22 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.66 2.907 . . . . 0.0 111.124 178.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 22.3 m -86.82 -7.96 10.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 114.594 -1.185 . . . . 0.0 109.039 -178.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 22.1 m170 -55.17 101.01 0.04 OUTLIER 'General case' 0 N--CA 1.426 -1.629 0 CA-C-N 112.741 -2.027 . . . . 0.0 111.676 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.68 -6.77 49.07 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.842 179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 26.3 mt -78.29 141.41 38.53 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.669 0.271 . . . . 0.0 110.469 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.674 HG12 ' HG3' ' A' ' 75' ' ' GLU . 2.0 p -78.58 169.82 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 177.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.462 ' CE1' ' HA ' ' B' ' 110' ' ' GLU . 8.6 t60 -48.19 -53.62 16.28 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.682 0.753 . . . . 0.0 112.352 -179.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 16.7 p -69.44 -22.66 63.64 Favored 'General case' 0 C--N 1.307 -1.253 0 CA-C-N 115.192 -0.913 . . . . 0.0 112.456 -177.247 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.674 ' HG3' HG12 ' A' ' 72' ' ' VAL . 24.4 mt-10 -69.06 -43.28 74.94 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 121.224 -0.191 . . . . 0.0 111.476 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.551 HG11 ' CD2' ' A' ' 38' ' ' HIS . 10.0 m -66.24 -44.61 91.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.726 178.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.458 HG13 HD23 ' B' ' 113' ' ' LEU . 54.0 t -56.57 -47.26 82.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.929 177.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -62.78 -43.46 98.73 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.55 178.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.38 -40.75 65.26 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.339 0.59 . . . . 0.0 109.915 178.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.633 HG23 HG11 ' A' ' 87' ' ' VAL . 28.1 mt -68.84 -51.58 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.889 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 64.1 mt -59.88 -36.03 76.08 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.1 0.476 . . . . 0.0 110.644 179.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 35.2 ttmt -57.91 -39.15 77.25 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.231 -0.895 . . . . 0.0 111.58 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 34.0 t -56.21 -44.87 79.91 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.244 179.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 136.29 -116.61 1.48 Allowed Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.323 -0.941 . . . . 0.0 113.71 178.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -102.85 9.1 39.1 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.475 0.655 . . . . 0.0 110.506 -178.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 10.1 pttp -161.36 173.53 14.82 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.499 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.633 HG11 HG23 ' A' ' 80' ' ' ILE . 10.4 p -167.76 145.13 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 N-CA-C 112.896 0.702 . . . . 0.0 112.896 -179.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.532 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -91.15 96.22 10.47 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.37 178.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.616 HG22 ' O ' ' A' ' 8' ' ' ILE . 11.1 tt -88.72 111.08 22.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.196 0.522 . . . . 0.0 110.831 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -87.93 106.0 17.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.982 -179.089 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.537 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 64.6 p -102.33 170.86 7.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.21 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.428 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 4.9 t -104.85 99.95 21.41 Favored Pre-proline 0 CA--C 1.534 0.358 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -178.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' ' 91' ' ' THR . 74.6 Cg_exo -51.73 167.63 0.41 Allowed 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.487 2.125 . . . . 0.0 113.204 178.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.431 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.0 OUTLIER -63.75 158.71 21.01 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.953 -179.937 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . 0.503 ' HG3' ' HA2' ' A' ' 1' ' ' GLY . 0.0 OUTLIER -159.7 167.13 29.07 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.529 -179.716 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 8.3 p30 . . . . . 0 C--O 1.25 1.082 0 CA-C-O 118.497 -0.763 . . . . 0.0 111.043 -179.934 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . 0.408 ' O ' ' HB3' ' B' ' 102' ' ' TRP . 0.8 OUTLIER . . . . . 0 N--CA 1.476 0.847 0 N-CA-C 110.581 -0.155 . . . . 0.0 110.581 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 102' ' ' TRP . . . . . 0.935 ' H ' HG12 ' A' ' 26' ' ' VAL . 65.0 t-105 72.25 150.23 0.1 Allowed 'General case' 0 N--CA 1.466 0.348 0 O-C-N 123.718 0.636 . . . . 0.0 111.796 179.6 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 103' ' ' GLU . . . . . 0.417 ' HB2' ' O ' ' A' ' 25' ' ' ARG . 0.0 OUTLIER -158.96 172.05 18.92 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.765 179.448 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 3.4 p -70.43 168.77 15.41 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.803 179.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -72.66 122.08 20.85 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.327 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -116.83 -155.62 0.59 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.003 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 1.5 m -50.21 132.93 24.07 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-O 121.086 0.47 . . . . 0.0 111.698 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 134.61 -41.46 1.45 Allowed Glycine 0 N--CA 1.445 -0.744 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.656 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 79.73 -151.03 33.49 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.944 -0.646 . . . . 0.0 112.424 179.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . 0.462 ' HA ' ' CE1' ' A' ' 73' ' ' HIS . 2.6 mm-40 -141.16 111.16 6.62 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -179.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 20.2 m -131.92 88.94 2.62 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.234 0.54 . . . . 0.0 109.915 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 112' ' ' ARG . . . . . 0.529 ' HB2' ' HA ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -83.06 150.08 26.54 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.954 -179.084 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . 0.63 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 0.3 OUTLIER . . . . . 0 C--O 1.244 0.787 0 CA-C-O 118.48 -0.772 . . . . 0.0 110.297 179.35 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.428 ' HA2' ' HG3' ' A' ' 95' ' ' GLU . . . . . . . . 0 N--CA 1.479 1.549 0 N-CA-C 112.171 -0.372 . . . . 0.0 112.171 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 159.88 -173.47 36.57 Favored Glycine 0 N--CA 1.444 -0.826 0 C-N-CA 121.078 -0.582 . . . . 0.0 111.702 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 53.2 m -148.59 169.88 19.35 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 110.381 -0.229 . . . . 0.0 110.381 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 9.0 mtp 60.65 77.53 0.32 Allowed 'General case' 0 C--O 1.233 0.185 0 O-C-N 123.476 0.485 . . . . 0.0 111.619 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.455 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.0 mpt_? -73.26 136.86 78.6 Favored Pre-proline 0 C--N 1.326 -0.421 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 179.198 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.455 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.5 Cg_endo -89.22 110.02 0.48 Allowed 'Trans proline' 0 C--O 1.235 0.326 0 C-N-CA 123.196 2.597 . . . . 0.0 113.021 -179.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.488 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 16.9 Cg_exo -69.78 122.52 9.19 Favored 'Trans proline' 0 CA--C 1.515 -0.453 0 C-N-CA 122.327 2.018 . . . . 0.0 113.112 179.166 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.549 HD13 ' HA ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -87.42 112.0 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.258 0 CA-C-N 115.129 -0.941 . . . . 0.0 108.778 178.317 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.401 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 3.2 mm -77.5 101.42 3.37 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.336 -178.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.672 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.4 mt -77.81 162.65 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.33 0 N-CA-C 106.904 -1.517 . . . . 0.0 106.904 176.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . 0.544 ' N ' HG22 ' A' ' 10' ' ' ILE . 15.0 t-80 -140.79 113.15 7.97 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.212 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 47.2 ttt180 -63.39 101.7 0.34 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.995 -178.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.12 49.95 1.0 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.45 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.12 12.7 81.5 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 121.199 -0.524 . . . . 0.0 113.1 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 3.8 ptpt -136.51 -82.59 0.38 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.849 0.325 . . . . 0.0 111.12 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.522 ' HB2' ' OXT' ' B' ' 113' ' ' LEU . 8.6 pttt -156.16 -179.59 8.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.421 -178.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . 0.672 ' HB3' HG21 ' A' ' 10' ' ' ILE . 19.3 m-85 -86.58 5.34 36.14 Favored 'General case' 0 CA--C 1.517 -0.308 0 CA-C-O 121.245 0.545 . . . . 0.0 110.191 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.576 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 54.46 49.22 61.49 Favored Glycine 0 C--O 1.215 -1.069 0 N-CA-C 116.697 1.439 . . . . 0.0 116.697 176.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.482 ' HB2' HG23 ' A' ' 40' ' ' VAL . 9.3 p90 -165.6 149.23 8.07 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-O 122.345 1.069 . . . . 0.0 113.068 176.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.427 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 94.8 m -95.25 118.37 31.91 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 113.643 -1.617 . . . . 0.0 112.724 -179.161 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.559 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -89.91 84.86 6.24 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.802 0.334 . . . . 0.0 110.248 178.511 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.566 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 5.1 tpt180 -68.74 142.66 54.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.222 -179.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.593 ' HB2' ' HD1' ' A' ' 73' ' ' HIS . . . -108.55 144.8 35.75 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 110.679 -0.119 . . . . 0.0 110.679 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 2.7 pt -148.29 141.0 18.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.236 0 CA-C-O 120.828 0.347 . . . . 0.0 111.389 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 11.6 mtm180 -105.93 93.6 4.72 Favored 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' A' ' 34' ' ' TYR . 10.9 m -81.43 114.29 22.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.508 -179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.465 ' HE1' ' HG ' ' B' ' 104' ' ' SER . 4.5 m-85 -82.83 121.91 27.54 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 36.6 mmt -84.8 93.58 8.51 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.898 -179.2 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.72 -146.7 18.34 Favored Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.008 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -100.09 -14.02 18.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.11 0.481 . . . . 0.0 110.643 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.516 ' HB2' HG12 ' A' ' 33' ' ' VAL . 0.7 OUTLIER -72.3 169.53 16.05 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.959 -179.836 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 2.1 p-10 -79.77 9.72 4.88 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -178.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.516 HG12 ' HB2' ' A' ' 31' ' ' SER . 3.6 p -78.75 130.02 36.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.425 0.631 . . . . 0.0 110.204 179.288 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.443 ' HA ' ' O ' ' A' ' 26' ' ' VAL . 51.2 p90 -142.21 146.69 35.49 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.786 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -107.69 133.8 51.59 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 178.404 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 6.2 t -84.91 108.7 17.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.893 -179.52 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -117.82 177.97 4.58 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.517 ' CD2' HG11 ' A' ' 76' ' ' VAL . 98.7 m-70 -148.15 153.35 38.71 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 -179.509 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.0 mtm -147.24 145.25 29.38 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.083 -178.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.564 HG11 ' CD2' ' A' ' 54' ' ' LEU . 3.4 p -73.33 102.52 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.71 0 CA-C-O 121.946 0.879 . . . . 0.0 109.576 179.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.566 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 2.5 t-105 -70.48 -39.36 74.26 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.699 -1.137 . . . . 0.0 111.89 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' HIS . . . . . 0.461 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 4.3 t60 -155.23 124.5 6.3 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.368 -178.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.576 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.2 p -122.04 124.92 72.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 CA-C-O 121.575 0.702 . . . . 0.0 109.975 179.258 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.504 ' OE1' ' HA2' ' A' ' 18' ' ' GLY . 49.3 mt-10 -66.99 120.12 13.11 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 114.396 -1.275 . . . . 0.0 111.307 -179.391 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.555 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 14.7 p-10 -85.84 24.8 1.2 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.84 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -82.98 -23.4 55.54 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.959 -179.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 170.92 -51.78 0.19 Allowed Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 119.568 -1.301 . . . . 0.0 114.745 -179.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -55.33 -128.45 0.0 OUTLIER 'Trans proline' 0 CA--C 1.546 1.085 0 C-N-CA 123.505 2.803 . . . . 0.0 116.92 -178.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.473 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -45.23 -40.01 6.97 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 114.496 1.295 . . . . 0.0 114.496 -176.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.555 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -60.5 -61.08 2.85 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -177.956 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 5.5 mm-40 -61.01 -32.49 72.08 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.372 0.606 . . . . 0.0 110.781 -178.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -60.34 -29.84 69.14 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.677 179.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 136.8 -11.84 3.95 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.511 -0.852 . . . . 0.0 113.092 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.564 ' CD2' HG11 ' A' ' 40' ' ' VAL . 0.8 OUTLIER -68.08 116.04 8.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.406 0.622 . . . . 0.0 111.074 -179.642 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.44 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -93.77 125.56 38.45 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.026 178.975 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -51.42 140.18 18.14 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 120.876 0.37 . . . . 0.0 111.036 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.71 10.09 67.72 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.95 -0.643 . . . . 0.0 113.161 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.562 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 5.3 t0 -88.5 148.91 23.91 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.0 0.429 . . . . 0.0 110.659 179.59 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.432 HD12 ' O ' ' A' ' 38' ' ' HIS . 10.1 tp -95.91 130.03 42.99 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.726 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.504 HG12 HD11 ' A' ' 89' ' ' ILE . 3.6 mp -88.15 126.14 41.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.127 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 41.9 p -102.8 -38.62 7.35 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.646 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 78.6 m80 -141.23 159.49 42.1 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.922 -178.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.404 HG21 HG13 ' A' ' 80' ' ' ILE . 7.3 p -140.65 111.14 3.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.125 0.488 . . . . 0.0 110.208 178.238 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.409 ' HA ' ' HB3' ' A' ' 88' ' ' ALA . 2.8 t30 60.76 26.34 16.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.372 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 82.18 44.41 7.57 Favored Glycine 0 N--CA 1.442 -0.943 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.935 -179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.496 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.5 tp10 -153.19 110.5 2.64 Favored Pre-proline 0 N--CA 1.433 -1.312 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.519 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.496 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 3.7 Cg_endo -49.99 131.88 31.24 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 123.725 2.95 . . . . 0.0 111.407 179.153 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 33.5 m -88.23 -8.61 10.94 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.289 -178.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -56.75 94.85 0.01 OUTLIER 'General case' 0 N--CA 1.429 -1.51 0 CA-C-N 112.95 -1.932 . . . . 0.0 111.566 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 112.47 -11.82 25.91 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.603 -0.808 . . . . 0.0 112.435 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 29.7 mt -74.87 138.82 42.72 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 179.527 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.507 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.8 OUTLIER -77.79 167.19 2.39 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.276 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.593 ' HD1' ' HB2' ' A' ' 23' ' ' ALA . 48.2 t60 -44.75 -46.42 10.46 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.779 0.8 . . . . 0.0 112.939 -179.314 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.496 ' H ' HG13 ' A' ' 72' ' ' VAL . 19.3 p -80.51 -21.06 42.27 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 115.274 -0.875 . . . . 0.0 112.755 -176.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.507 ' HG3' HG12 ' A' ' 72' ' ' VAL . 25.5 mt-10 -70.23 -40.31 74.56 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 121.319 -0.153 . . . . 0.0 111.354 -179.626 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.559 HG21 ' HG ' ' A' ' 21' ' ' LEU . 4.5 m -65.45 -45.76 91.97 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.183 0 C-N-CA 120.251 -0.58 . . . . 0.0 109.597 178.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.485 HG13 ' CD1' ' B' ' 113' ' ' LEU . 99.5 t -55.24 -47.02 78.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.187 -0.915 . . . . 0.0 109.926 177.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -64.81 -43.97 91.41 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.607 179.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.48 -42.08 66.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.768 178.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.677 HG23 HG11 ' A' ' 87' ' ' VAL . 16.2 mt -67.81 -52.15 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.719 179.484 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 93.1 mt -59.95 -32.78 71.12 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.017 179.312 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 8.3 ttmm -61.55 -38.91 89.19 Favored 'General case' 0 CA--C 1.518 -0.27 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.352 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 36.2 t -56.0 -52.99 62.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.961 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 137.73 -134.43 6.96 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 119.96 -1.114 . . . . 0.0 113.132 179.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -73.67 -2.01 21.37 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.853 0.358 . . . . 0.0 111.799 -179.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -159.93 175.26 13.26 Favored 'General case' 0 N--CA 1.444 -0.773 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.503 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.677 HG11 HG23 ' A' ' 80' ' ' ILE . 13.4 p -166.84 147.1 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 O-C-N 123.596 0.56 . . . . 0.0 112.465 -179.062 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.488 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -93.51 96.76 10.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.642 179.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.543 HG22 ' O ' ' A' ' 8' ' ' ILE . 6.9 tt -88.8 111.57 22.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-O 120.973 0.416 . . . . 0.0 110.255 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -89.11 112.25 23.19 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.825 0.345 . . . . 0.0 111.074 -178.908 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.562 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 61.3 p -109.76 171.73 7.27 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.306 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 3.9 t -104.21 105.48 49.34 Favored Pre-proline 0 CA--C 1.537 0.464 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -55.73 175.24 0.22 Allowed 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.622 2.215 . . . . 0.0 113.403 178.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.402 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.0 OUTLIER -63.71 159.95 18.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.287 -179.647 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . 0.428 ' HG3' ' HA2' ' A' ' 1' ' ' GLY . 0.0 OUTLIER -157.05 157.19 34.16 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.073 0.463 . . . . 0.0 110.677 -179.988 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 8.1 p30 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 118.504 -0.76 . . . . 0.0 110.891 -179.586 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.2 m . . . . . 0 N--CA 1.48 1.042 0 CA-C-O 120.658 0.266 . . . . 0.0 110.953 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 102' ' ' TRP . . . . . . . . . . . . . 4.3 t-105 179.2 83.93 0.01 OUTLIER 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 8.5 mp0 -106.93 -76.46 0.61 Allowed 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.44 -177.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 104' ' ' SER . . . . . 0.465 ' HG ' ' HE1' ' A' ' 27' ' ' TYR . 0.7 OUTLIER -99.99 144.88 28.51 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.796 0.332 . . . . 0.0 111.098 -179.438 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 3.4 t60 -108.9 -14.4 14.58 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.109 0.481 . . . . 0.0 110.592 179.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -67.42 97.3 0.56 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.792 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -156.58 25.83 0.34 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.29 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 147.65 -98.08 0.19 Allowed Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 121.066 -0.588 . . . . 0.0 111.945 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -175.71 -129.59 1.23 Allowed Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.939 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -130.71 35.83 3.97 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.208 0.528 . . . . 0.0 110.11 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 8.4 m -71.14 98.3 1.66 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.218 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 112' ' ' ARG . . . . . 0.406 ' CB ' ' HA ' ' A' ' 20' ' ' THR . 6.1 ptm180 -91.28 173.58 7.84 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.542 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . 0.522 ' OXT' ' HB2' ' A' ' 16' ' ' LYS . 3.4 mm? . . . . . 0 C--O 1.249 1.063 0 CA-C-O 117.907 -1.044 . . . . 0.0 109.223 179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.671 0 N-CA-C 112.029 -0.428 . . . . 0.0 112.029 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -127.73 177.58 17.47 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 121.078 -0.582 . . . . 0.0 111.725 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.0 m -128.09 -178.93 4.73 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 28.6 mtp 57.06 74.05 0.43 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.008 0.432 . . . . 0.0 111.3 179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.49 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.6 mpt_? -73.31 135.53 79.23 Favored Pre-proline 0 C--N 1.32 -0.692 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.49 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 1.9 Cg_endo -87.31 116.88 1.22 Allowed 'Trans proline' 0 N--CA 1.462 -0.371 0 C-N-CA 123.3 2.666 . . . . 0.0 112.842 -178.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.466 ' CB ' ' HB1' ' A' ' 88' ' ' ALA . 7.5 Cg_exo -75.12 122.08 6.93 Favored 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.078 1.852 . . . . 0.0 112.843 178.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.62 HD13 ' HA ' ' A' ' 54' ' ' LEU . 2.3 mt -86.71 112.41 22.91 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.101 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.356 178.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.8 mm -79.06 99.74 3.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.218 -0.446 . . . . 0.0 112.049 -178.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.695 HG21 ' HB3' ' A' ' 17' ' ' TYR . 4.3 mt -77.64 160.47 4.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 106.997 -1.483 . . . . 0.0 106.997 177.059 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . 0.523 ' N ' HG22 ' A' ' 10' ' ' ILE . 24.8 t-80 -138.17 111.59 8.06 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.01 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . 0.422 HH11 ' HD3' ' A' ' 12' ' ' ARG . 30.8 ttt180 -62.89 103.71 0.47 Allowed 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.838 -179.009 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -78.77 47.7 0.76 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.373 -0.83 . . . . 0.0 111.482 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.17 -4.86 65.04 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 121.287 -0.482 . . . . 0.0 113.344 179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.8 ptpt -120.61 -80.12 0.62 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.996 0.398 . . . . 0.0 111.44 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.503 ' HB2' ' OXT' ' B' ' 113' ' ' LEU . 20.5 pttt -155.76 -174.96 5.19 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 120.64 0.257 . . . . 0.0 110.558 -178.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . 0.695 ' HB3' HG21 ' A' ' 10' ' ' ILE . 18.4 m-85 -89.71 5.65 44.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.254 0.55 . . . . 0.0 109.661 179.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.521 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 54.26 48.31 64.49 Favored Glycine 0 C--O 1.219 -0.842 0 N-CA-C 116.423 1.329 . . . . 0.0 116.423 176.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.458 ' HB3' HG23 ' A' ' 43' ' ' VAL . 10.4 p90 -164.09 146.56 9.2 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-O 122.627 1.203 . . . . 0.0 112.836 176.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 91.8 m -93.64 114.83 27.24 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 113.46 -1.7 . . . . 0.0 112.51 -178.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.598 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -91.14 82.47 5.53 Favored 'General case' 0 N--CA 1.472 0.662 0 CA-C-O 120.577 0.227 . . . . 0.0 111.218 179.119 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 1.3 tpt180 -73.22 144.63 46.68 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.761 -0.2 . . . . 0.0 111.185 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -100.66 146.08 27.63 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.039 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.5 pt -145.25 139.74 22.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 178.613 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.473 ' HB3' ' CD1' ' A' ' 34' ' ' TYR . 29.7 mtt180 -111.09 101.7 10.21 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.734 0.302 . . . . 0.0 110.998 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.3 m -84.3 115.47 26.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.696 179.081 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.483 ' CD1' ' HB2' ' B' ' 103' ' ' GLU . 8.6 m-85 -80.22 148.08 30.97 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 48.3 mtt -87.18 62.82 7.5 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.9 -134.05 16.46 Favored Glycine 0 N--CA 1.447 -0.623 0 N-CA-C 110.917 -0.873 . . . . 0.0 110.917 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -90.47 86.08 6.33 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 178.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.0 p -163.32 162.29 25.03 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.858 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -81.63 -17.16 49.11 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.454 0.645 . . . . 0.0 110.615 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.7 p -79.75 138.78 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 CA-C-N 115.434 -0.803 . . . . 0.0 110.879 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.473 ' CD1' ' HB3' ' A' ' 25' ' ' ARG . 51.3 p90 -149.71 155.96 41.07 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.827 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -103.78 128.53 51.19 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.021 0.439 . . . . 0.0 110.138 179.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t -86.3 107.17 16.35 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.605 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.6 m-70 -112.86 179.65 3.91 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.18 -0.463 . . . . 0.0 109.953 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.501 ' O ' HD12 ' A' ' 59' ' ' LEU . 99.1 m-70 -148.92 152.43 36.38 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 41.0 mtm -148.07 146.15 28.73 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.573 HG11 ' CD2' ' A' ' 54' ' ' LEU . 2.7 p -72.28 102.89 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.989 0.9 . . . . 0.0 109.342 179.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 2.1 t-105 -68.86 -39.92 79.61 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.442 -178.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' HIS . . . . . 0.498 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 2.0 t60 -158.34 128.46 6.02 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.67 -179.674 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.3 p -124.66 126.06 71.01 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.04 0 CA-C-O 121.642 0.734 . . . . 0.0 110.422 179.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.508 ' O ' ' HB2' ' A' ' 50' ' ' SER . 5.7 mt-10 -68.69 123.06 19.85 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.279 -1.328 . . . . 0.0 111.914 -179.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.499 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 12.2 p-10 -86.11 20.3 2.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.925 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.36 -19.63 66.17 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 116.006 -0.543 . . . . 0.0 113.666 -179.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 168.18 -49.77 0.23 Allowed Glycine 0 CA--C 1.522 0.486 0 C-N-CA 119.134 -1.508 . . . . 0.0 114.733 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_exo -60.33 -132.48 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.967 0 C-N-CA 123.117 2.544 . . . . 0.0 116.318 -179.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.499 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -39.79 -41.63 1.15 Allowed 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 114.88 1.437 . . . . 0.0 114.88 -176.703 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.508 ' HB2' ' O ' ' A' ' 44' ' ' GLU . 0.4 OUTLIER -63.07 -59.5 4.7 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 118.385 0.538 . . . . 0.0 112.227 -178.098 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -63.62 -21.93 66.63 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.272 0.558 . . . . 0.0 110.847 -179.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -72.2 -26.15 61.94 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.463 178.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 135.09 -12.95 4.41 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.204 179.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.62 ' HA ' HD13 ' A' ' 8' ' ' ILE . 1.2 tt -69.54 115.24 8.56 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.312 0.577 . . . . 0.0 111.646 -179.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.413 ' O ' ' HB2' ' A' ' 58' ' ' ASP . 0.0 OUTLIER -93.86 123.53 37.27 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.666 178.035 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.498 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 34.4 tt0 -49.36 143.77 6.13 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.945 0.402 . . . . 0.0 111.893 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.6 5.66 74.54 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.951 -0.643 . . . . 0.0 112.737 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.487 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 6.3 t0 -86.61 144.07 27.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.854 0.359 . . . . 0.0 110.693 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.501 HD12 ' O ' ' A' ' 38' ' ' HIS . 4.0 tp -92.17 134.12 35.16 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.509 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.539 HG12 HD11 ' A' ' 89' ' ' ILE . 3.4 mp -91.45 125.23 44.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.042 -179.311 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 45.8 p -101.66 -37.56 8.3 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.386 0.612 . . . . 0.0 110.886 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 69.5 m80 -141.73 157.68 44.75 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.148 -178.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.446 HG21 HG13 ' A' ' 80' ' ' ILE . 12.2 p -144.29 122.07 5.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.008 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 56.78 27.06 12.23 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.611 -179.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 75.28 43.25 26.04 Favored Glycine 0 C--N 1.333 0.387 0 C-N-CA 120.917 -0.659 . . . . 0.0 111.596 -178.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.458 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.8 tp10 -150.42 104.4 3.11 Favored Pre-proline 0 N--CA 1.433 -1.319 0 C-N-CA 122.949 0.5 . . . . 0.0 109.732 -178.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 47.3 Cg_exo -41.48 128.41 3.42 Favored 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 124.114 3.21 . . . . 0.0 111.512 177.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 32.7 m -86.25 -11.32 11.2 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 114.675 -1.148 . . . . 0.0 109.321 -178.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.7 m170 -54.6 97.09 0.02 OUTLIER 'General case' 0 N--CA 1.424 -1.728 0 CA-C-N 112.697 -2.047 . . . . 0.0 111.667 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.03 -13.86 23.97 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.828 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 41.2 mt -74.54 145.13 43.69 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.693 0.246 . . . . 0.0 110.349 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.638 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -79.2 168.95 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 179.268 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.503 ' HB2' ' O ' ' B' ' 107' ' ' SER . 2.2 t60 -45.79 -50.19 14.28 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 121.45 0.643 . . . . 0.0 112.628 -179.234 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.478 ' H ' HG13 ' A' ' 72' ' ' VAL . 18.0 p -81.64 -14.54 56.56 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.484 -0.78 . . . . 0.0 112.84 -177.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.638 ' HG3' HG12 ' A' ' 72' ' ' VAL . 15.2 mt-10 -69.81 -42.6 73.48 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 121.25 -0.18 . . . . 0.0 111.286 -179.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.598 HG21 ' HG ' ' A' ' 21' ' ' LEU . 4.3 m -65.1 -44.56 95.63 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 CA-C-O 121.369 0.604 . . . . 0.0 109.43 179.006 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.433 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 83.5 t -53.14 -49.5 50.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 114.829 -1.078 . . . . 0.0 110.043 177.315 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 67.3 mt-10 -59.84 -45.33 92.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.754 -0.657 . . . . 0.0 111.005 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -54.16 -40.78 67.77 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.347 0.594 . . . . 0.0 110.216 178.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.754 HG23 HG11 ' A' ' 87' ' ' VAL . 14.5 mt -73.17 -49.75 36.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.722 0 CA-C-N 115.321 -0.854 . . . . 0.0 111.091 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.433 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 91.1 mt -57.83 -41.67 82.75 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.837 0.351 . . . . 0.0 111.069 179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 18.8 ttmt -60.58 -37.85 82.67 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.703 -0.68 . . . . 0.0 112.026 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 8.1 t -51.41 -45.81 62.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.456 -179.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.71 -132.49 7.95 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 119.879 -1.153 . . . . 0.0 114.023 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -73.14 -6.66 47.19 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 111.948 0.351 . . . . 0.0 111.948 -178.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.1 pttp -160.17 175.1 13.3 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-O 120.618 0.247 . . . . 0.0 110.985 -179.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.754 HG11 HG23 ' A' ' 80' ' ' ILE . 11.4 p -167.42 146.19 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.737 -0.665 . . . . 0.0 112.516 -179.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.466 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -92.87 98.57 11.46 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.886 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.55 HG22 ' O ' ' A' ' 8' ' ' ILE . 8.6 tt -92.62 113.32 27.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 120.81 0.338 . . . . 0.0 110.352 178.606 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.423 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -92.03 112.77 24.83 Favored 'General case' 0 C--N 1.323 -0.559 0 O-C-N 122.189 -0.32 . . . . 0.0 111.106 -179.052 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.487 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 77.6 p -108.41 175.68 5.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.525 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 4.1 t -104.04 102.14 30.12 Favored Pre-proline 0 CA--C 1.535 0.403 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -177.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.405 ' HD3' ' O ' ' A' ' 91' ' ' THR . 76.2 Cg_exo -53.99 170.9 0.41 Allowed 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 122.403 2.068 . . . . 0.0 112.913 177.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.409 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.0 OUTLIER -63.66 157.86 22.91 Favored 'General case' 0 C--N 1.319 -0.717 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.57 179.789 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -160.33 161.95 33.36 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.943 0.402 . . . . 0.0 111.311 -179.202 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 5.7 p30 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 118.608 -0.71 . . . . 0.0 109.579 178.645 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 6.1 m . . . . . 0 N--CA 1.48 1.05 0 CA-C-O 120.665 0.269 . . . . 0.0 110.904 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 102' ' ' TRP . . . . . . . . . . . . . 35.2 p90 -147.77 147.67 30.12 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 103' ' ' GLU . . . . . 0.483 ' HB2' ' CD1' ' A' ' 27' ' ' TYR . 16.0 mp0 -91.72 -23.92 19.62 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.008 0.432 . . . . 0.0 110.698 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 1.4 m -136.93 147.61 46.49 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.299 -0.41 . . . . 0.0 109.939 179.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -116.39 -74.81 0.59 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.565 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -54.21 113.56 1.3 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.096 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . 0.503 ' O ' ' HB2' ' A' ' 73' ' ' HIS . 3.6 m -140.31 66.76 1.38 Allowed 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.133 -179.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 112.97 8.8 19.73 Favored Glycine 0 N--CA 1.449 -0.482 0 N-CA-C 111.671 -0.571 . . . . 0.0 111.671 -179.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . 113.46 -156.43 15.63 Favored Glycine 0 N--CA 1.445 -0.742 0 C-N-CA 120.991 -0.624 . . . . 0.0 111.943 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -135.33 60.84 1.68 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.298 0.57 . . . . 0.0 109.592 179.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 111' ' ' THR . . . . . 0.42 HG22 ' H ' ' B' ' 112' ' ' ARG . 0.2 OUTLIER -73.95 177.05 5.88 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.468 -179.413 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 112' ' ' ARG . . . . . 0.42 ' H ' HG22 ' B' ' 111' ' ' THR . 14.5 ptt180 -162.09 171.68 17.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.029 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . 0.503 ' OXT' ' HB2' ' A' ' 16' ' ' LYS . 3.3 mm? . . . . . 0 C--O 1.249 1.071 0 CA-C-O 117.752 -1.118 . . . . 0.0 110.074 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.691 0 N-CA-C 112.275 -0.33 . . . . 0.0 112.275 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -173.03 -179.07 43.47 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 121.131 -0.557 . . . . 0.0 111.737 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -139.16 -176.66 4.59 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 39.2 ttp 55.24 70.48 0.62 Allowed 'General case' 0 C--N 1.331 -0.223 0 O-C-N 123.514 0.508 . . . . 0.0 110.915 179.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.456 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.1 mpt_? -70.73 132.47 87.07 Favored Pre-proline 0 C--N 1.323 -0.558 0 N-CA-C 109.36 -0.608 . . . . 0.0 109.36 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.456 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -87.28 109.58 0.74 Allowed 'Trans proline' 0 N--CA 1.463 -0.306 0 C-N-CA 122.884 2.39 . . . . 0.0 113.15 -178.396 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 15.0 Cg_exo -69.16 124.22 11.11 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.183 1.922 . . . . 0.0 112.34 178.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.571 HD13 ' HA ' ' A' ' 54' ' ' LEU . 2.6 mt -88.49 109.43 19.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 CA-C-N 115.166 -0.924 . . . . 0.0 108.784 178.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.416 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 4.2 mm -76.1 99.97 2.07 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.084 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.586 -178.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.703 HG21 ' HB3' ' A' ' 17' ' ' TYR . 4.8 mt -76.67 159.85 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . 0.533 ' N ' HG22 ' A' ' 10' ' ' ILE . 14.7 t-80 -137.98 109.67 7.08 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 47.2 ttt180 -63.58 104.32 0.64 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.59 -179.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -79.4 50.07 1.06 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.539 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.05 -37.86 2.85 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 121.237 -0.506 . . . . 0.0 112.289 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.5 ptpt -84.09 -86.63 0.12 Allowed 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.654 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 7.5 pttp -154.89 -174.4 4.97 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 121.116 -0.234 . . . . 0.0 111.374 -178.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . 0.703 ' HB3' HG21 ' A' ' 10' ' ' ILE . 19.8 m-85 -87.98 1.63 53.68 Favored 'General case' 0 C--O 1.224 -0.238 0 CA-C-O 121.019 0.438 . . . . 0.0 109.858 179.119 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 52.38 53.37 31.99 Favored Glycine 0 C--O 1.22 -0.766 0 N-CA-C 116.738 1.455 . . . . 0.0 116.738 176.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.562 ' HB3' HG23 ' A' ' 43' ' ' VAL . 9.3 p90 -165.49 144.88 6.51 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 122.409 1.099 . . . . 0.0 113.018 175.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.432 ' O ' ' HA ' ' A' ' 40' ' ' VAL . 92.2 m -91.27 116.08 28.54 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 113.434 -1.712 . . . . 0.0 112.921 -178.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.598 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -90.34 82.15 5.98 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 121.063 0.459 . . . . 0.0 110.133 178.491 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.527 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 4.5 tpt180 -70.21 125.02 25.57 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.379 -179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.552 ' HA ' ' ND1' ' A' ' 38' ' ' HIS . . . -81.17 140.32 35.04 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.258 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.1 pt -141.02 139.9 33.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-O 121.235 0.541 . . . . 0.0 111.66 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 36.3 mtm180 -106.5 93.76 4.77 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.704 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.4 m -81.28 100.91 5.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-O 121.069 0.461 . . . . 0.0 110.574 179.131 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . 0.402 ' CD2' ' HB3' ' A' ' 34' ' ' TYR . 24.8 m-85 -81.57 158.75 24.29 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 116.242 -0.436 . . . . 0.0 109.845 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 99.7 mmm -93.88 55.66 2.16 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.176 0.512 . . . . 0.0 110.248 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 67.42 -126.01 24.51 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.63 -0.713 . . . . 0.0 112.012 -179.555 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -82.35 71.23 9.41 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.434 0.635 . . . . 0.0 109.574 179.303 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.412 ' HB3' HG12 ' A' ' 33' ' ' VAL . 49.1 m -161.76 149.41 14.7 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.483 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -78.84 -12.39 60.03 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.127 0.489 . . . . 0.0 111.416 -179.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.412 HG12 ' HB3' ' A' ' 31' ' ' SER . 4.5 p -76.58 132.05 33.7 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.586 0.708 . . . . 0.0 110.784 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.402 ' HB3' ' CD2' ' A' ' 27' ' ' TYR . 27.8 p90 -150.29 148.5 28.94 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.56 179.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.15 128.99 48.41 Favored 'General case' 0 C--N 1.318 -0.797 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 178.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.9 t -81.59 96.41 3.25 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.049 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 -110.06 -173.88 2.36 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.816 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.552 ' ND1' ' HA ' ' A' ' 23' ' ' ALA . 95.2 m-70 -149.7 166.29 29.82 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 48.4 ttm -153.19 138.17 17.22 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.894 -0.409 . . . . 0.0 109.894 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.669 HG11 HD21 ' A' ' 54' ' ' LEU . 2.6 p -71.6 102.52 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 CA-C-O 122.007 0.908 . . . . 0.0 108.871 178.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.527 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.1 t-105 -69.75 -41.16 75.59 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.814 -177.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' HIS . . . . . 0.449 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -154.59 128.09 8.55 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.076 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.562 HG23 ' HB3' ' A' ' 19' ' ' PHE . 5.8 p -125.47 124.77 67.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 CA-C-O 121.834 0.826 . . . . 0.0 110.534 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.589 ' O ' ' HB2' ' A' ' 50' ' ' SER . 32.5 mt-10 -68.63 118.38 11.56 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-N 114.171 -1.377 . . . . 0.0 112.41 -178.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.609 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 14.7 p-10 -87.47 32.66 0.7 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.772 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -92.21 -22.66 29.16 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.866 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.526 ' O ' ' HB2' ' A' ' 51' ' ' GLU . . . 174.85 -51.42 0.13 Allowed Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 119.534 -1.317 . . . . 0.0 114.281 -179.095 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -60.81 -131.13 0.0 OUTLIER 'Trans proline' 0 CA--C 1.543 0.931 0 C-N-CA 123.401 2.734 . . . . 0.0 116.409 -179.009 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.522 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -42.12 -44.71 3.75 Favored 'General case' 0 N--CA 1.464 0.273 0 N-CA-C 114.644 1.35 . . . . 0.0 114.644 -176.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.609 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -62.12 -58.32 8.24 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -177.661 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.526 ' HB2' ' O ' ' A' ' 47' ' ' GLY . 2.3 mm-40 -62.2 -24.68 67.35 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.213 0.53 . . . . 0.0 110.799 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -70.68 -24.58 62.7 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.267 178.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 136.31 -12.87 4.07 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.914 179.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.669 HD21 HG11 ' A' ' 40' ' ' VAL . 1.1 tt -69.29 116.29 9.55 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.623 0.725 . . . . 0.0 112.036 -179.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.86 125.71 42.88 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.587 177.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -50.87 141.76 12.82 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.894 0.378 . . . . 0.0 111.209 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 86.19 37.85 8.83 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.628 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.633 ' OD1' ' HB ' ' A' ' 91' ' ' THR . 1.9 t70 -120.52 142.73 49.04 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 179.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.535 HD12 ' O ' ' A' ' 38' ' ' HIS . 12.2 tp -89.72 128.1 36.05 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.89 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.511 HG12 HD11 ' A' ' 89' ' ' ILE . 4.0 mp -86.19 126.63 40.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.975 -179.629 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 41.1 p -102.27 -41.27 6.42 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.871 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 59.3 m80 -138.94 160.24 40.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.176 -178.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.411 HG21 HG13 ' A' ' 80' ' ' ILE . 10.6 p -142.74 115.81 3.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.192 -0.458 . . . . 0.0 109.913 177.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 56.45 31.17 18.37 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.745 -0.662 . . . . 0.0 111.467 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.31 41.03 17.92 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.973 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.522 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.2 tp10 -152.15 108.48 2.82 Favored Pre-proline 0 N--CA 1.432 -1.373 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.522 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 1.3 Cg_endo -48.48 134.61 26.48 Favored 'Trans proline' 0 N--CA 1.45 -1.061 0 C-N-CA 123.636 2.891 . . . . 0.0 111.066 178.284 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 32.9 m -87.57 -7.65 10.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 CA-C-N 114.373 -1.285 . . . . 0.0 109.288 -178.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 18.9 m170 -55.59 96.12 0.02 OUTLIER 'General case' 0 N--CA 1.427 -1.591 0 CA-C-N 112.771 -2.013 . . . . 0.0 111.744 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 111.9 -12.56 27.1 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.291 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 31.1 mt -74.84 138.22 42.37 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 110.005 -0.368 . . . . 0.0 110.005 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.641 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -77.93 169.86 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.267 179.801 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -42.79 -48.9 5.76 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 123.76 0.824 . . . . 0.0 112.711 -179.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.517 ' H ' HG13 ' A' ' 72' ' ' VAL . 25.1 p -84.52 -15.38 46.06 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 113.309 0.855 . . . . 0.0 113.309 -177.049 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.641 ' HG3' HG12 ' A' ' 72' ' ' VAL . 18.7 mt-10 -69.56 -43.39 73.0 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 121.096 -0.242 . . . . 0.0 111.35 -179.176 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.598 HG21 ' HG ' ' A' ' 21' ' ' LEU . 3.8 m -64.4 -45.23 96.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.26 0.552 . . . . 0.0 109.632 179.185 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.41 HG13 ' CD1' ' B' ' 113' ' ' LEU . 79.4 t -54.48 -48.28 69.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.877 177.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -59.56 -49.53 77.4 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.825 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.13 -41.31 62.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.605 179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.702 HG23 HG11 ' A' ' 87' ' ' VAL . 16.0 mt -68.75 -52.88 30.81 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.622 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.972 179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.402 ' HG ' ' O ' ' A' ' 77' ' ' VAL . 46.4 mt -59.05 -37.5 77.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.201 0.524 . . . . 0.0 111.088 179.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -61.71 -38.62 88.53 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.928 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 40.4 t -52.76 -47.29 67.57 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.283 179.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 136.57 -135.39 7.7 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.122 -1.037 . . . . 0.0 112.921 179.146 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -79.6 1.76 24.89 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.132 0.491 . . . . 0.0 111.374 -179.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 10.9 pttp -159.67 175.46 13.15 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.173 -179.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.702 HG11 HG23 ' A' ' 80' ' ' ILE . 12.2 p -167.55 147.18 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 O-C-N 123.567 0.542 . . . . 0.0 112.342 -179.105 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.43 93.84 7.9 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.867 179.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.511 HD11 HG12 ' A' ' 60' ' ' ILE . 7.3 tt -88.3 113.59 25.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-O 121.055 0.455 . . . . 0.0 110.474 179.078 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.463 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -90.58 110.83 21.97 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.945 0.402 . . . . 0.0 111.235 -179.005 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.633 ' HB ' ' OD1' ' A' ' 58' ' ' ASP . 26.1 p -103.77 169.54 8.46 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.217 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.432 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 8.6 t -107.25 104.59 52.92 Favored Pre-proline 0 CA--C 1.534 0.342 0 C-N-CA 120.444 -0.502 . . . . 0.0 112.191 -178.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_exo -53.09 172.24 0.2 Allowed 'Trans proline' 0 C--N 1.351 0.669 0 C-N-CA 122.311 2.007 . . . . 0.0 113.039 178.099 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -64.28 163.39 13.0 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.317 -0.856 . . . . 0.0 111.048 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -156.72 177.98 10.86 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.4 -179.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 7.5 p30 . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.529 -0.748 . . . . 0.0 110.733 179.985 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 N--CA 1.478 0.971 0 CA-C-O 120.911 0.386 . . . . 0.0 110.354 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 102' ' ' TRP . . . . . 0.443 ' HH2' ' CH2' ' A' ' 41' ' ' TRP . 22.9 p90 -132.9 163.02 30.07 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.034 179.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -63.08 -73.09 0.12 Allowed 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.954 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -159.24 169.61 23.72 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.245 0.545 . . . . 0.0 111.466 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 8.0 t-160 -109.82 106.12 15.59 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.605 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 12.7 mptt -131.54 20.93 4.7 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.257 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 46.2 m -122.94 111.21 16.35 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.682 -179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 79.83 165.09 30.58 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.789 -0.719 . . . . 0.0 111.821 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -80.56 -109.52 0.29 Allowed Glycine 0 N--CA 1.447 -0.577 0 C-N-CA 120.964 -0.636 . . . . 0.0 111.874 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 mt-10 -142.98 44.39 1.57 Allowed 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 179.498 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 7.0 m -62.57 148.55 45.71 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.157 -0.929 . . . . 0.0 110.877 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 112' ' ' ARG . . . . . . . . . . . . . 13.4 ptp180 -143.67 168.14 20.6 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.894 0.378 . . . . 0.0 110.692 -179.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . 0.654 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 3.3 mm? . . . . . 0 C--N 1.318 -0.764 0 CA-C-O 118.588 -0.72 . . . . 0.0 109.761 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.877 0 N-CA-C 111.92 -0.472 . . . . 0.0 111.92 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -149.13 169.42 29.51 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.159 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.6 m -135.4 157.84 45.87 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 110.38 -0.229 . . . . 0.0 110.38 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 93.4 mtp 61.23 75.75 0.4 Allowed 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.148 0.499 . . . . 0.0 110.752 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.484 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.0 mpt_? -72.91 134.98 80.77 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.515 179.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 5.0 Cg_endo -92.24 116.02 0.37 Allowed 'Trans proline' 0 CA--C 1.531 0.355 0 C-N-CA 123.326 2.684 . . . . 0.0 113.408 -178.623 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.497 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 12.3 Cg_exo -73.88 124.22 9.02 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 122.439 2.093 . . . . 0.0 113.17 178.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.499 HD13 ' HA ' ' A' ' 54' ' ' LEU . 1.1 mt -87.45 110.33 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.836 177.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.414 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 3.2 mm -78.16 97.91 2.27 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-N 116.354 -0.384 . . . . 0.0 111.569 -178.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.639 HG21 ' HB3' ' A' ' 17' ' ' TYR . 5.2 mt -77.35 162.08 4.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 177.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . 0.52 ' N ' HG22 ' A' ' 10' ' ' ILE . 53.0 t-80 -137.51 114.44 10.64 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 108.11 -1.071 . . . . 0.0 108.11 178.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 30.6 ttt180 -61.34 107.14 0.72 Allowed 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.675 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -80.68 50.68 1.37 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.432 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.34 23.54 74.97 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.638 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.497 ' HG3' ' H ' ' A' ' 16' ' ' LYS . 9.8 ptpt -150.76 -80.6 0.11 Allowed 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 111.651 0.241 . . . . 0.0 111.651 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.642 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 21.7 pttm -158.42 178.25 10.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.377 0.132 . . . . 0.0 110.822 -178.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . 0.639 ' HB3' HG21 ' A' ' 10' ' ' ILE . 6.4 m-85 -89.22 4.44 48.67 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-O 121.54 0.686 . . . . 0.0 109.536 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.408 ' O ' ' HG3' ' A' ' 44' ' ' GLU . . . 64.16 -27.48 0.09 OUTLIER Glycine 0 C--N 1.335 0.528 0 N-CA-C 116.925 1.53 . . . . 0.0 116.925 177.249 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.579 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.4 p90 -81.7 147.64 29.38 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 122.445 1.117 . . . . 0.0 113.459 -176.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.435 ' HA ' ' HB2' ' B' ' 112' ' ' ARG . 87.5 m -97.0 112.55 24.26 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 113.344 -1.753 . . . . 0.0 111.575 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.652 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -85.37 86.78 7.35 Favored 'General case' 0 N--CA 1.466 0.36 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.316 178.985 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.516 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 5.5 tpt180 -68.71 146.13 53.23 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.472 179.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.729 ' HB2' ' HD1' ' A' ' 73' ' ' HIS . . . -105.7 149.36 26.46 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.661 0.267 . . . . 0.0 111.177 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 3.5 pt -146.26 173.21 3.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.555 178.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 6.0 mtp180 -146.15 87.14 1.73 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.7 m -76.22 103.28 3.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 121.391 0.615 . . . . 0.0 111.673 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 23.3 m-85 -82.42 134.49 35.23 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.405 179.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 22.5 mmt -90.21 83.2 5.98 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.58 -161.37 44.45 Favored Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 -178.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -92.87 85.61 5.22 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -165.87 179.92 5.62 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.596 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -80.61 -6.58 58.51 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.749 0.309 . . . . 0.0 111.685 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 1.5 p -78.29 119.26 26.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.556 0.693 . . . . 0.0 110.764 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 29.0 p90 -159.93 148.59 17.36 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.974 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.83 130.21 55.0 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.958 0.409 . . . . 0.0 110.435 179.286 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 t -85.78 95.43 4.55 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.794 179.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 41.6 m-70 -104.94 -174.88 2.64 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.61 179.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.534 ' O ' HD12 ' A' ' 59' ' ' LEU . 99.1 m-70 -150.9 164.61 35.9 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -152.44 139.74 19.45 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.586 -178.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.874 HG11 HD21 ' A' ' 54' ' ' LEU . 1.9 p -73.64 105.51 3.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 121.808 0.813 . . . . 0.0 109.466 178.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.516 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 4.4 t-105 -69.87 -44.39 69.9 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.446 -1.252 . . . . 0.0 112.292 -177.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' HIS . . . . . 0.482 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 2.1 t60 -154.29 133.75 12.72 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.229 -0.896 . . . . 0.0 110.046 -178.332 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.579 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 3.0 p -126.87 129.16 71.36 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 CA-C-O 121.629 0.728 . . . . 0.0 110.859 179.238 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.419 ' O ' ' HB2' ' A' ' 50' ' ' SER . 15.5 mt-10 -66.05 119.79 12.01 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 114.74 -1.118 . . . . 0.0 111.583 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.567 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 9.4 p-10 -88.07 19.16 3.78 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.174 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.03 4.12 60.7 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.372 -0.918 . . . . 0.0 113.837 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 161.27 -55.74 0.31 Allowed Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 118.795 -1.669 . . . . 0.0 115.187 179.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.406 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 50.5 Cg_exo -60.57 -135.14 0.0 OUTLIER 'Trans proline' 0 CA--C 1.545 1.04 0 C-N-CA 123.043 2.495 . . . . 0.0 116.679 -178.079 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.549 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -43.17 -36.99 1.9 Allowed 'General case' 0 CA--C 1.532 0.269 0 N-CA-C 115.208 1.558 . . . . 0.0 115.208 -176.582 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.567 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 1.9 m -62.29 -55.08 31.77 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 118.655 0.661 . . . . 0.0 111.546 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -63.5 -24.31 67.76 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.008 -179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.08 -24.79 60.71 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.905 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.54 -7.33 6.23 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.565 -0.826 . . . . 0.0 113.104 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.874 HD21 HG11 ' A' ' 40' ' ' VAL . 5.1 tt -70.59 113.81 8.07 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.044 0.45 . . . . 0.0 110.88 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.17 122.32 32.35 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.931 178.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.455 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 36.3 tt0 -49.49 131.73 20.88 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 120.905 0.383 . . . . 0.0 110.664 177.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 87.37 65.89 1.35 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.294 -178.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.497 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.7 t0 -144.84 148.31 33.84 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.534 HD12 ' O ' ' A' ' 38' ' ' HIS . 8.7 tp -92.5 127.78 38.12 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.22 -179.635 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.443 ' CG1' HD11 ' A' ' 89' ' ' ILE . 4.0 mp -87.05 125.18 40.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.704 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 52.8 p -102.07 -39.08 7.46 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.379 0.609 . . . . 0.0 110.599 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 59.0 m80 -139.31 155.26 47.83 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.089 -178.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.565 HG21 HG13 ' A' ' 80' ' ' ILE . 7.7 p -138.2 113.07 9.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.851 177.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.8 t30 56.46 32.84 21.44 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.786 -179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 76.12 43.22 22.02 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.12 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.503 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 3.5 tp10 -149.99 106.2 3.21 Favored Pre-proline 0 N--CA 1.44 -0.949 0 C-N-CA 122.578 0.351 . . . . 0.0 110.375 179.673 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.503 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 5.7 Cg_exo -45.09 129.51 10.16 Favored 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 123.71 2.94 . . . . 0.0 111.538 177.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 31.3 m -86.76 -9.56 11.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-N 114.419 -1.264 . . . . 0.0 109.18 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.3 m170 -54.51 97.64 0.02 OUTLIER 'General case' 0 N--CA 1.426 -1.633 0 CA-C-N 112.602 -2.09 . . . . 0.0 112.074 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 108.98 -11.02 34.44 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.63 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.6 mt -75.79 139.96 42.08 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.655 HG12 ' HG3' ' A' ' 75' ' ' GLU . 0.3 OUTLIER -79.3 170.47 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.632 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.729 ' HD1' ' HB2' ' A' ' 23' ' ' ALA . 55.4 t60 -44.37 -54.75 5.55 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 121.668 0.747 . . . . 0.0 112.417 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 27.6 p -73.14 -20.69 60.86 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-N 115.111 -0.949 . . . . 0.0 112.788 -177.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.655 ' HG3' HG12 ' A' ' 72' ' ' VAL . 26.4 mt-10 -69.21 -41.81 76.57 Favored 'General case' 0 N--CA 1.447 -0.583 0 C-N-CA 121.271 -0.171 . . . . 0.0 111.168 -179.261 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.652 HG21 ' HG ' ' A' ' 21' ' ' LEU . 13.6 m -67.05 -46.95 83.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 C-N-CA 120.476 -0.49 . . . . 0.0 110.024 178.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.466 HG23 ' O ' ' A' ' 73' ' ' HIS . 40.6 t -53.13 -46.49 55.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.18 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -66.6 -42.48 86.82 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.836 179.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -54.04 -39.27 66.06 Favored 'General case' 0 C--N 1.327 -0.388 0 O-C-N 123.681 0.613 . . . . 0.0 109.801 178.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.675 HG23 HG11 ' A' ' 87' ' ' VAL . 16.4 mt -71.28 -51.91 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.494 179.472 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 82.5 mt -57.95 -32.69 68.08 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-O 121.104 0.478 . . . . 0.0 110.609 179.076 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 24.8 ttmt -58.67 -40.0 82.28 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.226 179.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 26.1 t -56.9 -55.04 39.65 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.745 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 134.99 -127.96 4.59 Favored Glycine 0 N--CA 1.449 -0.447 0 C-N-CA 120.069 -1.063 . . . . 0.0 113.807 178.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -75.18 -2.9 29.95 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -178.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.422 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 18.5 pttp -159.77 175.33 13.25 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.249 -179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.675 HG11 HG23 ' A' ' 80' ' ' ILE . 13.5 p -166.67 145.1 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.781 0 CA-C-N 115.633 -0.712 . . . . 0.0 112.505 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.472 ' HB1' ' CB ' ' A' ' 7' ' ' PRO . . . -93.88 92.36 7.37 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.3 -0.864 . . . . 0.0 111.665 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.449 HG22 ' O ' ' A' ' 8' ' ' ILE . 6.8 tt -88.05 112.24 23.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-O 121.014 0.435 . . . . 0.0 110.346 179.262 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 1.0 OUTLIER -91.95 115.39 28.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.779 0.323 . . . . 0.0 111.326 -178.829 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.497 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 64.5 p -109.4 175.39 5.47 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.315 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.499 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 6.3 t -103.9 105.16 46.96 Favored Pre-proline 0 C--N 1.325 -0.459 0 N-CA-C 113.04 0.755 . . . . 0.0 113.04 -178.059 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -52.8 171.86 0.2 Allowed 'Trans proline' 0 C--O 1.236 0.421 0 C-N-CA 122.64 2.226 . . . . 0.0 112.928 177.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -66.47 159.16 27.74 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.462 -0.79 . . . . 0.0 110.796 179.532 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -155.47 160.31 40.49 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.218 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 10.8 p30 . . . . . 0 C--O 1.25 1.096 0 CA-C-O 118.47 -0.776 . . . . 0.0 110.516 -179.709 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 15.9 m . . . . . 0 N--CA 1.477 0.902 0 CA-C-O 120.566 0.222 . . . . 0.0 110.597 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 102' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -136.37 34.27 2.76 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.301 0.572 . . . . 0.0 109.877 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -74.61 -71.98 0.31 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.397 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 57.3 m -155.7 -160.03 0.98 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.193 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 105' ' ' HIS . . . . . 0.528 ' HA ' ' O ' ' A' ' 23' ' ' ALA . 4.5 p80 -73.01 82.31 1.23 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.343 0.592 . . . . 0.0 111.178 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 83.2 mttt -94.98 12.81 27.1 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.96 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.03 21.87 5.34 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.56 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 167.28 -123.95 1.17 Allowed Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.533 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -158.63 -128.78 1.02 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.057 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -117.43 33.15 5.77 Favored 'General case' 0 C--N 1.325 -0.493 0 O-C-N 122.79 -0.241 . . . . 0.0 111.317 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 111' ' ' THR . . . . . 0.402 ' HB ' ' CD2' ' A' ' 73' ' ' HIS . 25.8 m -72.45 93.67 1.57 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.438 0.637 . . . . 0.0 110.022 179.336 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 112' ' ' ARG . . . . . 0.435 ' HB2' ' HA ' ' A' ' 20' ' ' THR . 6.8 ptp85 -81.9 174.06 11.64 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.54 -0.755 . . . . 0.0 110.459 -179.567 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . 0.642 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 4.1 mm? . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.517 -0.754 . . . . 0.0 110.852 -179.179 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.458 ' HA2' ' HG3' ' A' ' 95' ' ' GLU . . . . . . . . 0 N--CA 1.482 1.72 0 N-CA-C 111.721 -0.552 . . . . 0.0 111.721 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -112.45 -169.32 17.87 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.173 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.4 m -134.03 152.56 51.89 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.574 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 89.9 mtp 62.3 78.28 0.3 Allowed 'General case' 0 N--CA 1.463 0.192 0 O-C-N 123.715 0.635 . . . . 0.0 110.631 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.441 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.9 mpt_? -72.02 148.92 92.07 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.264 -179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 8.4 Cg_endo -95.43 113.06 0.15 Allowed 'Trans proline' 0 N--CA 1.461 -0.414 0 C-N-CA 123.742 2.961 . . . . 0.0 113.173 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 90' ' ' SER . 12.5 Cg_exo -72.86 122.87 8.51 Favored 'Trans proline' 0 N--CA 1.46 -0.469 0 C-N-CA 122.463 2.109 . . . . 0.0 113.299 178.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.54 HG21 ' N ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -83.38 109.14 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.28 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.072 177.708 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.401 ' H ' HG12 ' A' ' 9' ' ' ILE . 3.2 mm -77.36 97.31 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.174 -178.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.539 HG12 ' HB2' ' A' ' 49' ' ' ALA . 5.7 mt -76.89 159.1 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 177.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . 0.494 ' N ' HG22 ' A' ' 10' ' ' ILE . 47.3 t-80 -136.5 112.18 9.41 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 46.7 ttt180 -63.67 109.16 1.6 Allowed 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.728 -178.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -83.36 52.31 2.19 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.87 178.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.54 -49.65 4.21 Favored Glycine 0 N--CA 1.449 -0.452 0 CA-C-N 115.767 -0.652 . . . . 0.0 112.243 -179.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 10.5 ptpt -71.76 -90.41 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.547 ' HB2' ' O ' ' B' ' 113' ' ' LEU . 16.4 pttm -158.53 -171.56 3.5 Favored 'General case' 0 C--N 1.327 -0.4 0 O-C-N 122.434 -0.166 . . . . 0.0 111.092 -178.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . 0.477 ' HB3' HG21 ' A' ' 10' ' ' ILE . 12.2 m-85 -88.11 -1.76 58.2 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.517 0.675 . . . . 0.0 109.744 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.558 ' HA3' ' HB2' ' A' ' 44' ' ' GLU . . . 63.62 -19.34 0.09 OUTLIER Glycine 0 CA--C 1.519 0.342 0 N-CA-C 117.057 1.583 . . . . 0.0 117.057 177.507 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.591 ' HA ' ' HA ' ' A' ' 43' ' ' VAL . 8.4 p90 -85.44 146.89 26.75 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 122.505 1.145 . . . . 0.0 113.524 -177.253 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.406 HG21 HH11 ' A' ' 22' ' ' ARG . 86.1 m -94.65 113.55 25.37 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.601 -1.636 . . . . 0.0 112.364 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.568 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -89.49 81.5 6.54 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.931 0.396 . . . . 0.0 110.692 178.694 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.452 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 0.1 OUTLIER -69.87 134.42 48.44 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.259 179.417 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.429 ' HB3' ' HD1' ' A' ' 73' ' ' HIS . . . -103.37 141.63 35.61 Favored 'General case' 0 C--N 1.328 -0.344 0 O-C-N 123.011 0.195 . . . . 0.0 111.141 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -146.48 -171.92 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.758 179.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.43 ' HD2' ' OG ' ' B' ' 107' ' ' SER . 0.6 OUTLIER -150.08 118.69 6.53 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 121.26 0.552 . . . . 0.0 110.643 179.326 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.532 ' O ' ' HB2' ' A' ' 34' ' ' TYR . 14.3 m -84.19 -167.77 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.367 178.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -156.19 136.35 12.9 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 22.3 mmt -121.78 112.49 18.43 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 112.385 0.513 . . . . 0.0 112.385 -177.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.33 -156.7 45.43 Favored Glycine 0 N--CA 1.453 -0.2 0 CA-C-N 116.07 -0.513 . . . . 0.0 113.623 178.24 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -91.48 -19.79 22.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.035 0.445 . . . . 0.0 110.274 179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 58.7 m -71.0 160.53 32.75 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.071 179.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.89 21.05 0.57 Allowed 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 3.9 p -81.35 131.06 34.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-O 121.416 0.627 . . . . 0.0 110.081 179.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . 0.532 ' HB2' ' O ' ' A' ' 26' ' ' VAL . 54.1 p90 -147.37 156.06 42.55 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.626 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.474 ' O ' HG22 ' A' ' 26' ' ' VAL . 0.0 OUTLIER -116.05 129.96 56.59 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.86 0.362 . . . . 0.0 110.861 179.209 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 9.4 t -81.01 102.37 6.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.403 ' NE2' ' HB ' ' A' ' 35' ' ' THR . 98.4 m-70 -108.48 -176.06 2.95 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.238 -179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.537 ' CD2' HG11 ' A' ' 76' ' ' VAL . 97.7 m-70 -148.46 168.5 22.51 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 -179.535 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . 0.411 ' HG2' ' O ' ' A' ' 58' ' ' ASP . 3.1 mtm -157.05 137.76 13.24 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 120.61 0.243 . . . . 0.0 110.425 -178.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.927 HG11 HD21 ' A' ' 54' ' ' LEU . 1.9 p -72.83 100.63 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-O 122.126 0.965 . . . . 0.0 108.817 178.625 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.452 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.2 t-105 -69.77 -41.08 75.61 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 114.025 -1.443 . . . . 0.0 112.711 -177.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' HIS . . . . . 0.463 ' O ' ' HA ' ' A' ' 19' ' ' PHE . 1.6 t60 -156.39 127.19 6.81 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.374 -178.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.591 ' HA ' ' HA ' ' A' ' 19' ' ' PHE . 2.4 p -118.84 129.0 75.65 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 CA-C-O 121.251 0.548 . . . . 0.0 110.024 179.18 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.558 ' HB2' ' HA3' ' A' ' 18' ' ' GLY . 5.2 mt-10 -63.9 114.04 3.83 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 114.735 -1.121 . . . . 0.0 111.645 -178.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.485 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 11.8 p-10 -83.17 39.54 0.65 Allowed 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.92 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -122.75 11.88 8.83 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.407 -0.901 . . . . 0.0 113.935 -179.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 156.75 -61.99 0.33 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 118.633 -1.746 . . . . 0.0 115.153 179.314 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . 0.466 ' HB3' ' HA ' ' A' ' 17' ' ' TYR . 51.2 Cg_exo -61.04 -133.41 0.0 OUTLIER 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 123.17 2.58 . . . . 0.0 116.958 -177.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.539 ' HB2' HG12 ' A' ' 10' ' ' ILE . . . -42.13 -35.36 0.91 Allowed 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 114.95 1.463 . . . . 0.0 114.95 -176.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.485 ' CB ' ' HA ' ' A' ' 45' ' ' ASP . 0.4 OUTLIER -61.13 -59.61 5.07 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 118.33 0.513 . . . . 0.0 111.706 -178.921 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -63.61 -30.24 71.38 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.548 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.19 -29.28 70.26 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.673 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.3 -10.5 5.59 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.589 -0.815 . . . . 0.0 113.196 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.927 HD21 HG11 ' A' ' 40' ' ' VAL . 5.6 tt -66.85 114.45 5.71 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.849 0.357 . . . . 0.0 110.48 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.15 122.49 32.5 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.486 178.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.438 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 40.2 tt0 -51.34 138.0 22.17 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.989 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 83.14 47.35 5.82 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.222 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.582 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.3 t0 -127.24 149.23 50.1 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.967 -0.382 . . . . 0.0 109.967 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.507 HD12 ' O ' ' A' ' 38' ' ' HIS . 19.9 tp -93.03 125.8 37.8 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.149 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.451 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.8 mp -83.82 124.74 39.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.276 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 57.8 p -99.51 -40.0 8.06 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.378 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -142.05 157.31 45.06 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.122 -178.349 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.5 p -139.67 115.21 8.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 177.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 59.62 31.1 20.72 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.418 -179.4 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 73.23 45.5 30.78 Favored Glycine 0 N--CA 1.444 -0.789 0 C-N-CA 120.575 -0.821 . . . . 0.0 111.372 -178.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.499 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 1.5 tp10 -151.75 111.23 2.93 Favored Pre-proline 0 N--CA 1.433 -1.316 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 -179.246 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.499 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 4.7 Cg_endo -50.99 133.47 40.65 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 123.551 2.834 . . . . 0.0 111.257 178.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 35.1 m -90.01 -7.87 10.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 114.4 -1.273 . . . . 0.0 109.806 -178.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 14.8 m170 -55.41 95.06 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.54 0 CA-C-N 112.977 -1.919 . . . . 0.0 111.96 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 113.29 -9.37 24.59 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.47 -0.871 . . . . 0.0 112.394 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 32.2 mt -77.39 139.76 39.78 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.505 HG13 ' H ' ' A' ' 74' ' ' THR . 0.6 OUTLIER -81.14 171.18 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 179.162 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.508 ' HB2' ' O ' ' B' ' 107' ' ' SER . 2.1 t60 -42.02 -49.02 4.71 Favored 'General case' 0 N--CA 1.471 0.59 0 C-N-CA 123.682 0.793 . . . . 0.0 112.934 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.505 ' H ' HG13 ' A' ' 72' ' ' VAL . 30.6 p -82.11 -21.14 36.88 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 113.624 0.972 . . . . 0.0 113.624 -176.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.402 ' HG3' HG12 ' A' ' 72' ' ' VAL . 28.2 mt-10 -67.53 -40.83 85.06 Favored 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 121.082 -0.247 . . . . 0.0 111.38 -178.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.568 HG21 ' HG ' ' A' ' 21' ' ' LEU . 3.9 m -65.68 -46.85 88.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 121.267 0.556 . . . . 0.0 109.599 178.66 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.42 HG13 HD13 ' B' ' 113' ' ' LEU . 58.4 t -54.79 -45.71 74.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.295 177.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -62.96 -45.12 93.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.942 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.53 -41.66 66.63 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.34 0.59 . . . . 0.0 110.041 178.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.637 HG23 HG11 ' A' ' 87' ' ' VAL . 12.0 mt -68.77 -50.66 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.964 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 65.9 mt -59.23 -39.54 83.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.252 0.549 . . . . 0.0 110.478 178.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 21.4 ttmt -61.46 -36.58 80.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.69 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 44.3 t -53.76 -47.64 70.49 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.129 -179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 138.06 -124.45 2.96 Favored Glycine 0 N--CA 1.449 -0.455 0 C-N-CA 120.264 -0.969 . . . . 0.0 113.295 179.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 9.6 p30 -93.65 7.07 46.16 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.265 0.555 . . . . 0.0 110.887 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.419 ' HB2' ' O ' ' A' ' 10' ' ' ILE . 19.8 pttp -161.12 179.21 8.59 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.859 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.637 HG11 HG23 ' A' ' 80' ' ' ILE . 11.4 p -170.15 143.68 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 O-C-N 123.609 0.568 . . . . 0.0 112.439 -179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.09 90.44 6.4 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.649 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.451 HD11 ' CG1' ' A' ' 60' ' ' ILE . 5.0 tt -87.78 115.65 28.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-O 120.954 0.407 . . . . 0.0 110.553 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 3.6 t -94.76 116.04 28.25 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 120.777 0.322 . . . . 0.0 111.395 -178.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.582 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 81.4 p -109.37 173.31 6.38 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.7 179.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.402 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 3.6 t -101.44 104.18 32.11 Favored Pre-proline 0 CA--C 1.536 0.414 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 91' ' ' THR . 77.1 Cg_exo -54.37 177.46 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.577 2.185 . . . . 0.0 113.015 177.609 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -62.55 156.47 23.0 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.396 -179.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . 0.458 ' HG3' ' HA2' ' A' ' 1' ' ' GLY . 0.7 OUTLIER -158.78 160.29 36.12 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.764 -179.951 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 10.2 p30 . . . . . 0 C--O 1.251 1.162 0 CA-C-O 118.362 -0.828 . . . . 0.0 109.319 178.925 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 73.3 m . . . . . 0 N--CA 1.475 0.799 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 102' ' ' TRP . . . . . 0.455 ' H ' ' HA ' ' A' ' 26' ' ' VAL . 1.9 t90 66.26 49.17 1.51 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-O 121.75 0.786 . . . . 0.0 109.034 -179.028 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 10.9 mp0 -74.66 -21.94 59.15 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.284 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 69.5 p -170.42 176.65 4.34 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.105 0.479 . . . . 0.0 111.617 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -113.01 27.42 9.63 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.499 -0.773 . . . . 0.0 109.381 178.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 57.2 mtpt -75.52 34.38 0.11 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.714 -178.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . 0.508 ' O ' ' HB2' ' A' ' 73' ' ' HIS . 9.4 m -113.07 6.47 17.63 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 121.213 0.53 . . . . 0.0 109.751 178.838 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.29 -161.37 28.17 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.628 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -114.75 -92.59 1.88 Allowed Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.196 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -156.98 97.73 1.7 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 4.1 m -127.1 79.33 1.87 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.144 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 112' ' ' ARG . . . . . 0.42 HH11 ' HD3' ' B' ' 112' ' ' ARG . 7.2 ptt180 -67.8 162.8 23.16 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.537 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . 0.547 ' O ' ' HB2' ' A' ' 16' ' ' LYS . 4.5 mm? . . . . . 0 C--O 1.25 1.099 0 CA-C-O 118.711 -0.662 . . . . 0.0 110.78 -178.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.782 0 N-CA-C 112.1 -0.4 . . . . 0.0 112.1 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -169.28 -171.25 34.78 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.863 -0.684 . . . . 0.0 111.899 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.7 m -147.19 158.22 43.87 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 110.386 -0.227 . . . . 0.0 110.386 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' MET . . . . . . . . . . . . . 77.4 mtp 63.41 78.94 0.27 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.183 0.516 . . . . 0.0 110.939 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.432 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 7.9 mpt_? -72.78 139.31 80.26 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.733 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 5' ' ' ARG . 0.9 OUTLIER -87.87 109.8 0.66 Allowed 'Trans proline' 0 C--O 1.236 0.418 0 C-N-CA 123.204 2.603 . . . . 0.0 112.826 -179.026 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.472 ' HA ' ' O ' ' A' ' 89' ' ' ILE . 12.0 Cg_exo -72.81 121.39 7.31 Favored 'Trans proline' 0 N--CA 1.459 -0.523 0 C-N-CA 122.368 2.045 . . . . 0.0 113.041 179.02 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.466 HG21 ' N ' ' A' ' 54' ' ' LEU . 0.9 OUTLIER -83.0 110.86 18.51 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.295 0 CA-C-N 115.388 -0.824 . . . . 0.0 108.802 178.12 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.4 mm -77.16 100.75 2.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.75 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.698 HG21 ' HB3' ' A' ' 17' ' ' TYR . 6.0 mt -76.54 163.51 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 177.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' HIS . . . . . 0.55 ' N ' HG22 ' A' ' 10' ' ' ILE . 29.0 t-80 -141.53 107.1 5.06 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.105 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 52.6 ttt-85 -62.19 110.31 1.58 Allowed 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.164 -178.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -81.72 46.47 0.98 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.774 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.79 -0.26 66.32 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 121.163 -0.541 . . . . 0.0 112.814 -179.626 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 9.1 ptpt -119.65 -82.38 0.64 Allowed 'General case' 0 C--N 1.325 -0.458 0 O-C-N 122.891 -0.182 . . . . 0.0 111.277 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.516 ' HB2' ' OXT' ' B' ' 113' ' ' LEU . 17.1 pttt -155.14 -178.71 7.45 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.702 -178.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' TYR . . . . . 0.698 ' HB3' HG21 ' A' ' 10' ' ' ILE . 16.9 m-85 -88.28 5.64 40.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.17 0.51 . . . . 0.0 110.223 -179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . 0.548 ' O ' HG23 ' A' ' 43' ' ' VAL . . . 53.27 48.99 58.18 Favored Glycine 0 C--O 1.217 -0.909 0 N-CA-C 116.744 1.458 . . . . 0.0 116.744 177.062 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.499 ' HB3' HG23 ' A' ' 43' ' ' VAL . 6.3 p90 -164.42 147.38 9.04 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 122.457 1.123 . . . . 0.0 112.977 176.304 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 97.9 m -92.39 115.31 27.97 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 113.42 -1.718 . . . . 0.0 112.414 -179.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' LEU . . . . . 0.665 ' HG ' HG21 ' A' ' 76' ' ' VAL . 0.2 OUTLIER -89.22 84.48 6.51 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.74 0.305 . . . . 0.0 110.449 178.487 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.512 ' HB2' ' HB2' ' A' ' 41' ' ' TRP . 6.1 tpt180 -68.73 140.24 55.37 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.453 179.736 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.44 ' CB ' ' HD1' ' A' ' 73' ' ' HIS . . . -105.33 138.49 41.45 Favored 'General case' 0 C--N 1.328 -0.363 0 O-C-N 123.074 0.234 . . . . 0.0 110.462 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 4.3 pt -143.04 144.52 23.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-O 121.298 0.57 . . . . 0.0 111.765 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 91.0 mtt180 -115.56 90.51 3.35 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.446 179.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.2 m -75.69 118.03 21.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.12 -179.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' TYR . . . . . . . . . . . . . 11.2 m-85 -78.19 156.55 29.77 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.256 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 73.0 mtm -136.41 80.15 1.8 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.789 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 117.18 -157.76 14.9 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.375 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -93.36 -19.22 21.54 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.921 0.391 . . . . 0.0 111.054 -179.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -73.69 172.08 12.09 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.163 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -81.22 22.16 0.68 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.417 0.627 . . . . 0.0 110.676 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.8 p -81.83 127.54 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 CA-C-O 121.455 0.645 . . . . 0.0 110.439 179.362 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' TYR . . . . . . . . . . . . . 19.0 p90 -147.43 157.26 43.5 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.418 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.77 124.64 50.9 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 178.198 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 t -82.55 102.31 8.35 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.789 -179.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 54.9 m-70 -115.41 -175.46 2.71 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.678 -0.692 . . . . 0.0 109.676 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.529 ' CD2' HG11 ' A' ' 76' ' ' VAL . 97.1 m-70 -148.79 153.3 37.95 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 -179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 48.3 mtm -148.68 141.02 24.15 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.033 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.913 HG11 HD21 ' A' ' 54' ' ' LEU . 2.3 p -72.55 104.78 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-O 121.784 0.802 . . . . 0.0 109.581 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . 0.512 ' HB2' ' HB2' ' A' ' 22' ' ' ARG . 1.2 t-105 -70.07 -42.55 72.65 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.476 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' HIS . . . . . 0.442 ' HA ' ' CD ' ' A' ' 56' ' ' GLN . 0.9 OUTLIER -155.08 132.56 11.18 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.158 -179.125 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 18' ' ' GLY . 4.0 p -127.75 130.08 70.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 121.575 0.702 . . . . 0.0 110.508 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.564 ' O ' ' HB2' ' A' ' 50' ' ' SER . 37.1 mt-10 -67.04 115.07 6.34 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 114.583 -1.19 . . . . 0.0 111.811 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.539 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 11.9 p-10 -84.19 35.72 0.55 Allowed 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.649 179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.94 -26.12 8.09 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.708 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -179.93 -54.4 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 119.439 -1.362 . . . . 0.0 114.688 -178.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 77.4 Cg_exo -58.07 -129.57 0.0 OUTLIER 'Trans proline' 0 CA--C 1.544 0.975 0 C-N-CA 123.524 2.816 . . . . 0.0 116.68 -178.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.522 ' HB1' HD13 ' A' ' 54' ' ' LEU . . . -43.36 -42.87 4.8 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -176.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.564 ' HB2' ' O ' ' A' ' 44' ' ' GLU . 0.4 OUTLIER -62.09 -62.25 1.91 Allowed 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 112.742 0.645 . . . . 0.0 112.742 -177.668 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -62.04 -22.69 65.94 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.02 0.438 . . . . 0.0 111.072 -178.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -71.06 -24.57 62.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.692 179.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.05 -15.05 3.76 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.75 -0.738 . . . . 0.0 113.03 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LEU . . . . . 0.913 HD21 HG11 ' A' ' 40' ' ' VAL . 5.1 tt -69.42 113.07 6.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.049 0.452 . . . . 0.0 110.787 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ARG . . . . . 0.502 ' HD3' ' O ' ' A' ' 55' ' ' ARG . 0.0 OUTLIER -93.74 123.73 37.27 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.573 178.313 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.442 ' CD ' ' HA ' ' A' ' 42' ' ' HIS . 37.0 tt0 -49.08 134.43 17.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.247 0.546 . . . . 0.0 111.31 178.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 89.77 60.79 1.4 Allowed Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.734 -0.745 . . . . 0.0 111.681 -179.222 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.605 ' CG ' ' HB ' ' A' ' 91' ' ' THR . 7.4 t0 -140.75 155.25 46.48 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 38' ' ' HIS . 13.3 tp -102.75 125.27 49.42 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 116.137 -0.483 . . . . 0.0 109.931 -179.414 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.433 ' CG1' HD11 ' A' ' 89' ' ' ILE . 3.5 mp -82.68 122.75 37.67 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.276 -179.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.435 ' O ' HG22 ' A' ' 68' ' ' VAL . 44.8 p -100.59 -34.1 10.03 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.652 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 75.2 m80 -146.04 162.53 37.68 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.081 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.3 p -145.89 114.83 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.65 177.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 57.58 32.57 22.03 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.766 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 68.98 47.44 54.47 Favored Glycine 0 N--CA 1.444 -0.768 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -178.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.41 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 2.9 tp10 -149.55 99.98 3.34 Favored Pre-proline 0 N--CA 1.442 -0.835 0 C-N-CA 122.834 0.454 . . . . 0.0 110.079 -179.077 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 66' ' ' GLU . 80.4 Cg_exo -36.37 124.36 0.35 Allowed 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 124.424 3.416 . . . . 0.0 112.564 177.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 61' ' ' THR . 27.0 m -86.68 -11.11 11.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.055 -179.411 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' HIS . . . . . . . . . . . . . 13.5 m170 -56.57 98.14 0.03 OUTLIER 'General case' 0 N--CA 1.425 -1.688 0 CA-C-N 112.83 -1.986 . . . . 0.0 111.301 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 109.51 -6.41 31.71 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.441 -179.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 25.0 mt -79.01 137.76 37.72 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.717 0.259 . . . . 0.0 110.517 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -79.92 170.05 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.28 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.44 ' HD1' ' CB ' ' A' ' 23' ' ' ALA . 38.3 t60 -44.09 -54.4 5.56 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.643 0.735 . . . . 0.0 112.764 -179.452 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 21.1 p -73.53 -21.0 60.5 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 115.312 -0.858 . . . . 0.0 113.236 -176.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -68.4 -41.97 79.72 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 120.969 -0.292 . . . . 0.0 111.608 -179.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.665 HG21 ' HG ' ' A' ' 21' ' ' LEU . 3.4 m -66.39 -44.58 90.67 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 C-N-CA 120.125 -0.63 . . . . 0.0 109.95 179.04 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.425 HG13 ' CD1' ' B' ' 113' ' ' LEU . 50.2 t -53.68 -47.99 60.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.826 177.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 56.8 mt-10 -63.6 -45.2 91.45 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.894 178.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.41 -40.48 65.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.294 0.569 . . . . 0.0 109.822 178.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.707 HG23 HG11 ' A' ' 87' ' ' VAL . 21.8 mt -70.58 -53.21 23.39 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.775 0 CA-C-N 115.395 -0.821 . . . . 0.0 111.267 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 83.8 mt -57.57 -38.39 74.73 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 120.887 0.375 . . . . 0.0 111.294 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' LYS . . . . . . . . . . . . . 17.8 ttmt -59.6 -37.96 79.95 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.753 179.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' SER . . . . . . . . . . . . . 34.8 t -56.25 -39.52 72.71 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.972 -179.286 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 125.63 -141.38 12.91 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.11 -1.043 . . . . 0.0 112.997 179.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ASN . . . . . . . . . . . . . 23.5 p30 -75.13 5.5 5.3 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -179.101 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 16.0 pttp -162.71 171.18 17.22 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.726 -0.215 . . . . 0.0 110.452 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.707 HG11 HG23 ' A' ' 80' ' ' ILE . 11.6 p -164.96 147.06 2.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 112.619 0.6 . . . . 0.0 112.619 -178.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.73 94.22 7.98 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.748 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.472 ' O ' ' HA ' ' A' ' 7' ' ' PRO . 4.5 tt -88.61 116.16 29.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-O 120.749 0.309 . . . . 0.0 110.492 179.277 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 7' ' ' PRO . 0.1 OUTLIER -93.39 112.9 24.93 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 120.628 0.251 . . . . 0.0 111.508 -178.752 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.605 ' HB ' ' CG ' ' A' ' 58' ' ' ASP . 80.4 p -107.14 179.99 4.1 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 178.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.417 ' CG2' ' HB3' ' A' ' 59' ' ' LEU . 4.0 t -114.1 104.11 54.95 Favored Pre-proline 0 C--N 1.326 -0.424 0 CA-C-O 121.232 0.539 . . . . 0.0 112.322 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -56.31 175.53 0.25 Allowed 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.68 2.253 . . . . 0.0 113.344 178.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.436 ' HG ' ' H ' ' A' ' 94' ' ' LEU . 0.1 OUTLIER -65.32 162.33 17.74 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.476 -179.715 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -160.3 154.73 23.66 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.143 179.57 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 12.8 p30 . . . . . 0 C--O 1.251 1.132 0 CA-C-O 118.532 -0.747 . . . . 0.0 110.535 -179.926 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.478 0.965 0 CA-C-O 120.636 0.255 . . . . 0.0 110.808 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 102' ' ' TRP . . . . . . . . . . . . . 6.5 t90 -174.76 115.68 0.17 Allowed 'General case' 0 C--O 1.233 0.235 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.265 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 103' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -87.55 -85.58 0.17 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.884 178.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 104' ' ' SER . . . . . . . . . . . . . 5.3 m -138.7 -162.21 1.28 Allowed 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.209 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 105' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -115.03 97.25 6.11 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.171 0.51 . . . . 0.0 110.418 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 106' ' ' LYS . . . . . . . . . . . . . 58.7 mttp -130.96 23.61 4.94 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 107' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.24 4.64 51.8 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.961 -179.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 108' ' ' GLY . . . . . . . . . . . . . . . 151.42 -166.45 30.66 Favored Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.515 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 109' ' ' GLY . . . . . . . . . . . . . . . -86.66 -143.02 7.37 Favored Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.192 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 110' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -131.53 39.36 3.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.192 0.52 . . . . 0.0 110.204 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 111' ' ' THR . . . . . . . . . . . . . 11.5 m -69.83 103.43 2.19 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.71 179.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 112' ' ' ARG . . . . . . . . . . . . . 6.1 ptm180 -95.39 168.09 10.93 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.85 -0.613 . . . . 0.0 111.969 -178.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . 0.516 ' OXT' ' HB2' ' A' ' 16' ' ' LYS . 3.4 mm? . . . . . 0 C--O 1.249 1.061 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.3 179.784 . . . . . . . . 1 1 . 1 stop_ save_